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Abstract 
Background: Thirty years on into the HIV epidemic women comprise over 50% of the 
global HIV prevalence, yet only 74% of pregnant women achieved optimal ART 
adherence in both developing and developed countries. Antiretroviral therapy for 
pregnant women is essential for reducing vertical transmission and maintaining their 
own health. Understanding adherence and the predictors of adherence is therefore 
necessary to provide appropriate prevention and treatment modalities to this key 
population. There is currently limited knowledge of adherence among HIV-positive 
women in the Caribbean region in general, and Guyana specifically. To gain an 
understanding of these dynamics, the primary objective of this thesis was to explore and 
identify the factors associated with ART adherence within the Guyana setting. 
Methods: The thesis comprised the following studies: 1) a systematic review of the 
literature to understand the global knowledge base on ART adherence among HIV-
positive pregnant women, and investigate relevant studies from the region; 2) semi-
structured in-depth interviews on adherence perspectives of 33 key informants 
(pregnant and postpartum women, and healthcare providers); 3) a cross-sectional survey 
which examined: (a) general adherence to pregnancy-related health behaviors between 
108 HIV-negative and 108 HIV-positive women; (b) compared adherence to pregnancy-
related behaviors with ART adherence among 108 pregnant women; and c) investigated 
the efficacy of the Health Belief Model to predict and understand ART adherence. 
Participants were recruited from 11 primary care clinics throughout Regions 3, 4 and 6, 
and completed interviewer-administered questionnaires which included demographic, 
psychosocial, pregnancy health behaviors, clinical, and medication adherence measures. 
Adherence was measured with self-reports for recent (past 4 days, weekend) and distal 
(3 months) adherence. Thematic analysis was used to explore themes from the in-depth 
interviews, and multivariate regression analysis identified factors associated with 
adherence. 
Results: The systematic review yielded no studies relevant to the region and Guyana. 
Findings from the in-depth interviews indicated that adherence levels varied during both 
pregnancy and postpartum. Facilitators of adherence centered on women as caregivers, 
with pregnancy or existing children being strong motivating factors. Barriers included 
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lack of food, finances and medication side effects. Religion/spirituality was a source of 
comfort (positive), yet also contributed to non-adherence (negative) influence. 
Disclosure was not necessary to facilitate adherence in this population, as women took 
initiatives to ensure ART was taken.  
Overall, 19%, 15% and 67% of the pregnant women were recently non-adherent, 
recently adherent (but with past non-adherence), and always adherent respectively. 
Although the level of vitamin knowledge was the same (65%) for infected and 
uninfected pregnant women, higher vitamin intake occurred among HIV-positive 
women. While women experienced high levels of mental health disorders (suicidal 
ideation, depression), depression was a predictor of poor vitamin adherence (p=0.03) 
only among HIV-negative women. The absence of suicidal ideation (OR =2.74, 
p=0.049) and daily prenatal vitamin intake (OR =3.63, p=0.011) predicted ART 
adherence among the HIV-positive group. The Health Belief Model did not seem to be 
a useful tool as it did not help in understanding or predicting adherence in this 
population. 
Conclusion: The fact that 67% of the women were always adherent with ART is 
commendable given the health system constraints and psychosocial issues identified. 
However, the levels of sub-optimal adherence coupled with mental health and other 
socioeconomic issues are causes for concern. Longitudinal studies are warranted to 
determine the magnitude of these issues followed by appropriate interventions 
grounded in the psychosocial needs of mental health and poverty, adapted to the 
cultural context of the lives of the women. Although the ADQ or the HBM did not 
contribute to a deeper understanding or provide insight into pathways that can be 
targeted for intervention, theoretical models play a key role in identifying these 
pathways. 
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NNRTI Non-nucleoside reverse transcriptase inhibitors 
NPHRL National Public Health Reference Laboratory 
NRTI  Nucleoside reverse transcriptase inhibitors 
NTD  Neural tube defects 
NVP  Nevirapine 
PAHO  Pan American Health Organization 
PCL-C  PTSD Checklist – Civilian Version 
PCR  Polymerase chain reaction test 
PEPFAR United States President’s Emergency Fund for AIDS Relief 
PHQ  Patient Health Questionnaire 
PI  Protease inhibitors 
PICOS Participants, interventions, comparators, outcomes and study design 
PLHIV People living with HIV 
PMTCT Prevention of mother-to-child transmission of HIV 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
PTSD  Posttraumatic stress disorder 
PUSH  Positively United to Support Humanity project 
RDC  Regional Democratic Councils 
RHA  Regional Health Authority 
sdNVP  Single dose Nevirapine 
SPH  Solutions for Public Health 
STI  Sexually transmitted infections 
TDF  Tenofovir Disoproxil Fumarate   
UK  United Kingdom 
UNAIDS Joint United Nations Program on HIV/AIDS 
USA  United States of America 
VCT  Voluntary counselling and testing 
VDRL  Venereal Disease Research Laboratory test 
WB  World Bank 
WDRH West Demerara Regional Hospital 
WHO  World Health Organization 
ZDV  Zidovudine
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Preface – Structure of the thesis 
The overall objective of this thesis was to describe the nature and scope of ART 
treatment adherence among pregnant women and determine factors that may contribute 
to pregnant and postpartum women’s adherence in Guyana. Each study chapter will 
conclude with a discussion section. The final chapter (Chapter 9) well include a 
substantive discussion on the key interrelated results and implications for research and 
practice. 
The Introduction, Chapter 1, presents the background and justification for the research, 
discussion on the relevant literature on adherence in general and particularly among the 
target population, followed by an overview of Guyana’s history, its healthcare system, 
and HIV epidemic inclusive of prevention of mother-to-child transmission (PMTCT) of 
HIV. This chapter concludes with the theoretical framework and research paradigm that 
guided the study and the research questions. Chapter 2 presents the findings of a 
systematic review of the global and regional literature on ART adherence, in order to 
address questions on factors impacting adherence among pregnant and postpartum 
women. Through in-depth interviews, Chapter 3 explores the ART experiences of a 
group of pregnant and postpartum women and the perspectives of their healthcare 
providers. Chapter 4 describes the study methods detailing the instruments, 
measurements and data analysis for the cross-sectional descriptive study of pregnant 
women with and without HIV. Chapter 5 describes the general and health behaviour 
characteristics of pregnant HIV-positive and uninfected women. 
Drawing from both the research literature and the findings from the in-depth 
interviews, Chapters 6 through 8 discuss the findings of three sub-studies of a cross-
sectional descriptive study. Chapter 6 examines general adherence to pregnancy-related 
behaviours among HIV-negative and HIV-positive pregnant women. Chapter 7 
investigates ART adherence and its predictors among HIV-positive pregnant women. 
Chapter 8 examines the efficacy of the Health Belief Model to understand and predict 
ART adherence among HIV-positive pregnant women. The final chapter, Chapter 9 
brings the whole thesis together, providing a detailed discussion and interpretation of 
key findings within the existing research literature, followed by the strengths and 
limitations of the study and key implications and recommendations for future research.  
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Figure 1-1: Map of Guyana1 
 
 
                                                 
1 Source: Guyana Lands and Surveys Commission 
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Chapter 1 - Introduction 
1.1 Statement of the problem 
In a recent systematic review and meta-analysis on antiretroviral therapy (ART) 
adherence in developing and developed countries Nachega et al. (2012), reported that 
only 74% of pregnant women achieved optimal adherence. Adherence to ART in 
pregnant women is an important public health concern, since non-adherence can lead to 
resistant strains of the virus in the individual and the public, debilitating health for the 
mother, and possible HIV transmission to the baby (Ickovics et al., 2002; Ciambrone et 
al., 2006; Vaz et al., 2007; Bardeguez et al., 2008), particularly the potential for vertical 
transmission of resistant virus (Persaud et al., 2007; Nachega et al., 2012; Hamers et al., 
2013; Ngarina et al., 2013). The literature defines adherence as the level to which 
patients follow medical advice or treatment plans such as taking medications, keeping 
medical appointments and maintaining lifestyle changes (Morisky, Green and Levine, 
1986; DiMatteo, 2004).  
Although use of ART to treat HIV has significantly reduced AIDS-related morbidity 
and mortality, success is closely associated with consistent and correct use of ART 
medication. Maintaining adherence with medication of 95% or greater has been 
associated with adequate viral suppression, defined as having a viral load of less than 
400 copies/ml (Paterson et al., 2000; Turner, 2002; Battaglioli-DeNero, 2007). 
The nonexistence of a standardised ART assessment tool remains a challenge as a range 
of measures such as pill counts, plasma levels and self-reports have been used 
(Kunutsor et al., 2010; Leierer et al., 2014; Teshome et al., 2015), each with its own 
strengths and weaknesses, making comparisons of study findings difficult. 
1.2 Rationale for the study 
Adherence rates vary widely in developed and developing countries and also within 
developing countries. Few studies have examined adherence among HIV-positive 
women during pregnancy and postpartum, particularly the complex and myriad issues of 
demographic, social, and psychological factors associated with HIV-infection and 
treatment. If we hope to achieve the new “90-90-90” UNAIDS vision of diagnosing, 
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treating and achieving viral suppression among 90% PLHIV by 2020, as well as the 
global plan to eliminate new HIV infections among children and keep their mothers 
alive (UNAIDS, 2014; UNAIDS, 2015), we need to gain an understanding of the factors 
that affect women’s adherence with their ART regimens, to be able to provide them 
with appropriate treatment and support to safeguard their own health and that of future 
generations. 
To the author’s knowledge, there have been no studies to date examining those issues in 
Guyana or the wider Caribbean region. It is important to understand the factors 
affecting adherence among pregnant and postpartum women, since existing studies may 
not account for cultural and other local variations. The findings from this study will 
provide insight into the local situation, and will also inform policy and practice in 
Guyana and the wider Caribbean region. 
1.3 Background 
Thirty years on into the HIV pandemic, women account globally for about 47% 
(UNAIDS, 2013a) of new HIV infections, while women in the Caribbean are more 
affected with a rate of 53% (UNAIDS, 2011b). The Caribbean, with a prevalence of 1% 
has the second highest level of adult HIV prevalence after Sub-Saharan Africa’s rate of 
4.7%, while Guyana’s HIV prevalence is 1.3% (UNAIDS, 2013b). Guyana’s HIV 
prevalence of 1.3% in 2012, though higher than the other two regions, represents a 
decline in prevalence which stood at 2.4% in 2004 (MOH, 2012). Moreover, high 
prevalence rates of 16.6% and 19.4% respectively among two key most-at-risk 
populations (MARPs) of female sex workers and men who have sex with men (MSM) 
during the last biologic behavioural surveillance survey (BBSS) conducted in 2009 
appears to be a contributing factor in the overall prevalence rate (MOH, 2012). 
As the HIV/AIDS pandemic enters its third decade, women have been 
disproportionately affected and a growing casualty of this disease (UNAIDS, 2011a; 
UNAIDS, 2013b). Women are more vulnerable to HIV than men due to 
biology/physiology (porous vaginal tract, presence of other STIs) and social/cultural 
(gender inequality, gender-based violence, cultural and sexual norms, stigma and 
discrimination) factors (Türmen, 2003; Quinn and Overbaugh, 2005; Higgins, Hoffman 
and Dworkin, 2010). 
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Among adolescents and young women, infection rates are significantly higher than their 
male counterparts. Worldwide, only 58% of HIV-positive pregnant women received 
antiretrovirals (ARVs) to prevent MTCT, while the Caribbean region has made 
substantial progress with coverage greater than 95% (UNAIDS, 2013b). Without ART 
treatment, HIV-positive women of reproductive age carry the risk of transmitting the 
virus to their offspring via mother-to-child transmission (MTCT). A woman who is 
infected with HIV can transmit the virus to her baby during pregnancy, childbirth and 
through breastfeeding. According to UNICEF (2012), over 90% of children living with 
HIV were infected through MTCT. 
Without intervention, the risk of MTCT can be as high as 45% in resource-poor 
countries (De Cock et al., 2000; Newell, 2006; WHO, 2010a; Taha, 2011). However, 
transmission can be reduced to less than 2% (Newell, 2006; WHO, 2010a) through the 
use of ART during pregnancy, delivery and breastfeeding; through delivery by caesarean 
section; and through practicing either exclusive replacement feeding or exclusive 
breastfeeding (De Cock et al., 2000; Thorne and Newell, 2004; Newell, 2006). Read and 
Newell (2005) systematic review reported significant reductions in MTCT through 
elective caesarean sections, provided the surgeries are conducted prior to onset of 
labour or rupture of membranes. However, these surgeries primarily occur in developed 
countries located in North America and Europe with high morbidity and mortality risks 
for infant and mother (haemorrhage, anaemia, and pneumonia in the mother; and 
respiratory infections in the new-born), particularly in developing countries (Read and 
Newell, 2005; Sturt, Dokubo and Sint, 2010). 
1.4 Guyana - country background 
Guyana (Error! Reference source not found.), a former British colony (British 
uiana) of about 83,000 sq. miles (215,000 sq. km) lies on the north-east coast of South 
America. It is bounded by Venezuela to the north and north-west; Brazil to the south 
and south-west; Suriname to the east; and the Atlantic Ocean in the east and north-east. 
The revised name ‘Guyana’ originates from the Amerindian language meaning “land of 
many waters” since the country has a vast network of rivers and waterfalls (Ramnath, 
1998). 
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Although there are no known documents on who first discovered Guyana, the 
Amerindian tribes have been identified as the first inhabitants of the country. In 1492 
Christopher Columbus was the first European explorer to discover Guyana. According 
to Dalton (1855), Guyana was subsequently invaded by the Dutch, Spanish, French and 
English, but finally came under British rule in July 1831. 
Guyana became a republic when it gained its independence from the British on May 26, 
1966. It is governed by an executive President using the Westminster style of 
government. During the colonial period the country was subdivided into three counties, 
namely Essequibo, Demerara and Berbice (Dalton, 1855). However, after independence 
it was divided into 10 Administrative Regions (Table 1-1) with a local government 
system of 10 Regional Democratic Councils (RDC); 65 Neighbourhood Democratic 
Councils (NDC); 6 Municipalities; and 76 Amerindian Village Councils (PAHO/WHO, 
2009). 
Table 1-1: Guyana's 10 administrative regions 
No. Region No. Region 
1 Barima-Waini 6 East Berbice-Corentyne 
2 Pomeroon-Supenaam 7 Cuyuni-Mazaruni 
3 West Demerara-Essequibo Islands 8 Potaro-Siparuni 
4 Demerara-Mahaica 9 Upper Takutu-Upper Essequibo 
5 Mahaica-Berbice 10 Upper Demerara-Upper Berbice 
Being the only English-speaking country in South America, Guyana aligned itself with 
the English-speaking Caribbean islands than its neighbouring countries. This union with 
the Caribbean was fermented in August 1973 by the Treaty of Chaguaramas which 
created the Caribbean Community, better known today as CARICOM. CARICOM is an 
association of 15 Caribbean countries with a mandate to expand trade and economic 
activities within and outside the region; and to promote social, cultural and technological 
expansion for its citizenry (CARICOM, 2014). 
About three-quarters of Guyana’s land mass consist of rain forests. The majority of the 
population resides on the coastline of Regions 3, 4 and 6 with the bulk (43%) of the 
population in Region 4 (PAHO/WHO, 2009). It is a multi-ethnic society, and data from 
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the GOG (2002) indicate a country with a population of 754,493 and a racial breakdown 
of Indians (43.5%), Africans (30.2%), Mixed (16.7%), Amerindians (9.2%), Portuguese 
(0.20%), Chinese (0.19%) and Other (0.07%). The World Bank (2014a) lists Guyana as a 
lower middle income country with per capita income of US$3,584. Its economy is based 
on a combination of agriculture (sugar, rice), forestry, fishing and extraction of precious 
minerals (gold, diamonds, manganese, bauxite). 
1.4.1 Health system overview 
Guyana has a primary health care system. The Ministry of Health (MOH) has overall 
responsibility for the nation’s health services, with the Regional Democratic Councils 
(RDC) coordinating care within their respective regions. The passage of the Regional 
Health Authority (RHA) Act in 2005 paved the way for decentralizing health services in 
the regions through the creation of about five health authorities (MOH, 2008). To date, 
only one RHA for Region 6 was established in 2006, and almost a decade later it 
maintains a semi-autonomous management structure overseen by MOH and central 
Government  (USAID, 2011).  
Government health services are provided at a range of health facilities (Table 1-2) and 
are stratified by level based on the types of services and cadre of staff. The lowest level 
(Level 1) is the Health Post, primarily found in hinterland areas and staffed with 
Community Health workers, while the highest level (Level 5) is the National Referral 
Hospital in Georgetown with specialists and Registrars (GOG, 2009). 
Table 1-2: Type of health facilities 
Level Facility Staff 
Level 1 Health Post Community Health Worker and 
visiting Medex 
Level 2A Health Centre No doctor; registered nurse/midwife, 
nursing assistant, clerk 
Level 2B Health Centre (Poly Clinic) Doctor/Medex, plus Level 2A staff 
Level 3 Cottage/District Hospital Doctor and/or Medex 
Level 4 Regional Hospital GMOs, Registrars, some specialists  
Level 5 National Referral Hospital GMOs, Registrars, Specialists 
25 
 
Alongside the free public health services is a small network of private fee-based health 
sector facilities summarized in Table 1-3. While provision of health services on the 
coastal plain is relatively adequate, provision in the hinterland areas poses serious 
challenges due to geographical, infrastructure and human resource constraints, as 
highlighted by PAHO (PAHO/WHO, 2009, p.8): 
“Other key challenges that impact on quality availability, and accessibility of 
health services, particularly in the more under-served hinterland regions 
include inadequate health workforce, weak strategic planning and 
management processes, incomplete decentralization of health services, 
limited use of clinical protocols to support patient management, fragmented 
health information system, and limited use of available data for evidenced-
based decision making and policy formulation.” 
Table 1-3: Distribution of health facilities by region 
Type of 
facility 
National 
total 
Coastal regions Hinterland regions 
  3 4 5 6 10 1 2 7 8 9 
Specialist 
hospitals* 
4 0 2 0 2 0 0 0 0 0 0 
National 
hospitals 
1 0 1 0 0 0 0 0 0 0 0 
Regional 
hospitals 
6 1 2 0 1 1 0 1 0 0 0 
District 
hospitals 
20 3 0 2 2 2 4 1 2 2 2 
Health 
centres 
133 13 39 15 28 12 3 12 3 5 3 
Health posts 210 27 10 1 4 16 42 20 22 16 52 
Private 
hospitals 
7 0 6 0 1 0 0 0 0 0 0 
Total 381 44 60 18 38 31 49 34 27 22 57 
% total 
population 
 13.3 41.0 7.1 19.7 5.4 2.5 6.0 2.0 0.8 2.1 
Note: * includes geriatric and rehabilitation facilities 
Source: Guyana Health system assessment 2010 
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To overcome these health challenges and inequities in the population, the Guyana 
government commissioned an updated National Health Sector Strategy (NHSS) 2008-
2012, an extension of 2003-2007 National Health Plan (NHP), with the following key 
objectives: 
 Equitable distribution of health services 
 Provision of high standards of care 
 Consumer-friendly health services 
 Monitoring and evaluation structures to ensure Government and health 
workers are liable to the public 
1.4.2 General antenatal services 
Antenatal care in Guyana as per MCH’s Family Health Manual (GOG, 2009) is 
grounded in the safe motherhood initiative designed to reduce mortality among women 
of reproductive age. Its five components are preconception care, antenatal care, 
identifying high risk pregnancies, safe delivery and postpartum care. The antenatal care 
package includes: 
 Screening for Hb, grouping, Rh factor and VDRL 
 Treatment for intestinal parasites 
 Tetanus toxoid vaccine 
 Iron and folic acid supplementation 
 Routine screening of blood pressure, pulse and urine testing for sugar & 
protein 
 Full body physical examination 
 Measurement of the height of fundus, checking position of foetus, and 
monitoring of foetal heart sounds 
 Referrals to an obstetrician/gynaecologist for high risk conditions 
 
Women with normal pregnancies are seen monthly for up to 31 weeks; bimonthly from 
32 to 36 weeks; and weekly from 36 weeks until delivery. It should be noted that the 
HIV-positive woman is not considered high risk solely based on her status, and is 
managed according to the normal visit schedule. Although MCH policy indicates that all 
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pregnant women should be seen by a doctor at 36 weeks, this does not occur at all sites, 
particularly in the hinterland regions due primarily to human resource constraints. 
The public health sector in Guyana is the main provider of health care services with a 
small percentage of persons accessing care from private health facilities. World Bank 
(WB, 2009) statistics indicate that 92% of pregnant women received prenatal care in 
2009. From 2005, the annual number of live births has been approximately 15,000 
(MOH, 2011a). Table 1-4 below, lists other key indicators from the WB for 2009-2011. 
Table 1-4: Key health and socioeconomic indicators 
Indicator 2009 2011 
1 Crude birth rate (per 1000 people) 22 21 
2 Fertility rate, total (births per woman) 2.7 2.6 
3 Contraceptive prevalence (15-49 years) 43% Not 
available 
4 Life expectancy at birth (female) 68 69 
5 Life expectancy at birth (male) 63 63 
6 Pregnant women receiving prenatal care 92% Not 
available 
7 Births attended by skilled health care staff 92% Not 
available 
8 Maternal mortality ratio (per 100,000 live births) 270 280 (2010) 
9 Mortality rate, infant (per 1000 live births) 31 30 
10 Mortality rate, under-5 (per 1000 live births) 38 36 
11 Health expenditure per capita (US$) $173 $200 
1.5 HIV and AIDS in Guyana 
Guyana’s first case of AIDS was identified in a male in 1987. At the time of this 
discovery, there were no systems or infrastructure in place, so samples were diagnosed 
by the Caribbean Epidemiology Centre (CAREC), a specialized laboratory and 
epidemiology agency in Trinidad and Tobago affiliated with the Pan American Health 
Organization (PAHO). By 1989, a national AIDS program was established at the 
Ministry of Health (MOH). Subsequent funding from the European Union (EU) and 
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PAHO/WHO assisted with the creation of the Genito-urinary Medicine (GUM) clinic, 
the National Laboratory for Infectious Disease (NLID), and the National Blood 
Transfusion Service (NBTS) to aide in the prevention and control of HIV and AIDS, 
and other sexually transmitted infections (STIs). To comprehensively address this 
emergent disease, the Guyana Government in 1992 commissioned the National AIDS 
Program Secretariat (NAPS) to coordinate and monitor measures to combat the 
epidemic. Oversight for the national response was provided by the National AIDS 
Committee (NAC) in 1992 and the Presidential Commission on HIV and AIDS in 2005 
(MOH, GRPA and ORCM, 2006; MOH, 2012). 
1.5.1 Epidemiology of HIV and AIDS 
HIV disease was ranked as the 6th cause of death in Guyana (MOH, 2009).  Cases have 
increased over the years with 9,473 cases of HIV and 1,899 cases of AIDS being 
reported to the MOH during 2002-2011 (MOH, 2012). The epidemic is considered to 
be generalized with an HIV prevalence of 1.1% among the 15-49 age group. The 
primary mode of transmission is heterosexual sex with more females contracting HIV 
than males (Table 1-5) at a rate of 50.7% and 45.4% respectively (MOH, 2012).  
Table 1-5: Reported HIV cases by gender (2001-2011) 
Year Male Female Unknown Total 
2001 174 (42.5%) 226 (55.3%) 9 (2.2%) 409 
2002 301 (49.5%) 268 (44.1%) 39 (6.4%) 608 
2003 339 (44.5%) 368 (48.3%) 55 (7.2%) 762 
2004 368 (44.0%) 408 (48.7%) 61 (7.3%) 837 
2005 325 (41.6%) 421 (53.8%) 36 (4.6%) 782 
2006 591 (47.0%)  626 (49.8%) 41 (3.3%)  1258 
2007 422 (42.5%) 531 (53.5%) 40 (4.0) 993 
2008 446 (46.5%) 490 (51.1%) 23 (2.4%) 959 
2009 600 (51.0%) 567(48.2%) 9 (0.8%) 1176 
2010 449 (43.2%) 547 (52.6%) 43 (4.1%) 1039 
2011 432 (44.3%) 517 (53.2%) 23 (2.4%) 972 
Total 4447 (45.4%) 4969 (50.7%) 379 (3.9%) 9795 
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Over the years, the majority of HIV cases have occurred in Region 4, contributing to 
71.5% and 70.8% of the cases in 2010 and 2011 respectively. While Region 3 held the 
second highest rate in 2010(10.7%), this shifted to Region 5 (9.0%) in 2011. Region 4, 
which includes the capital city of Georgetown, is disproportionately affected since it 
accounts for 41.3% of the population, followed by Region 6 (16.6%), and Region 
3(13.7%). These three Regions combined contribute to 71.6% of the total population 
(MOH, 2011a; MOH, 2012). Although no reasons were proffered in official reports on 
the HIV trends seen below in Table 1-6, the author believes that Region 4 being the 
most populous one (41.3% population), coupled with the fact that persons from 
outlying regions would prefer to test there to avoid disclosure of their status in their 
small close-knit communities, due to high levels of stigma and discrimination. 
 Table 1-6: Proportion of HIV cases, 2009-11 
Region TOT 
Population 
% Population 2009 2010 2011 
   % HIV Cases 
Region 1 24,275 3.2 0.9 0.6 0.8 
Region 2 49,253 6.6 2.6 1.3 4.1 
Region 3 103,061 13.7 10.6 10.7 2.7 
Region 4 310,320 41.3 56.3 71.5 70.8 
Region 5 52,428 7.0 2.7 2.6 9.0 
Region 6 123,695 16.6 9.9 7.4 2.8 
Region 7 17,597 2.3 2.4 1.6 4.9 
Region 8 10,095 1.3 0.5 0.3 1.1 
Region 9 19,387 2.6 0 0.3 0.4 
Region 10 41,112 5.5 3.1 2.5 0.1 
Unknown 0 0 10.8 1.3 3.3 
TOTAL 751,223 100 100 100 100 
At the end of 2011, there were 19 (18 fixed, 1 mobile unit) HIV/AIDS treatment and 
care sites dispersed throughout the regions, with a total of 3,432 persons on ARV 
medication; of the 3,432 persons, 305 are being treated with 2nd line ARV regimen 
(MOH, 2012). 
30 
 
1.5.2 HIV programs and policies 
The Government of Guyana, through the Ministry of Health’s National AIDS Program 
Secretariat (NAPS), has established a comprehensive multi-faceted approach to the 
epidemic. NAPS have responsibility for the national HIV/AIDS response. All 
HIV/AIDS services accessed through the public health system are free-of-cost. 
Guyana’s national HIV/AIDS policy was tabled in Parliament in 1998 and subsequently 
updated in 2003 and 2006 (MOH, 2012). These revisions included plans to address 
stigma and discrimination and universal access to VCT and PMTCT. A national 
workplace policy was launched in 2009. The national HIV/AIDS response (Table 1-7) 
encompasses the following areas (MOH, 2011a; MOH, 2012). 
Table 1-7: Guyana's HIV/AIDS policies and programs 
Policies and Programs Description 
National Workplace Policy Launched in 2009 to control and prevent 
HIV in the workplace; to protect HIV-
positive workers against discrimination. 
National Blood Policy To ensure a safe blood supply; screening 
blood donors for infectious diseases and 
other blood anomalies; increasing the 
number of whole blood units from 
voluntary donors; training staff on needle-
stick injuries, safe injections and disposal 
of sharps; quality control. 
VCT Program Expansion of VCT sites across the 10 
regions, with mobile units for hinterland 
areas; VCT available at antenatal clinics 
and delivery wards, and also within the 
private sector; National day of HIV testing 
was launched in 2007 and due to demand 
evolved into National week of HIV testing 
in 2008. 
HEALTHQUAL Launched in 2008 to ensure quality care 
and treatment for HIV-positive adults and 
children. 
National Public Health Reference 
Laboratory (NPHRL) 
Established in 2008 with the capacity to 
provide CD4 testing, viral load testing and 
DNA-PCR testing for HIV diagnosis in 
infants. 
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Home-based Care Program Launched in 2005 to provide palliative 
care to home-bound HIV-positive 
persons; training of all cadre of nurses in 
palliative care. 
Food Bank Launched in 2007; provides short-term 
nutritional support (food hampers) to 
PLHIV; supported by the private sector 
Private Sector Partnership Program Collaboration with the private sector 
commenced in 2005 with a small number 
of business entities, which evolved to 
become the Guyana Business Coalition of 
HIV/AIDS in 2008; primary objective is 
to link employees of the private sector 
with HIV care, treatment, support and 
training. 
Behaviour Change Communication 
(BCC)  
The BCC strategy was launched in 2005 
with a focus on reducing stigma and 
discrimination, encouraging abstinence 
and faithfulness; encourage early testing; 
and community participation in treatment 
and care; subsequent strategies included 
manoeuvring condom use for women; 
interventions for high-risk groups and 
most-at-risk groups (MARPS); IEC 
materials; TV and radio programs; radio 
serial drama Merundoi (2006) to reinforce 
key messages in communities. 
Treatment and Care Program The first HIV and AIDS treatment 
guidelines were written in 2004 and 
updated in 2009 to reflect WHO 
guidelines; the National Care and 
Treatment Centre was launched in 2008, 
based in the capital city, Georgetown; 
other treatment sites have been established 
at regional hospitals and health care 
centres. 
Hotline Commenced in 2005 to serve as a clearing 
house of information and provide 
psychosocial support to callers; not a toll-
free number. 
Orphans and Vulnerable Children Providing health, nutrition and 
psychosocial care to caregivers and 
children regardless of HIV infection 
status. 
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Community Mobilization Strengthening the capacity of communities 
to deal with the epidemic; training of peer 
educators, in/out of school youth and 
community leaders. 
Monitoring and Evaluation Unit within NAPS to monitor key HIV 
indicators; use data from national surveys 
to set targets and monitor programs; 
routine data collection and analysis. 
 
1.5.3 Prevention-of-mother to child transmission (PMTCT) of HIV  
Guyana’s prevention of mother-to-child transmission (PMTCT) of HIV program has 
evolved over the years, from a pilot project in 11 health facilities across two out of ten 
regions in 2001, to a full-fledged national program in 181 sites from a total of 326 health 
facilities in all ten regions by the end of 2011(MOH, 2012). 
The piloting of Guyana’s PMTCT program was implemented by the NAPS of the 
Ministry of Health (MOH), however, when expansion commenced in 2003, the program 
was transferred to the Maternal and Child Health (MCH) Department of MOH, and has 
since been integrated into the services of that unit. 
1.5.3.1 National PMTCT program and policies 
The current PMTCT protocol includes changes in HIV testing, infant feeding, ARV 
treatment and infant testing. In the early years of the program, pregnant women were 
exposed to routine opt-in testing, whereby they were offered HIV testing and had the 
right to refuse. This was replaced in 2009 with opt-out testing in which women are 
tested routinely, and are not tested if they decline (PMTCT program policy). 
An antenatal survey conducted in 2006 found an HIV prevalence of 1.6% among 
pregnant women. Program data indicates a gradual decrease in the prevalence among 
the antenatal population – 1.3% (2007) and 1.1% (2011). Table 1-8 below summarizes 
some key indicators (MOH, 2011a; MOH, 2012; Karim, 2014). 
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Table 1-8: Key PMTCT indicators 
 Indicator 2009 2010 2011 2012 
1 PMTCT Sites 157 165 181 183 
2 Live births 14,584 14,528 12,518 11,778 
3 ANC women counselled & tested 11,776 11,441 13,490 12,697 
4 Counselling & testing uptake 89.8% 93.7% 94.8% 92.4% 
5 ANC women who received HIV 
test results 
10,046 
(85.3%) 
9,829 
(85.9%) 
11,641 
(86.3%) 
10,580 
(73.0%) 
 
 
 
6 Number of ANC women HIV 
positive 
130 101 147 88 
7 ANC HIV Prevalence 1.1% 0.9% 1.1% 0.7% 
8 Pregnant women receiving 
complete course of ART 
 95.8% 87.3% 85.1% 80.0% 
9 HIV-positive infants 8 (8.9%) 11 (6.9%) 5 (1.9%) 3 (1.7%) 
It should be noted that indicator number nine above titled “pregnant women receiving a 
complete course of ART” refers to data on ART (sdNVP and ART) received only from 
labour wards where ART drugs are available. 
In terms of infant feeding, women are given the option of exclusive breastfeeding from 
birth for a maximum of three months with rapid weaning, or exclusive formula feeding 
of the infant from birth with free infant formula until 18 months of age. The National 
HIV treatment guidelines (MOH, 2011b, p.84) recommends “the avoidance of all 
breastfeeding by HIV infected women.” Those who choose to breastfeed are advised to 
do so for no longer than three months, and are either placed or continued on ARVs for 
that period. The NAPS annual report (MOH, 2011a) data revealed that out of 158 HIV-
exposed babies on the labour ward, 152 (96.2% ) were formula-fed, while 6 (3.8% ) were 
breastfed. Diagnosis of the infant’s HIV status was based on antibody testing at 18 
months of age until DNA-PCR testing was introduced in 2007. Initially, the DNA-PCR 
testing was outsourced to an overseas laboratory, but in 2010, was transferred to the 
National Public Health Reference Laboratory (NPHRL) which had developed the 
technical capacity to conduct such tests (MOH, 2012). 
Guyana’s national PMTCT program currently includes the following services: 
 Opt-out HIV counselling and testing at antenatal clinics and select 
labour and delivery wards 
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 Infant feeding counselling with free infant formula up to age 18 months 
for mothers choosing formula feeding 
 DNA-PCR testing of infants beginning at 6 weeks of age and a final 
rapid antibody test at 18 months 
 Cotrimoxazole prophylaxis for HIV-exposed infants 
 All HIV-positive women are placed on ART beginning the 2nd trimester 
irrespective of CD4 count; If CD4 count is > 350, they will be given 
prophylactic ART until delivery, unless breastfeeding. If < 350, they will 
be placed on lifelong ART 
1.5.3.2 Antiretroviral therapy for PMTCT 
Up until 2004 (Persaud, 2014), antiretroviral medication for pregnant women consisted 
of a single dose, 200 mg tablet of Nevirapine (sdNVP) for the mother in established 
labour and a single dose of NVP syrup for the baby (2mg/kg) within 72 hours of birth. 
Due to concerns about monotherapy, Nevirapine resistance, and new treatment 
guidelines from WHO, sdNVP was replaced with ART, as outlined in Table 1-9 (MOH, 
2011b). Women who become pregnant while on ARVs are maintained on therapy, while 
ARV-naïve pregnant women commence therapy in the second trimester.  Women on 
ARVs solely to reduce MTCT can stop after delivery unless breastfeeding.  Exposed 
infants now receive sdNVP 2mg/kg and AZT 4mg/kg for six weeks (MOH, 2011b). 
Guyana recently updated its ART treatment guidelines to include Option B Plus for 
HIV-positive pregnant women (M.O.H, 2014). 
Table 1-9: ARV regimen for HIV-positive pregnant women and exposed infants 
CD4 Count Primary regimen in order of preference Alternate regimen 
1st Trimester If patient is on ART, evaluate for appropriateness of regimen 
If ARV-naïve, prepare for initiation in 2nd trimester (lab tests, adherence 
and other counselling) 
CTX prophylaxis 
2nd & 3rd  
Trimester 
 
 
CD4 < 350 
 
 
1. TDF+FTC+EFV 
2. TDF+FTC+NVP 
3. AZT+3TC+EFV 
4. AZT+3TC+NVP 
AZT+3TC+LPV/r 
 
(LPV/r will be used 
for women with 
previous exposure to 
sdNVP) 
 
CD4>350 
 
1. TDF+FTC+EVF 
 
AZT+3TC+LPV/r 
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CD4 Count Primary regimen in order of preference Alternate regimen 
 2. AZT+3TC+EFV 
ARV naïve 
in labour 
 
 
N/A 
 sdNVP 200mg 
 Dimune (AZT 300mg 
+3TC 150mg) 3 hours 
after sdNVP 
 Repeat sdNVP if still in 
labour after 24 hours 
 Dimune twice daily for 6 
weeks 
 
 
N/A 
HIV-
exposed 
 infant 
 sdNVP 2mg/kg at birth 
 AZT 4mg/kg twice daily for 6 weeks 
Prophylaxis must be given within 72 hours of birth to be effective 
Source: (MOH, 2011b) 
1.6 Study Sites 
Participants were interviewed at 11 clinics within Regions 3, 4 and 6 which are described 
below. These were selected to represent the diverse ethnic and socio-demographic 
characteristics of Guyana. The majority of the population (41.3%) reside in Region 4 
(GOG, 2002). Information for the Region 6 facilities was provided by social worker 
Jennifer Christopher (Christopher, 2014). 
1.6.1 Dorothy Bailey Health Centre 
The Dorothy Bailey Health Centre (DBHC) is located in the capital city (Picture 1), 
Georgetown, Region 4.  Initially founded as the Georgetown Municipality and Infant 
Welfare clinic in November 1931, it was subsequently renamed DBHC in 1967 in 
honour of the first female Mayor of Georgetown. At the time of its establishment, the 
primary purpose was to prevent morbidity in children less than one year old. Services 
have evolved over the years, and today DBHC is the largest of the four Georgetown 
municipal health centres and provides pre and post-natal care, family planning, infant 
and child health, school health, youth-friendly services, outpatient care, VCT, PMTCT, 
STI treatment and care, HIV treatment and care, and pharmacy services. 
DBHC’s catchment area includes Werk-en-Rust, Wortmanville, Bourda, Lacytown, 
South Cummingsburg, Robbstown, Stabroek, Kingston, North Cummingsburg, 
Alberttown, and Queenstown encompassing a total population of about 22,492. Despite 
its boundaries, DBHC also enrols patients from outside its defined catchment area. 
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Clinic staff includes six-midwives, one medex, two nurse assistants, one doctor, one 
programme nurse, two case navigators, one social worker/counsellor tester, one 
pharmacist, one phlebotomist, four clerks, one office assistant and one driver. DBHC 
was one of the first PMTCT sites launched in November 2001, with comprehensive 
HIV treatment and care services introduced in October 2007 (Stewart, 2013). 
1.6.2 Beterverwagting Health Centre 
Beterverwagting Health Centre (BVHC) located on the East Coast Demerara, Region 4, 
was initially opened in 1933 and rebuilt in 1998. It currently provides services to a 
population of about 10,000 residents on East Coast Demerara from Le Resouvenir on 
the West to Mon Repos on the East. Services provided include pre and post-natal care, 
child health, outpatient care, environmental health, dental care, sexual and reproductive 
health, chronic disease care, pharmacy services, VCT, PMTCT, and HIV treatment and 
care. Staff at the facility include one-doctor, one-staff nurse/midwife, two-nurse 
assistants, one-pharmacy assistant, one-community health worker, one-clinic attendant, 
one-VCT counsellor tester, one-social worker, one-dentist and two-environmental 
officers. PMTCT services were initiated in January 2004, while HIV treatment services 
were launched in October 2004 (Lowe, 2013). 
1.6.3 West Demerara Regional Hospital Antenatal Clinic 
The antenatal clinic is housed in the compound of the West Demerara Regional 
Hospital (WDRH) located in Region 3, West Coast Demerara. WDRH officially opened 
in 1983 with just two functioning units, a labour and delivery ward and an outpatient 
clinic, gradually increasing services to qualify as a Level 4 health facility in 1985, with a 
capacity of 225 beds. The antenatal clinic, established in 1985, currently has a staff 
complement of one-health visitor, one-midwife, one-nurse assistant and two-community 
health workers. PMTCT services were introduced in November 2003, while HIV care 
and treatment services commenced in 2002 (Karim, 2013). 
1.6.4 Campbellville Health Centre 
Campbellville Health Centre, located in Georgetown, Region 4 was built in the 1940s, 
and catered primarily for maternal and child health. This centre has now evolved into a 
poly-health clinic providing a comprehensive package of services, and is staffed by one-
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public health nurse, one-registered nurse, two-midwives, one-nurse assistant, three-
doctors, one-VCT counsellor-tester, two-dental technicians, one-laboratory assistant, 
two-pharmacy assistants and three-clerical staff. It was also one of the first sites to 
provide PMTCT services in 2001, and commenced HIV treatment and care services in 
May 2014. In January 2012, GPHC acquired the management of the clinic from the 
Ministry of Health (Corry, 2014; Khan, 2014). 
1.6.5 Georgetown Public Hospital Corporation OB/GYN clinic 
Georgetown Public Hospital, a Level 5 health facility, is the national referral hospital in 
the country. Located in Georgetown, Region 4, it has a rich history dating back to the 
early nineteenth century. Built in 1805 as a hospital for seamen, GPHC underwent 
several renovations and name changes to become a 450 bed Seamen’s Hospital in 1839. 
The GPHC obstetrics and gynaecology clinic provides high-risk antenatal care services, 
as well as routine gynaecological care. PMTCT services began in 2001. Persons in need 
of HIV treatment are referred to the National care and treatment clinic housed in the 
GPHC compound. Services are provided by a wide range of staff, inclusive of midwives 
and consultants (Corry, 2014; Khan, 2014). 
1.6.6 East La Penitence Health Centre 
The East LaPenitence Health Centre, located in Georgetown was officially launched in 
September 2009. It provides a comprehensive menu of services, inclusive of chronic 
non-communicable disease care, maternal and child health, and HIV care and treatment. 
Serving a population of 12,470, its catchment area encompasses Costello Housing 
scheme; West, East and NE LaPenitence; and East Ruimveldt. Staff at the site includes 
one doctor, medex, midwife, dentex, receptionist, pharmacy assistant, patient care 
assistant, outreach worker; two clinic attendants and three nursing assistants. HIV care 
and treatment services commenced October 2011 (Sears, 2013). 
1.6.7 Davis Memorial Hospital 
Davis Memorial, a Seventh-day Adventist Hospital in Georgetown, has been providing 
invaluable service to the community since 1967. The Positively United to Support 
Humanity (PUSH) project provides comprehensive care and treatment to persons who 
are HIV-positive. Initially funded by Catholic Relief Services (CRS) in 2006, the 
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program is currently supported with a grant by the United States President’s Emergency 
Fund for AIDS Relief (PEPFAR). The overall objective of this five-year project is to 
provide HIV and AIDS care, treatment and support within a faith-based environment. 
Davis Memorial is one of seven private medical institutions in the country, and has no 
boundaries in its mission of “service to humanity” (Chan, 2014; DMHAC, 2014). 
1.6.8 St. Joseph Mercy Hospital 
In June 2003, the management of St. Joseph Mercy Hospital established the Stemming 
the Tide program in collaboration with the Ministry of Health to reduce mother-to-child 
transmission given the high incidence of HIV infection in women of reproductive age. 
Catholic Relief Services provided funding in 2004 which enabled expansion of the 
services and ART was donated by the Guyana Government. In 2012, the hospital joined 
forces with Davis Memorial’s PUSH project to continue providing holistic HIV care 
and treatment services to women, their partners and HIV exposed or infected children. 
St. Joseph Mercy Hospital is operated by the Roman Catholic Church and managed by 
the Sisters of Mercy. It was built in the Kingston community of Georgetown, and began 
providing services in August 1945 (Sealey, 2014; SJMH, 2014). 
1.6.9 Cumberland Health Centre 
Cumberland Health Centre, East Canje Berbice, Region 6 began providing services to 
the community since the 1960s. The clinic delivers a range of health services, inclusive 
of HIV care to a population of about 30,000. PMTCT commenced in February 2002. 
The centre is staffed with a visiting doctor, Medex, social worker and phlebotomist; 
midwife, nurse assistant, community health worker, environmental health inspector and 
clinic attendant.  
1.6.10 Bohemia Health Centre 
Bohemia Health Centre (population approximately 20,000), located on the Corentyne 
Coast, Berbice, Region 6 (Picture 2) was also established in the 1960s, and provides 
similar services as Cumberland Health Centre. Staff include a visiting doctor, PMTCT 
counsellor and phlebotomist; a midwife and clinic attendant. PMTCT services were 
launched in November 2007. 
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1.6.11 New Amsterdam Family Health Clinic 
New Amsterdam Family Health Clinic, New Amsterdam, Berbice in Region 6 provides 
comprehensive health services inclusive of maternal and child health; chronic disease 
care; tuberculosis; and HIV and AIDS care and treatment. To adequately address the 
health needs of its community (approximately 30,000),  the poly-clinic is staffed with a 
doctor, health visitor, Medex, midwives, other nursing cadres, clerk, social worker, 
outreach worker, pharmacy assistant and clinic attendant. Patients in this Region can 
access their HIV treatment services at this facility. PMTCT commenced in September 
2005. 
1.7 Guiding frameworks for this study 
The sections below describe the theoretical and methodological frameworks that guided 
the study, followed by the overall purpose and associated research questions. 
1.7.1 Theoretical framework 
Adherence to ART in pregnancy is essential to achieve positive health outcomes for 
mother and infant, and requires and understanding of the health-related, behavioural 
and psychosocial factors contributing to regimen adherence or non-adherence. The 
Health Belief Model (HBM), one of the oldest and most widely used psychological and 
behavioural models, has been used to understand adherence in chronic health diseases, 
and now HIV (Malcolm et al., 2003; Reynolds et al., 2004; Barclay et al., 2007), but has 
not been incorporated in studies of HIV-positive pregnant women, and will be the 
theoretical approach to identify and understand the factors contributing to ART 
adherence. 
The Health Belief Model (HBM), an important theoretical framework, originated in the 
1950s by a group of social scientists from the United States Public Health Service who 
were concerned about the routine non-acceptance of disease prevention measures, such 
as screening tests for early identification of disease, despite the fact that the tests were 
either free or minimal cost (Rosenstock, 1974; Janz and Becker, 1984). This model for 
understanding psychological and behavioural factors that impact health behaviour has 
since been adopted in the public health arena to determine factors that may play a role 
in adherence (Malcolm et al., 2003; Williams and Manias, 2014). 
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The Health Belief Model (Figure 1-1), one of the most widely used frameworks in 
health behaviour research has been used to understand and guide interventions to 
change health behaviour including adherence to chronic health diseases, including HIV 
(Malcolm et al., 2003; Reynolds et al., 2004; Barclay et al., 2007; Turner et al., 2007). 
HBM dates back to public health circa 1950s (Rosenstock, 1974). The HBM constructs 
can help predict the rationale for prevention and control of ill health. It is based on the 
assumption that persons will change their behaviour if they believe that their health is at 
risk and their actions could lead to adverse consequences (Rosenstock, 1974; Janz and 
Becker, 1984; Champion and Skinner, 2008). In terms of adherence to HIV medication 
the HBM predicts that adherence is more likely to occur if the individual understands 
the gravity of their illness, the possibility of advanced HIV disease, the benefits of ARV 
treatment, and the negative consequences of prematurely discontinuing treatment (Janz 
and Becker, 1984; Blackwell, 1992). 
 
 
 
 
 
 
2Figure 1-1: Depiction of the Health Belief Model 
The HBM emphasizes the role of several factors: (1) perceived severity of a disease; (2) 
perceived susceptibility of an individual to that disease or susceptibility to disease 
progression; (3) perceived benefits linked with health behavior to combat the disease; 
(4) perceived barriers to practicing the health behaviour; (5) cues to action; and (6) self-
efficacy. 
                                                 
2 Source: Derived from Abraham, C. & Sheeran, P. 2005. The health belief model. In: CONNER, M. & 
NORMAN, P. (eds.) Predicting health behaviour: Research and practice with social cognition models. 2nd ed. England: 
Open University Press, Guest, G. & Namey, E. (eds.) 2015. Public health research methods, California: Sage. 
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 Perceived severity deals with a person’s belief about the medical, clinical, and social 
consequences of contracting an illness or of leaving it untreated; perceived susceptibility 
refers to a person’s belief that s/he is at risk of contracting an illness or worsening of 
the condition; perceived benefits address a person’s beliefs about the efficacy and 
feasibility of a particular action for treating or preventing illness; perceived barriers refer 
to a person’s beliefs about the problems s/he may face while trying to perform a health 
behaviour and weighing the benefits against the negatives; cues are either internal or 
external triggers resulting in a course of action; and self-efficacy refers to a person’s 
confidence in his/her ability to successfully execute the action. 
1.7.2 Use of the HBM to understand adherence 
The HBM has been used to predict a wide variety of health behaviours such as health 
screenings, exercise, smoking, alcohol use and adherence to medication for chronic 
diseases, such as, cancer (DiMatteo et al., 1993), diabetes (Brownlee-Duffeck et al., 
1987), hypertension (Hershey et al., 1980) and recently HIV (Barclay et al., 2007). 
 Turner et al. (2007) examined the use of the HBM to determine adherence among 
persons with multiple sclerosis. They found that the HBM predicted adherence and that 
perceived benefits was associated with at least 80% adherence. Moreover, demographic 
variables such as age, gender, and race did not impact adherence. 
In a study by Barclay et al. (2007) on predictors of medication adherence in HIV-
positive persons, some of the constructs of the HBM were used to predict adherence 
behaviour.  Results indicated that health beliefs, attitudes, and self-efficacy were 
indicative of adherence. In addition, older age (age 50 and above) was linked with higher 
medication adherence. 
Despite the popularity of this model, it has been the subject of some criticism in these 
areas: (1) the connection between the variables have not been fully explained and (2) 
there are no guidelines governing combination of the variables (Armitage and Conner, 
2000; Munro et al., 2007); (3) HBM does not take into consideration other variables 
such as how approval from others can impact behaviour and (4) it does not differentiate 
between the rankings, importance and connections among the constructs (Abraham and 
Sheeran, 2005). 
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Notwithstanding these criticisms, the HBM has been used to predict patient adherence 
(Janz and Becker, 1984; Kelly, Mamon and Scott, 1987; Muma et al., 1995).  In a review 
of studies utilizing the HBM over a 10-year period (1974-1984), Janz and Becker (1984)  
indicated that research conducted during that period validates the use of the HBM as a 
tool for interpreting persons’ decisions on health matters.  However, they posited that 
more research needs to be done to streamline the instruments used to measure HBM. 
Although the HBM has been used to predict adherence among various HIV-positive 
groups, it has not been used among HIV-positive pregnant and postpartum women.  As 
such, one of the components of this study will be to examine the usefulness of this 
theoretical model to predict adherence behaviour within this group. 
1.7.3 Research paradigm 
Creswell (2014) defines Epistemology as a framework or collection of ideas or beliefs 
guiding the methodological approach for research. Thus, researchers can have different 
viewpoints about their world resulting in various epistemologies or paradigms (Green 
and Thorogood, 2010). 
These research paradigms or theoretical approaches, influence the type of research 
design (quantitative, qualitative, mixed-methods) used. As such, they also determine the 
type of data collection and analysis used. Some of these paradigms include Post-
positivism, Constructivism, Transformative approaches and Pragmatism (Creswell, 
2014). It is possible to have two or more research paradigms guiding the same study 
(Sandelowski, 2000). 
Post-positivism originated in the 19th Century from writers like Mill and Durkheim. It is 
aligned with the scientific method or quantitative research. Proponents of this view 
believe in the notion of causality and that outcomes should be measured and hypotheses 
tested to be able to either reject or accept them. 
Constructivism (social constructivism) is aligned with the work of Mannheim, Berger 
and Luekmann in the 1960s, and focuses on qualitative research. Social constructivists 
try to understand the meaning behind the individual’s experiences using open-ended 
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dialog. The objective is to decipher the individual from his/her perspective within its 
social, cultural and historical context. 
Transformativism – this approach emerged during the 1980s and 90s, influenced by 
writers such as Karl Marx and Adonis. This type of research investigates social 
inequalities of race, ethnicity, sexual orientation and other marginalized groups, with the 
objective of effecting change. 
Pragmatism is a research paradigm based on the work of Pierce, James, Meade and 
Dewey  (Cherryholmes, 1992). Other researchers who have used a pragmatist approach 
include Patton (1990) and Morgan (2007). 
Pragmatism does not adhere to any one worldview, but utilizes any relevant approach 
(whether quantitative or qualitative) to address a given problem.  As the backbone for 
mixed-methods studies, it allows the researcher wide latitude on data collection and 
analysis methods (Cherryholmes, 1992; Morgan, 2007). Using a mixed-methods research 
strategy allows the researcher to use both qualitative and quantitative methods either at 
the same time or separately (Sandelowski, 2000; Creswell, 2009) to better comprehend 
the research problem. For this study, the author will be guided by a pragmatist 
approach.   
1.8 Purpose of study 
The purpose of this mixed-methods study was to describe the nature and scope of ART 
treatment adherence among pregnant and postpartum women, and to determine the 
factors that may contribute to their adherence within Guyana’s context. The first phase 
entailed a systematic review of the literature to understand the global knowledge base on 
ART adherence and investigate any relevant studies from the region.  
The second phase entailed a series of empirical studies. The first study explored the 
ART experiences of HIV-positive pregnant and postpartum women, with an 
understanding of adherence from their own perspective utilizing in-depth interviews, 
with a detailed exploration of the perspectives of their healthcare providers. Drawing 
from both the research literature and the findings from the in-depth interviews, a cross-
sectional descriptive study of pregnant women was undertaken which included three 
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sub-studies. The first investigated general adherence to pregnancy-related behaviours 
among HIV-negative and HIV-positive pregnant women; the second aimed to compare 
adherence to pregnancy-related behaviours with antiretroviral adherence among HIV-
positive pregnant women. The final study aimed to investigate the efficacy of the Health 
Belief Model to understand and predict ART adherence among HIV-positive pregnant 
women. The specific aims of the study were as follows: 
The use of a mixed-methods design allowed for a more comprehensive analysis of 
adherence rather than use of a single methodology. Triangulation of the findings from 
the qualitative and quantitative studies enhanced interpretation of the results (Creswell, 
2014). The specific research aims contributing to the overall thesis objective are 
presented in the table below (Table 1-10). 
Table 1-10: Research questions and methodology 
Study aims Research questions Methodology Chapter 
1. To provide a systematic 
review of the global and 
regional literature on 
ART adherence to 
address questions on 
factors contributing to 
adherence among 
pregnant and 
postpartum women 
What are the factors 
contributing to ART 
adherence among 
HIV-positive pregnant 
and postpartum 
women 
 
 
The PRISMA tool 
for systematic 
reviews and meta-
analyses guided this 
review. Studies 
identified from 
seven electronic 
databases; Out of  
6,622 screened 
records,  18 studies 
were included in the 
final review 
2 
2. To understand the ART 
adherence experiences 
of women living in 
Guyana 
How do HIV-positive 
pregnant and 
postpartum women 
describe their ART 
experiences? 
How do healthcare 
providers describe the 
Semi-structured 
interviews at five 
clinics (2 Regions) 
with 11 pregnant 
women, 13 
postpartum women 
and 9 healthcare 
3 
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Study aims Research questions Methodology Chapter 
adherence behaviour 
of HIV-positive 
pregnant and 
postpartum women? 
What are the factors 
that contribute to 
adherence and non-
adherence among 
pregnant and 
postpartum HIV-
positive women? 
workers. 
3. To examine general 
adherence to pregnancy 
health behaviours 
among HIV-negative 
and HIV-positive 
pregnant women 
What are the levels of 
prenatal vitamin 
supplement 
knowledge and 
vitamin use among 
HIV-negative and 
HIV-positive pregnant 
women and do these 
differ between the two 
groups? 
What are the levels for 
other prenatal health 
behaviours (alcohol 
use, tobacco use, and 
healthy nutrition) 
among HIV-negative 
and HIV-positive 
women, and do these 
differ between the two 
groups? 
What are the 
predictors of vitamin 
Cross-sectional 
study; Interviewer-
administered 
questionnaires at 12 
primary care clinics 
(3 Regions) with 
108 HIV-negative 
and 108 HIV-
positive pregnant 
women. 
6 
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Study aims Research questions Methodology Chapter 
knowledge, vitamin 
use, alcohol use, 
tobacco use and 
healthy nutrition 
among HIV-negative 
and HIV-positive 
women? 
4. To examine the factors 
contributing to pregnant 
women’s ART 
adherence 
What are the levels of 
ART adherence 
among HIV-positive 
pregnant women? 
What is the 
relationship between 
the demographic, 
social, psychological, 
knowledge, and 
clinical factors and 
ART adherence? 
What is the 
relationship between 
vitamin adherence and 
ART adherence? 
 
Cross-sectional 
study; Interviewer-
administered 
questionnaires at 12 
primary care clinics 
(3 Regions) with 
108 HIV-positive 
pregnant women. 
7 
5. To investigate the utility 
of a theoretical model to 
understand and predict 
adherence among HIV-
positive pregnant 
women 
What constructs of 
the Health Belief 
Model (HBM) as 
operationalised by the 
Adherence 
Determinants 
Questionnaire (ADQ) 
help understand and 
predict adherence. 
See methodology in 
Study Aim No. 4 
8 
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1.9 Candidate’s role in the thesis 
The ideas for this thesis emanated from my role developing and implementing the 
prevention of mother-to-child transmission (PMTCT) of HIV program in the resource-
limited setting of Guyana between 2001 and 2009. I subsequently resigned from this 
position to pursue my doctoral degree. While I was the recipient of a University College 
London tuition scholarship, I received no funding for fieldwork activities in Guyana. 
The entire project was conceptualized and implemented by me, and I was primarily 
responsible for data collection, data entry, analysis and interpretation. Other functions 
included transcribing the majority of interviews and designing an Epi-Info database for 
the quantitative data entry. 
My supervisors, Professor Lorraine Sherr, and Drs. Zelee Hill and Andrew Copas 
provided feedback on overall study design, conduct and interpretation of findings. Dr. 
Andrew Copas provided guidance on statistics. Drs. Zelee Hill and Audrey Prost 
provided oversight and feedback on the qualitative study. 
In the following chapter (Chapter 2), I present the results of a systematic review on 
adherence in HIV-positive pregnant and postpartum women using Liberati et al. (2009) 
guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA). 
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Picture 1: Dorothy Bailey Health Centre, Georgetown  
 
 
Picture 2: Bohemia Health Centre, Berbice 
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Chapter 2 - Systematic review of the literature3 
2.0 Abstract 
Objective: To assess the regional and global literature on ART adherence among 
pregnant and postpartum women. 
Methods: Using the PRISMA guidelines for systematic reviews and meta-analyses, an 
electronic search of bibliographic databases together with hand searches of select 
relevant journals, and ancestry searches of the bibliographies of journal articles. 
Results: The 18 studies included in the final review were conducted primarily in high 
income countries (11/18) with the remainder from low to middle income countries 
primarily in Africa. Both the measurement and levels of adherence varied across the 
studies. Facilitators included concern for the pregnancy/baby or other children, and 
support.  Barriers included non-disclosure of HIV status, stigma, health system issues, 
food insecurity, and financial constraints. 
Conclusion: There were no studies from the Caribbean region or Guyana specifically 
making it difficult to generalize results to this population and the peculiarities of its 
healthcare system. 
2.1 Introduction 
In this chapter, I will present the findings of a systematic review of the literature which 
aimed to investigate relevant studies on ART adherence during pregnancy and the 
postpartum period globally and the Caribbean region. The PRISMA tool for systematic 
reviews and meta-analyses (Liberati et al., 2009) guided the review.  
2.2 General medication adherence 
Adherence to treatment and care regimens has historically been challenging due to the 
increasing prevalence of chronic diseases and their reliance on individuals’ self-care 
(DiMatteo, 2004). The literature defines adherence as the level to which patients follow 
medical advice or treatment plans such as taking medications, keeping medical 
appointments and maintaining lifestyle changes (Morisky, Green and Levine, 1986; 
DiMatteo, 2004; DiMatteo, Haskard and Williams, 2007; Simek, McPhate and Haines, 
2012). 
Adherence to treatment for chronic diseases such as asthma, hypertension and diabetes 
is about 50% among persons who are aware of the gravity of their illness to 30% among 
                                                 
3 An adapted version of this chapter was published in the International Journal of STD and AIDS 
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those who don’t (Chesney, 2003). In a review of published studies on adherence over a 
50 year period, DiMatteo (2004) obtained a range of adherence from 65.5% for sleep 
disorders to 88.3% for HIV. 
2.3 Medication adherence during pregnancy 
Adherence to prescribed medication is also problematic in pregnant women. A study by 
Riley et al. (2005) among a cohort of 1626 pregnant women in the San Francisco Bay 
area found an overall adherence rate of 44%. Women with low levels of education and 
chronic disease had higher usage of prescribed drugs than their counterparts who were 
college graduates, while African American women more readily adhered to these drugs 
than white women. Sawicki et al. (2011) reported 59% non-adherence to prescribed 
drugs among 819 pregnant women at outpatient clinics in Australia, primarily due to 
forgetfulness. A similar study by Oliveira Filho et al. (2012) among 130 Brazilian women 
who were prescribed drugs, such as, iron supplements, pain killers and antibiotics found 
only 19% complied with their regimens. High educational background, financial 
independence, early antenatal care and a prior abortion were inversely associated with 
adherence. 
2.4 Adherence to HIV medication among pregnant and postpartum women 
Women are not adhering at the high levels needed to maintain viral suppression with 
some studies suggesting greater adherence during pregnancy than the postpartum period 
(Ickovics et al., 2002; Vaz et al., 2007; Bardeguez et al., 2008; Mellins et al., 2008). 
Although a study in South Africa showed better adherence postpartum (Peltzer, 
Sikwane and Majaja, 2011). 
Retention in care is important for effective PMTCT and successful maternal-infant 
outcomes (Aliyu et al., 2016). However, loss to follow-up (LTFU) is frequently observed 
both during and after pregnancy (Shaffer, Abrams and Becquet, 2014; Bengtson et al., 
2016). Risk factors for LTFU include young age, low educational level, unemployment, 
few antenatal care visits and late enrolment in antenatal care (Boyles et al., 2011; 
Bengtson et al., 2016; Haas et al., 2016). Interventions to stem these losses include 
community support, peer support, health system strengthening, improved quality of 
adherence and retention counselling, and active tracing of defaulters (Shaffer, Abrams 
and Becquet, 2014; Aliyu et al., 2016; Llenas-García et al., 2016).   
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2.5 Measuring ART adherence 
A wide range of measurement strategies (Table 2-1) such as pill counts (Minzi and 
Naazneen, 2008; Kunutsor et al., 2010), electronic caps (Turner, 2002; Lyimo et al., 
2011), provider reports (Walshe et al., 2010; Denison et al., 2015), pharmacy 
reports/refill records (Gutierrez et al., 2012; Tweya et al., 2012), plasma levels (Minzi, 
Mugoyela and Gustafsson, 2011; Leierer et al., 2014) and self-reports (Ndubuka and 
Ehlers, 2011; Teshome et al., 2015) have been used to measure adherence, each with its 
own strengths and weaknesses.  
2.5.1 Patient self-reports 
Self-reports (Table 2-2) are more commonly used to measure adherence in resource-
constrained settings because of ease of use and cheaper costs (Ndubuka and Ehlers, 
2011). Using this method, the patient is asked to recall the number of doses missed over 
a particular period of time. Although it is easy to use in the clinical setting, it is prone to 
biases such as recall and providing socially acceptable answers. Although self-reports 
have been shown to overestimate adherence (Bangsberg et al., 2001), they have been 
found to be useful and reliable since they are cheap and easy to use in a variety of 
settings, and have a strong correlation with plasma HIV levels (DeMasi et al., 2001; 
Simoni et al., 2006; Starace et al., 2006). 
2.5.2 Provider reports 
Health care practitioners estimates of adherence have proven to be unreliable and thus 
not recommended as a tool due to inconsistencies with actual patient levels (Wagner 
and Rabkin, 2000; Bangsberg et al., 2001; Martin et al., 2001). In a study by Paterson et 
al. (2000) both doctors and nurses misinterpreted the patient’s level of adherence by 
41% and 30% respectively. 
2.5.3 Pill counts and pharmacy reports 
Pill counts involve checking the number of pills remaining by a health care provider at 
the health facility as a percentage of the number of pills that should have been taken. 
This has been found to not only be labour-intensive, but can be prone to an erroneous 
count if pills were dumped by the patient rather than being ingested.  Pharmacy reports 
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can assist with indicating when prescriptions were received, but are subject to the same 
biases as pill counting (Becker, 1985; Wagner and Rabkin, 2000; Martin et al., 2001). 
2.5.4 Electronic devices 
The Medication Event Monitoring System (MEMS) is an electronic device attached to 
the cap of the pill bottle which records the opening of the bottle including the date and 
time. This data can then be downloaded into a database. MEMS can over- or under-
estimate adherence as it can record when a pill bottle was opened, but may not 
accurately reflect one’s behaviour, since one could either take out the pills and not use 
them or take out all the required daily doses and would be recorded as being non-
adherent – even if they were all subsequently taken (Arnsten et al., 2001; Turner, 2002; 
Sherr et al., 2008b). 
2.5.5 Biochemical Reports 
Plasma drug levels have been used to assess treatment failure (Wertheimer et al., 2006; 
Odaibo, Adewole and Olaleye, 2013). However, these are expensive and are problematic 
for measuring nucleoside reverse transcriptase inhibitors (NRTI). Testing at this one 
point in time may not be a true indication of adherence levels. Another indicator 
measuring mean corpuscular volume (MCV) is affected by the drugs Stavudine and 
Zidovudine. These markers can underreport adherence, particularly when drug resistant 
strains and other factors cause therapeutic failure, even though the person was adherent 
(Wall et al., 1995; Taiwo, 2009).  Moreover, some persons have demonstrated sustained 
viral suppression despite poor adherence which can vary with the regimen and pattern 
of non-adherence (Bangsberg, 2006; Shuter et al., 2007). 
2.5.6 Surrogate Markers 
Viral load and CD4 counts are regularly used as proxy measurements for adherence, 
although research has shown that viral load is a better indicator. Although these markers 
indicate a more accurate reflection of adherence they are more costly for use in limited 
resource settings (Kagee and Nel, 2012). 
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Table 2-1: Measures of adherence 
Measure Issues References 
Self-reports  Low cost  
 Ease of use 
 Correlates with plasma 
levels 
 Recall bias 
 Social desirability bias 
Becker, 1985; Wagner and 
Rabkin, 2000; Martin, et al., 
2001; DeMasi, et al., 2001; 
Arnsten, et al., 2001; 
Paterson, et al., 2002; 
Simoni, et al., 2006 
Provider reports  Easy to use 
 Unreliable 
Martin, et al., 2001; 
Bangsberg, et al., 2001; 
Paterson, Potoski and 
Capitano, 2002 
Pill counts and pharmacy 
reports 
 Labour-intensive 
 Can indicate if pills 
picked up from 
pharmacy 
 Unable to determine if 
pills ingested 
  
Becker, 1985; Wagner and 
Rabkin, 2000; Martin, et al., 
2001; Paterson, Potoski and 
Capitano, 2002 
Electronic devices 
(MEMS caps) 
 Indicates time & date 
of bottle openings 
 Unable to tell if pills 
were actually taken 
Wagner and Rabkin, 2000; 
Arnsten, et al., 2001; 
Turner, 2002; Shuter, et al., 
2007; Sherr, et al., 2008 
Biochemical reports 
(plasma drug levels) 
 Expensive 
 Poor correlation with 
adherence levels 
 Drug interactions 
resulting in inaccurate 
results 
Martin, et al., 2001; 
Paterson, Potoski and 
Capitano, 2002; Bangsberg, 
2006 
Surrogate markers (viral 
load, CD4) 
 Expensive 
 Treatment failure can 
mask results 
 Viral load better 
indicator 
Martin, et al., 2001; 
Mannheimer, et al., 2002; 
Shuter, et al., 2007 
Unfortunately, there is no ideal or ‘gold standard’ (Farmer, 1999) measurement for 
adherence since some of the methods listed above have either underestimated or 
overestimated adherence. Therefore multiple approaches are needed to assess adherence 
in order to tailor the regimen to individual circumstances. 
Researchers have also noted different patterns of adherence among non-adherers, 
including changes in the same individual over time and called for an understanding of 
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these patterns and “simple” measures of measurement in order to develop targeted 
interventions (Hill, Kendall and Fernandez, 2003; Sherr et al., 2010). 
2.6 Definitions of ART adherence in research 
Adherence has not only been defined differently, but studies have utilized different 
recall periods, even among researchers using the same instrument, thereby making 
comparisons difficult. Table 2-2 includes examples of the types of measures and 
definitions used for ART adherence from a PubMed review, 2001-2013. 
Table 2-2: Definitions of adherence, 2001-2013 
Authors Year Location Sample Measures Definition 
Wilson, T. et al 2001 USA 264 
pregnant 
women 
Self-reports of 
# of pills taken 
during prior 4-
day period; 
viral load 
Complete & 
incomplete 
adherence 
Complete = 
taking all 
drugs per 
day over 4-
day period 
Murphy, 
Greenwell & 
Hoffman 
2002 USA 65 women Self-reports of 
# pills taken 
daily in past 3 
days; pill 
counts 
Adherent = 
taking all 
meds all the 
time 
Carrieri, M. et al 2003 France 96 patients 
(66 men & 
30 women) 
Self-reports of 
# of pills taken 
daily during 
week prior to 
visit 
Non-
adherent = 
taking 
<80% of 
meds for 
the week 
Power, R. et al 2003 USA 73 men & 
women 
Self-reports of 
missed/delayed 
doses in prior 4 
days 
Non-
adherent = 
any missed 
dose during 
4-day 
period 
Murphy, D. et al 2004 USA 115 men & 
women 
Self-reports of 
3 measures – 
doses taken 
past 3 days; 
past week & 
past month 
Adherent = 
taking 
≥95% of 
meds 
Simoni, Frick & 
Huang 
2006 USA 136 men & 
women 
Self-reports of 
3 measures for 
prior 3 days – 
Adherent = 
average 
percentage 
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Authors Year Location Sample Measures Definition 
dose, pill & 
time 
adherence; 
viral load data 
for 3 
measures 
over 3-day 
period 
Wang & Wu 2007 China 181 men & 
women 
Self-reports of 
doses taken in 
3 days prior to 
visit 
Adherent & 
non-
adherent; 
Adherent = 
taking 
≥95% meds 
Reynolds, N. et 
al 
2007 USA 464 men & 
women 
Self-reports of 
# doses missed 
daily over 4-
day period; 
adherence to 
daily schedule, 
instructions, 
weekend, and 
last time 
missed; viral 
load data 
Adherence 
index of 0-
100 for all 
measures 
Schonnesson, L. 
et al 
2007 Sweden 193patients 
(145 men & 
48 women) 
Self-reports of 
3 types of 
adherence -
dose, schedule 
& diet during 
prior 4 days 
100% 
adherence 
or 
suboptimal 
adherence 
Vaz, M. et al 2007 Brazil 72 pregnant 
& 79 non-
pregnant 
women 
Self-reports on 
# missed doses 
for each drug 
during past 4 
days; pill 
counts 
Adherent = 
≥95% meds 
taken as 
prescribed 
at 2 
different 
times  
Williams, M. et 
al 
2007 Jamaica 101 men & 
women 
Self-reports of 
doses & pills 
taken in past 
week; provider 
reports on 
above 
Good 
adherence 
= mean 
levels of 
≥95%; non-
adherent = 
<95% 
Harvey, K. et al 2008 Jamaica 116 men & 
women 
Self-reports of 
doses missed 
in prior 24 hrs 
and 7 days 
Good 
adherence 
= no 
missed 
doses in 
24hr period; 
poor 
adherence 
= ≥ 1 
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Authors Year Location Sample Measures Definition 
missed dose 
in 24hr 
period 
Bardeguez, A. et 
al 
2008 USA 519 
pregnant 
women 
Self-reports of 
doses missed 
for each drug 
for prior 4 days 
& last time 
missed dose 
Perfect 
adherence 
= no 
missed 
doses 4 
days prior 
to visit 
Mellins, C. et al 2008 USA 399 
pregnant 
women 
Self-reports of 
each drug 
missed 2 days 
prior to visit & 
last time 
missed dose 
Complete 
adherence 
= complete 
doses in 
past 2 days 
+ no 
missed 
doses in the 
past month 
Cohn, S. et al 2008 USA 161 
pregnant 
women 
Self-reports of 
missed doses 
for each drug 
for prior 4 days 
& last time 
missed dose 
Recent 
adherence 
= no 
missed 
doses 
during 4 
days prior 
to visit; 
extended 
adherence 
= no 
missed 
doses for > 
3 months 
Mo & Mak 2009 China 102 men & 
women 
Self-reports of 
meds taken in 
prior 4 days 
Adherers = 
taking  
meds most 
of the time 
+ following 
diet most of 
the time 
+no missed 
doses in 
past 
weekend 
Igwegbe, 
Ugboaja & 
Nwajiaku 
2010 Nigeria 368 
pregnant 
women 
Self-reports on 
# pills missed 
in prior month 
Adherent = 
taking 
≥95% meds 
as 
prescribed 
Allen, C. et al 2011 Antigua & 394 men & Self-reports of Adherent = 
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Authors Year Location Sample Measures Definition 
Barbuda; 
Grenada; 
Trinidad & 
Tobago 
women meds taken 
daily over past 
7 days 
taking 
≥95% meds 
as 
prescribed 
Thirumurthy, H. 
et al 
2012 Kenya 720 men & 
women 
Self-reports of 
# doses missed 
in past 7 days; 
MEMS reports 
Adherence 
= no 
missed 
doses in 
past 7 days 
Achappa, B. et 
al 
2013 India 116 men & 
women 
Self-reports of 
meds taken in 
previous 4-day 
period 
High 
adherence 
= >95% 
adherence; 
Low 
adherence 
= <95% 
adherence 
Ayuo, P. et al 2013 Kenya 4284 
pregnant 
women 
Self-reports of 
# pills taken in 
past 7 days 
Perfect 
adherence 
= taking all 
meds in 
past 7 days; 
Imperfect 
adherence 
= any 
missed dose 
in past 7 
days 
 
2.7 Factors affecting adherence 
Sustained patient adherence to ART is necessary for successful treatment outcomes and 
reductions in morbidity and mortality (Allen et al., 2011; Matsui, 2012; Achappa et al., 
2013). ART adherence can be complicated by a variety of factors that can adversely 
affect treatment outcome. These factors can be grouped into three categories, namely 
treatment-related, patient-related and the health care system. 
2.7.1 Treatment-related factors 
Treatment-related factors include the number of pills taken, frequency of medication 
and adverse effects.  Protease inhibitors may cause nausea, vomiting and/or diarrhoea, 
while the non-nucleoside reverse transcriptase and nucleoside reverse transcriptase may 
affect the central nervous system, and skin and body image via abnormal fat deposits 
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(Chesney, 2003; Battaglioli-DeNero, 2007). Some of these effects can be temporary, 
while some may persist.  However, with the variety of medications available today, 
substitutions can be made to alleviate these effects. 
2.7.2 Patient-related factors 
Patient-related factors include income level, socioeconomic status, education, psychiatric 
issues, absence of social support, depression, stress, substance use and self-efficacy – 
persons’ belief that they are capable of complying with their treatment regimens (Poppa 
et al., 2004; Battaglioli-DeNero, 2007). 
2.7.3 Healthcare system-related factors 
Health care system-related factors include access to health care services, support from 
health care providers in terms of providing education on medications prescribed, 
medication reminders such as text messages and phone calls (Poppa et al., 2004; 
Battaglioli-DeNero, 2007). 
2.7.4 Facilitators and barriers to adherence in the general HIV population 
A systematic review of 37 qualitative and 47 quantitative studies by Mills et al. (2006), 
examining barriers and facilitators to adherence in both developed and developing 
countries identified barriers common to both settings, such as, non-disclosure; drug use; 
type of regimen and pill burden; forgetting; and personal commitments (job, family). 
Facilitators for developed countries included improved health outcomes, easy regimen, 
and acceptance of serostatus. 
Research by other authors have identified similar barriers as Mills (Hill, Kendall and 
Fernandez, 2003; Achappa et al., 2013). Other issues observed include ART side effects, 
busy schedules, medication costs, transportation costs, financial constraints, and feeling 
good (Hill, Kendall and Fernandez, 2003; Remien et al., 2003; Safren et al., 2005; 
Nachega et al., 2006; Roura et al., 2009; Allen et al., 2011); low self-efficacy (Barclay et 
al., 2007); lack of food (Kalichman et al., 2011); psychological issues (suicidal thoughts, 
anxiety, posttraumatic stress, depression) and stigma (De La Haye et al., 2010; Sherr et 
al., 2010; Peterson et al., 2012; Achappa et al., 2013). 
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Facilitators of adherence include free ART drugs, improved health, family obligations, 
pill reminder aides, incorporating ART into daily routine, disclosure, counselling and 
social support (Roura et al., 2009; Vervoort et al., 2009; Watt et al., 2009; Allen et al., 
2011). Being of older age was also associated with better adherence (Sherr et al., 2008b; 
Sherr et al., 2010). 
2.7.5 Facilitators and barriers of adherence in HIV-positive pregnant and 
postpartum women 
Facilitators and barriers to adherence in the pregnant and postpartum population are 
similar to what obtains in the general HIV population as identified in the studies below. 
A key motivator for pregnant women was the pregnancy itself and the desire to have an 
uninfected baby; while having a child or children helped improve adherence for 
postpartum women (Wood, Tobias and McCree, 2004; Ciambrone et al., 2006; 
McDonald and Kirkman, 2011). However, research has shown greater adherence during 
pregnancy and declining rates postpartum (Peltzer, Sikwane and Majaja, 2011). 
In a quantitative study on Zidovudine (ZDV) adherence among HIV-positive pregnant 
women Demas et al. (2005) found social support, disclosure to family and religion had a 
positive impact on adherence, while demographic and clinical variables were not 
significantly associated with adherence. Demographic variables were also not found to 
be associated with adherence by Mellins et al. (2008). 
In a qualitative study by Ciambrone et al. (2006) among pregnant and postnatal women 
attending a medical clinic in Puerto Rico, barriers identified were lifestyle issues, job-
related, forgetfulness, unstable living conditions, non-disclosure of status. Other factors 
identified in other studies include stigma and discrimination, financial constraints, 
transportation costs, lack of food, distance to clinic, long waiting times for care, low 
educational level, drug use, being away from home, sleeping through time for ART 
dose, poor relations with staff and depression (Mellins et al., 2008; Duff et al., 2010; El-
Khatib et al., 2011; Mepham et al., 2011; Peltzer, Sikwane and Majaja, 2011). 
While ART is known to significantly reduce the risk of MTCT, use of these drugs over 
time, particularly Nevirapine and Efavirenz can result in varying levels of hepatotoxicity 
(liver damage) (Marazzi et al., 2006; Huntington et al., 2015). Concerns have also been 
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raised about the use of protease-inhibitor (PI) based regimens which have resulted in 
low birth weight (LBW) and preterm birth (PTB) (Mesfin, Kibret and Taye, 2016), as 
well as small for gestational age (SGA) babies (Fekadu Mazengia Alemu and Fantahun, 
2015). 
2.8 Depression in HIV-positive persons 
Depression is more prevalent among HIV-positive persons than those who are not 
infected, adversely affecting medication adherence (Lewis et al., 2012; Peterson et al., 
2012). Antenatal maternal depression contributes to adverse outcomes on the foetus 
and infant, and places women at higher risk for postnatal depression (Pottinger, 
Trotman-Edwards and Younger, 2009; Fernandes et al., 2011; Hartley et al., 2011). 
2.8.1 Depression in the general HIV-positive population   
HIV-positive persons are twice as likely to suffer from a major depressive disorder as 
those who are HIV negative (Ciesla and Roberts, 2001). In a study on depression and 
anxiety in HIV-positive women, Morrison et al. (2002) discovered that major depression 
was four times more likely to occur in HIV-positive women (19.4%) than in those who 
are HIV-negative (4.8%), and that these women experienced higher anxiety levels than 
their negative counterparts. 
Among HIV-positive persons, untreated depression can affect their quality of life, lower 
CD4 count, and accelerate disease progression, and reduce their capacity to adhere to 
ART (Starace et al., 2002; Fialho et al., 2013; Zimpel and Fleck, 2014). 
2.8.2 Depression in the general antenatal and postpartum population 
Although pregnancy can be a period of joy and great expectations, it can also be a time 
of great psychological distress. Many women experience depression during pregnancy 
and the postpartum period. Researchers have found that depression and anxiety during 
pregnancy are strong predictors of postpartum depression (Robertson et al., 2004; 
Milgrom, 2008). Depression is also linked with poor attendance at antenatal clinic (Leigh 
and Milgrom, 2008). 
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In a systematic review on the prevalence of depression during pregnancy in developed 
countries, Bennett et al. (2004) found that rates across many countries ranged from 
7.4% to 12.8%, while high rates ranging from 41% to 48% were reported from three 
African studies (Hartley et al., 2011; Rochat et al., 2011; Lewis et al., 2012).  
Risk factors for antenatal and postnatal depression include anxiety, stress, abuse, 
maternal age, poverty, low educational level, and lack of social support (Leigh and 
Milgrom, 2008; Luke et al., 2009; Hartley et al., 2011; Koleva et al., 2011). 
The negative effects associated with depression for the health of the woman, the foetus 
and the infant’s future milestones (behavioural and cognitive) have been well 
documented, and include early delivery (pre-term) and pre-eclampsia (Marcus et al., 
2003); low birth weight, low Apgar scores, stunting, and low weight for age (Marcus et 
al., 2003; Rahman et al., 2004; Alder et al., 2007; Koleva et al., 2011; Parsons et al., 2012; 
Tsai and Tomlinson, 2012). 
Another mood disorder common among postpartum women is posttraumatic stress 
disorder (PTSD). In a review of the literature on depression and anxiety during 
pregnancy, Alder et al. (2007) found prevalence of PTSD ranging from 7.7% to 10.7%, 
with negative impact on maternal, foetal and delivery outcomes. Predictors of PTSD are 
anxiety in pregnancy and the delivery process (Zaers, Waschke and Ehlert, 2008). 
2.8.3 Depression among HIV-positive pregnant women 
HIV-positive pregnant women prone to depression as a result of their pregnancy are 
also at risk for depressive symptoms due to their HIV status (Blaney et al., 2004). 
Recent studies have found similar rates of depression and mood disorders among HIV-
positive and uninfected pregnant women. Rubin et al. (2011) in their study examining 
perinatal depression in the Women’s Interagency study reported no significant 
difference in the prevalence of depression symptoms between pregnant HIV-positive 
and uninfected women with rates of 44% and 50% respectively. Similarly, Bonacquisti, 
Geller and Aaron (2014), found the same levels of depression (36%) in a corresponding 
group. Untreated depression in HIV-positive pregnant women, like other populations, 
can affect their quality of life, CD4 counts and accelerate disease progression (Ross, 
Sawatphanit and Zeller, 2009). 
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2.9 Summary 
Adherence to antiretroviral therapy in pregnant and postpartum women is an important 
public health issue, since non-adherence can adversely affect maternal, foetal and infant 
health; perpetuate drug-resistant strains; and risk vertical transmission (Ickovics et al., 
2002; Ciambrone et al., 2006; Vaz et al., 2007; Mepham et al., 2011). 
Historically, adherence to prescribed medications in the general population have always 
been problematic (DiMatteo, Haskard and Williams, 2007; Simek, McPhate and Haines, 
2012), and these challenges are no different for HIV-positive pregnant and postpartum 
women, who not only have to grapple with pregnancy-related issues and child-rearing, 
but also this life-threatening, chronic incurable disease. 
Although mother-to-child transmission of HIV can be reduced to levels of 2% or less 
(WHO, 2010a) with consistent and appropriate ART regimens during pregnancy, 
delivery and breastfeeding, some women are not adhering at the high levels needed to 
maintain viral suppression (Nachega et al., 2012). Moreover, research undertaken by 
Mellins et al. (2008); and Peltzer, Sikwane and Majaja (2011) indicate greater adherence 
during pregnancy and declining rates postpartum. 
Adherence can be measured using a variety of methods such as self-reports, pill counts, 
pharmacy reports, and biochemical methods, all with advantages and disadvantages 
(Turner, 2002; Sethi et al., 2003). However, self-reports are more commonly used to 
measure adherence in resource-constrained settings due to ease of use and cheaper costs 
(Ndubuka and Ehlers, 2011). Though prone to recall and social desirability biases that 
can overestimate adherence (Bangsberg et al., 2001), self-reports have been validated as 
an accurate method for measuring adherence with the ability to predict virologic 
outcomes (Wagner and Rabkin, 2000; Martin et al., 2001). 
Sustained adherence to ART is necessary for successful treatment outcomes, but this 
can be complicated by a combination of patient, treatment, and health-system-related 
factors. Treatment-related factors include pill burden and adverse drug effects (Chesney, 
2003; Battaglioli-DeNero, 2007); patient-related factors such as socioeconomic issues, 
psychosocial and substance use); and health system-related factors encompass access 
and provider support (Poppa et al., 2004; Battaglioli-DeNero, 2007). 
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Some of the facilitators and barriers to adherence in pregnant and postpartum women 
are quite similar to those in the general HIV population, with a key motivator for the 
women being the desire to have an HIV-negative healthy baby as described below. 
Barriers identified in the literature are drug use, non-disclosure, pill burden, financial 
constraints, and psychological issues of anxiety and depression (Mellins et al., 2008; 
Duff et al., 2010; El-Khatib et al., 2011). Facilitators of adherence include disclosure, 
social support, having other children, being pregnant and wanting an uninfected baby 
(Ciambrone et al., 2006; McDonald and Kirkman, 2011). 
Many studies have linked depression among HIV-positive pregnant women and non-
adherence to ART (Vyavaharkar et al., 2007; Kapetanovic et al., 2009; Nel and Kagee, 
2013). Some of the risk factors for depression among HIV-positive pregnant women are 
similar to those in the general and non-infected population and include guilt, stigma, 
poverty, lack of social support, past history of depression and drug use (Rich-Edwards 
et al., 2006; Leigh and Milgrom, 2008; Kapetanovic et al., 2009). Since depression can 
have such damaging effects on both the mother and child, it is important to assess the 
role of this psychosocial dimension on adherence during pregnancy and postpartum. 
Given its public health implications, adherence during the prenatal and postpartum 
period is an important and relevant research topic, to not only gain an understanding of 
the issues impacting adherence behaviours, but also if we aim to achieve the laudable 
UNAIDS goal of eliminating HIV infections in children and reducing maternal 
mortality. 
2.10 Study objective 
The objective of this study was to provide a systematic review of the global and regional 
literature on ART adherence to address questions on the factors contributing to 
adherence among pregnant and postpartum women. 
2.10.1 Research question 
What are the factors contributing to ART adherence among HIV-positive pregnant and 
postpartum women in Guyana? 
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2.11 Methods 
2.11.1 Search strategy 
A systematic literature search was conducted for both qualitative and quantitative 
studies in both resource-rich and resource-constrained countries, with a focus on the 
latter settings to determine among other things what research had been done in the field 
of adherence as it pertains to pregnant and postpartum women. There were no date 
limits on the searches, but studies were limited to those written in English which 
included the study population. As this was a thesis, the review was conducted solely by 
me, however a minimum of two persons are recommended to reduce bias and error in 
study selection and the quality assessment process (CRD, 2009; Liberati et al., 2009). 
The review was limited to studies identified from the University College London (UCL) 
Library. Electronic databases included OVID Medline (1948 to Present), OVID 
Embase (1980 to Present), OVID PsycINFO (1806 to Present), EBSCO CINAHL Plus 
(1984 to Present), JSTOR (1995 to Present), ISI Web of Science (1900 to Present) and 
The Cochrane Library (1996 to Present). Key individual journals such as AIDS Care 
(July 7, 2011), AIDS Patient Care & STDs (July 6, 2011), International Journal of STDs 
& AIDS (July 6, 2011), AIDS & Behaviour (July 5, 2011), Women & Health (July 5, 
2011), and Social Science & Medicine (July 5, 2011) were also searched electronically. In 
addition, the reference section for selected studies from the electronic and hand 
searches above were screened for other relevant studies.  Search terms included ‘HIV’, 
‘AIDS’, ‘mother-to-child transmission’, ‘MTCT’, ‘PMTCT’, ‘ARV therapy’, ‘ART’ and 
‘medication adherence’. The search strategy for Medline is listed in Figure 2-1, while 
samples of searches for the other databases are listed in Appendix C. 
 1     HIV.mp. or exp HIV/ or exp HIV-2/ or exp HIV Infections/ or exp 
HIV-1/ (266081) 
 2     (HIV virus infection or human immunodeficiency virus infection).mp. 
[mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, 
unique identifier] (5762) 
 3     AIDS.mp. or exp Acquired Immunodeficiency Syndrome/ (162209) 
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 4     (acquired immune deficiency syndrome or acquired immuno-deficiency 
syndrome).mp. [mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier] (4767) 
 5     PMTCT.mp. (398) 
 6     (MTCT or mother-to-child transmission or mother-to-infant 
transmission or vertical transmission or perinatal transmission or postnatal 
transmission).mp. [mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier] (6787) 
 7     (ARV therapy or antiretroviral therapy or ARV prophylaxis).mp. 
[mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, 
unique identifier] (24828) 
 8     (HAART or highly active antiretroviral therapy).mp. [mp=protocol 
supplementary concept, rare disease supplementary concept, title, original 
title, abstract, name of substance word, subject heading word, unique 
identifier] (11067) 
 9     medication adherence.mp. or exp Patient Compliance/ or exp 
Medication Adherence/ (44031) 
 10     1 or 2 or 3 or 4 (305345) 
 11     5 or 6 (6860) 
 12     7 or 8 (25646) 
 13     9 and 10 and 11 and 12 (29) 
Figure 2-1: Medline search strategy 
2.12 Eligibility criteria for the systematic review 
The PICOS (participants, interventions, comparators, outcomes and study design) 
methodology as advocated by the PRISMA Statement (Liberati et al., 2009) was 
integrated into this systematic review process.   
Types of Studies: all types of designs (qualitative and quantitative) were considered 
since this was a scoping exercise to determine among other things what research has 
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been conducted in the field of adherence as it pertains to pregnant and postpartum 
women.  
Types of Participants: participants were HIV-positive pregnant and postpartum 
women receiving antiretroviral therapy. Studies incorporating men and women or men 
only were excluded in keeping with the overall aim of the review.  
Types of Interventions: ART adherence and adherence to other health behaviour for 
reducing HIV transmission from mother to infant.  
Types of Outcome Measures:  primary outcomes were facilitators and barriers of 
adherence, measures of adherence, participants’ views, provider views, levels of 
adherence and infant’s HIV status, and secondary outcomes were quality of life, adverse 
events of non-adherence, morbidity and mortality. 
2.12.1 Study selection 
The titles and abstracts identified from the PICOS search criteria were reviewed.  If the 
abstract was not available, the full text was sought, and if unavailable, the study was 
excluded. The final step was to critically examine the full text of the remaining abstracts 
to determine final eligibility based on the inclusion criteria.  Records, such as letters to 
the editor and commentaries were excluded from further review. 
Data was extracted using a modified data collection form designed using items from 
Table 7.3.a. of the Cochrane Handbook Version 5.1.0 (Higgins and Green, 2011). Key 
information (author, year, participants, methods, interventions, outcomes, and results) 
from each study was summarized on this form (Appendix D). 
2.12.2 Review of methodological quality 
This review resulted in both qualitative and quantitative studies and the author utilized 
the Critical Appraisal Skills Program (CASP) tool for qualitative studies (Solutions for 
Public Health (SPH) an NHS organization, England) and the Effective Public Health 
Practice Project (EPHPP) for quantitative studies from McMaster University, Canada 
recommended by the Cochrane Health Promotion and Public Health Field Guidelines 
(Armstrong et al., 2007).   
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The EPHPP for quantitative studies has rating scales of Strong =1; Moderate= 2; Weak 
=3 for measuring selection bias (external validity), study design, confounders, blinding 
(detection bias), data collection methods, and withdrawals and dropouts (attrition bias). 
After these individual ratings per component, a final overall rating is issued as follows.  
If the study has no ‘weak’ grades, it is considered ‘Strong’; one ‘weak’ grade, it is 
‘Moderate’; and at least two ‘weak’ grades, it is ‘Weak’. 
The qualitative studies were assessed using the Critical Appraisal Skills Program (CASP), 
a 10-item tool for qualitative research (CASP, 2011). Information for each study was 
noted on the extraction form. This tool involves a review of Aims, Methods, Research 
design, Sampling, Data collection, Reflexivity, Ethics, Data analysis, Findings and Value. 
Although this qualitative tool did not have grading criteria, an overall assessment was 
made of the study as being ‘good’, ‘fair’ or ‘poor’ based on the number of ‘yes’ 
responses. 
2.13 Results 
Searches of the electronic bibliographic databases yielded 881 studies, while hand 
searches of journals resulted in 5,756 studies. Finally, ancestry searches (checking the 
references of included studies) retrieved 57 references for a grand total of 6,694 research 
studies. 72 duplicate studies were eliminated for a balance of 6,622 studies. After 
screening by title and abstract, 37 full-text studies were subjected to complete review, 
resulting in a final selection of 18 included studies as depicted in the adapted PRISMA 
flow diagram in Figure 2-2 below, adapted from Liberati et al. (2009, p.4). 
68 
 
 
Figure 2-2: Study selection flow diagram 
2.13.1 Characteristics of excluded studies 
Although the 19 excluded studies dealt with adherence to ART, the study population 
did not include HIV-positive pregnant and/or postpartum women. The studies were 
conducted in USA (11), UK (1), Africa (3) and non-specific (4) countries. 
2.13.2 Characteristics of included studies 
The 18 studies which satisfied the eligibility criteria for inclusion were conducted in 
USA (8), Africa (7), Australia (1), Brazil (1) and Puerto Rico (1). None of the studies 
were randomized control trials (RCT).  Key characteristics are listed below: 
# of records identified through 
database searching 
n=881 
# of additional records identified through 
other sources (hand & ancestry searching)  
n=5,813 
# of records after duplicates removed 
n=6,622 
# of records screened 
n=6,622 
# of records excluded by 
title & abstract 
n=6,584 
# of full-text articles assessed 
for eligibility 
n=37 
# of studies included in 
systematic review 
n=18  
# of full-text articles 
excluded, with reasons 
n=19 
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2.13.2.1 Participants   
Participants ranged in age from 12 to 42 years. Seven of the studies were conducted in 
Africa, while the eight studies in the USA were primarily among African Americans, 
Hispanics and Whites. Participants were HIV-positive pregnant or postpartum women 
or HIV-positive women with young children. Studies were conducted at clinics and/or 
hospitals managed by governments or universities. 
2.13.2.2 Interventions 
Adherence to ARVs was measured by self-reports (Albrecht et al., 2006; Bii et al., 2007; 
Bardeguez et al., 2008; Cohn et al., 2008; Delvaux et al., 2009; Peltzer et al., 2010), pill 
counts (Mepham et al., 2011), MEMS caps (Ickovics et al., 2002), blood & urine assays 
(Kirsten et al., 2011), pharmacy or Medicaid claims (Laine et al., 2000; Turner et al., 
2000) and multiple methods (Wilson et al., 2001; Demas et al., 2005; Vaz et al., 2007; 
Mellins et al., 2008). Three studies used in-depth interviews and focus group discussions 
to highlight the personal perspectives or experiences of the women. Other key variables 
considered were socio-demographics, drug/alcohol use, mental health/depression, 
social support and disclosure. 
2.13.2.3 Outcomes  
The primary outcome of adherence was assessed with different criteria and 
measurements in the various studies. Measures of adherence included good adherence, 
with a cut-off rate greater than or equal to 95% (Mepham et al., 2011); recent and 
extended adherence (Cohn et al., 2008); and complete adherence - taking all ARVs over 
the past 4 days  (Wilson et al., 2001).  
2.13.2.4 Barriers to adherence  
Major barriers to adherence included depression (Turner et al., 2000; Mellins et al., 
2008), non-disclosure of HIV status (Ciambrone et al., 2006; Delvaux et al., 2009; Duff 
et al., 2010), substance use (Cohn et al., 2008), safety issues/concern for foetus’s health 
(Mellins et al., 2008; Peltzer et al., 2010; McDonald and Kirkman, 2011), young age of 
mother (Laine et al., 2000; Bii et al., 2007; Kirsten et al., 2011). Lack of finances, stigma, 
fear of violence and lack of self-efficacy were other contributors to non-adherence. 
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2.13.2.5 Facilitators of adherence 
Major facilitators of adherence were social support from family/friends/partners 
(Demas et al., 2005; Ciambrone et al., 2006), concern for the foetus/pregnancy 
(Ciambrone et al., 2006; Vaz et al., 2007; Mellins et al., 2008), disclosure to 
family/friends (Demas et al., 2005; Kirsten et al., 2011), and simplified pill regimen (Vaz 
et al., 2007). Other variables such as older age of the mother, religion, not using 
drugs/alcohol and not missing prenatal vitamins were more likely to contribute to good 
adherence. Demographic variables such as ethnicity, marital status (Demas et al., 2005) 
were not associated with adherence. 
2.14 Included studies – Quantitative 
2.14.1 EPHPP guidelines 
None of the studies received a ‘strong’ rating as per the EPHPP guidelines4 (Appendix 
E); four (Demas et al., 2005; Cohn et al., 2008; Peltzer et al., 2010; Kirsten et al., 2011) 
were considered ‘moderate’ and the remaining eleven (Laine et al., 2000; Turner et al., 
2000; Wilson et al., 2001; Ickovics et al., 2002; Albrecht et al., 2006; Bii et al., 2007; Vaz 
et al., 2007; Bardeguez et al., 2008; Mellins et al., 2008; Delvaux et al., 2009; Mepham et 
al., 2011) were ‘weak’.  
2.14.2 Levels of adherence   
Adherence varied across studies.  In the prenatal period it was as low as 34% (Laine et 
al., 2000), with significant decline in one study to 21% in the postpartum period (Vaz et 
al., 2007). 
2.14.3 Factors impacting adherence   
There was also a range of factors affecting adherence. Use of illegal drugs, not taking 
prenatal vitamins (Cohn et al., 2008); no support systems (Peltzer et al., 2010),  
perception that drugs were harmful (Wilson et al., 2001), depression (Turner et al., 2000) 
were predictors of poor adherence, while disclosing HIV status to family/friends 
(Kirsten et al., 2011) had a positive influence on adherence. 
                                                 
4 The global rating for each article was based on the following grading system: strong (no weak ratings); 
moderate (one weak rating); and weak (two or more weak ratings). 
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2.15 Included studies – Qualitative 
2.15.1 CASP guidelines 
Three qualitative studies (Ciambrone et al., 2006; Duff et al., 2010; McDonald and 
Kirkman, 2011) satisfied the inclusion criteria, and received a ‘good’ rating using the 
Critical Appraisal Skills Program (CASP) tool (Appendix F).  All had comprehensive 
aims and appropriate design. Factors affecting adherence both negative and positive 
were visible during and after pregnancy.  Some of the facilitators identified included (1) 
concern for health of the new-born/infant (Ciambrone et al., 2006; McDonald and 
Kirkman, 2011); and (2) support from family and friends (Ciambrone et al., 2006). 
2.15.2 Barriers to adherence 
Barriers highlighted were (1) issues around daily living (Ciambrone et al., 2006); (2) non-
disclosure of HIV status (Ciambrone et al., 2006; Duff et al., 2010); (3) financial 
constraints inclusive of high cost of transportation, poverty, dependence on partner 
(Duff et al., 2010); (4) stigma (Duff et al., 2010; McDonald and Kirkman, 2011); (5) 
health system issues, such as long waiting periods for care (Duff et al., 2010); (6) 
concerns about safety of the ARV (McDonald and Kirkman, 2011); (7) being 
responsible for taking care of others such as other children and family (Ciambrone et al., 
2006). 
2.15.3 Women’s experiences with adherence 
These three qualitative studies provided an opportunity to understand the experiences 
of the women from a personalized perspective. Women were concerned about the 
teratogenic effects of the medication on their offspring (Ciambrone et al., 2006) and 
their poor adherence at times stemmed from the women’s innate desire to protect their 
children from harm. This was also fuelled by sparse or no information being provided 
to women about the drugs. 
Some women felt that providers only saw them as a disease to be cured and not a 
person with a disease (McDonald and Kirkman, 2011). Their views and input into the 
treatment process were not taken into consideration, resulting in poor self-esteem, 
adversely affecting adherence. 
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Concern for one’s children served as a facilitator for some women and a barrier for 
others (Ciambrone et al., 2006; McDonald and Kirkman, 2011). Women who thought 
that the drugs would be toxic to the foetus and infant were poor adherers, while those 
who thought that there would be a reduction in transmission to their offspring, and 
women who wanted to remain in good health to care for themselves and their children 
were better adherers. Non-disclosure of HIV status to family and friends (Ciambrone et 
al., 2006; Duff et al., 2010) served as a barrier, since women were unwilling to take 
medication in their presence.  
2.16 Summary 
The objective of this systematic review was to determine what studies had been 
conducted on the facilitators and barriers of ART adherence among HIV-positive 
pregnant women globally and specifically in Guyana and the wider Caribbean region, 
and is the first such review of this nature (Table 2-3). Few studies were found which 
satisfied the primary inclusion criterion – pregnant and postpartum women. Moreover, 
studies were predominantly carried out in developed countries, as opposed to 
developing or resource-poor countries. Eight and seven studies were conducted in the 
USA and Africa respectively, while Brazil, Australia and Puerto Rico contributed one 
study each. There were no studies identified from Guyana or the Caribbean region. In 
addition, studies in the USA are primarily conducted among pregnant drug-using 
women making it difficult to generalize to non-drug using populations. 
Some of the facilitators identified included (1) concern for health of the new-
born/infant and/or for one’s children (Ciambrone et al., 2006; McDonald and Kirkman, 
2011); and (2) support from family and friends (Ciambrone et al., 2006). Barriers 
highlighted were (1) issues around daily living (Ciambrone et al., 2006); (2) non-
disclosure of HIV status (Duff et al., 2010); (3) financial constraints inclusive of high 
cost of transportation, poverty, dependence on partner (Duff et al., 2010); (4) stigma 
(Duff et al., 2010; McDonald and Kirkman, 2011); (5) health system issues, such as long 
waiting periods for care (Duff et al., 2010); (6) concerns about safety of the ARV 
(McDonald and Kirkman, 2011); (7) being responsible for taking care of others such as 
other children and family (Ciambrone et al., 2006). 
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Table 2-3: Key findings from systematic review 
Facilitators of ART adherence 
Concern for the health of new-born or other children 
Support from family/friends/partner 
Simplified ART regimen 
Barriers to ART adherence 
Nondisclosure of HIV status 
Financial constraints in general and poverty in particular 
Stigma and discrimination 
Health system issues such as long waiting time for care 
Concerns about safety of ART drugs 
Caretaking responsibilities for family and children 
Mental health issues, such as depression 
Other findings 
Few studies (18) identified which met inclusion criteria 
No studies identified from the Caribbean and Guyana 
Pregnancy emerged as a better period of adherence 
Definitions, measurements and levels of adherence varied across studies 
 
2.17 Discussion 
This review process highlights the fact that in addition to the few studies on pregnant 
and postpartum women, adherence is a complex issue and that there is still no 
consensus on its measurement and definition.  Both the observational and qualitative 
studies identified myriad factors from the individual to the environment that affects a 
woman’s ability to adhere to her medications. 
Overall, the majority of studies were conducted in high income nations with no studies 
identified from the Caribbean region or Guyana specifically. Both the measurement and 
levels of adherence varied across the studies, making comparisons difficult. However, 
adherence was reported as being better during pregnancy than postpartum. This finding 
points to a lack of data in resource poor settings where the majority of HIV-positive 
women reside making it difficult to generalize results to this population, but also to the 
different types of healthcare systems. Provision of healthcare in Guyana is a challenge 
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due to a combination of factors. A large percentage of the population live in rural and 
interior locations contributing to vast inequalities in health services (MOH, 2013). Yet 
despite these limitations, the findings indicate higher motivation levels during pregnancy 
with several contributing factors. HIV treatment and care in Guyana is provided by a 
core group of trained staff who closely monitor the pregnant woman’s care through to 
the postpartum period. Counselling is routinely provided by a mixed cadre of staff 
(doctor, nurse, social worker) in which key information is reinforced. 
The paucity of information on adherence among pregnant and postpartum women, 
particularly in resource-constrained countries warrants urgent attention, not only for 
providing appropriate treatment and care, but also prudent management of dwindling 
resources as highlighted by UNAIDS (UNAIDS, 2013b, p.70).   
“In 2012, HIV disbursements by donor governments, bilaterally and 
multilaterally, and by private philanthropic funders increased nominally but 
remained essentially flat in real terms…most European donor governments 
decreased their HIV assistance in 2012. Without renewed commitment 
from international donors, it is projected that international funding for HIV 
activities will not grow in coming years.”  
Similarly, Guyana which was previously the beneficiary of significant HIV funding is 
now confronted with this grim financial reality of sustaining its programs as outlined in 
a recent country report (MOH, 2012, p.73).  
“Over the recent 5 years funding has been decreased with the close out of 
the World Bank multi-country AIDS program. PEPFAR in its second phase 
has recommitted to Guyana through a similar bilateral arrangement 
however with reductions in the yearly amount of funds allocated.”  
As these major funding agencies scale back on financial resources for this epidemic, 
targeted research is needed on the facilitators and barriers to adherence among pregnant 
and postpartum women that not only measures adherence, but provides insight on the 
myriad reasons why women fail to adhere. 
It is only by knowing the underlying reasons for this problem can we provide 
meaningful solutions which go beyond just mere pill counting, but research that can 
provide us with the framework for making changes at the individual level, reduce 
treatment costs and ensure better health outcomes for women and children.  
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This systematic review provided an overview of the factors affecting adherence among 
HIV-positive women in general in both rich and low to middle income countries. The 
following chapter (Chapter 3) will provide a detailed account of the specific issues 
contributing to women’s adherence in Guyana. 
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Chapter 3 - Understanding women’s experiences of ART 
adherence 
“...they would come and say nurse I drink my tablets cause I want me baby 
for born good and I don’t want nothing happen to me baby...” - midwife, 
11 years HIV and AIDS experience. 
3.0 Abstract 
Objective: To understand the ART experiences of women living in Guyana. 
Methods: 33 key informants (HIV-positive women, healthcare providers) were 
interviewed at five clinics using a semi-structured guide. The Framework method was 
used to analyse the data for emerging themes. 
Results: Adherence during pregnancy and postpartum was not straightforward as 
missed doses were commonly reported during both periods. However, pregnancy was 
reported as a time of better adherence by both the women and their healthcare 
providers, as the desire for a healthy baby or being around for other children were 
strong motivating factors. ART side effects and food insecurity emerged as the two 
main reasons for non-adherence. Non-disclosure was not a barrier to adherence as 
women found creative ways to ensure medication was taken. 
Conclusion: There appears to be a pattern of sporadic non-adherence among pregnant 
and postpartum women in this study which needs to be addressed. Food insecurity 
which can also be a barrier to other health advice and the potential to cause adverse 
maternal and child health outcomes should be tackled within the wider umbrella of 
poverty alleviation. 
3.1 Introduction 
As outlined in the introductory chapter, Guyana had an estimated adult HIV prevalence 
of 1.3% in 2012 (UNAIDS, 2013a) with over 50% of women (53.2%) shouldering the 
disease (MOH, 2012). A recent systematic review and meta-analysis on ART adherence 
in developing and developed countries (Nachega et al., 2012), reported that only 74% of 
pregnant women achieved optimal adherence, making this an important public health 
issue. 
In this chapter, I will describe the methodology, data analysis process, and findings of 
the in-depth interviews which aimed to explore the perspectives and experiences of 
HIV-positive pregnant and postpartum women and healthcare providers about barriers 
and facilitators to ART adherence. The Framework Method was used to analyse the 
women and healthcare workers’ interviews. The results of the study included a 
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description of the sites and participants, adherence patterns of the women, barriers and 
facilitators of adherence, and a summary of the key findings.   
3.1.1 Rationale for use of qualitative method 
Qualitative research aims to explore the ‘lived’ experiences of individuals from their 
own perspective to gain meaningful understanding of the underlying issues impacting 
their behaviour, thereby generating knowledge on the phenomena being studied 
(Sandelowski, 1995; Malterud, 2001; Onwuegbuzie and Leech, 2007; Green and 
Thorogood, 2010).Qualitative methods focusing on in-depth exploration of phenomena 
use purposeful sampling of “information-rich cases” (persons, groups, events) for 
contextual understanding rather than generalization to the wider population 
(Sandelowski, 1995; Malterud, 2001; Patton, 2002; Onwuegbuzie and Leech, 2007).  
Data from interviews with healthcare workers (doctors, nurses, social workers) will be 
used to understand their perspective on factors that contribute to HIV-positive 
women’s adherence, and will help triangulate data from interviews with HIV-positive 
women. Finally, perspectives that contradict identified themes will be presented, as 
divergent information can make the findings more nuanced and pragmatic (Creswell, 
2009). 
3.2 Study objective 
The objective of this study was to explore the perspectives and experiences of HIV-
positive pregnant and postpartum women and healthcare providers about barriers and 
facilitators to ART adherence.  
3.2.1 Research questions 
In particular, I explored the following questions: 
a. How do HIV-positive pregnant and postpartum women describe their ART 
experiences? 
b. How do healthcare providers describe the adherence behaviour of HIV-positive 
pregnant and postpartum women? 
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c. What are the factors that contribute to adherence and non-adherence among 
pregnant and postpartum HIV-positive women? 
3.3 Methods 
3.3.1 Study setting 
Interviews were conducted at five clinics within Regions 3 (West Demerara Regional 
Hospital) and 4 (Campbellville Health Centre, Dorothy Bailey Health Centre, 
Georgetown Public Hospital, and Beterverwagting Health Centre). As I did not have 
any research assistants, I was responsible for recruiting from all potential sites and 
conducting all the interviews. Some clinics had antenatal care on the same day, so this 
meant visiting these sites every other week. Other challenges included interviewing 
persons during clinic appointments, which sometimes required rescheduling to a more 
convenient time, and keeping track of eligible candidates attending clinic to be able to 
conduct the interview. 
3.3.2 Sample and recruitment 
Participants (clinic patients, healthcare staff) were selected through homogenous 
sampling method (Patton, 2002), a purposive technique to choose a group based on 
similar characteristics (pregnant and postpartum women of diverse parities) to obtain an 
in-depth understanding of the determinants and characteristics of ART adherence. 
Similar numbers of pregnant and postpartum women were selected. Clinic patients had 
to be at least 16 years of age, HIV-positive and able to give consent. Healthcare staff 
comprised social workers, nurses, and doctors and were eligible if they provided care to 
HIV-positive women at the facility. I was facilitated by the nurse supervisor to identify 
patients representative of the target group. Patients were considered for inclusion if they 
were pregnant or up to one year postpartum and had initiated ART prior to or in the 
current pregnancy. Participants were sampled until no new information was obtained 
from the interviews (saturation).  
Each week during the study period, I spent the allotted time for each clinic session at 
the clinic to ensure access to all eligible participants. At each of the five study sites, 
nurses initially informed the women about the study, and I subsequently gave detailed 
information about the nature and purpose of the study to those who expressed an 
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interest. Of the 25 women invited, one declined, resulting in 24 interviews. All nine 
healthcare providers I contacted accepted and were interviewed on site. Participants 
gave written informed consent and received copies of the information sheet and 
consent form.  
3.3.3 Data collection methods 
Although I was the previous PMTCT coordinator, I had since resigned from that post 
about three years prior to the start of data collection, so there were no conflicts of 
interest in my role as the qualitative researcher. 
Data were collected between February 2012 and April 2012 and consisted of semi-
structured interviews with 24 patients and nine healthcare providers. Participants were 
interviewed at their convenience in a private room during clinic sessions, and if not 
feasible, an appropriate date and time was negotiated for the same venue. Personal 
identifiers were removed from transcripts to maintain confidentiality and were secured 
in a separate file. All transcripts and audio files were maintained in accordance with the 
UK Data Protection Act, 1998. Interviews were conducted in English and their duration 
averaged 30 minutes. All interviews were audio taped and transcribed verbatim. I made 
notes on the clinic environment, non-verbal cues, demographic data, and start and end 
times. These notes were then used to add context to the analysis. Patients received a 
hand-out titled “You and your HIV medication” at the conclusion of the interview. The 
hand-out highlighted general information and tips on the importance of taking ART. 
Although financial incentives were not provided, each patient received a sandwich and a 
bottle of juice at the conclusion of the interview, in keeping with local customs. 
3.3.3.1 Interview guides 
The interview topic guides were developed taking into consideration the literature on 
adherence and PMTCT (Simoni et al., 1995; Carver, 1997; Armistead et al., 1999; 
Bachrach and Newcomer, 1999; Kalichman, Ramachandran and Catz, 1999; Proctor, 
Tesfa and Tompkins, 1999; Koopman et al., 2000; Farber et al., 2003; Sowell et al., 
2003; Kirshenbaum et al., 2004; Kumar et al., 2006; Wesley, 2007; Rivero-Mendez, 
Dawson-Rose and Solis-Baez, 2010; Ladzani et al., 2011). The guides for the HIV-
positive women captured participants’ experiences relating to adherence and HIV 
treatment and care. The guides were pretested by the supervisory team and a local health 
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provider. Based on feedback from supervisors, they were refined to include a section on 
pregnancy thoughts, desires and expectations. There were no other changes. 
As ART adherence can be impacted by a variety of factors, the topic guides explored 
issues such as: HIV-positive patients’ living situation; their experiences with an HIV 
diagnosis; disclosure (Simoni et al., 1995; Armistead et al., 1999; Kalichman et al., 2003; 
Sowell et al., 2003; Kumar et al., 2006); mental health and coping (Carver, 1997; 
Koopman et al., 2000; Farber et al., 2003); pregnancy thoughts, desires and expectations 
(Bachrach and Newcomer, 1999; Kirshenbaum et al., 2004; Wesley, 2007);  medication 
history; adherence; medical care; delivery; and infant feeding (Ladzani et al., 2011). The 
patients’ interview guides are included in Appendix G-H. Healthcare providers’ guide 
included questions on their role in the clinic; treatment criteria and response; women’s 
adherence; strategies by health workers to improve adherence; and infant feeding (see 
interview guide in Appendix I). Prompts were used where necessary to gather more 
detailed information from participants. The UCL supervisory team reviewed the guides, 
which were refined during initial interviews, and listened to the initial audio recordings 
to give feedback on implementation.  
3.4 Research ethics 
Ethical approval was granted by University College London Research Ethics Committee 
(ID 3518/001) in the United Kingdom, and the Ministry of Health Institutional Review 
Board (Protocol #48) in Guyana. To protect the identity of the participants, personal 
identifiers and demographic data were collected on a separate sheet, and safely secured, 
while code numbers were used for the audio tapes. Prior to giving consent, participants 
were apprised of the following: 
 They were not obliged to take part in the study 
 They could withdraw from the study at any time without any negative 
repercussions to their care at the site 
 They could refuse to answer any question without having to provide a reason 
 Their names and other personal identifiers would not be used in any public 
documents 
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Participants were encouraged to ask questions before and after the interview and given 
my local contact number (printed on the consent form and information sheet). All 
recordings and documents were safely secured on a password-protected computer and 
locked file cabinet. Information provided has been kept in confidence and in 
compliance with the UK Data Protection Act, 1988. 
3.5 Data management and analysis 
I recorded the interviews using an Olympus digital voice recorder (WS-750M) and 
uploaded them to a laptop computer where they were transcribed with Microsoft Word. 
I transcribed the majority of transcripts (25/33), while university students transcribed 
the remaining (8/33) to accelerate the transcription process. It should be noted that 
there were no personal identifiers on the voice recordings. 
Interviews were transcribed verbatim maintaining the local vernacular, and all transcripts 
were double-checked against the voice data files for completeness and accuracy, then 
imported into NVIVO QSR International, version 10 for qualitative data analysis (QSR, 
2012). 
I used the Framework Method (FM) for managing and analysing qualitative data. The 
Framework Method was developed during the 1980s by Jane Ritchie and Liz Spencer 
who were affiliated with the National Centre for Social Research (NATCEN) in the 
United Kingdom (Green and Thorogood, 2010; Gale et al., 2013). Although initially 
used in social policy research, FM is now increasingly used for health research 
(Chakrapani et al., 2011; Mbilinyi, Daniel and Lie, 2011; King et al., 2012; Paul et al., 
2013). 
Green and Thorogood (2010) outlined the five steps of Framework analysis as follows: 
1. Familiarization – in-depth knowledge of the data by listening to the audio 
recordings, reading the transcripts and associated notes 
2. Thematic analysis – developing codes 
3. Indexing – applying the codes to relevant segments of the data transcripts 
4. Charting – use of a spreadsheet to reduce the volume of data by creating 
summaries or snapshots of the data in cells aligned with key themes, tagged to 
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the relevant participant. This process allows the researcher to see and compare 
relationships within and between  codes 
5. Mapping and interpretation – to identify and generate concepts or themes 
emanating from the data and explore any associations within those relationships 
The first step in the analysis process entailed multiple readings of the transcripts. Initial 
coding was generated from themes in the interview guides and the research questions. 
The first ten transcripts were hand coded for ease of double coding and to develop a 
draft coding frame. Two of the authors initially hand coded the same transcripts to 
increase coding rigour by engaging in reflexive discussions and sharing conceptual 
thoughts and interpretations. New codes were then created to fit sections of the data 
that did not conform to the pre-existing codes. The pre-existing and newly defined 
codes were subsequently assigned to the remaining transcripts.  During this process, 
additional codes were created to identify other themes that emerged in the transcripts 
and did not fit established codes. 
After the manual (hand-coding) process, the transcripts were uploaded to NVIVO 
software for data management and continuation of the coding process. A coding tree 
with parent-child nodes was created using the themes from the hand-coded transcripts. 
This was an iterative process since sections of text which upon reflection did not fit 
existing codes were assigned new codes. This process continued until all transcripts 
were coded in NVIVO. The coding tree of parent-child nodes was further reduced by 
merging and reorganizing themes. A framework matrix was designed in Microsoft Excel 
for the major themes containing brief sections of the relevant quote in the 
corresponding cell. Finally, these themes were further refined and reduced (mapping) 
into a manageable hierarchy of themes for discussion. The coding process inclusive of 
generation of themes were reviewed and discussed with supervisors. 
3.6 Reflexivity 
As described in the qualitative research literature, being reflexive serves two main 
purposes: to critically examine the overall research process; and to discuss the 
researcher’s role in the context of collecting and analysing data (Green and Thorogood, 
2010; Creswell, 2014). The study was undertaken in a country where I had worked for a 
nine-year period as the coordinator of the PMTCT program, from a pilot project to one 
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of national scope, and this doctoral research project is the culmination of  my work in 
that field. 
Guyana is a multiracial society of six ethnicities. As such, my African ancestry made it 
easy for me to blend in with the ethnic mix. Clinic nurses’ initial discussion of the study 
with participants helped to allay any reluctance and fears of confidentiality breeches. 
Furthermore, I apprised respondents of my involvement in the PMTCT program and 
subsequent departure to advance my studies. In addition, being female and conducting 
interviews at the clinic site enabled an atmosphere of trust and a good rapport, which 
may have contributed to the rich personal stories told by the women. 
As the former coordinator of the PMTCT program, I was curious about its status and 
progress, and about the personal accounts of the women and health workers. This 
interest could have led me to downplay problems with adherence or problems at the 
clinics, but this was minimized with supervisory oversight. The initial hand coding was 
reviewed and discussed with the UCL supervisory team which helped identify any biases 
I may have had. In addition, I sought to maintain objectivity through rigorous indexing 
and charting. Further, the taped audio recordings and verbatim translations would have 
greatly reduced those inherent biases. 
3.7 Results 
3.7.1 Characteristics of healthcare providers 
The nine healthcare providers included all eligible clinic staff (three doctors, one 
medex5, four midwives and one social worker). They ranged in age from 28 to 61 years, 
with the majority having a university education and being of Christian faith. All were 
Guyanese nationals, except one Cuban doctor. Health workers’ experience providing 
care and support to HIV-positive women ranged from one year to twelve years, with an 
average of seven years of experience. 
                                                 
5 A medex is a cadre of health worker comparable to that of a physician assistant with the ability to 
prescribe certain types of medication. 
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3.7.2 Characteristics of HIV-positive pregnant and postpartum women 
Clinic participants were all Guyanese nationals, 11 pregnant and 13 postpartum, aged 18 
to 39. Three of the women were prima-gravidas, while the others already had children: 
five women had one child and 16 women had at least two children. The majority (15) of 
the women were prescribed Atripla, a fixed dose combination (FDC) of three drugs 
(efavirenz, emtricitabine and tenofovir disoproxil fumarate) to be taken once daily, with 
the remainder being on multiple-compound regimes. The demographic characteristics 
of the 24 HIV-positive women are presented in Table 3-1.  
Table 3-1: Demographic characteristics of HIV-positive women 
Characteristics            n =24 
Age 
<20                                       
20-29                                    
30-39                                    
 
1
16
7
Ethnicity 
African                               
East Indian                        
Mixed                                 
Amerindian                       
 
9
7 
7
1 
Education 
None                                 
Primary                            
Secondary                        
 
1 
4 
19 
Religion 
Muslim                            
Hindu                              
Christian                         
 
1 
3 
20 
Marital Status 
Single                             
Married                          
Common-law                 
 
9 
3 
12 
Occupation 
Counsellor                             
Domestic                         
Security guard 
Hair/Cosmetologist 
Self-employed 
Housewife             
 
1
1 
2 
2 
2 
16 
ART regimen 
Fixed-dose drug 
Multiple compound 
 
15 
9 
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3.8 Context of women’s lives with HIV 
In the following section, I will describe the circumstances of the respondents in terms 
of the effects of their HIV positive diagnosis, ART medication adherence, while being 
pregnant for the first time or having other children, amidst the socioeconomic and 
psychosocial issues impacting their daily lives. 
3.8.1 Diagnosis 
The majority of women I spoke with were diagnosed with HIV during pregnancy while 
receiving antenatal care. Of the remainder who were tested when they were not 
pregnant, many did so after becoming ill, while the others just took a routine test. Two 
young women had tested positive in their teens as a result of being raped. Time since 
diagnosis was as recent as a few months to as many as nine years, with many women 
being diagnosed at least three years before the interview. 
Many women were shocked and saddened on receiving an HIV-positive diagnosis:  
“Because I never really go out and have myself wild around the place and 
deh with this person. I was in de house all de time. I marry to him and I 
never use to go anyway. I does be home all the time, unless he take me 
out.” – 32-year old, 15-weeks pregnant, 2 children (PR023).  
Another 29-year old, 16-week pregnant mother of four children (PR009) simply stated 
in tears “Because I was faithful.” A 22-year old pregnant woman initially stated that she 
was not surprised with her HIV test result:  
“I din feel no way, cause I know my chile [child] father, he’s that kind of 
person. He don’t stick to one person, so I expect anything.”  
However, when asked if she expected her result to be positive, she replied “not really” – 
39-week gestation, common-law status (PR016). 
Whether the HIV test results were expected or not, many of the women diagnosed in 
pregnancy or another period, experienced mood disorders, and either harboured suicidal 
thoughts or attempted suicide:  
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“I had want to commit suicide, kill meself, but I remember I have three 
children to live for” – 22-years, married, three children (PP013)  
“I tell yuh, I was like all thing, bad thoughts da coming in my mind, commit 
suicide, go away, drink poison, kill maself, yuh know, alotta things…” – 29-
years, common-law status, three children (PP024).  
Some contemplated having an abortion, but were persuaded otherwise by family, friends 
and healthcare providers:  
“…I wanted, I had wanted to do an abortion, but when I got counselled 
they told me that I could have had the baby, and that there was treatment 
so the baby wouldn’t um born positive, so I agreed to keep the pregnancy” 
– 27-years, 33-weeks pregnant, common-law status (PR022).  
3.8.2 Coping 
The women I spoke with were strong-willed and focussed on staying alive to care for 
their children, despite a few not having anyone to confide in or discuss their day-to-day 
problems. Many were able to cope using a variety of strategies, such as, trying not to 
think about their illness, trying to “live a normal life”, and with the support of family 
friends and partners. 
“…I don’t study that, cause I does, I does always told my kids if one day 
your mom wake up, if one day you all wake up and you all see I die, done 
know that your mom gone to a safe place…but I don’t take it on. I jus do 
what I got to do, everyday stuff…because I don’t study it, and to me if you 
have a sick and you keep studying it, studying it, then is when you mentally 
does get sick, you physical does get sick. But if you just put God in front 
and explore de world, everything will go right” – 27-year old, 6 children 
(PP007). 
Where reactions to disclosure were positive, social support from either family or friends 
facilitated coping.  A 31-year old single mother (PP003) stated:  
“So at first when I find out I was HIV it was very stressful…so it take me 
about a while, like two weeks because I was hospitalized…and when I came 
out back, the strength and courage from friends and some family, I learn to 
cope with it and everything was Ok.”  
Partners also created an environment conducive to effectively cope, as expressed by this 
pregnant 27-year old mother in a common-law relationship (PR022):  
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“his reaction actually help me to get through it, because he wasn’t like mad 
or anything. He say it done happen and you got live with it and stuff…” 
A strong belief in God also helped women to cope, like this 18-year old single, 31-weeks 
pregnant mother:  
“…but the only person I find comfort in, is like when I feel down, 
depressed and devastated at the same time, I pick up my bible and I read 
Psalm 121 and I talk to God and he would comfort me; there is where I 
find comfort” (PR017).  
Similarly, a 29-year old mother of four children (PR018) stated that praying helped her 
cope:  
“well, I does try not to take it on. I cya [can’t] really say cause I don’t take it 
on, you know, I does mostly pray a lot…” 
One mother found solace in a support group, though not available at all sites. Some 
clinics with functioning groups met on a day other than the women’s clinic day, so some 
were unable to attend due to financial and time constraints. 
3.8.3 HIV care and relationship with healthcare providers 
A majority of the pregnant and postpartum women were satisfied with the services and 
support they received from the staff at the clinics, as described by a 24-year old mother 
(PP021):  
“they pay a good tention [attention] to yuh. Ah like come here. They does 
look after yuh good…”  
Another 24-year old mother (PP010) stated:  
“Yes, I like becah [because] I get nuff support and so on. Everything is 
alright, all the nurse dem and so, everybody alright. I ain’t get no complain 
about de clinic.”  
They also felt quite comfortable approaching any member of staff to discuss their 
issues:  
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“…you could speak to anybody if ya want, if ya have problems, to da nurse, 
to da social worker, to da doctor, dey very cooperative” – 29-year old, three 
children (PP024). 
Women did not feel stigmatised by the staff and appreciated the manner in which they 
were treated:  
“well everybody treat you normal. Nobody don’t discriminate like you have 
HIV or so, they treat you like a normal person” – 21-year old (PP020).  
A 31-year old mother (PP003) stated:  
“the nurses dem are outgoing, and the doctors dem they have 
understanding. Along with the staff, they make you feel at home.”  
They also valued the staff for maintaining the privacy of their medical information:  
“I doan have a problem with none of them…certain things are confidential, 
especially my status. Since I’m coming here in 2006, nobody don’t know 
that I’m HIV-positive” - 32-year old mother, two children (PR023). 
Postpartum women were grateful for the free infant formula since some of them would 
not have been able to afford it on their own: 
 “…what I like about it, is it helping me supported by some milk, because I 
cya afford to buy milk every month…” – 34-year old, single, two children 
(PP011). 
Although many patients were happy with the services at the clinic, a few were 
dissatisfied with the long waiting time for care, and how they were treated by some 
nurses.  A mother stated that she would be reprimanded in a loud manner whenever she 
came to clinic late: 
“some of dem nurses does behave too impolite…dey does talk too rough to 
me…well, for instance, when I came here late, dey does holler up on me an 
stuff” – 24-year old, single, three children (PP021).  
Amidst the positive reviews of services and staff, there were a few instances of breaches 
of information, though for two of the cases, the women could not attribute the 
disclosures to staff. However, they continued to attend clinic:  
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“Well, I didn’t like coming to this clinic, because people does know your 
story more than you. Right now I want ask them like fo give me about two 
months [laughs] not to come back, like every two months, because right 
now people talking about me…is somebody call me and told me…so I feel 
bad about it, so like I feel discouraged, like I getting break mind out of the 
clinic. Because I does deh, people does just watch, people don’t know wha 
you coming clinic for, but they does jus talk. I does still come yes, cause me 
don’t bother with people. By the time, you don’t bother with nobody, 
whosoever talk, talk” – 21-year old, common-law status, two children 
(PP015). 
Another mother had a negative experience at a local hospital while waiting for an 
electrocardiogram (ECG). She was feeding her baby formula in a public area when she 
was spotted by a nurse: 
“…I was on da bench with couple patients, an she start open she mouth, 
why yuh ain’t breastfeeding dis baby, if yuh see I had de time, I woulda 
carry yuh in duh room fa yuh breastfeed da baby. An ya know she kinda 
went on, an going on, an performing…an I was in da ECG room an hear 
dat she telling da people on da bench, um she’s HIV-positive, an she shame 
fuh talk, an she ain’t want nobody know. An I kinda come out an I look up 
in her face, an I go round da turn, an I come back…feel very bad because 
yuh have to say dat is discriminating, an she for a nurse da suppose to know 
better, so I was yuh know, kinda upset…” – 29-year old, three children 
(PP024). 
3.8.4 Pregnancy desires and expectations 
News of a pregnancy brought joy and excitement to women and their partners who 
wanted children. Women in new relationships with HIV-negative partners “took a 
chance” while being cognizant of the risk of HIV transmission, in order to fulfil their 
desire of having a child: 
 “Yea, we planned it, an when I found out I was, dat was da best thing… an 
we still know that it, it still a risk there, but um is like we, we were 
desperately praying an, an saying well we try” – postpartum, 27-year old, 
married hairdresser, two children (PP008). 
Similarly, a woman who thought she was “barren” since she had been trying for many 
years attributed her positive serostatus to years of unprotected sex because of her desire 
for a child: 
“Because I have never get pregnant in my entire life. When I found out I 
was pregnant, that was the most, that was the most exciting night of my life, 
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because I had wanted a child so badly. I had wanted a child so badly, so 
when I found out I was pregnant, I was so much glad” – postpartum, 31-
year old, single housewife, one child (PP003). 
Two women, currently pregnant who had children before, opted for another child as 
this pregnant 32-year old mother of two describes:  
“Yes, my children father want to have a nex [another] baby. He said this is 
the last” (PR023). Another pregnant mother stated “well I had wanted 
another child, so I wasn’t sad or anything” – 27-years old, common-law 
status, two children (PR022). 
When asked if they wanted more children, a majority of the women emphatically stated 
“No”, primarily because of their serostatus and not wanting to worry about the 
possibility of an HIV-positive baby. Others stated they had enough children, they or 
their partner were unemployed, or they had tubal ligations. Many of those who wanted 
more children were in relationships with new partners, between 21 to 39 years old, and 
had secondary education. A couple of the women were employed or had their own 
business, while the majority were housewives. 
3.8.5 Living situation 
“Um, da environment is nah really healthy cuz deh have aloda um drug 
addict people living dere, and um everybody jus keep um talking each oda 
name, an cursing, an is not really for children.” – 29-year old single 
housewife, 3 children (PP012). 
Only two of the women I interviewed lived alone with their children. The others lived 
with extended families, relatives and/or partners. While the majority of the women lived 
in rented homes, many owned their homes, some lived rent-free in family-owned 
property, and a few lived in homes owned by their partners. 
The living arrangements with extended family and other relatives provided much needed 
support for some:  
“Ah went to my grandmother house an ah told her wah happen, and um I 
told my family, like my aunts an stuff an dey took me back to Georgetown 
da next day an we did da test back again jus to make sure an um, from then 
onwards ah went through a lot a different feelings, but de overall thing my 
family dey jus everybody jus try to make me feel as comfortable…” – 27-
year old, married, two children (PP008).  
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A 29-year old single mother of three children had a comparable experience:  
“Well my aunt an my cousin always supported me no matta what, um dey 
always encourage me, dey neva really make me feel like an outsider, no. 
When I go by dem, dey always, everything dey use I could use, dey always 
make me feel comfortable, dey always support me in every decision I made” 
(PP012). 
Other women had stressful living situations, which included taunts and disparaging 
comments. A 22-year old housewife (PP013) described this incident with her uncle: 
 “…he turn and tell me that how I dead, already dead, how he don’t want I 
touch him or nutten. He don’t want I touch nutten for he or so, cause I 
dead already.” Another 34-year old housewife (PP011) was cursed at by her 
mother whenever she was under the influence of alcohol: “But when my 
mother drink alcohol and suh, I don’t know, when she ready fo curse me 
she does tell me about the virus and ting.”  
One 29-year old (PR001) pregnant mother’s relationship with her in-laws after her 
diagnosis, took a toll on her, which resulted in her and partner moving out of the home: 
“…his mother vex because he living with me… and the sisters, one minute 
them and you talking, one minute they ain’t talking to you… actually what 
made me decide to move out is because the mother start curse when he’s 
not at home, and like if I walking she would pass and jamming me down 
and dem tings…”  
A 37-year old pregnant mother (PR002) and her infant son living with her sister and her 
sister’s four children in cramped quarters on the outskirts of town was constantly 
harassed by her sister over her living arrangements, but was unable to leave since both 
she and her partner were unemployed:  
“Ah doan, ah doan know what to do. My sister she gave me the room, and 
she tell me how me gat she pon floor ah sleeping, cause she does put she 
mattress on de floor and she give me de bed, but she does talk about it, so 
ah don’t know what to do.” 
Although the majority of women lived with family, for some, their living conditions 
were far from ideal and were considered untenable, unsafe and uncomfortable because 
they lived in drug-affected areas or had housing issues. A 33-year old single mother of 
nine children described her situation (PP006):  
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“It is not a proper house we deh in, it don’t have nutten. I need a home wid 
everything. I have to be comfortable, because remember you got children 
you gotta think about. If you die now, there is nothing…maybe if I should 
die now, I don’t think I would die happy at all.” 
Another 29-year old housewife with three children (PP024) described dangerous living 
conditions with a bleak future:  
“Um, where I’m living da yard does flood out a lot, an da land is very low, 
but I’m trying to fill it piece by piece. And I have a small house on da land, 
so it leaking, it falling apart. Ah trying to get a nex one to build, but things is 
rough. But right now, I’m living in a terrible situation, where I’m living right 
now.”  
3.8.6 Individual factors or influences 
“…that just like how you know you gotta get up and bathe, you gotta eat, 
you gotta sleep, and now I gotta take my pills, that’s it.” – 27-year old, 34-
weeks pregnant, on Atripla (PR022). 
Success in maintaining adherence is based on a variety of factors, and individual-level 
factors do play a role in this process. Some of the women began incorporating taking 
ART into their daily routine, so that it became a “normal” part of their lives.  
As described above, many women did not need medication reminders as they were self-
motivated to adhere to their regimen out of concern for their own health, delivering an 
HIV-free healthy baby, and to be around to care for their children. A 27-year old 
mother on a first-line multi-drug regimen (PP007) expressed:  
“Say if you wake up in the morning, and you know that you going on the 
table for do x, y, z, you gotta take your medication bottle there. So you 
know well you gotta go check this hey, you open, you take out, you drink. 
Even now, I don’t need no one cause I have it in my work bag, an um so if 
I forget I don’t drink it at home, since I reach in de bus, I drink one with 
my water.” 
Other women relied on their watches, clocks or cell phone alarms, like this 21-year old 
mother on Atripla (PP020):  
“normally I does put the phone to alarm for 8:30 every night.”  
Similar statements were made by a 29-year old mother (PR018):  
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“well I does always get de phone nex to me an watching de time. So as soon 
as I see like quarter to eight or so, I does get de tablet and de water and wait 
on time, and mek sure I tek it on time. When I finish, I going in my bed”  
Others were reminded by relatives or children, even though the children were not aware 
of their mother’s status. 
Some women, like this 39-year old pregnant mother on Atripla (PR019) associated 
taking their medication with routine activities like watching a particular television 
program: 
 “I know I have to drink my tablet at 7:30, an I look at news 7:00 O’ clock, 
so I know Channel 7 news does finish 7:30. So when dat news finish, I 
drink it same time…” 
3.9 ART adherence among pregnant and postpartum women 
A majority of the pregnant women reported always taking their ART medication. 
Among the pregnant women who stated they always took their ART, only a few were 
treatment naive, having been placed on ART during the current pregnancy. Many had 
initiated treatment in a previous pregnancy or when they were not pregnant. Pregnant 
women who were non-adherent missed their ART doses from a few days to a week at a 
time. 
The pregnant women who consistently took their ART varied in terms of age, number 
of children, gestation, ethnicity, marital and educational status. All pregnant women who 
adhered except one were prescribed Atripla. Similar characteristics existed among the 
pregnant women who skipped or missed their ART medication, with one woman being 
on a second-line ART regimen. 
Among the postpartum women who were on ART, the majority stated they always took 
their medication, and there was no change in their medication adherence pattern 
whether pregnant or not. A few stated that they took it better during pregnancy than 
postpartum. Some postpartum women who had skipped or missed when they were not 
pregnant, indicated that they were more adherent during pregnancy, never missing any 
doses in that period. Only one postpartum woman skipped during pregnancy and the 
postpartum period, and described a pattern of taking her ART every other day:  
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“Yeah, I use to miss. Say that ah drink today, I might skip tomorrow, drink 
de nex day” – 34-year old housewife, two children, second-line regimen 
(PP011). 
A few postpartum women were not prescribed ART at the time of interview, but 
described their adherence during prior pregnancies. A 27-year old married mother of 
two children (PP008) took all ART doses, while the 33-year old mother of nine (PP006) 
admitted a pattern of consistently not taking her ART after a certain period for all her 
pregnancies:  
“…I does drink it like, I drink like in the 5th, 6 months. I drink it like the 7 
month, and then after that I find I couldn’t drink it… I would drink it till 
mornings…and so I stop drinking it, yeah…I stop drink it till I done get 
baby. I don’t drink it back. When I stop, I don’t drink it back…I studying 
de baby and sometimes my mind say drink this tablet, get up and drink de 
tablet. And then in the morning I would get up and drink it again, and then 
it gone again, I can’t take it anymore.” 
Both postpartum women were on the same regimen of Combivir and Kaletra and had 
secondary education, but their characteristics differed in terms of age, employment 
status, ethnicity, marital status and number of children. 
3.9.1 Adherence to infant’s ART and feeding method 
Most women adhered with their baby’s ART doses prescribed after delivery, and only a 
few missed doses. The women who missed doses or discontinued the paediatric ART 
formulations were also non-adherent with their own ART:  
“But like the first three days you would give them morning, afternoon. You 
gon continue it for the three days straight…but sometime I would stop, and 
then I remember the nex day or so and would give them a dose or so…” – 
33-years, nine children (PP006). Fortunately, all their children are HIV-
negative.  
Another period of adherence for postpartum women was infant feeding, and all opted 
to formula feed based on advice from healthcare providers and the prospect of free milk 
until the baby attained age 18 months. Pregnant women also indicated that they would 
not breastfeed. They were able to maintain this decision:  
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“well dey tell me that when is born, I can’t breastfeed. You could transmit 
da disease through breastfeeding, so I use to give her bottle” – 29-year old, 
three children (PP012). 
 Those who were queried by in-laws, relatives, and others for not breastfeeding, 
responded with creative reasons, for their choice, such as, being able to leave the baby 
with anyone:  
“Ah does tell dem, because I could leave her any way if ah want to go any 
way, could leave her any way” – 29-year old housewife, 3 children (PP024).  
A 24-year old mother of one child (PP010) and her partner would inform curious 
outsiders that the baby was breastfed at home, but used formula when away from home: 
“…when you go out sometimes, they does ask we why we feeding wid 
bottle. Sometimes he father first does talk and say he does nurse, but when 
we deh home; when we come out he does use bottle.”  
3.10 ART adherence perspectives of HIV-positive women and providers 
In this section, I will first discuss the overall adherence behaviour of pregnant and 
postpartum women followed by the seven key themes of ART facilitators and barriers 
identified from the in-depth interviews. 
3.10.1 Women’s adherence to ART medications 
Adherence during pregnancy and postpartum was not straightforward. During both 
pregnancy and the postpartum period missed doses were commonly reported. On 
exploration, it appeared that the rate and duration of adherence for pregnant women 
varied. There were those who reported being non-adherent from a few days to a week at 
a time. As many studies look at episodic adherence, this qualitative data reflects the 
adherence course over the duration of pregnancy. There is little information in the 
literature on sporadic and non-adherence and how it may affect pregnancy outcome. 
The interview delved into the underlying reasons for such non-adherence. 
Although most postpartum women reported no change in their adherence patterns 
during or after pregnancy, since they always took their ART, a few admitted taking ART 
better during pregnancy. Overall, healthcare workers indicated better adherence during 
pregnancy, attributing this to concern for the baby. 
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Theme 1: Wanting a healthy baby or wanting to be around for other children 
“…I was saying to myself, don’t let my baby get it, let it be me alone. That 
was all I was saying to myself, and I keep coming to clinic every day, I never 
missed a clinic date…” – 32-year old housewife, two children, never 
skipped/missed ART (PR023). 
Many women were preoccupied with concerns for the well-being of their children 
throughout their pregnancy, and expressed these sentiments in different ways. One 31-
year old housewife (PP003) who had not been compliant before pregnancy, admitted to 
taking her ART better during pregnancy. A 29-year old mother of three children 
(PP012) articulated why she did not skip or miss any doses:  
“because dat was da um, da tablets dat gon help me from preventing my 
child from getting HIV.”  
Mothers were worried about the wellbeing of their children if they should get very ill or 
die, like the 29-year old single mother of four children (PR009) who cried while 
expressing this sentiment: 
“that anything happen to me, what gon become of my children.”  
Having other children to care for gave women the courage to live despite wanting to 
give up as expressed by this 29-year old mother (PP024) of three young children: 
 “…sometimes ah doan wan drink it, like ah does jus feel like giving up, so 
to jus avoid from giving up, ah does always seh my children are there an ah 
have to be there for my children, an without this medication, ah mighten be 
dere, so ah jus, ya know, keep drinking it.” 
The desire to deliver a healthy baby (protect the unborn child), or to be around to see 
their children grow up was shared by both pregnant and postpartum women and was a 
strong motivating factor for adherence. Women were also concerned about the fate of 
their children if something happened to them, and worried about how they would be 
cared for in their absence. Similar sentiments of children as a source of inspiration for 
adherence were echoed by healthcare staff. Children as facilitators of adherence have 
been identified in similar studies among HIV-positive women and provide them with 
motivation to keep appointments, take their medication, and take better care of 
themselves (Wood, Tobias and McCree, 2004; Stinson and Myer, 2012). However, sub-
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optimal adherence can occur when caring for children becomes burdensome such as 
with deteriorating health of the mother or other sick family members to care for 
(Holstad, DiIorio and Magowe, 2006; Reda and Biadgilign, 2012), although this issue 
was not reported by the women in this study. 
Theme 2: Being pregnant for the first time  
Being pregnant for the first time or being pregnant with a child for a new partner (who 
wanted a child) served as a strong motivating force for adherence, as women in these 
types of situations reported that they never missed taking their ART medication. The 
desire to have children in spite of sero-positivity is quite common among women 
PLHIV (Cooper et al., 2007; Nobrega et al., 2007; Finocchario-Kessler et al., 2010), and 
many continue to have more children (Craft et al., 2007; Bravo et al., 2010) which was 
also evident in this study as most women had at least two children. A strong desire to be 
a mother (Smith and Mbakwem, 2007) was the reason advanced by an HIV-positive 
woman in this study for getting  pregnant. While other studies have reported an 
association with having more children as a means of avoiding stigma, the issue was not 
explored in this study. However, not all women wanted more children (although there 
was desire) citing concerns about their own health and potential to infect the child as 
reported in studies by Kanniappan, Jeyapaul and Kalyanwala (2008) and Oosterhoff et 
al. (2008). 
Theme 3: Simplified ART regimen 
The majority of pregnant and postpartum women were prescribed the once-daily 
regimen, Atripla. Although all women reported that having to take just one pill was 
much easier than taking multiple tablets, this simplicity did not translate into complete 
adherence as some women were non-adherent due to varied reasons such as medication 
side effects (Theme 4) and lack of food (Theme 5). It should be noted that Atripla a 
combination of three drugs (Efavirenz, Emtricitabine and Tenofovir disoproxil 
fumarate) manufactured by Bristol-Myers Squibb and Gilead lists many of the side 
effects which were reported by the women such as drowsiness, dizziness, nausea, 
vomiting and nightmares. The manufacturers recommend taking this medication on an 
empty stomach and at bedtime to reduce the severity of these effects (Bristol-Myers, 
2015). However, the findings indicated that women were not aware of these side effects 
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as some would stop taking their medication until they were able to consult with 
providers. 
Theme 4: ART medication side effects 
More than half of the women were prescribed a fixed-dose combination drug Atripla, 
others were on another first-line regimen of multiple drugs, and two women were on a 
second-line regimen of at least seven tablets. Women experienced side effects 
irrespective of whether they were prescribed the fixed-dose or multiple compound 
regimen and this was one of the primary reasons for non-adherence. A majority of the 
women experienced ART side effects which varied from mild or moderate (feeling faint, 
drowsiness, headache, upset stomach) to quite severe (vomiting, diarrhoea, feeling 
intoxicated, nightmares):  
“…cah de tablet does mek I feeling bad, ah bringing up, and ah does cya 
eat, cah it mek ah vomiting every minute.”- 37-year old, 33-weeks pregnant, 
on Atripla (PR002).  
One pregnant mother on Atripla stopped taking her medication after initially 
experiencing headaches and drowsiness for three consecutive days. She was advised by 
clinic staff to take it before bedtime, significantly reducing her symptoms and enabling 
here to adhere thereafter. Another 18-year old pregnant woman described her 
experience with the same drug:  
“…I feel like I drink two bottles of vodka…large bottles of vodka. I feel 
really intoxicated, like I was just at a rum shop and all I was doing is sitting 
there and drinking…I go in my bed and lie down and sleep, sleep it off; you 
wake up fresh, you don’t feel anyway” – 31-weeks pregnant with first child 
(PR017). 
The women opined that these intolerable side effects were the reasons for their 
intermittent or complete non-adherence. One such woman, a 22-year old security guard, 
pregnant with her first child on a second-line regimen (PR005), had stopped completely, 
and commented:  
“I does feel drowsy, drowsy; yeah I miss sometime when I feel bad; I does 
vomit, every time I drink it I does vomit, so I don’t drink it.” 
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Both mild and serious symptoms resulted in missed doses. Reaction to side effects 
varied, as some women who experienced adverse effects for a few days rallied through 
and others skipped or stopped until their next clinic appointment. Those who 
experienced adverse effects for longer periods skipped from a few days to a week at a 
time. Women experiencing side effects from the once-daily regimen were advised by 
staff to take it at bedtime. According to the women, this change in dose time helped 
alleviate their symptoms and enabled better adherence. 
Adverse drug reactions to ART regimens are not uncommon among pregnant women 
as they are in other HIV-positive populations. While the use of ART has revolutionized 
treatment of HIV-positive pregnant women for their own health and MTCT, ART has 
also been associated with adverse effects for the pregnancy, mother, infected as well as 
exposed children (Weinberg et al., 2011; Newell and Bunders, 2013). Pregnancy 
outcomes can include pre-term deliveries, hypertension, and small-for-gestational age 
(SGA) infants (Ndirangu et al., 2012; Watts and Mofenson, 2012). 
The prevalence of adverse reactions in pregnant women can range from 5% to 78% 
based on geographic location, socio-economic status, time on ART and immune system 
(Santini-Oliveira et al., 2014). About 80% of the pregnant women in this survey were on 
the fixed-dose combination drug (FDC), Atripla, 5% on a PI plus NRTI regimen and 
15% on a PI plus NNRTI regimen which includes the drug Nevirapine (NVP). 
Prolonged use of NVP has been associated with liver toxicity and rash, particularly at 
higher CD4 levels, though symptoms dissipate on cessation of drug (Ford et al., 2013; 
Santini-Oliveira et al., 2014). Abdominal pain, nausea and vomiting are known side 
effects of PIs (Santini-Oliveira et al., 2014), the regimen which the majority of women 
were prescribed in this study. As more women are placed on lifelong ART based on 
WHOs revised treatment guidelines (WHO, 2013), the nature and frequency of adverse 
events need to be monitored routinely given the limited laboratory capacity in low to 
middle income countries (Newell and Bunders, 2013) like Guyana, compounded by the 
pervasive effects of poverty on health outcomes. 
Theme 5: Socio-economic hardships – lack of food and finances 
For some of the women, lack of food and finances contributed to ART non-adherence. 
About half of the pregnant women who were non-adherent cited lack of food as the 
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reason for skipping doses. These women divulged that taking ART on an empty 
stomach would give them “bad feelings” or make them feel sick, while few women who 
indicated they did not have money to pay transportation costs missed some clinic 
sessions. Healthcare providers also emphasized the negative impact of these two issues 
on the women’s ability to adhere to ART. 
Many of the women I interviewed were dependent on family or a combination of family 
and partner for financial support. A few were abandoned by partners. Some of the 
women claimed that they were unable to take their medication due to lack of food, as 
described by this 37-year old pregnant housewife of four children (PR002):  
“ah does skip one or two times when me ain’t get nothing fuh eat.”  
Another 22-year old, single pregnant woman with her first child, working as a security 
guard (PR005) expressed similar sentiments:  
“Yeah, I miss, I stop off couple times, because how I does deh, plus you 
does got fo eat, so if I ain’t get nuffing fo eat, I don’t drink it.” 
Although many women were poor and sometimes did not have the necessary funds for 
transportation costs to attend clinic, they recognized the importance of keeping their 
clinic appointments and resorted to borrowing money just to be there as this 31-year old 
single mother of one child (PP003) explains:  
“Only sometimes, I does be passage wise, but I does work it out, even 
though I have to borrow money and refund it back, I does make sure I 
come.”  
Another 34-year old single mother of two children (PP011  with similar circumstances: 
 “well right now my worry is finance, finance money, that does give me 
headache right now, cause I’m not working. Right now, my brother is at 
home, he ain’t working; my mother doan work, so fo come to clinic today is 
borrow I had to borrow $1000 [US$5] from a friend, till when my brother 
get money, he give me and I could pay her back.” 
Issues of inadequate food and finances are really grounded in the underlying issues of 
poverty and socio-economic status and have been described in prior studies as potential 
barriers of ART adherence (Kalichman et al., 2011; Musumari et al., 2013; Ngarina et al., 
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2013). Financial woes relate to money for transportation and other treatment-related 
costs (Duff et al., 2010; Wasti et al., 2012a). Inadequate food (food insecurity) 
encompasses insufficient caloric intake, consumption of inappropriate nutrients and 
anxiety in trying to obtain food (Singer, Weiser and McCoy, 2014). Food insufficiency 
can contribute to reduced quality of life, opportunistic infections, and poor mental 
health. ART medications can cause an increase in appetite which leads to hunger, while 
some medications require being taken with food to minimize side effects, subjecting 
women to a vicious cycle (Weiser et al., 2010; Musumari et al., 2013). The participants in 
this study would have been confronted with similar issues as they grappled with these 
barriers. 
Theme 6: Non-disclosure of HIV status 
Only one woman did not disclose her status to anyone because she thought that her 
family would “spread it”. Most women had disclosed to at least one person, family, 
partner or friend, while others only disclosed to a friend out of fear of being shunned by 
relatives. Reaction to the women on disclosure of their status varied. Some women 
selectively disclosed to certain family members based on how they felt they would react 
towards them. Many of the families and partners were quite supportive as experienced 
by this 27-year old married mother of two children (PP008):  
“An everybody show me love, an dey jus show me that it’s not the end, an I 
have to jus think positive an don’t take it on…”  
Some women endured a period of abuse as discussed by this 29-year old mother of 
three children (PP024):  
“An from since den, I went through a lot, a very lot, a bad situation wit him. 
He use to beat me, put me out, ill-treat me, allota things he do. Neva use to 
care about me, neva use to care about mah kid…eventually we start live an 
cooperate with one anotha [another]…”  
Though it was not possible to link causality between disclosure and adherence, the 
women who had not disclosed to anyone reported being adherent with ART, and some 
women who had disclosed skipped or missed doses. For those women who had limited 
or no disclosure, storing and taking their ART was a challenge, yet they found creative 
ways to do so. ART medication was stored in handbags, closets, and in a suitcase under 
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the bed. One 32-year old housewife (PR023) described taking her ART whenever her 
family visited for a few days as having “to hide and sneak to use the medication”. She 
described those family visits as follows:  
“Sometimes, I would take the medication out and they would be outside 
talking to me and I’ll say excuse me one minute and I’ll go inside and take 
up the medication and have it on me in my pocket, or have it on me 
somewhere, and then me say I have to go to de washroom and I take it. 
Sometimes I take it into the washroom. I don’t miss it, I don’t miss my 
medication, I don’t.” 
Non-disclosure of HIV status was only identified as a barrier to ART adherence by 
healthcare providers. However, this did not appear to affect adherence as women who 
had not disclosed their status to family members described the creative ways they used 
to store and take their medication such as keeping it in their handbag, in closets or 
suitcases under their beds. Medication would sometimes be taken in the bathroom or 
other private space. This finding highlights a few issues. The first being providers need 
to delve deeper into revelations of non-disclosure to determine how this translates into 
adherence or lack thereof. Secondly, women are highly motivated to protect the health 
of their babies, and pregnancy is a strong motivating factor for ART adherence as 
highlighted in similar studies of pregnant women (Vaz et al., 2007; Bardeguez et al., 
2008; Nachega et al., 2012). Finally, non-disclosure is inextricably linked with fear of 
stigma and discrimination which has been attributed to non-adherence in other studies 
(Awiti Ujiji et al., 2011; Mepham et al., 2011; Ngarina et al., 2013). It should be noted 
that a recent Guyana HIV country progress report (MOH, 2012, p.72) describes the 
continuing “challenge” of stigma and discrimination despite the wide-ranging efforts of 
the Government of Guyana. 
Theme 7: Religious and superstitious beliefs 
“Um, well it didn’t really affect me that much because like I pray, I use my 
tablets and I pray God an I umm I wanna see my daughta grow up when 
she was young now she is eighteen an she, I jus wanna see good fuh she an 
now dat I’m pregnant an I don’t wan dis baby fuh have any sick. So I jus 
pray God, he mus help me, leh me alone mus be sick nobody, no family 
member fuh me.” – 36-year old pregnant housewife, 1 child (PR019) 
“Well, I does try not to take on…I don’t take it on, you know, I does 
mostly pray a lot…is only now that I, if I gotta talk about it, I would break 
down, but I does try not to think about it…I does think positive and ask 
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God for the strength because it’s not something I ask for, at least for my 
kids’ sake [cries]…” – 29-year old housewife, 27 weeks gestation, 4 children 
(PR018) 
Religious beliefs/spirituality served as both a facilitator and a barrier. Enquires to the 
women about coping mechanisms revealed the important role of religion/spirituality in 
their lives, and how these beliefs had both positive and negative influences. Some 
women made direct reference to God for strength to persevere, hope for a cure, and 
hope that their babies would not be infected with the virus which served as a motivating 
factor. One pregnant woman with superstitious beliefs mentioned that there were non-
medicinal cures, as that provided by the indigenous groups that would free her of HIV. 
However, she stated that she would wait until after delivery to try these non-ART 
concoctions.  
I: Alright. Um, have you taken any bush medicine or anything like that? 
P: No. uh uh.  
I: No, Ok. And why haven’t you tried any bush medicine?  
P: Bush medicine? 
I: You never tried any. 
P: Them seh because ah pregnant.  
I: Because you’re pregnant? 
P: Yeah. 
I: Oh, ok. 
P: When ah done get de baby. 
I: Then you’ll take the bush medicine? 
P: Yeah. 
I: Why? 
P: Becah ah want it come out out o’ meh body. 
I: Ok. You think that is truth? 
P: Yeah. 
I: You think the bush medicine will work? 
P: It will work, yeah.  
P: I have a friend, right.  
I: Uh huh. 
P: And she goh fuh kill she self 
I: Uh huh.  
P: And the Amerindian man seh she pick some kinda bush. 
I: Mm hmm. 
P: Fuh get fuh boil it and drink it. 
I: Mm hmm. 
P: And the bush cure she. 
I: She’s now cured? 
P: Yes. And she ain’t got it. She went and she tek nuff nuff test. 
I: Ok. 
P: And Doctor seh she don’t have it. (PR002) 
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A postpartum woman expressed her intention to attend a local church where in her 
view persons were being healed of HIV by the pastor. However, the negative 
association with religion and adherence was expressed by a healthcare worker who 
stated that she had been called by a patient who claimed to be healed by a pastor and 
had no need for ART. 
Spirituality/religion has been defined in the literature as being a complex construct 
which encompasses a belief in God, faith in a higher power, and a sense of peace and 
wellbeing, allowing persons with a devastating illness such as HIV to cope and improve 
their quality of life (Cotton et al., 2006; Trevino et al., 2010). However, spirituality has 
also been described as having a negative influence on behaviour resulting in adverse 
outcomes and suboptimal ART adherence when there is an over reliance on God at the 
expense of taking prescribed ART (Parsons et al., 2006; Tarakeshwar, Khan and 
Sikkema, 2006; Trevino et al., 2010; Szaflarski, 2013). Thus spirituality has the potential 
to affect both mental and physical health (Brown et al., 2014). Although in this study 
more women reported positive than negative effects, the few who reported negative 
effects are a cause for concern as these behaviours will have implications for HIV 
management and care. While the true extent of this phenomenon in this population is 
unknown, its potential negative influence could adversely impact ART adherence and 
hasten disease progression.  
3.10.2 Health system and perspectives of service providers 
“Because they think that during the pregnancy they want the best for their 
child, they don’t want the child get sick, and once they deliver, they think 
that the medication is just for them, but most of them I’m telling you take 
the medicine. When they use it, they use it during pregnancy, they using it 
postpartum, and they using it even when they are not pregnant…” – 
medical doctor (HW001). 
“I would say pregnancy, because they within their cognitive they’re thinking 
this is a short-term thing and they adhere well during that period…that 
whatsoever should happen after, let it happen, but once the baby is safe…” 
– social worker, regional hospital (HW009). 
Although some of the health workers had differing views on the levels of adherence 
among pregnant and postpartum women, they all agreed that pregnant women had 
better adherence than non-pregnant women, as expressed by this midwife (HW003): 
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 “I think, um when they’re pregnant they take it better, because as I would 
say, as I said earlier, the baby is the motivator.”  
Similar views were stated by a medical doctor (HW006): 
 “…when they’re pregnant. I think because of the fact that we, you know 
they have an unborn child and we have to stress the importance of taking 
the medication for the very reason of reducing mother-to-child 
transmission, so just being aware of that you know, that message is really 
deep for them.” 
Health workers provided counselling as the primary method of enhancing adherence. 
Nurses, social workers and pharmacists were tasked with conducting counselling 
patients throughout enrolment:  
“we give them counselling all the time, starting from me here in the room, 
social worker, the pharmacist, at least when they leave this institution, at 
least three different person, at least talk to them about their adherence” – 
medical doctor at a health centre (HW001). 
Some clinics had active support groups. Others provided food hampers, pill boxes and 
frequent reminders during clinic visits. Health workers reported the following factors as 
motivators of adherence: Wanting a healthy, HIV-negative baby; the desire to see their 
children grow up: 
“because of the other children, they want to live for the children” – midwife 
(HW002);  
a negative HIV-test for their infant:  
“…for some reason, it could all be psychological, but when we do the very 
first test for the infant, the dry blood spot testing and it’s negative, you 
know they’re so happy, and I think too because of the fact that they knew 
they would have taken their medication during that pregnancy, and 
following that they feel encouraged because they say, oh well, if my 
inf..baby is well, oh my, you know I’ve got to do well.” – Medical doctor 
(HW006DB);  
improved health:  
“when they feeling better, when they see that the tablet responds, they see 
the benefit of the medication, that made them don’t miss a dose at all” – 
medical doctor (HW001); 
106 
 
 supportive partner or family:  
“I think support. Once you have family support that is tremendous…you 
know if the support is there, many times the pregnant mothers they have 
their, their mothers to help them. They may not tell their partner, they may 
not tell their sister, but their mother…” – medical doctor (HW006);  
and wanting to look normal and healthy: 
“I think this is a woman who wanna stay strong and healthy. You know, 
even though she’s HIV-positive, she wants to stay strong and healthy. 
When she goes out there, she wants to look normal, and she wants to feel 
good about herself…” – midwife (HW008). 
Some of the barriers reported by health workers mirrored those expressed by the 
women. Financial problems was one such barrier, and eventually may have contributed 
to the death of a mother of six children as illustrated by this quote from a 61-year old 
midwife (HW002):  
“I say doctor, I don’t think she’s taking her tablet; doctor say well alright we 
gon do de test [CD4]; when it come she was 18 [CD4 count]; and she lef an 
gon in de bush, is right there she tek in and they bring she back, and she die 
de nex day, lef six children, she did say she did going to get money.” 
Lack of food was another reason for non-adherence cited by health workers. Women 
were unable to take their medication on an empty stomach:  
“…but then the problem with food, lots of them they come and they 
complain about you know not having food, they can’t drink the tablet on an 
empty stomach and stuff…” - 50-year old medical doctor (HW007). 
Other barriers were work-related, and included women who worked nights and did not 
take their tablets since it made them drowsy. Women who lived in far-flung 
communities or other regions were sometimes unable to attend clinic in a timely 
manner. Another barrier discussed by health workers was non-disclosure: 
 “…you find that the problem that some of the women they would have is 
like not disclosing their status to their family, so they can’t take home these 
pills, they can’t let their family see them using these pills, so that is where 
the problem for all categories…” - 53-year old midwife (HW003).  
Similar sentiments were expressed by a health visitor and midwife: 
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 “there was this young girl, who she did not comply because she did not tell 
anybody she was HIV-positive, and to take the treatment she had to be 
hiding, and hiding and hiding, and after a while she jus get fed up hiding. So 
she was placed on second-line, and even onto the second-line treatment she 
didn’t, she didn’t continue with the second-line, and so um I think right 
now she is offa treatment…” – 53-years (HW004). 
Some health workers reported that women’s beliefs that religion would cure them 
resulted in non-adherence to their medication:  
“…they would drop [out of clinic] for three, four months and they gon call 
and say they been to some Pentecostal church and de Pastor say they heal, 
and they ain’t got need for treatment; and now we got one of them, she say 
she heal, now she turn up, if you see she skin; she want doctor give she 
something for she skin…” - 61-year old midwife (HW002). 
Too many clinic appointments made it difficult for women who were poor, had other 
children to care for, or those who were employed to attend all appointments. Some sites 
did not have integrated care, which meant that a pregnant woman could have antenatal 
care on one day, HIV treatment on another, and associated blood work on yet another 
day, as described by this 28-year old male social worker (HW009) at a regional hospital: 
 “…you know the clinic, they have to come to the hospital too many times; 
because they might have children, they have to take them to the health 
centre, then they have to come here to the clinic; they have to come back 
on a Friday to get the test done, because only on Fridays we do CD4 and 
these sort of tests.” 
Some healthcare providers reported that women with certain characteristics such as 
having a high educational background or older age were more likely to adhere to their 
ART.  
“…you know because we got people up there doing good jobs and suh, 
they you will find they taking the tablet, teachers, you understand what I 
mean; older folks, but de young ones, you know, oh God nurse I fed up 
drinking tablets; why I must drink this tablet every day; oh God man nursie 
I fed up…” - midwife (HW002).  
Other workers opined that persons who lived alone, or with partners who were also 
HIV-positive, women who want to be healthy, those who disclose their status and had 
supportive families were also good at taking their medication. Finally, all providers 
108 
 
expressed that being pregnant and/or having other children to care for was a powerful 
motivator that contributed to better adherence. 
3.10.3 Summary of the women’s ART perspectives 
The picture emerging from the lived experiences of the women in this study is one of 
determination and resilience. Women were determined to be around to care for their 
children and this concern served as a motivating factor. Further, to ensure ART was 
taken in a timely manner a variety of mechanisms were used, such as alarms, integration 
into the daily routine, or anchoring intake with their favourite television programs.  
Tenacity was seen in women living with HIV in the absence of disclosure, ensuring 
medications were taken, making efforts to keep clinic appointments and managing side 
effects. Women who had not disclosed their HIV status to partners or relatives found 
creative ways maintain adherence as described in Theme 6. Women also grasped the 
importance of clinical appointments, few were missed and when there were obstacles to 
attendance, some borrowed money to enable them to keep these appointments. Those 
experiencing side effects tried to minimize them by adjusting their regime to maximize 
their ability to be adherent. For example, women on the single-tablet regimen chose to 
take their medication before bedtime to avoid experiencing side effects. 
However, some women’s efforts at maintaining adherence were thwarted due to 
primarily socio-economic factors, such as lack of food and financial resources, both of 
which have been reported in the literature as contributors of suboptimal adherence 
(Kalichman et al., 2011; Singer, Weiser and McCoy, 2014; Young et al., 2014). Pregnant 
women tend to experience higher levels of food insecurity due to the levels of nutrients 
required for themselves and baby. The studies highlighted that food insecurity is not 
only a barrier to ART adherence but also other health advice, and has the potential to 
adversely affect maternal and child health (Young et al., 2014).  
3.11 Pregnancy, motherhood, and adherence within the context of HIV 
infection 
Pregnancy is a period in women’s lives which engenders a key focus on self and keen 
attention is paid to adopting health and lifestyle recommendations with the primary 
objective of delivering a healthy baby (Verbeke and De Bourdeaudhuij, 2007; Heil et al., 
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2014). Motherhood is considered a major milestone which plays a key role in the 
maternal identity of both HIV-positive and uninfected women (Mercer, 2004; Wilson, 
2007). For HIV-positive women, motherhood is focussed on their HIV illness and is 
characterized by periods of acute stress as a result of worrying about their own health, 
guilt on the potential harm to the baby and the stigma of HIV (Sandelowski and 
Barroso, 2003; Sanders, 2008). Despite these stressors, motherhood for HIV infected 
women is geared towards preserving their maternal identity by working towards 
protecting their children from being infected, adhering to ART and utilizing other 
health care services (Sandelowski and Barroso, 2003). Motherhood not only allows them 
to cope with their diagnosis, but also gives them a reason to live for the sake of their 
children and combat the disease (Sandelowski and Barroso, 2003; Doyal and Anderson, 
2005; Wilson, 2007). This determination to maintain an identity as a good mother 
motivates them to adhere to treatment. 
As pregnancy entails several clinical visits, healthcare providers can use these visits to 
capitalize on the importance of motherhood in the lives of the women and their 
motivation to adhere to reinforce the benefits of ART to self and children thereby 
establishing the groundwork for lifelong maintenance of ART adherence. Healthcare 
providers should also provide timely and non-judgemental interventions to address 
potential problems as providers may be the only source of support for the women, 
which will ultimately impact their adherence behaviour. 
3.12 Summary 
In this chapter, I described the experiences of HIV-positive pregnant and postpartum 
women, and the perspectives of healthcare providers about barriers and facilitators to 
ART adherence. Healthcare staff included doctors, midwives, a social worker and a 
medex with many years of experience working with HIV-positive women. The HIV-
positive women were predominantly multi-gravida, with at least two children, and were 
aged 18 to 39 years. Many women were in relationships, had at least a primary school 
education, and were mostly Christian. 
Many of the women I spoke with were diagnosed during a prior pregnancy, with most 
being HIV-positive for over five years. A few lived alone with their children, and others 
resided with family, relatives and/or partners. For some women, living arrangements 
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and reactions to disclosure were sources of stress, with some experiencing verbal abuse, 
stigma and discrimination, and uncomfortable and unhealthy living conditions. As a 
result, women found solace in religious and spiritual beliefs, developing a positive 
attitude, focussing on being around for their children, and relying on the support of 
family, partner, friends and healthcare providers. 
A majority of the pregnant and postpartum women reported consistent ART adherence 
during pregnancy, and were quite creative and determined in their efforts to prevent 
MTCT and safeguard their own health. Postpartum women who had been on regimens 
prior to pregnancy, particularly those on ART for many years, were most likely to have 
intentionally skipped or missed doses, stopping for weeks or months at a time because 
they were just “fed up” taking pills. However, women who were non-adherent pre-
pregnancy, reported never missing a dose during pregnancy. A few postpartum women 
who skipped ART doses during pregnancy were also non-adherent with the paediatric 
ART formulations prescribed upon discharge after delivery. These women were single 
housewives with similar ethnicities. All postpartum women indicated that they opted to 
formula-feed and had no problems maintaining their choice despite strong community 
views on breastfeeding. Pregnant women also selected this mode of infant feeding. The 
women’s choices were based on the advice of health workers and free supplies of 
formula from the Government.   
ART side effects and lack of food emerged as the two major reasons for non-adherence 
in both groups. Some side effects were as mild as drowsiness, but could be as severe as 
vomiting, diarrhoea, and nightmares. Mild effects were resolved by switching the 
regimen to evening hours, preferably before bedtime. Taking ART on an empty 
stomach may have contributed to some of the more severe side effects and resultant 
non-adherence. 
My interviews with pregnant and postpartum women and their healthcare providers 
highlights some of the myriad issues confronting women as they initiate or try to 
maintain their antiretroviral regimens. Similar issues were observed irrespective of 
whether the women were pregnant or postpartum. This study identified a variety of 
barriers and facilitators including individual factors and beliefs, regimen-related factors, 
and social and economic issues. 
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Facilitators were primarily centred on concern for their children whether unborn or 
alive, with both the women and their healthcare providers reporting that being pregnant 
and wanting a healthy uninfected baby were significant contributors of good adherence. 
In the following chapter (Chapter 4), I discuss the methodology and data analysis for the 
cross-sectional descriptive studies on adherence among pregnant women with and 
without HIV. 
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Chapter 4 - Methodology – adherence among pregnant 
women with and without HIV infection 
“Drugs don’t work in patients who don’t take them.”6  
4.1 Introduction 
In the previous chapter, I presented the methodology, data analysis, and results of the 
in-depth interviews which explored the perspectives and experiences of HIV-positive 
pregnant and postpartum women, and healthcare providers, about barriers and 
facilitators to ART adherence. The HIV-positive women and their providers were 
interviewed at primary care clinics using an open-ended question format. Among the 
findings discussed were variations in adherence patterns during pregnancy and 
postpartum, and that children were the primary contributing factor to the women’s 
adherence. In this chapter, I will describe the methodology and data analysis plan for the 
study examining adherence among HIV-positive and uninfected pregnant women. 
Antenatal care (ANC) attendance is important in order to identify ill health and 
infections that can cause complications during pregnancy and delivery resulting in 
morbidity/mortality for mother and infant (Hagey, Rulisa and Pérez-Escamilla, 2014; 
Mason et al., 2015). ANC is also a key entry point for HIV prevention and treatment 
(AbouZahr and Wardlaw, 2003). WHO guidelines recommend a minimum of four ANC 
visits for pregnant women with normal pregnancies (Villar et al., 2001). Early initiation 
of ANC is considered a strong predictor of other ANC visits and adherence to ART 
recommendations (Wilson et al., 2004; Psaros, Geller and Aaron, 2009; Hagey, Rulisa 
and Pérez-Escamilla, 2014). 
Pill burden has been identified as a barrier to ART adherence during pregnancy and the 
postpartum period (Bardeguez et al., 2008; Nachega et al., 2012), while a single 
tablet/fixed dose regimen contributes to better adherence and improved clinical 
outcomes (Bangsberg et al., 2010; Hernández Arroyo et al., 2016; Scott Sutton, 
Magagnoli and Hardin, 2016). Use of another pill, albeit a prenatal vitamin, may 
contribute to the pill burden resulting in poor adherence. 
                                                 
6 Dr. C. Everett Koop, former United States of America Surgeon General 
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4.2 Study objectives 
The purpose of this study was to identify the factors contributing to women’s adherence 
to ART in Guyana. The first phase entailed a systematic review of the literature to 
understand the global knowledge base on ART adherence among HIV-positive 
pregnant women, and investigated any relevant studies from the region. The second 
phase gathered data from key informants (pregnant and postpartum women and 
healthcare providers). Drawing from both the research literature and the findings from 
the in-depth interviews, a cross-sectional descriptive study of pregnant women was 
undertaken and included three sub-studies: 1) investigated general adherence to 
pregnancy-related behaviors among HIV-negative and HIV-positive pregnant women; 
2) compared adherence to pregnancy-related behaviors with antiretroviral adherence 
among HIV-positive pregnant women; and 3) aimed to investigate the efficacy of a 
theoretical model by operationalizing the four constructs of the Health Belief Model 
(perceived susceptibility, perceived severity, perceived barriers and perceived benefits) to 
understand and predict ART adherence among HIV-positive pregnant women. 
4.2.1 Research questions 
The specific research questions for the cross-sectional descriptive studies of pregnant 
HIV-positive and uninfected women were as follows: 
Study 1 – General adherence to pregnancy health behaviours among pregnant HIV-
positive and uninfected women 
 What are the levels of prenatal vitamin supplement knowledge and vitamin 
use among HIV-negative and HIV-positive pregnant women and do these 
differ between the two groups? 
 What are the levels for other prenatal health behaviours (alcohol use, tobacco 
use, and healthy nutrition) among HIV-negative and HIV-positive women, 
and do these differ between the two groups? 
 What are the predictors of vitamin knowledge, vitamin use, alcohol use, 
tobacco use and healthy nutrition among HIV-negative and HIV-positive 
women? 
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Study 2 – Factors contributing to pregnant women’s ART adherence 
 What are the levels of ART adherence among HIV-positive pregnant 
women? 
 What is the relationship between the demographic, social, psychological, 
knowledge, and clinical factors and ART adherence? 
 What is the relationship between vitamin adherence and ART adherence? 
Study 3 – The utility of the Health Belief Model to understand and predict ART 
adherence 
 What constructs of the Health Belief Model (HBM) as operationalised by the 
Adherence Determinants Questionnaire (ADQ) help understand and predict 
adherence? 
4.3 Research ethics and governance 
Ethical approval was obtained from University College London Research Ethics 
Committee (ID 3518/002) in the United Kingdom, and the Guyana Ministry of Health 
Institutional Review Board (Protocol #76). 
Prior to the administering the questionnaire, participants were given a copy of the 
information sheet and consent form, which were also verbally explained. Participants 
were apprised of the following: 
 They were not obliged to take part in the study 
 They could withdraw from the study at any time without any negative 
repercussions to their care at the site 
 They could refuse to answer any question without having to provide a reason 
 Their names and other personal identifiers would not be used in any public 
documents 
Participants were encouraged to ask questions before and after the interview and given a 
local contact number (printed on the consent form and information sheet). All 
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documents were secured in a locked file cabinet. Information provided has been kept in 
confidence and in compliance with the UK Data Protection Act, 1988. 
4.4 Methods 
4.4.1 Study design 
A cross-sectional survey to: (1) compare general adherence to medication and health 
behaviours (prenatal vitamins, alcohol, tobacco and diet) between HIV-negative and 
HIV-positive pregnant women; (2) determine levels of ART adherence and its 
predictors among HIV-positive women; (3) compare ART adherence with general 
health adherence among HIV-positive women; and (4) test the constructs of a 
theoretical model to understand and predict adherence. The study population included 
HIV-negative and HIV-positive pregnant women on ART attending primary care clinics 
in Guyana, South America. 
4.4.2 Sample size and sampling strategy 
A sample size of 200, 100 HIV-negative and 100 HIV-positive women was calculated to 
be adequate. The sample size of 100 HIV-positive women provided sufficient power of 
80% with a significance level of 5% to detect an association with the adherence rate, if 
the predictor of adherence has 50% prevalence and women without the predictor are 
80% adherent, whilst those with the predictor are 99% adherent. The original study 
design had proposed random sampling selection of the women. However, the realities 
on the ground of few HIV-positive women enrolled at the sites necessitated using a 
convenience sample of all available eligible women. The study sites in Regions 3, 4 and 6 
were the sites with the highest numbers of the study population during the data 
collection period, and it is thought that most eligible women attending there in the 
period were recruited to the study, providing a broadly representative sample of the 
study population. 
4.4.3 Study setting and inclusion criteria 
Interviews were conducted at 11 clinics within Regions 3, 4 and 6. Region 3 interviews 
took place at the West Demerara Regional Hospital; Region 4 interviews were at 
Campbellville Health Centre, Dorothy Bailey Health Centre, Georgetown Public 
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Hospital, Beterverwagting Health Centre, East La Penitence Health Centre, Davis 
Memorial Hospital and Mercy Hospital; Region 6 interviews were conducted at New 
Amsterdam Health Centre, Cumberland Health Centre, and Bohemia Health Centre. 
Eligibility included participation in the PMTCT program for HIV-positive women, or 
enrolment in regular antenatal clinic for those who were HIV-negative. In addition 
women had to be at least 16 years of age, capable of completing a questionnaire in 
English, and able to provide consent. Eligibility criteria initially included being on ART 
for at least one month. However, this was modified to include women on ART from at 
least one week due to time constraints and few women enrolled at sites as previously 
discussed. 
4.4.4 Recruitment process 
Participants were recruited during routine clinic appointments. Women fulfilling the 
pre-specified criteria were invited to participate in the study by the nurses, then referred 
to the researcher for further information. The researcher provided verbal and written 
information about the nature and purpose of the study. Participants gave written 
informed consent and received copies of the information sheet and consent form. 
Interviewer-administered questionnaires were completed in a private room during the 
participants’ clinic session, or if not feasible, an appropriate date and time would be 
negotiated for the same venue. Out of the 112 HIV-negative women approached, four 
declined (3.6%), resulting in 108 interviews, while there were three refusals (2.7%) 
among the 111 HIV-positive women approached as eligible, resulting in a sample of 108 
with an overall 3.1% refusal rate and a 96.9% inclusion rate. Recruitment was hampered 
by a variety of challenges and included: 
 Long approval (over five months) process delay by one local partner, which the 
researcher  was subsequently informed was not needed 
 Low numbers of currently enrolled pregnant HIV-positive women at sites 
 Women being identified HIV-positive in the third trimester 
 Uncooperative staff at some sites 
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4.5 Data collection 
Data was collected between August 2012 and August 2013. A PMTCT social worker 
resident in Region 6 was recruited as the field worker for that Region, located 
approximately 66 miles (107 km) from the Capital city of Georgetown. Data collection 
consisted of questionnaires in the English language which did not require translation 
into other languages. The HIV-negative pregnant women completed one questionnaire, 
averaging 15 minutes, while the HIV-positive pregnant women completed two 
questionnaires (general questionnaire identical to that of the HIV-negative women plus 
a second HIV specific adherence information questionnaire), averaging 45 minutes. 
4.5.1 Development of instruments and field testing 
The consent forms, participant information sheets, and data collection instruments were 
developed as follows: 
 They were designed based on published studies in the literature with input and 
oversight from the supervisory team 
 They were reviewed by the supervisory team 
 They were reviewed by two local clinic nurse supervisors for appropriateness 
and comprehension 
 The revised tools were piloted with six local persons (3-healthcare staff, 2-
pregnant women, and 1-lay person) 
 The tools were updated, and the refined versions submitted for final supervisory 
approval 
 The tools did not have to be translated into other languages , since English is 
the country’s primary language 
4.5.2 Measures 
The data collection instruments were compiled from several validated and study specific 
measures that included: (a) demographics; (b) general beliefs about medications (BMQ-
G12); (c) depression and anxiety (PHQ); (d)domestic violence (HITS); (e) healthy 
nutrition, (f) knowledge and use of prenatal vitamins; (g) alcohol and tobacco use; (h) 
posttraumatic stress (PCL-C); (i) physical and emotional symptoms of HIV (MSAS-SF); 
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(j) coping with HIV (Brief Cope); (k) health beliefs and attitudes towards ART (ADQ); 
(l) quality of life with HIV (HIV-QoL); (m) HIV general knowledge and beliefs, (n) HIV 
treatment knowledge; and (o) ART adherence (AACTG instruments). The finalized 
study instruments comprised two questionnaires - a general questionnaire inclusive of 
demographic characteristics for both HIV-negative and HIV-positive women, and an 
ART adherence questionnaire for only HIV-positive women (Appendix K-M). 
4.5.2.1 Demographics 
Demographic items were: age; race (African, Amerindian, East Indian, Chinese, Mixed, 
Portuguese, White and Other); religion (Christian, Hindu, Muslim, Rastafarian, None 
and Other); education (Nursery/Kindergarten, Primary, Secondary, Post-secondary, 
University, None and Other); marital status (Married, Single, Common-law, Separated, 
Widowed and Divorced); main source of income (Employment, Remittances, Pension, 
Savings, Disability benefits, Partner support and Other); type of job (Housewife, 
Domestic, Cleaner, Security guard, Hairdresser, Teacher, Clerk and Other); frequency of 
payments for primary job (Daily, Weekly, Fortnightly and Monthly); Salary; health 
insurance (Yes or No); type of health insurance (National Insurance Scheme, Private, 
Employer, Foreign and Other); number of people living in household; number of 
children less than 18-years living in household; type of household (Home ownership, 
Renting, Rent-free, Living with friends, Living with family and No permanent 
residence); region of residence (Region 3, Region 4 and Region 6). 
4.5.2.2 General beliefs about medicine questionnaire  
General beliefs about medications were measured using the Beliefs about Medicines 
Questionnaire (BMQ-G12). According to studies by Horne, Weinman and Hankins 
(1999) and Horne et al. (2004) people’s beliefs about medications affect how they 
comply with them. This 12-item scale, with Likert responses of 1 (strongly disagree) to 5 
(strongly agree) compared personal views about medication in general between HIV-
negative and HIV-positive women. The BMQ-G12 consists of three 4-item subscales: 
general overuse (views on how doctors prescribe medications); general harm 
(perceptions on whether medications are inherently harmful); and general benefit (the 
positive effects of medication). Each of these subscales can be summed for total scores 
ranging from 4-20, or as a total score of all three scales, with higher scores indicating 
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stronger beliefs. The scale has been reliable for different types of illnesses and 
populations. Cronbach’s alpha for the harm, overuse and benefits sub-scales were 0.62, 
0.72 and 0.62 respectively. 
4.5.2.3 Depression and Anxiety – The brief patient health questionnaire (PHQ) 
The Brief Patient Health Questionnaire (Spitzer, Kroenke and Williams, 1999) is a self-
administered validated questionnaire for depression and anxiety modelled on the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The 
15-item Likert scale has subscales for anxiety and depression. The nine depression items 
were prefaced by “over the past 2 weeks, have you been bothered by any of the 
following problems” with responses ranging from 0 (not at all) to 3 (nearly every day). 
The anxiety/panic disorder subscale inquired about anxiety attacks in the past 4 weeks, 
using 5 questions with yes or no responses. Total scores for depression can range from 
0 to 27, with depression severity scores of 1-4 (minimal), 5-9 (mild), 10-14 (moderate), 
15-19 (moderate severe), and 20-27 (severe). The PHQ has been validated in primary 
care settings and among various racial/ethnic groups (Lowe et al., 2004; Huang et al., 
2006; Martin et al., 2006). 
4.5.2.4 Domestic abuse/violence – The HITS Scale 
The Hurt, Insulted, Threatened and Screamed at (HITS) 4-item questionnaire was 
originally developed by Sherin et al. (1998) to screen for domestic violence. It is a four 
item, 5-point scale ranging from 1 (never) to 5 (frequently) for a score of 4-20. HITS 
can be easily administered in primary care settings, and has been used with all types of 
populations. Cronbach’s alpha is 0.80 (Punukollu, 2003; Chen et al., 2007). 
4.5.2.5 The prenatal health behaviour scale 
The prenatal health behaviour scale is a 24-item measurement developed by DeLuca and 
Lobel (1995) to assess health behaviours such as smoking, nutrition and exercise among 
pregnant women. It is a 5-point Likert scale ranging from 0 (never) to 4 (always) about 
behaviours engaged in over the past two weeks. This scale was found to be reliable in 
other studies (Lobel et al., 2000; Lobel et al., 2008). The scale was modified for use in 
this study, with a total of four questions on diet only, since some of the other health 
behaviour items were already incorporated in other measures of the questionnaire. The 
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four questions included: eating a balanced diet; drinking milk and eating dairy products; 
eating more food than needed; and skipping meals with a minimum score of zero and a 
maximum score of 16. 
4.5.2.6 Knowledge and use of prenatal vitamin supplements 
Knowledge and use of prenatal vitamins was determined with the following questions 
from a study by Cleves et al. (2004): “Doctors recommend that women take a 
multivitamin (iron/folic acid) during pregnancy for which of the following reasons?” 
Responses included: “to prevent high blood pressure;” “to prevent birth defects and 
anaemia (weak blood);” “to make strong bones;” “some other reason;” and “don’t 
know.” Women who selected “to prevent birth defects and anaemia (weak blood)” were 
considered to have correct knowledge of the benefits of multivitamin use during 
pregnancy. Use of prenatal vitamins (iron and folic acid) was assessed with the question: 
“In the past month, how often, if at all have you taken your iron tablets, iron syrup or 
sprinkles?” Potential responses included “every day”, “5 or 6 days a week”, “3 or 4 days 
a week”, “1 or 2 days a week” and “not at all.” Women who took their supplements at 
least “1 or 2 days a week” were considered to be taking it at least weekly. 
4.5.2.7 Alcohol and tobacco use 
Substance use was assessed with items from the ACTG adherence/psychosocial factors 
questionnaire by the AIDS Clinical Trials Group (Chesney et al., 2000). Use of alcohol 
was measured by asking participants: “During the past 30 days, how often have you had 
a drink containing alcohol - beer, wine, a mixed drink, or any kind of alcoholic 
beverage?” Possible responses ranged from 0 (never) to 6 (daily). Tobacco use was 
measured with the question: “When was the last time you used tobacco (cigarettes, 
cigars)?” Responses ranged from 0 (never used) to 3 (within the past month). 
4.5.2.8 The post-traumatic stress disorder checklist civilian version (PCL-C) 
Post-traumatic stress disorder associated with highly stressful events such as wars and 
natural disasters, has now been linked with poor adherence to ART (Sledjeski, 
Delahanty and Bogart, 2005; Vranceanu et al., 2008; Sherr et al., 2011). PTSD can occur 
from being directly or indirectly involved in a traumatic event. The PTSD checklist 
(PCL-C) is a 17-item self-report measure developed in 1993 (Weathers, Ruscio and 
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Keane, 1999), and updated in 1994 to reflect the DSM-IV categories. It has a 5-point 
Likert scale ranging from 1 (not at all) to 5 (extremely) for each symptom experienced in 
the past month. Scores for the PCL-C scale ranged from 17 to 85 with a cut-off score of 
44 to identify persons with PTSD. Being diagnosed with HIV can trigger an episode of 
PTSD which can adversely affect treatment compliance (Martinez et al., 2002; Safren, 
Gershuny and Hendriksen, 2003). 
4.5.2.9 Physical & emotional symptoms of HIV– The memorial symptom 
assessment scale, Short Form (MSAS-SF) 
The Memorial Symptom Assessment Scale Short Form (MSAS-SF) is an abbreviated 
version of the original MSAS (Portenoy et al., 1994). It is a validated 32-item scale 
assessing 28 physical and four psychological symptoms which have occurred in the past 
week. An additional four items (feeling hopeful/optimistic, feeling happy, and feeling 
confident) were added to reflect positive mood; and an item on suicide ideation based 
on the work of Warner et al. (2004) and Sherr et al. (2008a). Responses for the physical 
symptoms range from 0 (not at all) to 4 (very much); while responses for the 
psychological symptoms range from 1 (rarely) to 4 (almost constantly).  
MSAS-SF (Table 4-1) is comprised of three subscales: (1) Global distress index, an 
average of four psychological symptoms (feeling sad, worrying, feeling irritable and 
feeling nervous) and six physical symptoms (lack of appetite, lack of energy, pain, 
feeling drowsy, constipation, and dry mouth); (2) physical symptoms (lack of appetite, 
lack of energy, pain, feeling drowsy, constipation, dry mouth, nausea, vomiting, change 
in taste, weight loss, feeling bloated and dizziness); and (3) psychological symptoms 
(worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and difficulty 
concentrating). The scale has been used among cancer patients as well as HIV/AIDS 
patients (Chang et al., 2000; Cheng et al., 2009). Internal consistency for the modified 
scale was good (α=0.83).  
The physical symptom subscale (PHYS) score is the average score for 12 physical 
symptoms (lack of appetite, lack of energy, pain, feeling drowsy, constipation, dry 
mouth, nausea, vomiting, change in taste, weight loss, feeling bloated and dizziness). 
Scoring for the scale is based on increments of 0.8, with zero for no symptoms, and a 
score of 4 if the symptom is present and very distressful.  
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The psychological symptoms (PSYCH) subscale score is the average of six psychological 
symptoms (worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable and 
difficulty concentrating). Scoring is based on increments of one, with zero for no 
symptoms to a maximum score of four if the symptom is present and experienced 
constantly. 
The global distress index (GDI) measures overall symptom distress. Total scores are 
based on the average of four psychological symptoms (feeling sad, worrying, feeling 
irritable and feeling nervous) and six psychological symptoms (lack of appetite, lack of 
energy, pain, feeling drowsy, constipation, and dry mouth). 
Table 4-1: Cronbach's alpha - MSAS-SF 
Dimension  # Items Cronbach’s alpha (α) 
MSAS-PHYS 12 0.73 
MSAS-PSYCH 6 0.71 
MSAS-GDI 10 0.73 
Positive mood 3 0.62 
Full Scale 36 0.82 
4.5.2.10 Coping with HIV– The Brief Cope 
The Brief Cope was developed to assess how persons respond to stressful events 
(Carver, Scheier and Weintraub, 1989; Carver, 1997) for all types of illnesses. In this 
study it measured coping with the stress of living with HIV/AIDS over the past month 
and consisted of 28 questions (14 categories, 2 items each) on a 4-point scale, with 
responses from 1 (I haven’t been doing this at all) to 4 (I have been doing this a lot). 
The 14 categories are active coping, planning, positive reframing, acceptance, humour, 
religion, emotional support, instrumental support, self-distraction, denial, venting, 
substance use, behavioural disengagement and self-blame. There is no composite coping 
score, but comparisons can be made on the individual subscales. Stress and the inability 
to cope adversely affects the immune system contributing to the advancement of HIV 
disease (Lutgendorf et al., 1998; Balbin, Ironson and Solomon, 1999). Meyer (2001) sub-
divided the scale into adaptive (dimensions 1-8) and maladaptive (dimensions 9-14). 
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4.5.2.11 Health beliefs and attitudes – Adherence determinants questionnaire 
(ADQ) 
Health beliefs and attitude constructs of the Health Belief Model (HBM) were assessed 
with the ADQ. The ADQ was first developed and validated to assess factors related to 
cancer control by DiMatteo et al. (1993). It consists of seven subscales and a total of 38 
Likert scale statements varying from 1 (strongly disagree) to 5 (strongly agree). The 
seven subscales include interpersonal care and relationship with healthcare providers, 
perceived utility of treatment, perceived severity of illness, perceived susceptibility to 
illness progression, subjective norms (beliefs that family and friends support adherence 
to treatment plan), intentions to comply with treatment, and support/barriers to 
adherence. Cronbach’s alpha of internal consistency for the subgroups ranged from 0.65 
to 0.85 (DiMatteo et al., 1993). Since the original ADQ was designed for patients with 
cancer, question 15 (I believe that my treatment plan will prevent me getting cancer 
again) and 21 (The chances I might develop cancer again are pretty high) were omitted, 
while questions 17 to 20 were modified (there are many diseases more severe than HIV; HIV 
is not as bad as people say; HIV is a terrible disease; and there is little hope for people with HIV) to 
reflect HIV dynamics, resulting in a 36-item scale.  
In addition to the four HBM constructs, two other ADQ constructs, namely, 
Interpersonal aspects of care and Intentions to adhere with the treatment plan were 
assessed for predictors of adherence. The construct ‘Intentions’ of the ADQ is a 
component of the Integrated Behavioural Model (IBM) conceptualized by Fishbein and 
Ajzen (Ajzen and Fishbein, 1977; Fishbein, 2008) from multiple theories (HBM, Social 
cognitive, Reasoned action and Planned behaviour). The HBM posits that intention, 
attitude, perceived norms, perceived behavioural control and behavioural beliefs are the 
contributing factors toward behaviour change of which behavioural intention plays a 
key role (Fishbein et al., 2003; Fishbein, 2008). Fishbein (2008) defines ‘Intention’ as the 
willingness to execute a particular behaviour and that the higher these expectations, the 
more likely it is that the person will implement the behaviour. However, he cautions that 
a strong intent may not lead to a desired outcome since unexpected barriers (personal, 
environmental) could impede an individual’s intent. 
Studies that have examined factors associated with adherence have identified 
interpersonal aspects of care such as the patient-provider relationship a key variable to 
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facilitate adherence (Chesney et al., 2000; Ickovics and Meade, 2002; Remien et al., 
2003). Adherence is more likely to occur if the individual has a positive relationship with 
a health care provider who also shows an interest in managing their illness (Blackwell, 
1992). The internal consistency reliability coefficient for the full seven subscales was 
α=0.48 Table 4-2. To facilitate comparison among the subscales, scores were linearly 
transformed to a 0-100 scale. 
Table 4-2: Cronbach's alpha for ADQ constructs 
 
ADQ constructs 
 
No. of Items 
Cronbach’s 
alpha 
 
Perceived severity 
 
4 
 
α = 0.30 
Perceived susceptibility 3 α = 0.50 
Perceived benefits 4 α = 0.10 
Perceived barriers 4 α = 0.35 
Intentions 4 α = 0.29 
Interpersonal aspects of care 8 α = 0.61 
Full instrument  α = 0.48 
 
ADQ subscales 
The ADQ perceived susceptibility subscale comprised three questions such as ‘No 
matter what I do, there’s a good chance of my HIV getting worse.’ Two of the three 
items were reverse scored, where higher scores indicated greater perceived susceptibility 
to advanced HIV disease. The perceived severity of HIV as a condition consisted of 
four questions which included ‘There are many diseases more severe than HIV’, of 
which two items were reverse scored to yield a total score where higher scores 
represented higher perceived severity of HIV disease. The perceived benefits of ART 
medication construct comprised four questions measuring benefits of ARV treatment 
such as ‘The benefits of my treatment plan outweigh any problems I might have in 
following it’. Two of the four items were reverse scored to produce a total score in 
which higher scores represented higher perceived benefits of taking ART medication. 
Perceived barriers of ART construct consisted of four questions such as ‘Lots of things 
get in the way of following my treatment plan,’ of which two were reverse scored, where 
higher values represented higher perceived barriers to adhering to the ART treatment 
plan. The intentions to adhere to ART construct comprised four questions which 
included ‘I have made a commitment to follow my treatment plan,’ of which two were 
125 
 
reverse scored. Higher values indicated stronger intentions to adhere to the ART 
treatment plan. Finally, the interpersonal aspects of care construct consisted of eight 
questions such as ‘The doctors and other health staff treat me in a very friendly and 
courteous manner.’ Four items were reverse scored, where higher scores indicated 
greater perceived perceptions of the type of care and treatment received from health 
care staff. Reverse scoring was used to guard against participants’ indicating one type of 
response. Coding was adjusted to obtain a single score reflecting the overall direction of 
the item. The ADQ subscales and associated items utilized in this study are outlined in 
Table 4-3  below. 
Table 4-3: Adapted ADQ scale 
HBM constructs of ADQ Scale item 
Perceived susceptibility 1. I expect to be free of HIV in the future* 
 2. No matter what I do, there’s a good chance of my 
HIV getting worse 
 3. My body will fight off HIV in the future* 
Perceived severity 1. There are many disease more severe than HIV* 
 2. HIV is not as bad as people say* 
 3. HIV is a terrible disease 
 4. There is little hope for people with HIV 
Perceived benefits 1. The benefits of my treatment plan outweigh any 
problems I might have in following it 
 2. My treatment plan is too much trouble for what I get 
out of it* 
 3. Because my treatment plan is too difficult it is not 
worth following* 
 4. Following my treatment plan is better for me than not 
following my treatment plan 
Perceived barriers 1. Lots of things get in the way of following my 
treatment plan 
 2. I need more assistance in order to follow my 
treatment plan 
 3. I get the help I need to carry out my treatment plan* 
 4. I am able to deal with my problems in following my 
treatment plan* 
Other ADQ constructs Item 
Intentions 1. I have made a commitment to follow my treatment 
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HBM constructs of ADQ Scale item 
plan 
 2. Following my treatment plan is not in my plans* 
 3. I intend to follow my treatment plan 
 4. I have no intentions of following my treatment plan* 
Interpersonal aspects of 
care 
1. The doctors and other health staff sometimes ignore 
what I tell them* 
 2. The doctors and other health staff listen carefully to 
what I have to say 
 3. The doctors and other health staff answer all my 
questions 
 4. Sometimes the doctors and health staff use medical 
terms without explaining what they mean* 
 5. I trust that the doctors and other health staff have my 
best interest at heart 
 6. The doctors and other health staff act like I’m wasting 
their time* 
 7. The doctors and other health staff treat me in a very 
friendly and courteous manner 
 8. The doctors and other health staff show little concern 
for me* 
* Item reverse scored 
4.5.2.12 Quality of Life – HIV/AIDS targeted quality of life questionnaire 
(HAT-QoL) 
The HIV/AIDS-targeted quality of life instrument (HAT-QoL) was initially developed 
by Holmes and Shea (1997) with nine quality of life dimensions and 42 items. It was 
subsequently revised by Holmes and Ruocco (2008) with the same number of 
categories, but reduced to 34 items. For this study, a two-item dimension on sexual 
function was not included since this was assessed in the MSAS. The final instrument 
consisted of 32 items and inquired about “how the virus has affected your daily life 
during the past month.” Responses ranged from 1 (all the time) to 5 (none of the time). 
Eight questions were reverse scored: Overall function – “in the past 4 weeks, I’ve been 
satisfied with my physical activity”; all four questions in the Life satisfaction dimension; 
and all three questions in the Provider trust subscale. The total score was obtained by 
summing up the responses in the individual dimensions, with higher scores indicating 
higher quality of life. To facilitate comparison among the subscales, the sum of the 
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responses were linear-transformed to a 0-100 scale. Cronbach’s alphas for five of the 
eight dimensions were robust (Table 4-4), with good internal consistency for the 
remaining three items (life satisfaction, α=0.69; medication worries, α=0.62; and 
provider trust, α=0.65). 
Table 4-4: Cronbach's alpha for HAT-QoL 
Dimension  # Items Cronbach’s alpha (α) 
Overall function 6 0.79 
Life satisfaction 4 0.69 
Health worries 4 0.84 
Financial worries 3 0.89 
Medication worries 5 0.62 
HIV mastery 2 0.75 
Disclosure worries 5 0.78 
Provider trust 3 0.65 
Full Scale 32 0.87 
4.5.2.13 The HIV general knowledge scale 
The HIV knowledge scale (Appendix L, Section 11) had 15 items testing HIV and 
AIDS knowledge, with responses of true, false and don’t know. It was adapted from 
questions located in multiple sources (Messiah et al., 1998; Carey and Schroder, 2002; 
Humana, 2002; Ananth and Koopman, 2003; Iliyasu et al., 2006; Balfour et al., 2010). 
Although multiple sources were consulted for appropriate questions, only those that 
were relevant for the population and those in which the knowledge had not changed at 
the time of the study were selected. Correct answers for the questions were as follows - 
True (8) and False (7). Don’t know answers were graded as being incorrect. The 15-item 
knowledge scale had good internal consistency with a coefficient alpha of 0.71. Each 
correct response was awarded a score of “1”, while incorrect or “don’t know” responses 
were assigned a score of “0”. A total score was obtained from the sum of all correct 
responses. 
4.5.2.14 The HIV treatment knowledge scale 
The HIV treatment knowledge scale (Appendix L, Section 11) of 20 questions were 
adapted from a validated 21-item questionnaire (Balfour et al., 2010) with true, false and 
don’t know responses. These questions were used to gauge knowledge about ART, side 
effects and the immune system. Correct answers for the questions were as follows - 
True (9) and False (11). Don’t know answers were graded as being incorrect. Internal 
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consistency for the final 20-item scale was good (α=0.75). Each correct response was 
awarded a score of “1”, while incorrect or “don’t know” responses were assigned a 
score of “0”. A total score was obtained from the sum of all correct responses. 
4.5.2.15 ART medication adherence  
AACTG adherence instruments 
The Adult AIDS Clinical Trials Group (AACTG) adherence instruments were used as a 
self-reported measure of adherence (Chesney et al., 2000). These instruments were 
designed by a group of researchers and healthcare providers in the United States (US), 
and   have been widely used in the US and internationally (Power et al., 2003; Sethi et al., 
2003; Murphy et al., 2004; Reynolds et al., 2004; Simoni, Frick and Huang, 2006; 
Schonnesson et al., 2007; Mo and Mak, 2009; Jaquet et al., 2010). A modified version of 
the instruments was used in this study as described below. 
ART adherence measures for this study 
Adherence in this study was measured through self-reports (Ndubuka and Ehlers, 2011; 
Teshome et al., 2015) and utilized three ordered categories of adherence: recent non-
adherence; recent adherence, but distal non-adherence; and always adherent. Although 
there was a short recall period of four days and the weekend, participants were also 
queried on an extended period of non-adherence of three months. Respondents were 
queried on ART medication use during the four weekdays and weekend prior to the 
interview, and a global question on the last time missed (distal non-adherence).Recent 
non-adherence was classified as non-adherence during the past four days or weekend 
prior to the interview. Participants were asked to respond to the question: “During the 
past 4 days, on how many days have you missed taking all your doses – None; 1-day; 2-
days; 3-days; 4-days?” and “Did you miss any of your HIV medications last weekend – 
Yes, No?” Participants who reported 1, 2, 3, or 4 weekdays missed and ‘Yes’ to the 
weekend question were coded as being recently non-adherent. Recent adherence (but 
distal non-adherence) referred to those who did not miss doses in the past four days 
or weekend but missed anywhere from the past week to three months. Questions 
included the past 4 days and weekend questions above, plus “When was the last time 
you missed any of your HIV medications – within the past week; 1-2 weeks ago; 2-4 
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weeks ago, 1-3 months ago; more than 3 months ago; never skipped/missed 
medications.” Participants who reported ‘none’ for past 4 days and ‘No’ for the 
weekend, but missed any period from the past week to three months were coded as 
being recently adherent, but distal non-adherent. Finally, always adherent meant 
participants reported never missing doses during the last 4 weekdays, weekend, and 
from the past week to 3 months. Participants who reported ‘none’ to the past 4 days, 
‘no’ to the weekend, and ‘never’ to the last time missed questions were coded as always 
adherent. 
4.6 Analysis 
4.6.1 Data management and quality control 
All questionnaires were labelled with a unique participant identification number, and 
included the clinic name, Region, date and time of interview. The researcher reviewed 
each completed questionnaire for missing data and inconsistencies. Once resolved, the 
questionnaire was filed in a secure location. All forms with personal identifiable 
information were kept in separate files from the data collection forms. The author 
entered the pre-coded questionnaire data into an Epi-Info, version 7.1.0.6 database 
(CDC, 2012). 
The entries in the database were double-checked by two university students. Any 
discrepancies found were cross-checked against the relevant questionnaire and corrected 
as warranted. No missing data was identified during this exercise. The data set was then 
transferred to Microsoft Excel (2010) and subsequently imported into Stata for further 
management and analysis. The final data set was further scrutinized in Stata. The 
researcher checked the continuous variables for outliers and other inconsistencies using 
tabulations and cross-tabulations. Histograms were used to check outliers for numerical 
variables and to assess normal distributions. Inconsistent data was corrected or coded as 
missing after cross-checking against original questionnaires.  
4.6.2 Statistical analysis 
Analysis was performed using Stata-IC, version 13.1 (StataCorp, 2014).Categorical 
variables with several groups were simplified when appropriate by merging categories: 
When necessary continuous variables were categorised and the choice of categories was 
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based on studies in the literature or otherwise selected to suit the distribution in the 
study. The normality of the distributions for continuous variables was assessed with q-q 
plots, histograms and the Shapiro-Wilk test. Non-parametric tests were used whenever 
variables violated the assumptions of parametric tests.  Multiple regression models for 
Chapters 6 and 7 were set up to examine the relationship between several independent 
(predictor) variables and each dependent (outcome variable) together, and to determine 
which independent variables best predict the outcome after adjusting for other factors. 
Initial univariate testing was done to identify the explanatory variables that seemed 
associated with the outcome, and all those with a p-value of less than 0.1 were included 
in the regression models.  Results were presented as odds ratios (OR) or coefficients (β) 
with 95% confidence intervals (CI). All other associations were considered significant at 
p< 0.05. The statistical methodologies for Chapters 5 through 8 are presented below. 
Chapter 5 
The distributions of explanatory variables (sociodemographic, pregnancy-related, 
psychological, health behaviours, and general HIV knowledge) were summarised for 
HIV-negative and HIV-positive women separately. For categorical variables percentages 
are displayed, and for continuous variables means with standard deviations (SD), or 
medians with interquartile range (IQR). To test for a different distribution between 
HIV-negative and HIV-positive women the independent samples t-test or the Wilcoxon 
Mann-Whitney test was used for continuous variables. For categorical explanatory 
variables, the chi-square test or Fisher’s exact test was used as warranted. 
Chapter 6 
The outcomes analysed in this chapter were as follows: prenatal vitamin knowledge, 
prenatal vitamin use, alcohol use and tobacco use (binary); and healthy eating 
(continuous). Explanatory factors included: sociodemographic (age, race, religion, 
marital status); pregnancy (gestation, parity); psychosocial (domestic violence, 
depression, suicidal ideation); health behaviour (prenatal vitamin intake, healthy eating, 
general beliefs in medicine, prenatal vitamin knowledge, and alcohol and tobacco use). 
Chi-square or Fisher’s exact tests were performed to test associations between 
categorical explanatory and outcome variables. The independent samples t-test, or the 
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non-parametric equivalent Wilcoxon rank-sum (Mann-Whitney) test were used to test 
the association between binary explanatory variables and the continuous outcome 
variable. One way analysis of variance (ANOVA) was used to test the association 
between a categorical explanatory variable and the continuous outcome. Multiple 
logistic regression was used to assess which factors may determine each of the binary 
outcomes (a separate model for each) and multiple linear regression was used to assess 
which factors may determine healthy eating habits. 
Chapter 7 
 The outcome analysed in this chapter was ART adherence (ordinal). Explanatory 
factors included: sociodemographic (age, race, religion, marital status); pregnancy 
(gestation, parity); psychosocial (domestic violence, depression, suicidal ideation, PTSD, 
coping); health behaviour (prenatal vitamin intake, healthy eating, general beliefs in 
medicine, prenatal vitamin knowledge, and alcohol and tobacco use); HIV diagnosis, 
disclosure and support; ART and ART-related factors (CD4 count, type of regimen, 
HIV general and treatment knowledge). 
To test associations between categorical explanatory variables and the ordinal adherence 
outcome, univariate ordinal logistic regression was used. For continuous explanatory 
factors, Spearman’s rank correlation coefficient and test were used. Multiple ordinal 
logistic regression was then used to assess which factors are associated with adherence. 
Chapter 8 
The outcome analysed in this chapter was again ART adherence (ordinal) and the 
explanatory factors (all ordinal) were the ADQ constructs (perceived susceptibility, 
perceived severity, perceived benefits, perceived barriers, interpersonal aspects of care 
and intentions). Descriptions of the responses to the ADQ constructs were reported as 
numbers and percentages in each category and presented in figures. For many 
constructs little variability in responses was found, in the sense that almost all 
respondents provided responses in one of two adjacent categories, typically agree and 
strongly agree, or disagree and strongly disagree.  Subsequently, only ADQ constructs 
with sufficient variation in responses were tested for association with the level of 
adherence using Spearman’s rank correlation coefficient and test.  
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Chapter 5 - Characteristics of pregnant women with and 
without HIV 
5.1 Introduction 
The previous chapter dealt with a discussion on the methodology for the cross-sectional 
studies on general and ART adherence behaviours. In this first chapter for the results of 
the analysis of adherence among pregnant women with and without HIV, I will discuss 
the additional settings used for the study, and characteristics of the HIV-negative and 
HIV-positive women. 
5.2 Characteristics of HIV-positive and uninfected pregnant women 
The following section outlines the characteristics of HIV-positive and uninfected 
women. 
5.2.1 Socio-demographic characteristics 
Age and marital status were the only two socio-demographic characteristics which 
differed significantly between HIV-positive and HIV-negative women (Table 5-1). HIV-
positive women were older, with a median 29 years of age, while the HIV-negative 
women had a median age of 23 years. In terms of marital status, more HIV-negative 
women were in a partnered relationship than HIV-positive women. 
Table 5-1: Socio-demographic characteristics 
Characteristic HIV-negative 
(n= 108)       n (%) 
HIV-positive 
(n = 108)    n (%) 
p-value 
Region7 
Reg 3/6 
Reg 4 
 
16 (14.8) 
92 (85.2) 
 
14 (12.96) 
94 (87.04) 
p=0.69 
Age  
15-24 
25-34 
35-44 
 
62 (57.4) 
39 (36.1) 
7 (6.5) 
 
28 (25.9) 
63 (58.3) 
17 (15.7) 
p <0.001* 
Race 
African 
Mixed 
East Indian 
 
42 (38.9) 
37 (34.3) 
21 (19.4) 
 
49 (45.4) 
44 (40.7) 
12 (11.1) 
p=0.12 
                                                 
7 Regions 3 and 6 were combined since they are two urban regions with a small number of respondents 
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Characteristic HIV-negative 
(n= 108)       n (%) 
HIV-positive 
(n = 108)    n (%) 
p-value 
Other 8 (7.4) 3 (2.8) 
Religion 
Christian 
Non-Christian 
 
94 (87.0) 
14 (13.0) 
 
98 (90.7) 
10 (9.3) 
p=0.39 
Education 
None-Primary 
Secondary 
Post-Secondary -University 
 
13 (12.0) 
82 (75.9) 
13 (12.0) 
 
16 (14.8) 
83 (76.9) 
9 (8.3) 
p=0.59 
Marital Status 
Single 
Married 
Common-law 
 
24 (22.2) 
28 (25.9) 
56 (51.9) 
 
36 (33.3) 
13 (12.0) 
59 (54.6) 
p=0.02* 
Employed 
Yes 
No 
 
42 (39.9) 
66 (61.1) 
 
49 (45.4) 
59 (54.6) 
p=0.34 
Income – main source 
Family 
Job 
Partner 
 
4 (3.7) 
42 (38.9) 
62 (57.4) 
 
10 (9.3) 
49 (45.4) 
49 (45.4) 
p=0.10 
Home ownership 
Own-home 
Rental 
Other 
 
58 (53.7) 
35 (32.4) 
15 (13.9) 
 
65 (60.2) 
25 (23.2) 
18 (16.7) 
p=0.31 
5.2.2 Pregnancy-related characteristics 
The number of live births differed significantly between the two groups. HIV-positive 
women reported more live births than HIV-negative women, (Table 5-2). Forty-one 
percent of the HIV-positive women had more than two children compared with 14.8% 
of HIV-negative women. Gestational age was higher among HIV-negative women than 
those who were HIV-positive. HIV-positive women reported more pregnancies than 
HIV-negative women. Finally, more HIV-positive women had unwanted pregnancies 
than HIV-negative women. 
Table 5-2: Pregnancy-related characteristics 
Characteristic HIV-negative 
(n=108)   n(%) 
HIV-positive 
(n=108)      n(%) 
p-value 
Live births (Median, IQR) 0, 0-2 2, 1-3 p<0.001* 
Live birth groups 
0 
1-2 
>2 
 
56 (51.9) 
36 (33.3) 
16 (14.8) 
 
24 (22.2) 
40 (37.0) 
44 (40.7) 
 
p<0.001* 
Gestation (Median, IQR) 30, 22-36 26.5, 21-32 p=0.02* 
Parity    
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Characteristic HIV-negative 
(n=108)   n(%) 
HIV-positive 
(n=108)      n(%) 
p-value 
Primiparous 
Multiparous 
56 (51.9) 
52 (48.2) 
24 (22.2) 
84 (77.8) 
 
p<0.001* 
Planned/wanted pregnancy 
Wanted 
Unwanted 
 
48 (44.4) 
60 (55.6) 
 
31 (28.7) 
77 (71.3) 
 
 
p=0.02* 
5.2.3 Psychological and social characteristics 
Domestic violence did not differ significantly between the two groups. Although the 
mood disorders of depression and suicidal ideation did not differ significantly between 
the women, those who were HIV-positive experienced somewhat more mood disorders 
than those who were HIV-negative (Table 5-3). 
Table 5-3: Psychosocial characteristics 
Characteristic HIV-negative 
(n=108)       n(%) 
HIV-positive 
(n=108)   n(%) 
p-value 
Domestic violence 
HITS-negative 
HITS-positive 
 
81 (96.4) 
3 (3.6) 
 
69 (94.5) 
4 (5.5) 
p=0.71 
Depression 
None-minimal 
Mild 
Major depression 
 
42 (38.9) 
39 (36.1) 
27 (25.0) 
 
40 (37.0) 
32 (29.6) 
36 (33.3) 
p=0.36 
Suicidal ideation 
No 
Yes 
 
93 (86.1) 
15 (13.9) 
 
85 (78.7) 
23 (21.3) 
p=0.15 
5.2.4 Health behaviour and knowledge characteristics 
Among the health behaviours and knowledge characteristics (Table 5-4), only vitamin 
intake, beliefs about medication and general HIV knowledge differed significantly 
between HIV-positive and HIV-negative women. More HIV-positive women (82%) 
than HIV-negative women (68%) took daily vitamin supplements. In terms of general 
overuse of medication, more HIV-negative women than HIV-positive women felt that 
doctors prescribed too many medications. Similarly, for the general harm subscale, HIV-
negative women had stronger beliefs than HIV-positive women that medications do 
more harm than good. However, on the general benefit subscale, more HIV-positive 
women, than HIV-negative women felt that there were positive outcomes (living longer 
and better lives) associated with taking medications. 
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Table 5-4: Health behaviour and knowledge characteristics 
Characteristic HIV-negative 
(n=108)    n (%) 
HIV-positive 
(n=108)    n (%) 
p-value 
Experience taking pills 
No difficulty 
Unpleasant 
 
81 (75.0) 
27 (25.0) 
 
91 (84.3) 
17 (15.7) 
p=0.09 
Readiness to take pills 
Usually-always 
Rarely-never 
 
22 (20.4) 
86 (79.6) 
 
23 (21.3) 
85 (78.7) 
p=0.87 
Knowledge of prenatal 
vitamins 
Correct knowledge 
Incorrect knowledge 
 
 
70 (64.8) 
38 (35.2) 
 
 
70 (64.8) 
38 (35.2) 
p=1.0 
Vitamin intake in past month 
None 
Weekly 
Daily 
 
6 (5.6) 
29 (26.9) 
73 (67.6) 
 
5 (4.6) 
15 (13.9) 
88 (81.5) 
p=0.05* 
Nutritional health behaviour 
Nutrition score 
Total score  
Median (IQR) 
12 (10-13.5) 
0-16 
Median (IQR) 
12 (10-14) 
0-16 
p=0.62 
Beliefs about medicine  
(BMQ-G) 
 
General harm 
General overuse 
General benefit 
Total score 
Mean (SD) 
 
11.6 (2.0) 
Median, IQR 
13, 12-14 
15, 13-16 
4-20 
Mean (SD) 
 
9.7 (1.5) 
Median, IQR 
10, 9-12 
16, 15-16 
4-20 
 
 
p<0.001* 
 
p<0.001* 
p<0.001* 
General HIV knowledge 
 
Total score 
Median, IQR 
11, 9-13 
15 
Median, IQR 
 13, 11-14 
15 
p<0.001* 
Alcohol use 
Never 
1-2 times a week 
1-3 times a month 
 
96 (88.9) 
0 (0) 
12 (11.1) 
 
93 (86.1) 
1 (0.9) 
14 (13.0) 
p=0.68 
 
 
Tobacco use 
Never 
Past month 
≥ 1 year 
 
96 (88.9) 
2 (1.9) 
10 (9.3) 
 
87 (80.6) 
1 (0.9) 
20 (18.5) 
p=0.12 
Results for HIV knowledge (Table 5-5) suggest that there is a significant difference 
between the distribution of HIV knowledge scores of HIV-negative women and that of 
HIV-positive women. HIV-positive women had a higher knowledge score than the 
HIV-negative women. 
There was high knowledge (over 80%) from both HIV-negative and HIV-positive 
women respectively (Table 5-5) on HIV risk factors and modes of adult HIV 
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transmission: having many sexual partners, through a blood transfusion, and through 
sex without using condoms. However, both groups of women harboured 
misconceptions about how HIV was not transmitted, such as, mosquito bites and 
donating blood. In terms of mother-to-child transmission, knowledge was high for two 
of the three modes of transmission, pregnancy and breastfeeding. Both HIV-negative 
and HIV-positive women did not respond with the correct answer to the question that 
HIV transmission could also occur during delivery. 
The general HIV knowledge questions (Table 5-5) that differed significantly between 
the two groups were as follows: 
 Q3: It is possible to get HIV from using public toilets (F) 
 Q5: It is possible to get HIV from mosquito bites (F) 
 Q6: It is possible to get HIV from sharing food or utensils with a person 
who has HIV/AIDS (F) 
 Q8: Using a condom every time you have sex can protect against HIV 
transmission (T) 
 Q11: A woman with HIV can transmit the virus to her baby during 
breastfeeding (T) 
 Q12: All pregnant women with HIV/AIDS will have babies born with HIV 
(F) 
 Q13: You can always tell that a person has HIV/AIDS by just looking at 
him/her (F) 
 Q15: Taking HIV medication (ARVs) can help reduce mother-to-child 
transmission during pregnancy (T) 
Table 5-5: HIV knowledge questions 
 
Knowledge item                               
HIV-
negative 
 n (%) 
correct 
HIV-
positive 
n (%) 
correct 
 
 
 
p-value 
1. It is possible to get HIV from having many 
sexual partners (T) 
95 (87.9) 94 (87.0)  
p=0.84 
2. It is possible to get HIV from a blood 
transfusion (T) 
96 (88.9) 101 (93.5)  
p=0.23 
3. It is possible to get HIV from using public 
toilets (F) 
80 (74.1) 93 (86.1)  
p=0.03* 
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Knowledge item                               
HIV-
negative 
 n (%) 
correct 
HIV-
positive 
n (%) 
correct 
 
 
 
p-value 
4. It is possible to get HIV from donating 
blood (F) 
35 (32.4) 35 (32.4)  
p=1.0 
5. It is possible to get HIV from mosquito bites 
(F) 
64 (59.6) 84 (77.8)  
p=0.004* 
6. It is possible to get HIV from sharing food 
or utensils with a person who has 
HIV/AIDS (F) 
 
86 (79.6) 
 
102 (94.4) 
 
 
p=0.001* 
7. A person infected with HIV can transmit the 
virus to his/her sexual partner during sex 
without a condom (T) 
 
106 (98.2) 
 
107 (99.1) 
 
p=0.56 
 
8. Using a condom every time you have sex can 
protect against HIV transmission (T) 
 
84 (77.8) 
 
102 (94.4) 
 
p=0.0004* 
9. A pregnant woman with HIV can transmit 
the virus to her unborn baby during 
pregnancy (T) 
 
88 (81.5) 
 
87 (80.6) 
 
 
p=0.86 
10. A pregnant woman with HIV can transmit 
the virus to her baby during delivery (T) 
 
49 (45.4) 
 
61 (56.5) 
 
 
p=0.10 
11. A woman with HIV can transmit the virus to 
her baby during breastfeeding (T) 
 
87 (80.6) 
 
101 (93.5) 
 
 
p=0.005* 
12. All pregnant women with HIV/AIDS will 
have babies born with HIV (F) 
 
65 (60.2) 
 
101 (93.5) 
 
p<0.001* 
13. You can always tell that a person has 
HIV/AIDS by just looking at him/her (F) 
 
96 (88.9) 
 
107 (99.1) 
 
 
p=0.002* 
14. There is a cure for HIV/AIDS (F) 
 
53 (49.1) 59 (54.6)  
p=0.42 
15. Taking HIV medication (ARVs) can help 
reduce mother-to-child transmission during 
pregnancy (T) 
 
84 (77.8) 
 
102 (94.4) 
 
 
p=0.0004* 
Beliefs about HIV differed significantly between the HIV-positive and negative women 
(Table 5-6).  More HIV-positive than HIV-negative women believed that it was not 
possible to get HIV through witchcraft. Similarly, over two-thirds (71%) of the HIV-
positive and 55% of HIV-negative women believed that bush medicine or herbs could 
not cure HIV. 
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Table 5-6: HIV beliefs' questions 
 
Beliefs’ item 
HIV-
negative 
 n (%) 
HIV-
positive 
n (%) 
 
p-value 
 
1. It is possible to get HIV through a 
curse or obeah (witchcraft) 
True 
False 
Don’t know 
 
 
2 (1.9) 
82 (75.9) 
22 (22.2) 
 
 
3 (2.8) 
94 (87) 
11 (10.2) 
 
 
 
p=0.05* 
2. The use of bush medicine/herbs can 
cure HIV/AIDS 
True 
False 
Don’t know 
 
 
8 (7.4) 
59 (54.6) 
41 (38) 
 
 
5 (4.6) 
77 (71.3) 
26 (24.1) 
 
 
 
p=0.04* 
 
5.3 Characteristics of the HIV-positive women 
The data presented in the following sections applies only to the HIV-positive women, 
since some questions were only relevant for this group. 
5.3.1 Diagnosis and disclosure characteristics 
Less than twenty percent (18.5%) of the women were diagnosed with HIV in their 
current pregnancy at the time of interview. The median time since HIV diagnosis was 
182 weeks. For over fifty percent (56.5%) of the women, this was not their first 
pregnancy since diagnosis. Overall, most women (92.6%) had disclosed their HIV status 
to at least one person, family, friend or partner. More than one-third (35.2%) of the 
women did not know the HIV status of their partner. Where disclosure had taken place, 
friends and family were more supportive than partners. See Table 5-7. 
Table 5-7: Diagnosis and disclosure characteristics 
Characteristic HIV-positive                
(n/%) 
HIV diagnosis (current pregnancy) 
Yes 
No 
 
20 (18.5) 
88 (81.5) 
Time since diagnosis (weeks) 
Median, IQR 
 
182, 52-312 
1st pregnancy since diagnosis 
Yes 
No 
 
47 (43.5) 
61 (56.5) 
Disclosure of HIV status  
No 
 
8 (7.4) 
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Characteristic HIV-positive                
(n/%) 
Yes 100 (92.6) 
Disclosure to partner/spouse 
No 
Yes 
 
22 (20.4) 
86 (79.6) 
Disclosure to family 
No 
Yes 
 
31 (28.7) 
77 (71.3) 
Disclosure to friends 
No 
Yes 
 
33 (50.0) 
33 (50.0) 
HIV status of partner 
Positive 
Negative 
Don’t know 
 
34 (31.5) 
36 (33.3) 
38 (35.2) 
Family support 
No 
Yes 
 
11 (14.3) 
66 (85.7) 
Friends’ support 
No 
Yes 
 
2 (6.1) 
31 (93.9) 
Partner support 
No 
Yes 
 
18 (20.5) 
70 (79.6) 
5.3.2 ART and ART-related characteristics 
At the time of the study, all HIV-positive women had been prescribed ART. About 
one-third of the women (32.4%) were placed on ART for the first time during the 
current pregnancy. The median time period on ART was 52 weeks. Less than 50% of 
the women (43.4%) had CD4 counts greater than 500 cells/mm3. The most common 
ARV prescribed was Atripla (75.9%), a fixed dose combination (FDC) of two 
nucleoside analogue reverse transcriptase inhibitors (NRTI) of Tenofovir (TDF), 
Emtricitabine (FTC), and Efavirenz (EFV), a non-nucleoside reverse transcriptase 
inhibitor (NNRTI). (See Table 5-8). 
Table 5-8: ART and ART-related characteristics 
Characteristic             HIV-positive              (n/%) 
ART prescribed in current pregnancy 
Yes 
No 
 
35 (32.4) 
73 (67.6) 
Time on ART (weeks) 
Median, IQR 
 
52, 5-208 
CD4  
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Characteristic             HIV-positive              (n/%) 
Median, IQR 441, 325-665 
CD4 group 
≤ 350 
351-500 
> 500 
 
33 (31.1) 
27 (25.5) 
46 (43.4) 
ARV regimens 
Atripla 
Truvada + NVP 
Combivir + NVP 
2b (AZT + Truvada + Aluvia) 
Combivir + LPV/r 
Combivir + EVF 
 
82 (75.9) 
10 (9.3) 
6 (5.6) 
5 (4.6) 
4 (3.7) 
1 (0.9) 
HIV-treatment knowledge 
Median, IQR 
Total score 
 
16, 14-17 
0-20 
5.3.3 HIV treatment knowledge 
The median score for HIV treatment knowledge was 16. Although 93.5% of the women 
were aware that ARVs helped to strengthen the immune system, only 77.8% knew that 
drug resistance could occur if ARVs were not taken in a timely manner. Many women 
(98.2%) knew that ARVs could reduce the risk of mother-to-child transmission. Gaps in 
knowledge surrounded the use of bush/herbal medication, where only 50% of women 
correctly identified that using these herbs could adversely affect the effectiveness of 
ARVs, while 78.7% knew that taking antibiotics could not protect a person from getting 
HIV as illustrated in Table 5-9. 
Table 5-9: HIV treatment knowledge questions 
Treatment knowledge  % correct  
n = 108 
 n (%) 
1. Once the viral load results are undetectable, HIV medications 
should be stopped  (F) 
 
93 (86.1) 
2. If HIV medications are not taken at the right time of day, HIV drug 
resistance can occur  (T) 
 
84 (77.8) 
3. HIV is cured when the HIV viral load blood test result is 
undetectable  (F) 
 
60 (55.6) 
4. Condoms during sex are not needed when the HIV viral load blood 
test results are at undetectable levels  (F) 
 
84 (77.8) 
5. It is better to take a half dose of HIV medications than stopping the 
HIV medications completely  (F) 
 
62 (57.4) 
6. One can get infected with a drug-resistant type of HIV  (T) 24 (22.2) 
7. HIV medications can cause unpleasant side effects (e.g. nausea, 
diarrhoea vomiting)  (T) 
 
90 (83.3) 
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Treatment knowledge  % correct  
n = 108 
8. If sexual partners are both HIV-positive, condoms are no longer 
needed  (F) 
 
94 (87.0) 
9. Treatments are available to reduce HIV medication side effects  (T) 86 (79.6) 
10. Recreational drugs (e.g. cocaine) can affect the effectiveness of HIV 
medications  (T) 
 
90 (83.3) 
11. Providing HIV medications to a pregnant woman reduces her 
baby’s risk of being infected with HIV  (T) 
 
106 (98.2) 
12. There currently exists an HIV vaccine that prevents HIV infection   
(F) 
 
40 (37.0) 
13.  HIV medication can be taken at a different time of day on 
weekends or holidays  (F) 
 
101 (93.5) 
14. The use of bush medicine could make HIV medications less 
effective  (T) 
 
54 (50.0) 
15. It is best to stop HIV medications as soon as you feel better  (F) 104 (96.3) 
16. Missing a few doses of HIV pills can increase the amount of virus in 
the body  (T) 
 
92 (85.2) 
17. After a few months it becomes less important to take HIV 
medications at the right time of day  (F) 
 
96 (88.9) 
18. HIV medications help the body’s immune system to get stronger  
(T)  
 
101 (93.5) 
19. When HIV medications work well, the HIV viral load increases  (F) 86 (79.6) 
20. Taking antibiotic medication protects a person from getting infected 
with HIV  (F) 
 
85 (78.7) 
5.3.4 Psychosocial characteristics 
Data from the analysis of the psychosocial characteristics of quality of life (HAT-QoL), 
post-traumatic stress disorder (PCL-C), coping (Brief Cope), and HIV symptoms 
assessment (MSAS-SF) are listed in Table 5-10. 
Table 5-10: Psychosocial characteristics 
Psychosocial characteristics  
HAT-QoL 
Overall function 
Life satisfaction 
Health worries 
Financial worries 
Medication worries 
HIV mastery 
Disclosure worries 
Provider trust 
Median, IQR 
91.7, 75-100 
81.3, 62.5-100 
81.3, 50-100 
100, 50-100 
100, 85-100 
75, 50-100 
20, 0-50 
100, 100-100 
PCL-C (PTSD) score 
 
Median, IQR 
27.5 (22.5-35.5) 
PCL-C (PTSD) 
PTSD-negative 
n (%) 
101 (93.5) 
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Psychosocial characteristics  
PTSD-positive 7 (6.5) 
Brief Cope 
Adaptive 
Total score 
Maladaptive 
Total score 
Mean (SD) 
45.2 (8.1)  
16-64 
21.8 (5.8) 
12-48 
MSAS-SF 
Physical symptom subscale 
Psychological symptom subscale 
Global distress index 
Total score 
Median, IQR 
0.5, 0.13-0.93 
0.9, 0-1.3 
0.8, 0.3-1.3 
0-4 
MSAS-SF 
Positive mood 
Total score 
Median, IQR 
8.5, 6-11 
0-12 
5.3.4.1 HIV quality of life 
Median scores for the HAT-QoL (Table 5-10) ranged from 20 (disclosure worries) to 
100 (finance worries, medication worries, provider trust). The women had good quality 
of life scores in all but one dimension - disclosure worries. 
5.3.4.2 Post-traumatic stress disorder 
The women had a median score of 27.5. A small percentage (6.5%) of the women met 
the criteria for PTSD (Table 5-10). 
5.3.4.3 Coping 
In terms of the Brief Cope (Table 5-10), women tended to display more adaptive coping 
mechanisms, with a mean adaptive score of 45 and a mean maladaptive score of 22. 
5.3.4.4 HIV physical and psychological symptoms 
Of the 36 symptoms evaluated on the MSAS-SF, HIV-positive women reported a 
median of 9 symptoms. The prevalence of individual symptoms ranged from zero 
percent to 91.7% (Table 5-11). Four of the 36 symptoms had over 50% prevalence: 
worrying; feeling hopeful; feeling confident; and feeling happy. Of the first 28 
symptoms measuring distress, ≥50% of the women experienced highly distressful 
symptoms: changes in the skin; sweats; and problems with urination. For the remaining 
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eight symptoms assessed, over 50% of the women had high frequencies for only the 
positive mood symptoms: feeling hopeful; feeling happy; and feeling confident. 
Table 5-11: MSAS symptom prevalence, distress and frequency 
Symptom Prevalence  
(%) 
High distressa 
(%) 
High frequencyb 
(%)   
Feeling happy 91.7 0 77.8 
Feeling confident 87.0 0 78.7 
Feeling hopeful 79.6 0 69.8 
Worrying 50.9 0 40.0 
Pain 48.2 40.4 0 
Feeling sad 46.3 0 38.0 
Difficulty sleeping 38.9 47.6 0 
Feeling drowsy 38.0 48.8 0 
Lack of energy 38.0 26.8 0 
Feeling irritable 32.4 0 40.0 
Feeling nervous 32.4 0 20.0 
Lack of appetite 29.6 34.4 0 
Sweats 27.8 70.0 0 
Numbness/tingling 25.9 42.9 0 
Vomiting 25.0 37.0 0 
Shortness of breath 23.2 40.0 0 
Dry mouth 22.2 33.3 0 
Dizziness 20.4 22.7 0 
Suicidal thoughts 19.4 0 9.5 
Change in food tastes 18.5 15.0 0 
Difficulty concentrating 18.5 15.0 0 
Feeling bloated 18.5 25.0 0 
Cough 17.6 21.1 0 
Nausea 17.6 26.3 0 
I don’t look like myself 15.7 29.4 0 
Swelling of arms/legs 14.8 31.3 0 
Itching 13.0 28.6 0 
Constipation 12.0 46.2 0 
Weight loss 11.1 8.3 0 
Diarrhoea 10.2 36.4 0 
Problems with urination 7.4 87.5 0 
Changes in skin 6.5 57.1 0 
Problems with sex 5.6 16.7 0 
Difficulty swallowing 2.8 33.3 0 
Hair loss 2.8 0 0 
Mouth sores 0 0 0 
aPercent of women with symptoms reporting 3 “quite a bit” or 4 “very much” distress 
bPercent of women experiencing symptoms of 3 “frequently” or 4 “almost constantly” 
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The HIV-positive women obtained median scores of 0.5, 0.9 and 0.8 for the physical, 
psychological symptoms and global distress index respectively. Details of this measure 
are available in Chapter 4. 
5.3.5 Adherence 
Questions on adherence (Chapter 4) queried both recent (past four days, weekend) and 
distal adherence (last time missed in past 3 months). For recent non-adherence, the 
question posed was “during the past 4 days, on how many days have you missed taking 
all your doses?” Eighty-one percent of women had not missed any doses, and 4.6% 
missed doses on all four days. There was a similar pattern of good adherence on the 
weekend, with a majority of the women not missing any doses on Saturday or Sunday. 
When asked to indicate “the last time you missed any of your HIV medications,” two-
thirds (66.7%) of the women had never missed any medication, 15.7% missed in the 
past week, and 1.9% missed over three months ago (Table 5-12). 
Table 5-12: ART adherence characteristics 
Characteristic n (%) 
Adherence (days missed past 4 days) 
None 
1 day 
3 days 
All 4 days 
 
88 (81.5) 
13 (12.0) 
2 (1.9) 
5 (4.6) 
Adherence (missed past weekend) 
Yes 
No 
 
6 (5.6) 
102 (94.4) 
Adherence (last time missed) 
Past week 
1-2 weeks ago 
2-4 weeks ago 
1-3 months ago 
> 3 months ago 
Never missed 
 
17 (15.7) 
4 (3.7) 
2 (1.9) 
11 (10.2) 
2 (1.9) 
72 (66.7) 
The reasons given by the 36 non-adherent women to the question “the last time you 
missed any of your HIV medications” are displayed in Table 5-13. The most common 
reasons for missing ART medications were forgetfulness (30.6%), being away from 
home (27.8%), and sleeping through dose time (25%). 
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Table 5-13: Reasons for any missed ART medication 
Reason for non-adherence  No. women  n(%)         n=36§ 
Forgetfulness 11 (30.6) 
Being away from home 10 (27.8) 
Slept through dose time 9 (25.0) 
Throwing up 6 (16.7%) 
Felt depressed/overwhelmed 5 (13.9) 
Felt sick 4 (11.1) 
To avoid side effects 4 (11.1) 
Busy with other things 3 (8.3) 
Ran out of pills 2 (5.6) 
Felt healthy 2 (5.6) 
Did not want others to see taking ART 2 (5.6) 
Too many pills to take 1 (2.8) 
Felt ART was harmful 1 (2.8) 
Note: § Number of women greater than 36 because of multiple responses 
5.3.6 Health beliefs and attitudes to ART adherence 
Four constructs of the HBM were utilised in this study to assess health beliefs and 
attitudes: perceived susceptibility to disease progression; perceived severity; perceived 
benefits; and perceived barriers. Results were as follows: The median score for the 
perceived susceptibility subscale was 6 indicating that women had a low perception of 
their susceptibility to disease progression; the mean score for perceived severity of HIV 
was 11.2, indicating low perceived severity of HIV; the median score for perceived 
benefits was 16, indicating moderate perceived benefits of taking ART medication; the 
median score for perceived barriers was 8, indicating low perception of barriers that 
could adversely affect adhering to ART treatment; and the median score for intentions 
was 12 indicating moderate intentions to take ART. 
5.4 Chapter summary 
This chapter provided a description of the remaining study sites and presented 
characteristics of: HIV-negative and HIV-positive women (demographics, pregnancy, 
psychosocial, and health behaviours and knowledge); and a separate section for HIV-
positive women with reference to: HIV diagnosis and disclosure; ART and ART-related 
characteristics; psychosocial characteristics; and adherence characteristics. 
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5.4.1 Characteristics of pregnant women with and without HIV 
Significant differences were observed for age, marital status, live births, gestation, parity, 
planned pregnancies and vitamin intake in the past month between the two groups of 
women. Although HIV-negative and infected women had high HIV knowledge (>80%), 
they still had misconceptions on how HIV was not spread (mosquitoes). In addition, 
they both did not answer correctly that HIV could be transmitted during delivery. 
5.4.2 Characteristics of HIV-positive women 
Over 80% of the HIV-positive women had been diagnosed prior to the current 
pregnancy. Overall, the majority (93%) had disclosed their status to someone other than 
a healthcare provider and received support from family, partner or friend. About 68% 
had been prescribed ART prior to the current pregnancy, and 76% were on a single-
tablet regimen. Although a majority of the women (98%) were aware that ARVs could 
reduce MTCT, there were gaps in their knowledge on the effects of bush/herbal 
medications on their ARVs. In terms of psychosocial characteristics, HIV-positive 
women tended to display more adaptive coping mechanisms and there was a high 
prevalence (>80%) of positive mood symptoms (happy, confident and hopeful). Over 
80% of the pregnant women had not reported missing doses of ART within the past 
four days and two-thirds never missed in the past three months. 
Constructs of the HBM as measured with the ADQ suggested that women did not 
perceive themselves vulnerable to worsening HIV disease as indicated by the low scores 
for perceived susceptibility and severity. Perceived barriers’ scores that could also 
adversely impact their ART were also low. 
After presenting the characteristics of the study population - pregnant HIV-positive and 
uninfected women, the next chapter (Chapter 6) will present the findings of general 
adherence to key health behaviours in pregnancy.  
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Chapter 6 - Adherence patterns to prenatal vitamins and 
pregnancy health behaviours 
6.0 Abstract 
Objective: To examine general adherence to pregnancy health behaviours among HIV-
negative and HIV-positive pregnant women. 
Methods:  A cross-sectional study was conducted on 216 HIV-negative and HIV-
positive pregnant women at 12 primary care clinics. An interviewer-administered 
questionnaire determined relationships between pregnancy-related behaviours (prenatal 
vitamins, healthy diet, alcohol and tobacco use), demographic and psychosocial 
characteristics and adherence. Chi-square or Fisher’s exact tests were performed to test 
associations between categorical explanatory and outcome variables. The independent 
samples t-test, or the non-parametric equivalent Wilcoxon rank-sum (Mann-Whitney) 
test were used to test the association between binary explanatory variables and the 
continuous outcome variable. One way analysis of variance (ANOVA) was used to test 
the association between a categorical explanatory variable and the continuous outcome. 
Multiple logistic regression was used to assess which factors may determine each of the 
binary outcomes (a separate model for each) and multiple linear regression was used to 
assess which factors may determine healthy eating habits. 
Results: Both groups of women had the same knowledge levels (65%) on the correct 
reason for taking prenatal vitamins. However, a higher proportion of HIV-positive 
women (82%) reported daily vitamin intake than those who were HIV-negative (70%). 
While both suicidal ideation (14%, 61%) and depression (21%, 63%) were high among 
HIV-negative and HIV-positive women respectively, depression was a predictor 
(p=0.03) of poor vitamin adherence only among the HIV-negative women. 
Conclusion: These findings suggest the antenatal period may provide an opportune 
moment to assess HIV-positive women for potential non-adherence to ART based on 
their patterns of prenatal vitamin adherence. The high levels of suicidal ideation and 
depression in both groups warrant urgent attention. Use of longitudinal studies to 
determine the magnitude of the problem, and RCTs to identify effective interventions 
relevant to this key population are warranted. 
6.1 Introduction 
Historically, adherence to treatment and care regimens has always been a challenge 
(DiMatteo, 2004), and this phenomenon is no different among pregnant women as was 
detailed in Chapter 1 and summarized in the studies below (Table 6-1). However, 
despite these lapses in adherence behaviour, research studies indicate that most women 
engage in healthier habits and reduce risky behaviours like alcohol use and cigarette 
smoking during pregnancy (Fingerhut, Kleinman and Kendrick, 1990; Pbert et al., 2004; 
Anderson et al., 2006). 
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Table 6-1: Summary of studies on general adherence in pregnancy 
Author Population & 
sample size 
Methods Measure of 
adherence 
Results 
van Trigt, A. 
M. et al (1994) 
Pregnant 
women; 
Netherlands; 
295 
participants;  
Cross-sectional 
study; 
Adherence to 
general 
medication, e.g. 
antibiotics, 
analgesics 
Self-report 39% 
participants 
non-adherent 
Sawicki, E. et al 
(2011) 
Pregnant 
women; 
Australia; 819 
participants 
Cross-sectional 
study; 
Adherence to 
prescribed 
medications for 
chronic 
diseases 
Self-report 59% 
participants 
non-adherent 
Oliveira-Filho, 
A. D. et al 
(2012) 
Postpartum 
women; Brazil; 
130 
participants 
Cross-sectional 
study; 
Adherence to 
prescribed 
medications 
during 
pregnancy 
Self-report Non-adherent 
– 81% 
participants 
Lupattelli, 
Spigset & 
Nordeng, 2014 
Pregnant 
women; 
Multinational 
study: 18 
countries; 315 
participants 
Cross-sectional 
study; internet-
based 
Self-report 36% 
participants 
with low 
adherence 
Pregnant women have to maintain a healthy lifestyle and adhere to health 
recommendations such as healthy diet, exercise, daily uptake of prenatal vitamins (iron 
and folate), and reduce risky behaviours, such as alcohol and tobacco use. Healthy 
maternal nutrition is necessary for maintaining optimal health of both mother and 
foetus. Pregnant women require higher consumption of protein (fish, eggs), iron (red 
meat, green leafy vegetables), fibre (fruits, vegetables) and calcium from dairy products 
(Ortega, 2001; Kaiser and Allen, 2002). 
Adequate maternal nutrition including folic acid and iron supplementation is essential 
for foetal growth and prevention of chronic disease for the mother and infant (Kloeblen 
and Batish, 1999; Gardiner et al., 2008; Pena-Rosas and Viteri, 2009).  Folic acid reduces 
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the risk of neural tube defects (birth defects of the brain and spine), while iron prevents 
anaemia during pregnancy and reduces adverse pregnancy outcomes (McDonnell et al., 
1999; Scholl and Johnson, 2000; Cleves et al., 2004; Pena-Rosas and Viteri, 2009). 
Guidelines on the use of folic acid by women of childbearing age or those who are 
pregnant to reduce the occurrence of neural tube defects (NTD) were issued by USA, 
European and other countries more than two decades ago (CDC, 1992; A.A.P., 1999; 
McDonnell et al., 1999). Studies have shown that the risk of NTDs can be reduced by 
over 50% if women consume 400ug (0.4mg) folic acid daily (CDC, 1992; A.A.P., 1999). 
In addition to daily vitamin supplementation and other lifestyle changes, the HIV-
positive pregnant woman has to consistently maintain a high level of ART adherence 
throughout the duration of pregnancy while coping with a chronic illness and the 
potential risk of transmission to her baby. A study by Cohn et al. (2008) on ART 
adherence patterns and health behaviours during and after pregnancy found that missed 
prenatal vitamins were associated with non-adherence to ART. Similar findings were 
obtained by Wilson et al. (2001). Their study established that pregnant women who did 
not take all their vitamins were three times likely to be non-adherent to ART. Bardeguez 
and colleagues (Bardeguez et al., 2008) also reported that women who were adherent 
with prenatal vitamins were also likely to be adherent to their ART medication. Thus, 
are there differences in women’s adherence to health behaviours during pregnancy 
based on their HIV status, and are these health adherence behaviours linked to other 
similar types of behaviours, such as ART medication adherence?  
The objective of this chapter was to examine general health adherence to prenatal 
vitamin medication, and healthy behaviours (alcohol use, tobacco use and nutrition) 
among HIV-negative and HIV-positive pregnant women attending antenatal clinics. 
This initial analysis is to determine if HIV-positive women differ or are similar to HIV-
negative women in prenatal and health behaviours. This will then lead to an examination 
of the relationship between vitamin adherence and ART adherence among HIV-positive 
women in the chapter on ART analysis (Chapter 7). 
Specifically, the research questions were as follows: 
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 What are the levels of prenatal vitamin supplement knowledge and vitamin 
use among HIV-negative and HIV-positive pregnant women and do these 
differ between the two groups? 
 What are the levels for other prenatal health behaviours (alcohol use, tobacco 
use, and healthy nutrition) among HIV-negative and HIV-positive women, 
and do these differ between the two groups? 
 What are the predictors of vitamin knowledge, vitamin use, alcohol use, 
tobacco use and healthy nutrition among HIV-negative and HIV-positive 
women? 
 Subsequently, what is the relationship between vitamin adherence and ART 
adherence? 
6.2 Methods 
6.2.1 Measures 
A summary of the measures (knowledge and use of prenatal vitamins, healthy eating 
habits, alcohol use and tobacco use) utilized in this chapter is presented below since 
detailed descriptions are available in Chapter 4. 
Knowledge of prenatal vitamins was determined with the following question: “Doctors 
recommend that women take a multivitamin (iron/folic acid) during pregnancy for 
which of the following reasons?” Responses included: “to prevent high blood pressure;” 
“to prevent birth defects and anaemia (weak blood);” “to make strong bones;” “some 
other reason;” and “don’t know.” Women who selected “to prevent birth defects and 
anaemia (weak blood)” were considered to have correct knowledge of the benefits of 
multivitamin use during pregnancy.  
Use of prenatal vitamins (iron and folic acid) was assessed with the question: “In the 
past month, how often, if at all have you taken your iron tablets, iron syrup or 
sprinkles?” Potential responses included “every day”, “5 or 6 days a week”, “3 or 4 days 
a week”, “1 or 2 days a week” and “not at all.” Women who took their supplements at 
least “1 or 2 days a week” were considered to be taking it at least weekly. 
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The four questions which assessed nutritional health behaviour included eating a 
balanced diet, drinking milk and eating dairy products, eating more food than needed, 
and skipping meals have a minimum score of zero and a maximum score of 16. 
Use of alcohol was measured by asking participants: “During the past 30 days, how 
often have you had a drink containing alcohol - beer, wine, a mixed drink, or any kind 
of alcoholic beverage?” Possible responses ranged from 0 (never) to 6 (daily). Tobacco 
use was measured with the question: “When was the last time you used tobacco 
(cigarettes, cigars)?” Responses ranged from 0 (never used) to 3 (within the past month). 
6.2.2 Analysis 
The statistical analysis for this chapter is discussed in Chapter 4, Section 4.6  
6.3 Results 
6.3.1 Knowledge of prenatal vitamins 
Correct knowledge of the benefits of taking iron and folate acid during pregnancy was 
not associated with HIV status. 
6.3.2 Prenatal vitamin knowledge and demographic characteristics 
There were no significant differences for either HIV-negative or positive pregnant 
women between most socio-demographic variables and vitamin knowledge. Among 
HIV-negative women, only one demographic variable, main source of income (p=0.02) 
was significantly associated with knowledge, suggesting having a job was related to 
higher correct knowledge (Appendix O). 
6.3.3 Prenatal vitamin knowledge and pregnancy-related characteristics 
As can be seen in Appendix O, none of the pregnancy-related characteristics were 
associated with knowledge for either HIV-negative or HIV-positive women. 
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6.3.4 Prenatal vitamin knowledge and psychosocial characteristics 
None of the psychosocial characteristics were associated with knowledge for either 
HIV-negative or HIV-positive women as shown in Appendix O. 
6.3.5 Prenatal vitamin knowledge and health behaviour characteristics 
Among HIV-negative women, behaviour and knowledge characteristics (Appendix O) 
significantly associated with vitamin knowledge were: 
 HIV knowledge (p=0.0004) -  higher HIV knowledge scores were associated 
with correct vitamin knowledge 
 Belief that one cannot get HIV through a curse or obeah/witchcraft (p=0.01); 
women who rejected this belief (72%) were more likely to have correct vitamin 
knowledge in contrast with the other groups (≤ 46%). 
Among HIV-positive women, behaviour and knowledge characteristics significantly 
associated with vitamin knowledge (Appendix O) were: 
 Beliefs about the overuse of medication in general (p=0.01); stronger beliefs that 
doctors overuse medications were related to correct vitamin knowledge 
 HIV knowledge (p=0.02) - higher HIV knowledge scores were related to correct 
vitamin knowledge 
 Belief that one cannot get HIV through a curse or witchcraft (p=0.02) - women 
who rejected this belief (69%) were more likely to have correct vitamin 
knowledge than women in the other two categories (≤ 45%) 
 Belief that the use of bush medicine cannot cure HIV/AIDS (p=0.01) - women 
who were unsure about this belief (85%) were more likely to have correct 
vitamin knowledge than women in the other two categories (≤ 61%) 
6.3.6 Predictors of prenatal vitamin knowledge for HIV-negative women 
The explanatory variables included in the multivariate logistic regression model (Table 
6-2) with a p-value <0.1 were: Source of income; beliefs about the general harm of 
medication; and HIV knowledge. This model resulted in no significant associations with 
correct prenatal vitamin knowledge. 
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Table 6-2: Logistic regression model for vitamin knowledge (HIV-negative) 
Vitamin 
knowledge 
Unadjusted 
 
Adjusted 
  
OR 
 
95% CI 
 
p-value 
 
OR 
 
95% CI 
 
p-value 
Income source 
Job 
Family-Partner 
 
1.0 
0.3 
 
- 
0.1 – 0.8 
 
 
p=0.02 
 
1.0 
0.5 
 
- 
0.2-1.4 
 
 
p=0.22 
General harm1 
 
 
 
 
0.8§ 
 
- 
 
0.7 – 1.0 
 
 
 
p=0.07 
 
 
 
0.9§ 
 
 
 
0.7-1.1 
 
 
 
p=0.33 
HIV knowledge2 
Poor (0-7)  
Good (8-11) 
Excellent (12-15) 
 
 
 
1.2§ 
 
- 
 
1.1 – 1.5 
 
 
 
p=0.0004 
 
 
 
1.2§ 
 
 
 
1.0-1.4 
 
 
 
p=0.07 
n = 108 
§ = OR from a one unit change in score variable 
1: Score range = 4-20 
2: Score range = 0-15 
6.3.7 Predictors of prenatal vitamin knowledge for HIV-positive women 
The explanatory variables included in the multivariate logistic regression model (Table 
6-3) with a p-value of <0.1 were belief about the general overuse of medication by 
doctors, and HIV knowledge. Only HIV knowledge was significantly predicted vitamin 
knowledge, suggesting that a higher HIV knowledge score is related to correct vitamin 
knowledge. 
Table 6-3: Logistic regression model for vitamin knowledge (HIV-positive) 
Characteristic  Unadjusted Adjusted 
Vitamin 
knowledge 
 
OR 
 
95% CI 
 
p-value 
 
OR 
 
95% CI 
 
p-value 
General overuse1 
 
 
 
 
0.8§ 
 
- 
 
0.7 – 1.0 
 
 
 
p=0.01 
 
 
 
0.8§ 
 
 
 
0.7-1.0 
 
 
 
p=0.06 
HIV knowledge2 
Poor (0-7)  
Good (8-11) 
Excellent (12-15) 
 
 
 
1.3§ 
 
- 
 
1.1 – 1.6 
 
 
 
p=0.02 
 
 
 
1.3§ 
 
 
 
1.0-1.6 
 
 
 
p=0.03* 
§ = OR from a one unit change in score variable 
1: Score range = 4-20 
2: Score range = 0-15 
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6.4 Use of prenatal vitamin supplementation 
There was a significant difference in vitamin intake between HIV-negative and positive 
women (p=0.03) - more HIV-positive women (82%, n=88) took vitamins daily than 
HIV-negative women (70%, n=73). 
6.4.1 Use of prenatal vitamins and demographic characteristics 
None of the demographic characteristics were associated with use of prenatal vitamins 
for either HIV-negative or HIV-positive women. 
Table 6-4: Prenatal vitamin use and explanatory variables 
Characteristic HIV-negative 
% (n) 
HIV-positive 
% (n) 
Vitamin use Daily <Daily p-value Daily <Daily p-value 
Pregnancy Characteristics 
Parity 
Primiparous 
Multiparous 
 
80 (44) 
58 (29) 
 
20 (11) 
42 (21) 
p=0.01*  
75 (18) 
84 (70) 
 
25 (6) 
16 (13) 
p=0.29 
 
Psychosocial Characteristics 
Depression 
None 
Some 
 
80 (33) 
63 (40) 
 
20 (8) 
37 (24) 
p=0.05*  
85 (33) 
81 (55) 
 
15 (6) 
19 (13) 
p=0.63 
Health behaviour Characteristics 
General 
Harm†1 
 
 
 
 p=0.01*  
 
 p=0.78 
Note: § = Fisher’s exact test; ‡ = Mann-Whitney test; † = T-test; 1: Score range = 
4-20 
6.4.2 Use of prenatal vitamins and pregnancy-related characteristics 
Parity was the only factor significantly associated with prenatal vitamin use among HIV-
negative women, suggesting that lower parity was related to daily vitamin use. In 
contrast, there were no significantly associated variables with vitamin usage among the 
HIV-positive group (Table 6-4). 
6.4.3 Use of prenatal vitamins and psychosocial characteristics 
There was significant evidence of an association for depression and vitamin use among 
HIV-negative women, suggesting the absence of depression was related to daily vitamin 
155 
 
use. In contrast, there were no significant associations with vitamin use for the HIV-
positive women (Table 6-4). 
6.4.4 Use of prenatal vitamins and health behaviour and knowledge 
There was a significant difference in the general harm scores of weekly vitamin users 
and daily users among HIV-negative women, suggesting that stronger beliefs that 
medications are harmful were related to weekly use of vitamins. In contrast, none of the 
variables for HIV-positive women was associated with vitamin use (Table 6-4). 
6.4.5 Predictors of prenatal vitamin use for HIV-negative women 
The explanatory variables included in the multivariate logistic regression model if p-
value <0.1 were: Parity; depression; readiness to take pills; beliefs about the general 
harm of medication. This model resulted in significant predictors for the following 
variables, after adjusting for other factors, as displayed in Table 6-5:  
 Parity – suggesting that higher parity was related to less daily vitamin use. 
 Depression – suggesting that depression was associated with less daily vitamin 
use. 
 Readiness to take pills – suggesting that not taking other types of pills was 
related to not taking daily vitamins. 
 Beliefs that medications are harmful – suggesting that beliefs that medications 
are harmful were related to a reduction in daily vitamin intake. 
Table 6-5: Multivariate logistic regression model for vitamin use - HIV-negative 
Characteristic Unadjusted Adjusted 
 
Daily vitamin use 
 
OR 
 
95%CI 
 
p-value 
 
OR 
 
95% CI 
 
p-value 
Parity 
Primiparous 
Multiparous 
 
1.0 
0.3 
 
- 
0.1 – 0.8 
 
 
p=0.01 
 
1.0 
0.3 
 
- 
0.1-0.8 
 
 
p=0.01* 
Depression 
None 
Some 
 
1.0 
0.4 
 
- 
0.2 – 1.0 
 
 
p=0.05 
 
1.0 
0.3 
 
- 
0.1-0.9 
 
 
p=0.03* 
Readiness to take 
pills 
Usually-always 
Rarely-never 
 
 
1.0 
0.3 
 
 
- 
0.08 – 1.1 
 
 
 
p=0.07 
 
 
1.0 
0.2 
 
 
- 
0.05-0.8 
 
 
 
p=0.02* 
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Characteristic Unadjusted Adjusted 
General Harm1 
 
 
 
 
0.8§ 
 
- 
 
0.6 – 1.0 
 
 
 
p=0.01 
 
 
 
0.7§ 
 
 
 
0.6-0.9 
 
 
 
p=0.02* 
§ = OR from a one unit change in score variable; 1: Score range = 4-20 
6.4.6 Predictors of prenatal vitamin use for HIV-positive women 
Multivariate logistic regression analysis was not conducted since there were no variables 
with p-values less than 0.1.  
6.5 Levels of healthy eating habits 
There was no significant difference for healthy eating habits for either HIV-negative or 
HIV-positive women. 
6.5.1 Relationship between healthy eating and demographic characteristics 
Religion was the only demographic variable significantly associated with healthy eating 
habits among HIV-positive women, suggesting that women of non-Christians faith have 
healthier eating habits than women of Christian faith. Similarly, only one factor, home 
ownership was significantly associated with healthy eating among HIV-negative women, 
suggesting that living in other types of housing is related to a decrease in healthy eating 
habits. Refer to Table 6-6. 
 Table 6-6: Relationship between healthy eating habits and explanatory variables 
Characteristic  HIV-
negative 
 HIV-
positive 
 
Healthy eating Mean (SD) p-value Mean (SD) p-value 
Sociodemographic Characteristics 
Religion 
Non-Christian 
Christian 
 
10.9 (1.8)† 
11.7 (0.3) 
p=0.25  
13.1 (1.1)† 
11.6 (2.9) 
p=0.003* 
Home ownership 
Other 
Own-home 
 
11.1 (0.3)† 
12.1 (0.3) 
p=0.04*  
12.3 (2.7)† 
11.4 (2.8) 
p=0.07 
Pregnancy Characteristics 
Parity 
Primiparous 
Multiparous 
 
12.1 (2.2)† 
11.1 (2.7) 
p=0.04* 
 
 
12.4 (2.8)† 
11.6 (2.8) 
p=0.18 
 
Type of pregnancy  p=0.01*  p=0.06 
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Characteristic  HIV-
negative 
 HIV-
positive 
 
Healthy eating Mean (SD) p-value Mean (SD) p-value 
Wanted 
Unwanted 
12.3 (2.4)† 
11.1 (2.4) 
12.5 (2.7)† 
11.4 (2.8) 
Psychosocial Characteristics 
Depression 
None 
Some 
 
12.3 (2.4)† 
11.2 (2.4) 
p=0.04*  
12.5 (2.6)† 
11.3 (2.8) 
p=0.04* 
 
Suicidal ideation 
Yes 
No 
 
10.3 (2.1)† 
11.8 (2.5) 
p=0.03*  
10.3 (3.2)† 
12.1(2.5) 
p=0.02* 
 
Health behaviour Characteristics 
Alcohol use 
Never 
≥  Once weekly 
 
11.7 (2.4)† 
11.1 (3.0) 
p=0.4 
 
 
12.0 (2.7)† 
10.5 (3.2) 
p=0.05* 
Tobacco use 
Never 
≥ past month 
 
11.9 (2.3)† 
9.8 (3.0) 
p=0.004*  
11.9 (2.7)† 
11.1 (2.9) 
p=0.23 
 
Note: †= T-test;  §=ANOVA 
6.5.2 Relationship between healthy eating and pregnancy-related 
characteristics 
There was a significant difference in the nutrition scores for primiparous and 
multiparous women among HIV-negative women, suggesting that lower parity was 
related to higher nutrition scores. A significant difference was also observed in the 
nutrition scores for HIV-negative women with a wanted pregnancy and those with an 
unwanted pregnancy, suggesting that a wanted pregnancy was related to higher nutrition 
scores (Table 6-6). 
6.5.3 Relationship between healthy eating and psychosocial characteristics 
6.5.3.1 Depression and suicidal ideation among HIV-negative women 
There was a significant difference in the nutrition scores for women who had no 
depression and those with some depression, suggesting an increase in healthy eating 
habits in the absence of depression (Table 6-6). 
A significant difference in nutrition scores for women who experienced suicidal ideation 
and those who did not, suggesting a decrease in healthy eating habits with the 
occurrence of suicidal ideation (Table 6-6). 
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6.5.3.2 Depression and suicidal ideation among HIV-positive women 
There was a significant difference in nutrition scores for HIV-positive women with no 
depression and those with some depression, suggesting an increase in healthy eating 
habits in the absence of depression (Table 6-6). 
A significant difference in nutrition scores for HIV-positive women who experienced 
suicidal ideation and those who did not, suggesting a decrease in healthy eating habits in 
the presence of suicidal ideation (Table 6-6). 
6.5.4 Relationship between healthy eating and health behaviours 
There was evidence of a significant difference in the nutrition scores for HIV-positive 
women who never consumed alcohol and those who consumed at least weekly, 
suggesting an increase in healthy eating habits with the absence of alcohol consumption 
(Table 6-6). 
In addition, a significant difference was observed in the nutrition scores of HIV-
negative women who never used tobacco and those who did, suggesting an increase in 
nutrition scores in the absence of smoking (Table 6-6). 
6.5.5 Predictors of healthy eating habits among HIV-negative women 
The explanatory variables included in the multivariate linear regression model if p-value 
<0.1 were: Home ownership; parity; wanted/unwanted pregnancy; depression; suicidal 
ideation; and tobacco use. The model explains 15% of the variance for healthy eating 
among HIV-negative women (Table 6-7). 
Only tobacco use was a significant predictor of healthy eating habits, after adjusting for 
all the other variables, suggesting lower nutrition scores with tobacco use (Table 6-7).  
Table 6-7: Multivariate linear regression for healthy eating habits –HIV-negative 
Characteristic   Unadjusted Adjusted 
Healthy eating β coef 95%CI p-value β coef 95% CI p-value 
Home 
ownership 
Other 
Own-home 
 
 
0 
1.0 
 
 
- 
0.04-1.9 
 
 
 
p=0.04 
 
 
0 
0.82 
 
 
- 
-0.07- 1.7 
 
 
 
p=0.07 
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Characteristic   Unadjusted Adjusted 
Healthy eating β coef 95%CI p-value β coef 95% CI p-value 
Parity 
Primiparous 
Multiparous 
 
0 
-1.0 
 
- 
-1.9- -0.05 
 
 
p=0.04 
 
0 
-0.62 
 
- 
-1.5 – 0.3 
 
 
p=0.17 
Type of 
pregnancy 
Wanted 
Unwanted 
 
 
0 
-1.2 
 
 
- 
-2.1 - -0.3 
 
 
 
p=0.01 
 
 
0 
-0.8 
 
 
- 
-1.7 – 0.1 
 
 
 
p=0.09 
Depression 
None 
Some 
 
0 
-1.0 
 
- 
-2.0 - -0.07 
 
 
p=0.04 
 
0 
-0.5 
 
- 
-1.5 – 0.5 
 
 
p=0.31 
Suicidal 
ideation 
Yes 
No 
 
 
0 
1.5 
 
 
- 
0.2 – 2.8 
 
 
 
p=0.03 
 
 
0 
0.9 
 
 
- 
-0.5 – 2.2 
 
 
 
p=0.21 
Tobacco use 
Never 
≥ past month 
 
0 
-2.1 
 
- 
-3.6 - -0.7 
 
 
p=0.004 
 
0 
-1.4 
 
- 
-2.9 – 0.02 
 
 
p=0.05* 
6.5.6 Predictors of healthy eating habits among HIV-positive women 
The explanatory variables (Table 6-8) included in the multivariate linear regression 
model were: Religion; home ownership; wanted/unwanted pregnancy; depression; 
suicidal ideation; and alcohol use. The model explains 14% of the variance for healthy 
eating among HIV-positive women. 
Only home ownership significantly predicted healthy eating after adjusting for other 
factors, suggesting that living in a home owned by the participant or another household 
member is related to a decrease in healthy eating.  
Table 6-8: Multivariate linear regression for healthy eating -HIV-positive 
Characteristic   Unadjusted Adjusted 
Healthy eating β coef 95% CI p-value β coef 95% CI p-value 
Religion 
Non-Christian 
Christian 
 
0 
-1.5 
 
- 
-3.3 – 0.3 
 
 
p=0.03 
 
0 
-0.67 
 
- 
-2.5 – 1.1 
 
 
p=0.46 
Home ownership 
Other 
Own-home 
 
0 
-1.0 
 
- 
-2.1 – 0.07 
 
 
p=0.07 
 
0 
-1.2 
 
- 
-2.3 - -0.2 
 
 
p=0.02* 
Type of 
pregnancy 
Wanted 
Unwanted 
 
 
0 
-1.1 
 
 
- 
-2.3 – 0.03 
 
 
 
p=0.06 
 
 
0 
-0.98 
 
 
- 
-2.1 – 0.1 
 
 
 
p=0.09 
Depression       
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Characteristic   Unadjusted Adjusted 
Healthy eating β coef 95% CI p-value β coef 95% CI p-value 
None 
Some 
0 
-1.2 
- 
-2.2- -0.07 
 
p=0.04 
0 
-0.74 
- 
-1.8 – 0.4 
 
p=0.18 
Suicidal ideation 
Yes 
No 
 
0 
1.8 
 
- 
0.5 – 3.0 
 
 
p=0.02 
 
0 
1.2 
 
- 
-0.06– 2.6 
 
 
p=0.06 
Alcohol use 
Never 
≥ Once weekly 
 
0 
-1.5 
 
- 
-3.0 – 0.02 
 
 
p=0.05 
 
0 
-1.3 
 
- 
-2.8 – 0.2 
 
 
p=0.1 
6.6 Levels of alcohol and tobacco use 
There was no significant difference in alcohol and tobacco use for either HIV-negative 
or HIV-positive women. 
6.6.1 Relationship between substance use and explanatory characteristics 
6.6.1.1 Alcohol use  
Only depression was significantly associated with alcohol use (p=0.03) among HIV-
negative women, suggesting that women who did not experience depression (98%) were 
more likely to ‘never’ consume alcohol than those with some depression (83%). In 
contrast, suicidal ideation was significantly associated (p=0.01) with alcohol for HIV-
positive women (Appendix P). 
6.6.1.2 Tobacco use 
Among HIV-negative women, the following factors (Appendix P) were significantly 
associated with tobacco use: 
 Race (p=0.02) - Africans (98%) were more likely than the other two ethnic 
groups (≤ 90%) to never have used tobacco 
 Source of income (p=0.03) - employed women (98%) were more likely to never 
have used tobacco, than those supported by partners/family (83%) 
 Domestic violence (p=0.04) - women who did not experience domestic violence 
(89%) were more likely to never use tobacco than those who did (33%) 
 Depression (p=0.03) - women who did not experience depression (98%) were 
more likely to never use tobacco than those with some depression (83%) 
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 Healthy eating (p=0.004) - women with excellent (97%) healthy eating habits 
were more likely to never use tobacco than the other two categories (≤ 91%) 
In contrast HIV-positive women had fewer statistically significant factors (Appendix 
P) as follows: 
 Marital status (p=0.04) - women with partners (married or cohabiting) were 
more likely (86%) to never have used tobacco than those who were single (69%) 
 Depression (p=0.02) - women who did not experience depression (93%) were 
more likely to never use tobacco than those who experienced some depression 
(74%) 
 Suicidal ideation (p=0.04) - women who did not experience suicidal ideation 
(85%) were more likely to never use tobacco than those who did (65%) 
6.6.2 Predictors of alcohol and tobacco use 
The explanatory factors for tobacco use among HIV-negative and HIV-positive women 
were not analysed further since there were too few smokers in the study to allow all 
factors to be included in a multivariate logistic regression model. Multivariate logistic 
regression was conducted for the two significant factors of alcohol use among HIV-
positive women with a p-value of less than 0.1 - suicidal ideation, and healthy eating. 
Only suicidal ideation was a significant predictor of alcohol use as HIV-positive women 
who did not experience suicidal ideation were about three times more likely to never use 
alcohol than those who did (Table 6-9). 
Table 6-9: Multivariate logistic regression model for alcohol use - HIV-positive women 
Characteristic Unadjusted Adjusted 
 
Alcohol use 
 
OR 
 
95% CI 
 
p-value 
 
OR 
 
95% CI 
 
p-value 
Suicidal ideation 
Yes 
No 
 
1.0 
 
 
- 
 
 
p=0.01 
 
1.0 
3.4 
 
- 
1.0 – 11.3 
 
 
p=0.05* 
Healthy eating1 
5-10 
11-12 
13-16 
 
1.0 
 
 
  
 
 
p=0.09 
 
1.0 
 
1.1§ 
 
- 
 
0.9 – 1.4 
 
 
 
p=0.20 
§ = OR from a one unit change in score variable; 1: Score range = 0-16 
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6.7 Results summary 
The following is a summary of the results for the four research questions that examined 
health behaviours among HIV-positive and uninfected women. 
6.7.1 Levels (unadjusted) of prenatal vitamin knowledge and vitamin use 
What are the levels of prenatal vitamin supplement knowledge and vitamin use among HIV-negative 
and HIV-positive pregnant women and do these differ between the two groups? 
Significant difference in vitamin use only and knowledge (p=0.03) for either HIV-
positive or uninfected pregnant women. 
Other significant differences in vitamin knowledge and use for either HIV-negative or 
HIV-positive women were HIV knowledge (p=0.0004, p=0.02) and beliefs that one can 
get HIV through a curse or witchcraft (p=0.01, p=0.02). 
Source of income was only significantly associated with vitamin knowledge among HIV-
negative women (p=0.02). 
Beliefs about the overuse of medication by doctors (p=0.01) and that bush medicine can 
cure HIV (p=0.01) were only significantly associated with vitamin knowledge among 
HIV-positive women. 
Significant associations between vitamin use and these variables were found only among 
HIV-negative women: parity (p=0.01); beliefs that medications are harmful (p=0.01; 
and depression (p=0.05). 
6.7.2 Levels (unadjusted) of other prenatal health behaviours 
What are the levels for other prenatal health behaviours (alcohol use, tobacco use, and healthy nutrition) 
among HIV-negative and HIV-positive women, and do these differ between the two groups? 
No significant differences for either HIV-negative or positive women for healthy eating 
habits, alcohol, and tobacco use. 
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Significant differences for either HIV-negative or HIV-positive women between healthy 
eating and depressive symptoms were depression (p =0.04, p=0.04) and suicidal 
ideation (p=0.03, p=0.02). 
Significant associations for healthy eating and the following variables were found only 
among HIV-negative women: home ownership (p=0.04); parity (p=0.04); 
wanted/unwanted pregnancy (p=0.01); and tobacco use (p=0.004). 
Significant associations for healthy eating and the following variables were found only 
among HIV-positive women: religion (p=0.003); and alcohol use (p=0.05). 
Depression was significantly associated with alcohol use only among HIV-negative 
women (p=0.03), while suicidal ideation was significantly associated with alcohol among 
HIV-positive women (p=0.01). 
Significant difference for either HIV-negative (p=0.03) or HIV-positive women 
(p=0.02) between tobacco use and depression. 
Significant associations for tobacco use and the following variables were found only 
among HIV-negative women: race (p=0.02; source of income (p=0.03); domestic 
violence (p=0.04); and healthy eating (p=0.004). 
Significant associations for tobacco use and the following variables were found only 
among HIV-positive women: marital status (p=0.04); and suicidal ideation (p=0.04). 
6.7.3 Predictors of prenatal health behaviours 
What are the predictors of vitamin knowledge, vitamin use, alcohol use, tobacco use and healthy 
nutrition among HIV-negative and HIV-positive women? 
Predictors (multivariate logistic regression) among HIV-negative women were as 
follows: 
 Parity (p=0.01) – suggesting that higher parity was related to less daily vitamin 
use. 
164 
 
 Depression (p=0.03) – suggesting that depression was associated with less daily 
vitamin use. 
 Readiness to take pills (p=0.02) – suggesting that not taking other types of pills 
was related to not taking daily vitamins. 
 Beliefs that medications are harmful (p=0.02) – suggesting that beliefs that 
medications are harmful are related to a reduction in daily vitamin intake. 
 Tobacco use (p=0.05) - suggesting lower nutrition scores with tobacco use. 
Predictors (multivariate logistic regression) among HIV-positive women were as 
follows: 
 HIV knowledge (p=0.03) - suggesting that high HIV knowledge is related to 
correct vitamin knowledge. 
 Home ownership (p=0.02) - suggesting that living in a home owned by the 
participant or another household member is related to a decrease in healthy 
eating habits. 
6.7.4 Relationship between vitamin adherence and ART adherence 
What is the relationship between vitamin adherence and ART adherence? 
This relationship will be examined in Chapter 7 where predictors of ART adherence are 
assessed. 
6.8 Discussion 
The major questions from this study exploring general health adherence to medication 
and health behaviours were to compare adherence to prenatal vitamins and health 
behaviours (smoking, substance use, diet) and to identify the demographic, social and 
psychological factors that may help in understanding general health adherence in 
pregnancy between HIV-negative and HIV-positive pregnant women.  
6.8.1 Knowledge of and use of prenatal vitamins   
Theoretical models of behaviour change show that knowledge is necessary but not 
sufficient for behaviour change (Fisher and Fisher, 1992; Munro et al., 2007; Levy et al., 
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2014). As a first step this study aimed to establish knowledge levels and then to move 
more broadly into the other related concepts that may affect adherence.  
Both HIV-negative and HIV-positive women had the same knowledge levels (65%) on 
the correct reason for taking prenatal vitamins. However, a higher proportion of HIV-
positive women (82%) reported daily vitamin intake than those who were HIV-negative 
(70%). Levels of knowledge and use of prenatal vitamins appear to be higher than that 
obtained in prior studies (Sayers et al., 1997; Cleves et al., 2004). Better use of vitamins 
among the HIV-positive may be attributed to frequent one-to-one counselling sessions 
where health information would be reinforced and the importance of taking better care 
of their health given their HIV status. In addition, taking ART might have been a trigger 
for using their prenatal vitamins. Another possible reason supported by data from the 
women’s in-depth interviews on their experiences with ART is that they would have a 
more heightened awareness of the risks of not maintaining good health for self and 
child, and as such would be more motivated to adhere.  
The findings from this study are consistent with that obtained in other studies in the 
literature (Wilson et al., 2001; Bardeguez et al., 2008; Cohn et al., 2008), which have 
identified adherence to prenatal vitamins as being associated with ART adherence. This 
significant association may suggest that adherence issues are not exclusive to ART. Thus 
the antenatal period may provide an opportune moment to assess women for potential 
non-adherence to ART based on their patterns of adherence to prenatal vitamin 
supplementation. 
6.8.2 The effect of alcohol and tobacco use on adherence 
The majority of HIV-negative (89%, 89%) and HIV-positive women (86%, 81%) did 
not report use of alcohol or tobacco products respectively. According to a recent WHO 
report on alcohol and health (WHO, 2014a), the prevalence of heavy episodic drinking 
and alcohol dependence among females in Guyana (15+) is 1.7% and 1.9% respectively. 
Although social desirability may have influenced the women’s responses, the low 
alcohol consumption levels among the pregnant women may be a reflection of the 
generally low drinking patterns in the country. 
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6.8.3 The effect of parity on adherence 
Lower parity was associated with elevated daily vitamin use and higher nutrition scores 
only for HIV-negative women and was a predictor of vitamin use for that group. This 
finding is consistent with DeLuca and Lobel’s work on prenatal health behaviours 
(DeLuca and Lobel, 1995) where multiparous women were found to be less attentive to 
healthy practices such as modest exercise and diet. According to the authors, women 
who are experienced with the perinatal process and have previously delivered healthy 
babies are less likely to adhere to health recommendations, or too busy with caring for 
other children to pay attention to their health. One possible reason for no association 
between parity and vitamin adherence among HIV-positive women is that they are more 
concerned about their health given their HIV status and this concern supersedes their 
parity. 
6.8.4 The effect of suicidal ideation and depression on adherence 
The survey findings indicated that women in this study experienced some form of 
mental health disorder as levels of suicidal ideation and depression respectively among 
HIV-negative (14%, 61%) and HIV-positive women (21%, 63%) were alarmingly high. 
Moreover, during the in-depth interviews many women reported depressive symptoms, 
such as feeling down, sadness, suicidal thoughts, and suicidal attempts on being 
diagnosed with HIV prior to or during pregnancy. Pregnancy usually acts as a shield 
against suicide, although depression during pregnancy and the postpartum is common 
(Hartley et al., 2011; Rochat et al., 2013). The presence of depression and suicidal 
ideation were associated with poor nutrition habits for both HIV-negative and HIV-
positive women. However, depression was a predictor of poor vitamin adherence only 
among HIV-negative women. High levels of depression have also been linked to 
reduced vitamin intake among 1760 pregnant women in Zimbabwe (Matare et al., 2015). 
Similarly, as with parity discussed above, the lack of association between depression and 
vitamins for HIV-positive women may be because they were more concerned about the 
health of the unborn child than their HIV-negative counterparts.  
The finding of no association between depression and non-adherence was unexpected, 
given the high levels of depression identified in the survey and its association with 
non/suboptimal adherence as reported in the literature (DiMatteo, Lepper and 
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Croghan, 2000; Starace et al., 2002; Chesney, 2003; Psaros, Geller and Aaron, 2009; 
Edwards et al., 2013). Suicidal ideation reported by 21% of the HIV-positive pregnant 
women in the survey was found to be associated with non-adherence and is known to 
be an important predictor of suicidal attempts and completed suicide in general, but also 
among PLHIVs specifically (Cooperman and Simoni, 2005; Sherr et al., 2008a; 
Ogundipe, Olagunju and Adeyemi, 2015). About 91% of the women who were 
depressed also experienced suicidal ideation. As both depression and suicidal ideation 
were measured during one interview session (recall period of the past two weeks), more 
women could be experiencing depressive symptoms at other points throughout the 
pregnancy. 
Levels (21%) of suicidal ideation (SI) among the HIV-positive pregnant Guyanese 
participants were high compared to some countries. Nock et al study (Nock et al., 2008) 
on suicidal ideation and behaviours among non-HIV infected participants within 17 
developed and developing countries found prevalence rates in adults ranging from 3.0% 
to 16%. Rates among PLHIVs vary. Sherr et al. (2008a) study among 778 UK 
participants identified a 31% SI prevalence rate, while a study in Nigeria among 295 
PLHIVs (Ogundipe, Olagunju and Adeyemi, 2015) found a prevalence of 13.6%. In a 
pregnant non-HIV infected pregnant population of 1369 Pakistani women 11% had SI 
(Asad et al., 2010). Rates were high (78%) among 207 HIV-positive pregnant women in 
New York City (Cooperman and Simoni, 2005). These variable rates are most likely due 
to the different study methodologies, the different subgroups of people with HIV, and 
differences between HIV-positive and HIV-negative respondents. 
Having examined general adherence to pregnancy-related behaviours between HIV-
positive and uninfected pregnant women, in the following chapter (Chapter 7), I will 
examine the predictors of ART adherence among HIV-positive women. 
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Chapter 7 - Predictors of ART adherence 
7.0 Abstract 
Objective: To examine the factors contributing to pregnant women’s ART adherence. 
Methods: A cross-sectional study was done among 108 HIV-positive pregnant women 
attending 12 primary care clinics. An interviewer-administered questionnaire determined 
levels of ART and prenatal vitamin adherence, pregnancy-related adherence, 
demographic, psychosocial and ART-related factors. To test associations between 
categorical explanatory variables and the ordinal adherence outcome, univariate ordinal 
logistic regression was used. For continuous explanatory factors, Spearman’s rank 
correlation coefficient and test were used. Multiple ordinal logistic regression was then 
used to assess which factors are associated with adherence. 
Results: The absence of suicidal ideation was significantly associated (p= 0.03) with 
ART adherence. Daily prenatal vitamin use was a predictor (p=0.01) of greater 
adherence. None of the demographic, pregnancy-related, or ART-related characteristics 
were significantly associated with adherence. 67% and 19% of the women were always 
and recently non-adherent to ART respectively. 
Conclusion: While the percentage of women who were always adherent is 
commendable, there is cause for concern among those who were recently non-adherent 
given the short duration of pregnancy and implications for maternal and foetal 
outcomes. Longitudinal studies are warranted to determine the magnitude of adherence 
with appropriate evidence-based interventions thereafter. 
7.1 Introduction 
In the previous chapter, I examined general adherence to pregnancy-related health 
behaviours between HIV-positive and uninfected women. Since adherence to ART is a 
key factor in maintaining the mother’s health and reducing vertical transmission, it is 
important to determine what other variables predict adherence. In this chapter I will 
examine the relationship of other factors identified in the literature with ART 
adherence, and whether adherence behaviour to general requirements during pregnancy 
transfers to ART adherence behaviour. These factors can be grouped into three 
categories, namely treatment-related, the healthcare system and patient-related. 
Treatment-related factors include the number of pills taken, frequency of medication 
and adverse effects (Chesney, 2003; Battaglioli-DeNero, 2007). Some of these effects 
can be temporary, while some may persist. Health care system-related factors include 
access to health care services, support from health care providers in terms of providing 
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education on medications prescribed, medication reminders such as text messages and 
phone calls (Poppa et al., 2004; Battaglioli-DeNero, 2007). 
Patient-related factors include socioeconomic status, psychiatric and mental health 
issues, substance use, knowledge, beliefs, attitudes, and social support (Poppa et al., 
2004; Battaglioli-DeNero, 2007). Patient-related factors like adherence behaviour to a 
non-ART medication regimen such as prenatal vitamins may be related to ART 
adherence behaviour and this relationship is examined in this chapter. Prenatal vitamin 
adherence was initially discussed in Chapter 6 with other pregnancy health behaviour 
characteristics. Its relevance to ART adherence has been reported in the literature 
(Wilson et al., 2001; Bardeguez et al., 2008; Cohn et al., 2008). Wilson’s cross-sectional 
study on AZT adherence among 336 pregnant women in four US cities identified 
missed prenatal vitamins as being significantly associated with incomplete Zidovudine 
adherence. Cohn and colleagues’ prospective study with 149 participants at 28 US sites 
examined ART adherence patterns and other behaviours such as illicit drug, tobacco 
and alcohol use among pregnant women. The authors reported that ART non-
adherence was likely to be higher among women who missed prenatal vitamins or used 
illicit drugs. Bardeguez et al. (2008) clinical trial in the USA on factors associated with 
antenatal and postnatal adherence among 519 participants indicated that those women 
who never missed their prenatal vitamins had better ART adherence. 
Prenatal vitamin use was examined to determine if there is any association between non-
use of vitamins and non-adherence to ART medication. Prenatal vitamin intake may 
serve as a proxy/predictor of ART medication use as highlighted in the above-
mentioned studies. An assessment of prenatal vitamin uptake of these pregnant women 
may help identify those who may be at risk for non-adherence to ART medication. In 
addition, daily intake of folic acid and iron is recommended to reduce the risk of neural 
tube defects and anaemia among babies and pregnant women respectively. Since 
prenatal vitamins are essential components for maternal and foetal health, adherence is 
an important component to assess in its own right. 
Specific objectives are as follows: 
 What is the relationship between the demographic, social, psychological, 
knowledge, and clinical factors and ART adherence? 
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 What is the relationship between vitamin adherence and ART adherence? 
7.2 Methods 
7.2.1 Measures 
The data collection instruments included the following measures for which detailed 
descriptions were presented in Chapter 4: (a) demographics; (b) general beliefs about 
medications (BMQ-G12); (c) depression and anxiety (PHQ); (d)domestic violence 
(HITS); (e) healthy nutrition, (f) knowledge and use of prenatal vitamins; (g) alcohol and 
tobacco use; (h) posttraumatic stress (PCL-C); (i) physical and emotional symptoms of 
HIV (MSAS-SF); (j) coping with HIV (Brief Cope); (k) health beliefs and attitudes 
towards ART (ADQ); (l) quality of life with HIV(HAT-QoL); (m) HIV general 
knowledge and beliefs, (n) HIV treatment knowledge; and (o) ART adherence.  
7.2.1.1 ART adherence measure 
Adherence to ART was measured via self-reports using three ordered categories of 
adherence: recent non-adherence; recent adherence, but distal non-adherence; and 
always adherent (Table 7-1). Although there was a short recall period of four days and 
the weekend, participants were also queried on an extended period of non-adherence of 
three months. Detailed descriptions of these measures are available in Chapter 4. 
Table 7-1: ART adherence & time since ART 
Adherence groups  % (n) Sensitivity 
analysis 
Recent non-adherence 19 (20) 19.4 (13) 
Recent adherence (but distal non-adherence) 15 (16) 16.4 (11) 
Always adherent 67 (72) 64.2 (43) 
Duration of ART (weeks)   
1 - 52 56.5 (61)  
53 - 260 31.5 (34)  
261 - 520 12.0 (13)  
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7.2.2 Analysis 
The statistical analysis for this chapter is discussed in Chapter 4, Section 4.6 
7.3 Results 
7.3.1 Relationship of demographic characteristics with ART adherence 
There were no significant associations between the demographic characteristics (region, 
age, race, religion, education, marital status, source of income, and home ownership) 
and ART adherence, as illustrated in Table 7-2. 
Table 7-2: Relationship between demographic factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Demographic characteristics† 
Region 
Region 3/68 
Region 4 
 
21 (3) 
18 (17) 
 
21 (3) 
14 (13) 
 
57 (8) 
68 (64) 
p=0.48 
 
Age 
15-25 
26-44 
 
28 (10) 
14 (10) 
 
6 (2) 
19 (14) 
 
67 (24) 
67 (48) 
p= 0.63 
 
Race 
E. Indian/Other 
Mixed 
African 
 
13 (2) 
20 (9) 
18 (9) 
 
13 (2) 
14 (6) 
16 (8) 
 
73 (11) 
66 (29) 
65 (32) 
p=0.65 
 
Religion 
Non-Christian 
Christian 
 
10 (1) 
19 (19) 
 
10 (1) 
15 (15) 
 
80 (8) 
65 (64) 
p=0.35 
 
Education 
≤ Primary 
≥ Secondary 
 
13 (2) 
20 (18) 
 
25 (4) 
13 (12) 
 
63 (10) 
67 (62) 
p=0.90 
 
Marital Status 
Single 
Partner 
 
17 (6) 
19 (14) 
 
14 (5) 
15 (11) 
 
69 (25) 
65 (47) 
p= 0.66 
 
Income source 
Job 
Family/Partner 
 
10 (5) 
25 (15) 
 
18 (9) 
12 (7) 
 
71 (35) 
63 (37) 
p= 0.19 
 
Home ownership 
Other 
Own-home 
 
19 (8) 
18 (12) 
 
16 (7) 
14 (9) 
 
65 (28) 
68 (44) 
p= 0.82 
 
Note: † = Univariate ordinal logistic regression 
                                                 
8 Regions 3 and 6 were combined since they are two urban regions with a small number of respondents 
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7.3.2 Relationship of pregnancy-related characteristics with ART adherence 
None of the pregnancy-related characteristics (gestation, parity, and wanted/unwanted 
pregnancy) were significantly associated with ART adherence as depicted in Table 7-3.  
Table 7-3: Relationship between pregnancy-related factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Pregnancy characteristics† 
Gestation 
≤ 26 weeks 
≥ 27 weeks 
 
20 (11) 
17 (9) 
 
13 (7) 
17 (9) 
 
67 (36) 
67 (36) 
p= 0.89 
 
Parity 
Primiparous 
Multiparous 
 
25 (6) 
17 (14) 
 
4 (1) 
18 (15) 
 
71 (17) 
65 (55) 
p= 0.88 
 
Type of Pregnancy 
Wanted 
Unwanted 
 
19 (6) 
18 (14) 
 
23 (7) 
12 (9) 
 
58 (18) 
70 (54) 
p= 0.33 
 
Note: † = Univariate ordinal logistic regression 
7.3.3 Relationship of psychosocial characteristics with ART adherence  
Among the psychosocial characteristics (depression, PTSD, coping, HIV physical and 
psychological symptoms, positive mood, and quality of life) only suicidal ideation 
(p=0.01) was significantly associated with non-adherence to ART (Table 7-4), 
suggesting that the absence of suicidal ideation may be related to greater adherence. 
Table 7-4: Relationship between psychosocial factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
Adherent 
p-value 
Psychosocial characteristics 
Domestic violence† 
HITS-positive 
HITS-negative 
 
25 (1) 
19 (13) 
 
25 (1) 
16 (11) 
 
50 (2) 
65 (45) 
p= 0.58 
Depression† 
None 
Some  
 
20 (8) 
18 (12) 
 
8 (3) 
19 (13) 
 
73 (29) 
63 (43) 
p= 0.48 
 
Suicidal ideation† 
Yes 
No 
 
30 (7) 
15 (13) 
 
26 (6) 
12 (10) 
 
43 (10) 
73 (62) 
p= 0.01* 
 
Post-traumatic stress† 
PTSD-positive 
PTSD-negative 
 
0 (0) 
20 (20) 
 
29 (2) 
14 (14) 
 
71 (5) 
66 (67) 
p=0.59 
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 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
Adherent 
p-value 
Coping – adaptive‡ 
0-40 
41-64 
 
15 (5) 
20 (15) 
 
18 (6) 
14 (10) 
 
68 (23) 
66 (49) 
rs = 0.01, 
p=0.88 
 
Coping – maladaptive‡ 
0-18 
19-38 
 
16 (6) 
20 (14) 
 
16 (6) 
14 (10) 
 
68 (25) 
66 (47) 
rs = -0.09, 
p=0.34 
 
Physical symptoms‡ 
0-0.26 
0.27-0.7 
0.8-2.3 
 
26 (9) 
8 (3) 
22 (8) 
 
9 (3) 
17 (6) 
19 (7) 
 
66 (23) 
75 (27) 
59 (22) 
rs = -0.08, 
p=0.44 
 
Psych symptoms‡ 
0-0.3 
0.4-1.1 
1.2-3.7 
 
20 (7) 
22 (8) 
14 (5) 
 
14 (5) 
17 (6) 
14 (5) 
 
66 (23) 
61 (22) 
73 (27) 
rs = 0.07, 
p=0.48 
 
Global distress index‡ 
0-0.3 
0.4-1.13 
1.14-2.8 
 
24 (7) 
12 (5) 
22 (8) 
 
7 (2) 
16 (7) 
19 (7) 
 
69 (20) 
72 (31) 
58 (21) 
rs = -0.02, 
p=0.81 
 
Positive mood‡ 
0-7 
8-12 
 
19 (7) 
18 (13) 
 
14 (5) 
15 (11) 
 
67 (24) 
67 (48) 
rs = -0.003, 
p=0.98 
 
Quality of life - overall 
function‡ 
0-25 
26-30 
 
 
17 (6) 
19 (14) 
 
 
26 (9) 
10 (7) 
 
 
57 (20) 
71 (52) 
rs = 0.11, 
p=0.28 
 
 
Quality of life – life 
satisfaction‡ 
0-15 
16-20 
 
 
22 (8) 
17 (12) 
 
 
14 (5) 
15 (11) 
 
 
64 (23) 
68 (49) 
rs = 0.08, 
p=0.44 
 
Quality of life – health 
worries‡ 
0-15 
16-20 
 
 
25 (9) 
15 (11) 
 
 
22 (8) 
11 (8) 
 
 
53 (19) 
74 (53) 
rs = 0.15, 
p=0.12 
 
 
Quality of life – 
financial worries‡ 
0-10 
11-15 
 
 
17 (6) 
19 (14) 
 
 
19 (7) 
13 (9) 
 
 
64 (23) 
68 (49) 
rs = -0.01, 
p=0.88 
 
Quality of life – 
medication worries‡ 
0-22 
23-25 
 
 
39 (11) 
11 (9) 
 
 
4 (1) 
19 (15) 
 
 
57 (16) 
70 (56) 
rs = 0.10, 
p=0.31 
 
Quality of life – HIV 
mastery‡ 
0-5 
6-10 
 
 
32 (7) 
15 (13) 
 
 
9 (2) 
16 (14) 
 
 
59 (13) 
69 (59) 
rs = 0.06, 
p=0.53 
 
 
Quality of life – 
disclosure worries‡ 
0-6 
 
 
20 (6) 
 
 
17 (5) 
 
 
63 (19) 
rs = 0.08, 
p=0.43 
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 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
Adherent 
p-value 
7-25 18 (14) 14 (11) 68 (53)  
Quality of life – 
provider trust‡ 
0-12 
13-15 
 
 
7 (1) 
20 (19) 
 
 
7 (1) 
16 (15) 
 
 
86 (12) 
64 (60) 
rs = -0.09, 
p=0.34 
 
Note: ‡ =Spearman’s; † = Univariate ordinal logistic regression 
7.3.3.1 Emotional burden of depression and suicidal ideation 
About 91% (21) of the women with depression also experienced suicidal ideation. 
However there was no significant association between emotional distress and levels of 
adherence as illustrated in Table 7-5. 
Table 7-5: Emotional distress and adherence 
Emotional 
distress§ 
% (n)  
 Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Suicide only 50 (1) 0 (0) 50 (1) X2(3) =4.55, 
p = 0.21 Depression only 13 (6) 15 (7) 72 (34) 
Both 29 (6) 29 (6) 43 (9) 
None 18 (7) 8 (3) 74 (28) 
Note: § = K. Wallis test 
7.3.4 Relationship of health behaviours with ART adherence 
The following health behaviour and knowledge factors (Table 7-6) were significantly 
associated with ART adherence: vitamin intake (p=0.02), suggesting daily vitamin use 
may be related to greater adherence; healthy eating (p=0.05), suggesting better nutrition 
habits (healthy eating) may be related to greater adherence; and belief that medications 
are harmful (p=0.05), as measured by the BMQ, suggest higher general harm scores 
might be related to greater non-adherence.  
 
 
175 
 
Table 7-6: Relationship between health behaviour factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Health behaviours and knowledge 
Experience taking pills†9 
Unpleasant 
No difficulty 
 
29 (5) 
16 (15) 
 
6 (1) 
16 (15) 
 
65 (11) 
67 (61) 
p= 0.61 
 
Readiness to take pills†10 
Usually-always 
Rarely-never 
 
9 (2) 
21 (18) 
 
26 (6) 
12 (10) 
 
65 (15) 
67 (57) 
p= 0.82 
 
Vitamin intake in past 
month† 
< Daily 
Daily 
 
 
32 (6) 
16 (14) 
 
 
26 (5) 
13 (11) 
 
 
42 (8) 
72 (63) 
p= 0.02* 
 
 
Healthy eating‡ 
5-10 
11-12 
13-16 
 
23 (7) 
16 (6) 
18 (7) 
 
16 (5) 
27 (10) 
3 (1) 
 
61 (19) 
57 (21) 
80 (32) 
rs = 0.19, 
p=0.05* 
 
Belief that taking 
medication in general is 
harmful‡ 
5-9 
10-11 
12-16 
 
 
 
12 (5) 
23 (12) 
21 (3) 
 
 
 
10 (4) 
17 (9) 
21 (3) 
 
 
 
78 (32) 
60 (32) 
57 (8) 
rs = -0.19, 
p=0.05* 
 
 
 
 
Beliefs in general overuse 
of medication by doctors‡ 
8-10 
11-12 
13-18 
 
 
 
23 (13) 
15 (4) 
12 (3) 
 
 
 
12 (7) 
12 (3) 
24 (6) 
 
 
 
65 (37) 
73 (19) 
64 (16) 
rs = 0.04, 
p=0.69 
 
 
Beliefs in general benefits 
of taking mediation in 
general‡ 
8-13 
14-15 
16-20 
 
 
 
0 (0) 
13 (4) 
21 (16) 
 
 
 
100 (2) 
16 (5) 
12 (9) 
 
 
 
0 (0) 
71 (22) 
67 (50) 
rs = -0.03, 
p=0.72 
 
Alcohol use† 
 ≥ weekly 
Never 
 
27 (4) 
17 (16) 
 
20 (3) 
14 (13) 
 
53 (8) 
69 (64) 
p=0.25 
 
Tobacco use† 
≥ past month 
Never 
 
14 (3) 
20 (17) 
 
38 (8) 
9 (8) 
 
48 (10) 
71 (62) 
p= 0.16 
 
Note: ‡ =Spearman’s; † = Univariate ordinal logistic regression 
                                                 
9 Experience in taking other types of pills 
10 Readiness to take other types of pills 
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7.3.5 Relationship of HIV diagnosis, disclosure, and support with ART 
adherence 
Only non-disclosure of HIV status to family (p=0.05) was significantly associated with 
ART adherence, suggesting that non-disclosure to family may be related to greater adherence 
(Table 7-7). 
Table 7-7: Relationship of HIV diagnosis factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
HIV diagnosis, disclosure and support 
Diagnosed current 
pregnancy† 
Yes 
No 
 
 
15 (3) 
19 (17) 
 
 
10 (2) 
16 (14) 
 
 
75 (15) 
65 (57) 
p=0.41 
 
1st pregnancy since 
diagnosis† 
Yes 
No 
 
 
17 (8) 
20 (12) 
 
 
15 (7) 
15 (9) 
 
 
68 (32) 
66 (40) 
p= 0.75 
 
 
Disclosure – partner† 
No 
Yes 
 
14 (3) 
20 (17) 
 
14 (3) 
15 (13) 
 
73 (16) 
65 (56) 
p=0.48 
 
Disclosure – family† 
No 
Yes 
 
10 (3) 
22 (17) 
 
10 (3) 
17 (13) 
 
81 (25) 
61 (47) 
p=0.05* 
 
Disclosure –friends† 
No 
Yes 
 
18 (6) 
12 (4) 
 
6 (2) 
24 (8) 
 
76 (25) 
64 (21) 
p=0.46 
 
Know partner’s status† 
No 
Yes 
 
16 (6) 
20 (14) 
 
14 (5) 
16 (11) 
 
71 (27) 
64 (45) 
p= 0.48 
 
Support – family† 
No 
Yes 
 
27 (3) 
21 (14) 
 
9 (1) 
18 (12) 
 
64 (7) 
61 (40) 
p=1.0 
 
Support – partner† 
No 
Yes 
 
33 (6) 
19 (13) 
 
11 (2) 
16 (11) 
 
56 (10) 
66 (46) 
p= 0.30 
 
Time since HIV 
diagnosis (weeks)‡ 
3 - 103 
104 – 259 
260 - 728 
 
 
16 (5) 
19 (6) 
20 (9) 
 
 
13 (4) 
22 (7) 
11 (5) 
 
 
72 (23) 
59 (19) 
68 (30) 
rs = -0.05, 
p=0.58 
 
Note: ‡ = Spearman’s; † = Univariate ordinal logistic regression 
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7.3.6 Relationship of ART and ART-related characteristics with adherence 
None of the ART and ART-related explanatory variables (time on ART, ART initiated 
in current pregnancy, CD4 count, ART regimen, and HIV general and treatment 
knowledge) were significantly associated with ART adherence (Table 7-8). 
Table 7-8: Relationship of ART & ART-related factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
ART and ART-related characteristics 
Time on ART (weeks)‡  
1-48 
49-520 
 
18 (9) 
19 (11) 
 
14 (7) 
16 (9) 
 
68 (34) 
66 (38) 
rs = -0.07, 
p=0.46 
 
ART initiated in 
current pregnancy† 
Yes 
No 
 
 
20 (7) 
17 (12) 
 
 
9 (3) 
18 (13) 
 
 
71 (25) 
65 (47) 
p= 0.61 
 
CD4† 
≤ 350 
351-500 
> 500 
 
21 (7) 
11 (3) 
22 (10) 
 
12 (4) 
26 (7) 
9 (4) 
 
67 (22) 
63 (17) 
70 (32) 
p= 0.83 
 
ARV regimen† 
Multi-drug 
Single drug 
 
27 (7) 
16 (13) 
 
0 (0) 
20 (16) 
 
73 (19) 
65 (53) 
p=0.76 
 
HIV knowledge score‡ 
0-7 
8-11 
12-15 
 
100 (1) 
7 (2) 
22 (17) 
 
0 (0) 
11 (3) 
17 (13) 
 
0 (0) 
82 (23) 
62 (49) 
rs = -0.16, 
p=0.09 
 
HIV belief: witchcraft† 
True 
False 
DK 
 
33 (1) 
18 (17) 
18 (2) 
 
0 (0) 
17 (16) 
0 (0) 
 
67 (2) 
65 (61) 
82 (9) 
p=0.37 
 
HIV belief: bush cure† 
True 
False 
DK 
 
20 (1) 
14 (11) 
31 (8) 
 
20 (1) 
17 (13) 
8 (2) 
 
60 (3) 
69 (53) 
62 (16) 
p=0.45 
 
HIV treatment know‡ 
0-6 
7-13 
14-20 
 
100 (1) 
17 (4) 
18 (15) 
 
0 (0) 
13 (3) 
16 (13) 
 
0 (0) 
71 (17) 
66 (55) 
rs = -0.02, 
p=0.81 
 
Note: ‡=Spearman’s; † = Univariate ordinal logistic regression 
7.3.7 Relationship between vitamin adherence and ART adherence 
Prenatal vitamin use was significantly associated with ART adherence at both the 
univariate level (p=0.02) and in the multivariate regression model below (p=0.01), 
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suggesting that daily prenatal vitamin usage is a predictor of greater ART adherence. 
This suggests that behaviour in other pregnancy-related adherence can be transferred to 
another type of adherence in the form of ART adherence. 
7.3.8 Multivariate analysis of explanatory variables 
Only three explanatory factors remained significant in the final multivariate ordinal 
regression model (Table 7-9): suicidal ideation (p=0.03); daily prenatal vitamin intake 
(p=0.01); and non-disclosure to family (p=0.04. 
Table 7-9: Ordered logistic regression model for ART adherence 
Characteristic Unadjusted Adjusted 
 OR 95% CI p-value OR 95% CI p-value 
Suicidal ideation 
Yes 
No 
 
1.0 
3.09 
 
- 
1.3 – 7.5 
 
 
p=0.01 
 
1.0 
2.95 
 
- 
1.1 – 8.0 
 
 
p=0.03* 
Vitamin intake 
< Daily† 
Daily 
 
1.0 
3.04 
 
- 
1.2 – 7.8 
 
 
p=0.02 
 
1.0 
3.92 
 
- 
1.4 – 10.9 
 
 
p=0.01* 
Healthy eating 
5-10 
11-12 
13-16 
 
 
 
1.12§ 
 
- 
 
1.0 – 1.3 
 
 
 
p=0.05 
 
 
 
1.02§ 
 
- 
 
0.9 -1.2 
 
 
 
p=0.77 
Belief that 
medication in 
general is harmful 
8-13 
14-15 
16-20 
 
 
 
 
0.78§ 
 
 
- 
 
0.6 – 1.0 
 
 
 
 
p=0.05 
 
 
 
 
0.80§ 
 
 
- 
 
0.6 – 1.1 
 
 
 
 
p=0.14 
Disclosure – family 
No 
Yes 
 
1.0 
0.38 
 
- 
0.1 – 1.0 
 
 
p=0.05 
 
1.0 
0.34 
 
- 
0.1 – 1.0 
 
 
p=0.04* 
§ = OR from a one unit change in score variable 
† = women who took zero pills or took them as few as once weekly to at most 6 days 
per week 
7.4 Sensitivity analysis 
A sensitivity analysis was conducted removing women who had been on ART for less 
than three months because their pattern of adherence may be different and not reflect 
longer-term adherence in women, and because for those recently starting ART, the 
category of recently adherent but past non-adherent does not fully apply (Appendix Q). 
Excluding women who met this criterion resulted in a total of 67 participants (Table 
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7-1). The findings indicated that medication worries (p= 0.011), use of prenatal vitamins 
(p= 0.058), and HIV knowledge (p= 0.038) were significantly associated with ART 
adherence. Of these three factors, only use of prenatal vitamins was retained from the 
primary analysis. The non-significance of the demographic and pregnancy-related 
factors was consistent with the findings of the primary analysis. 
The above-mentioned factors as well as two other variables with significant values of p 
less than 0.1 (belief that medications are generally harmful, tobacco use) were entered 
into a multivariate ordinal regression model (Appendix Q) resulting in statistically 
significant findings for medication worries (p= 0.001), never having used tobacco (p= 
0.028), and HIV knowledge (p= 0.028). Daily use of prenatal vitamins no longer 
emerged as a predictor of greater adherence. 
The results of this sensitivity analysis suggest that the findings of the primary analysis 
were affected by the presence of participants with less than three months of ART. 
Future research with a larger sample is warranted. 
7.5 Results summary 
The key findings from this chapter were as follows: 
 None of the demographic, pregnancy or ART characteristics were significantly 
associated with ART adherence 
 Among the psychosocial characteristics, only suicidal ideation was significantly 
associated with ART adherence 
 Factors associated were: suicidal ideation; daily vitamin intake; healthy eating; 
and beliefs that medications are harmful 
 Most women with depression also experienced suicidal ideation 
 Predictors of ART adherence – daily prenatal vitamin intake, absence of suicidal 
ideation, and non-disclosure to family 
 A sensitivity analysis which excluded women who had been on ART for less 
than three months resulted in prenatal vitamins no longer being a predictor of 
ART adherence  
180 
 
7.6 Discussion 
Pregnancy is a period when women are expected to embrace healthy behaviours which 
have important implications for their health and that of the unborn child. It would be 
interesting to determine if pregnancy behaviours were associated with each other, and 
more particularly, if an understanding of these behaviours enables some insight into the 
vitally important aspect of ART adherence. Although there were associations between 
ART adherence and vitamin intake, healthy eating, tobacco use and general beliefs that 
medications are harmful, only daily prenatal vitamin use was a predictor of ART 
adherence for pregnant women. These findings were discussed in Chapter 6. 
Overall, 19%, 15% and 67% of pregnant women from the survey were recently non-
adherent, recent adherence, but with past non-adherence, and always adherent 
respectively, while most of the pregnant women reported never missing any doses of 
ART during the in-depth interviews. Although studies among pregnant women by 
Mepham et al. (2011) and Nachega et al. (2012) have identified adherence levels of 61% 
and 74% respectively, these rates are not comparable as measures and definitions of 
adherence differed for each study as was highlighted in the systematic review chapter. 
The fact that 19% of the women in the survey were recently non-adherent is a worrying 
trend as this action not only compromises their own health but also that of the child. 
Moreover, as this was a cross-sectional survey, this proportion may not truly reflect 
adherence behaviour, as adherence levels could have fluctuated with the possibility that 
many more women were non-adherent at other times in the pregnancy, implying that 
levels of non-adherence are underestimated and could be much higher in this group, as 
the recall period included the most recent four week days and weekend prior to the 
interview. 
ART regimen was not significantly associated with adherence, suggesting that type of 
regimen did not have an impact on adherence in this study. However, prior research has 
found greater adherence with use of simplified regimens (Bangsberg et al., 2010; Cohen, 
Meyers and Davis, 2013; Hanna et al., 2014; Safren et al., 2014). Despite these advances 
in treatment, there is limited research on the effects of a single-tablet regimen on 
women’s adherence levels (Hanna et al., 2014). In the studies listed above, only Hanna 
et al. (2014) examined this critical issue, albeit in a treatment-experienced non-pregnant 
population in the US. The three existing single-tablet regimes were compared to multi-
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drug components at six-month intervals, and while the authors found significant 
associations with increased adherence, 15% of the women were still not fully adherent. 
Unfortunately, no reasons were advanced by the authors to account for this variance, 
but possible reasons may include the fact that 20% and 41% of the women in that study 
were currently using recreational drugs and alcohol respectively, and also 88% 
experienced severe depression, factors which have been reported in the literature to be 
associated with non-adherence. 
In the final analysis chapter (Chapter 8), I will examine the utility of a theoretical model 
- the Health Belief Model to understand and predict ART adherence among HIV-
positive women.
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Chapter 8 - Utility of the Health Belief Model to predict 
adherence 
8.0 Abstract 
Objective: To investigate the utility of a theoretical model, the Health Belief Model 
(HBM) to understand and predict adherence among HIV-positive pregnant women. 
Methods:  A cross-sectional study was done on 108 HIV-positive pregnant women 
attending 12 primary care clinics. A questionnaire was administered on the constructs of 
the HBM as operationalised by the Adherence Determinants questionnaire (ADQ). 
Descriptions of the responses to the ADQ constructs were reported as numbers and 
percentages in each category and presented in figures. For many constructs little 
variability in responses was found, in the sense that almost all respondents provided 
responses in one of two adjacent categories, typically agree and strongly agree, or 
disagree and strongly disagree. Subsequently, only ADQ constructs with sufficient 
variation in responses were tested for association with the level of adherence using 
Spearman’s rank correlation coefficient and test. 
Results: There was little or no variation in 19/27 of the ADQ constructs as participants 
overwhelmingly endorsed one response. Only one item from the perceived susceptibility 
construct was significantly associated (p=0.009) with adherence. 
Conclusion: Although the ADQ was unable to measure the HBMs constructs within 
this population, theoretical models play an important role in explaining and 
understanding behaviour. 
8.1 Chapter overview 
In this chapter, I will discuss the rationale for the use of a theoretical framework, the 
Health Belief Model (HBM) and its relevance for HIV prevention in general, and 
adherence in particular within the Guyana context (see Chapter 1). The Adherence 
Determination Questionnaire (ADQ) constructs (Chapter 4) relevant to the HBM will 
be examined for associations with adherence. Specifically, the objective of this chapter is 
to explore the constructs of the HBM as operationalised by the ADQ to understand and 
predict adherence. 
8.1.1 Role of theory in HIV prevention 
In general, behaviour change theories assist researchers in detecting the elements needed 
to be targeted in order to help persons prevent or manage disease. Behavioural risks 
such as non-adherence to medication or medical advice, risky sexual activities or the 
inability to engage in health promotion have serious implications for public health 
183 
 
(Champion and Skinner, 2008). Similarly, the use of theory for HIV and AIDS 
prevention can assist in identifying characteristics that play a role in predicting and 
understanding behaviour. Theory based interventions can provide the tools for reducing 
risky behaviour and maintaining healthy habits (Fishbein, 2000; Rhodes et al., 2007). 
8.2 Methods 
8.2.1 Measuring constructs of the HBM 
The constructs of the HBM as measured with the ADQ were discussed in detail in 
Chapter 4, Section 4.5.2.11. 
8.2.2 Analysis 
The statistical analysis for this chapter is discussed in Chapter 4, Section 4.6 
8.3 Results 
8.3.1 Assessing Cronbach’s alpha for ADQ scale 
The Cronbach’s alpha table (Table 8-1) displayed below lists the results of the analysis 
assessing the reliability of the ADQ scale: ‘Sign’ indicates the direction of the item with 
a ‘-‘ denoting that the item was reversed; ‘Item-test’ denotes how highly correlated each 
item is with the overall scale and should be similar for all items; ‘Item-rest’ denotes the 
correlation between that item and all other items; ‘Inter-item covariance’ denotes how 
much the items vary together; ‘Alpha’ denotes how the alpha for the scale would change 
if that item is dropped from the scale; and finally the ‘test scale alpha’ refers to the 
measure of internal consistency for the full scale which ranges from 0 to 1, with values 
closer to 1 reflecting greater internal consistency. Test scale alphas for perceived 
susceptibility, perceived severity, perceived benefits, perceived barriers, intentions, and 
interpersonal aspects of medical care were 0.5, 0.3, 0.1, 0.35, 0.29, and 0.61 respectively. 
All scores were below the acceptable alpha threshold of at least 0.7 (Bland and Altman, 
1997; Hinkin, 1998). 
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Table 8-1: Cronbach's alpha for ADQ subscales 
Item Obs Sign Item-test 
correlation 
Item-rest 
correlation 
Inter-item 
covariance 
Alpha 
Perceived susceptibility 
D1. Expect to be 
free of HIV in the 
future 
108 + 0.6367 0.2682 .1106784 0.4785 
D2. Good chance 
of HIV getting 
worse 
108 - 0.7133 0.3826 .0642091 0.3091 
D3. Body will fight 
off HIV in the 
future 
Test scale 
108 + 0.7734 0.3253 .0666321 
 
 
.0805065 
0.3091 
 
 
0.5017 
Perceived severity 
C1. Many diseases 
more severe than 
HIV 
108 + 0.5516 0.1641 .0693723 0.2244 
C2. HIV is not as 
bad as people say 
108 + 0.6358 0.1907 .0491808 0.1840 
C3. HIV is a 
terrible disease 
108 - 0.5454 0.0858 .0993712 0.3248 
C4. Little hope for 
people with HIV 
Test scale 
108 - 0.5336 0.1732 .06943 
 
.0718386 
0.2178 
 
0.2954 
Perceived benefits 
B1. Treatment 
benefits outweigh 
any problems I 
might have 
108 + 0.6234 0.0223 .0033172 0.1245 
B2. Treatment plan 
is too much trouble 
108 + 0.6880 0.0825 -.0002308 -- 
B3. Treatment plan 
too difficult, not 
worth following 
108 + 0.4412 0.0701 .0015865 0.0450 
B4. Following is 
better than not 
following treatment 
plan 
Test scale 
108 - 0.1522 -0.0015 .0047306 
 
 
 
.0023509 
0.1111 
 
 
 
0.0959 
Perceived barriers 
G1. Things get in 
the way of 
following treatment 
plan 
108 + 0.6328 0.2571 .0233645 0.2066 
G2. Need more 
assistance to follow 
treatment plan 
108 + 0.7533 0.2344 .0199896 0.2479 
G3. I get the help I 
need to carry out 
108 - 0.4180 0.0796 .056594 0.3868 
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Item Obs Sign Item-test 
correlation 
Item-rest 
correlation 
Inter-item 
covariance 
Alpha 
treatment 
G4. Able to deal 
with problems in 
following treatment 
Test scale 
108 - 0.4846 0.2237 .0397196 
 
 
 
.0349169 
0.2799 
 
 
 
0.3523 
Intentions 
F1. Made a 
commitment to 
follow treatment 
108 + 0.1550 -0.1668 .0095766 0.4856 
F2. Following 
treatment is not in 
my plans 
108 + 0.6994 0.0180 .0058844 0.5862 
F3. I intend to 
follow treatment 
plan 
108 + 0.8114 0.6419 -.0028845 -- 
F4. No intention of 
following treatment 
plan 
Test scale 
108 + 0.6473 0.3924 .0002308 
 
 
.0032018 
0.0171 
 
 
0.2898 
Interpersonal aspects of care 
A1. Health staff 
sometimes ignore 
what I say 
108 - 0.6966 0.3888 .0127784 0.5611 
A2. Health staff 
listen carefully to 
me 
108 + 0.7200 0.5633 .0129926 0.4904 
A3. Health staff 
answer all my 
questions 
108 + 0.5528 0.4133 .017443 0.5545 
A4. Health staff use 
medical terms 
without explaining 
108 - 0.4464 0.0910 .020616 0.6798 
A5. Trust that 
health staff have 
my best interest at 
heart 
108 + 0.3679 0.3042 .0213824 0.5975 
A6. Health staff act 
like I’m wasting 
their time 
108 - 0.5698 0.4469 .0175007 0.5521 
A7. Health staff 
treat me in a 
friendly manner 
108 + 0.6889 0.5583 .0146327 0.5104 
A8. Health staff 
show little concern 
for me 
Test scale 
108 - 0.2380 0.1006 .0220253 
 
 
.0174214 
0.6154 
 
 
0.6058 
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8.3.1.1 Alternatives to Cronbach’s alpha 
Although Cronbach’s alpha is the most widely regarded and reported measure of 
internal consistency for Likert-type scales (Gliem and Gliem, 2003; Ponterotto, 
Ponterotto and Ruckdeschel, 2007; Tavakol and Dennick, 2011), another group of 
researchers (Gadermann, 2012; Peters, 2014) believe that it is not a good assessment of 
internal consistency, since Likert-type responses are ordinal and not continuous. They 
advocate for use of the ordinal reliability coefficient, Omega or the greatest lower bound 
(GLB), which can be calculated using the open-source statistical package R (Peters, 
2014). Use of the Omega and the GLB did not improve the internal consistency for the 
subscales as all coefficients except for “Intentions” (0.87) were much lower than that 
obtained for Cronbach’s alpha as depicted in Table 8-2 below. 
Table 8-2: Cronbach's alpha and GLB coefficients 
ADQ  categories  Coef. calculated using R 
 Cronbach’s 
alpha 
Omega Greatest 
lower bound  
(GLB) 
Perceived susceptibility 0.50 0.05 -0.13 
Perceived severity 0.30 0.02 0.07 
Perceived benefits 0.10 -- 0.14 
Perceived barriers 0.35 -- 0.26 
Intentions 0.29 -- 0.87 
8.3.2 Levels of adherence with the ADQ constructs 
The ADQ was further examined using contingency table analysis (cross-tabulations) to 
check the frequency distribution for each ADQ construct against the three ordered 
adherence categories - recently non-adherent; recently adherent, but distal non-
adherence; and always adherent. The graphical display (Graph 1-6) of the raw ADQ 
scores revealed many scale items, such as perceived benefits, barriers, intentions, 
interpersonal aspects of care, and perceived susceptibility (D2- “no matter what I do 
there’s a good chance of my HIV getting worse”), for which in excess of 80% of 
respondents indicated the same answer. Items with such high endorsement of a 
particular response are usually dropped from further analysis, since they may be 
reflective of a homogenous population. The original five-point Likert scale scores for 
the six constructs of the ADQ utilized in this study are presented below (Graph 1-6). 
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8.3.2.1 Perceived susceptibility 
Women did not perceive themselves to be susceptible to worsening HIV disease since 
84% ‘agreed’ that they would be “free of HIV in the future”; 88% ‘disagreed’ that their 
HIV would get worse; and 78% ‘agreed’ that their body would fight off the virus as 
depicted in Graph 8-1. 
Graph 8-1: Raw scores, perceived susceptibility 
 
8.3.2.2 Perceived severity 
Perceptions of disease severity were dispersed among the range of responses (Graph 
8-2). Although 72% of women ‘agreed’ that there were other diseases worse than HIV, 
50% ‘disagreed’ that it was “not as bad as people say”, and 60% ‘agreed’ that it “is a 
terrible disease.” However, optimism was high as 80% ‘disagreed’ that there “is little 
hope for people with HIV.” 
Graph 8-2: Raw scores, perceived severity 
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8.3.2.3 Perceived benefits of medication 
Responses for the perceived benefits subscale (Graph 8-3) were clustered around ‘agree’ 
or ‘disagree’. For the two questions on the benefits of taking their medication, 96% and 
99% of the women respectively ‘agreed’ that taking their treatment was better for them. 
For the other two questions, 95% and 97% respectively ‘disagreed’ that their treatment 
was not worth following. 
Graph 8-3: Raw scores, perceived benefits 
 
8.3.2.4 Perceived barriers 
Responses to perceived barriers (Graph 8-4) were also polarized. A majority (94% and 
95%) of women respectively ‘agreed’ that they got help and were able to deal with 
problems that interfered with taking their medication. In contrast, 94% and 83% 
respectively ‘disagreed’ that things got in the way, and they required further assistance to 
adhere to treatment. 
Graph 8-4: Raw scores, perceived barriers 
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8.3.2.5 Intention to adhere to medication 
Responses to items in this subscale were not only polarised but were inconsistent as 
illustrated in Graph 8-5. Women who initially stated that they were committed to 
adhering to treatment (98%) subsequently responded (97%) that this was “not in my 
plans.” Similarly, although 98% expressed that they intended to “follow my treatment 
plan”, the same proportion responded that they “have no intention” of doing so. These 
apparent conflicting responses meant that these two items did not function as intended 
as respondents may have been confused by the wording. 
Graph 8-5: Raw scores, Intention to adhere to medication 
 
8.3.2.6 Interpersonal aspects of care 
Responses to the items in this subscale were consistent, but were primarily clustered 
around ‘agree’ and ‘disagree’ (Graph 8-6). For example, 99% of women ‘agreed’ that 
health staff “have my best interest at heart”, while 96% ‘disagreed’ that the health staff 
showed “little concern for me.” Overall respondents had positive views of their 
interactions with health staff. 
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Graph 8-6: Raw scores, Interpersonal aspects of care 
 
8.3.3 ART adherence and the ADQ constructs 
In the following section, individual ADQ constructs were examined to determine 
whether there were associations with adherence. However, based on the graphical 
display (Graphs 1-6), only perceived susceptibility and perceived severity had sufficient 
variation in responses to warrant testing for associations with adherence. The original 
five-point Likert scale responses ranging from ‘strongly disagree’ (1) to ‘strongly agree’ 
(5) were recoded into three responses of “Disagree”, “Neither”, and “Agree” to regroup 
the small numbers in some cells responses. The findings of these analyses are presented 
below (Table 8-3). 
Table 8-3: Recoded scores for ADQ constructs 
ADQ constructs Self-reported views    % (n) 
Perceived susceptibility Disagree Neither Agree 
I expect to be free of HIV in the future 5 (5) 11 (12) 84 (91) 
No matter what I do, there’s a good chance 
of my HIV getting worse 
88 (95) 6 (7) 6 (6) 
My body will fight off HIV in the future 9 (10) 13 (14) 78 (84) 
Perceived severity Disagree Neither Agree 
There are many disease more severe than 
HIV 
20 (22) 7 (8) 72 (78) 
HIV is not as bad as people say 50 (54) 8 (9) 42 (45) 
HIV is a terrible disease 33 (36) 6 (7) 60 (65) 
There is little hope for people with HIV 81 (88) 3 (3) 16 (17) 
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ADQ constructs Self-reported views    % (n) 
Perceived benefits Disagree Neither Agree 
The benefits of my treatment plan outweigh 
any problems I might have in following it 
4 (4) 0 (0) 96 (104) 
My treatment plan is too much trouble for 
what I get out of it 
96 (104) 0 (0) 4 (4) 
Because my treatment plan is too difficult it is 
not worth following 
99 (107) 0 (0) 1 (1) 
Following my treatment plan is better for me 
than not following my treatment plan 
0 (0) 0 (0) 100 (108) 
Perceived barriers Disagree Neither Agree 
Lots of things get in the way of following my 
treatment plan 
94 (101) 0 (0) 6 (7) 
I need more assistance in order to follow my 
treatment plan 
83 (90) 0 (0) 17 (18) 
I get the help I need to carry out my 
treatment plan 
5 (5) 0 (0) 95 (103) 
I am able to deal with my problems in 
following my treatment plan 
3 (3) 1 (1) 96 (104) 
Intentions Disagree Neither Agree 
I have made a commitment to follow my 
treatment plan 
0 (0) 0 (0) 100 (108) 
Following my treatment plan is not in my 
plans 
2 (2) 0 (0) 98 (106) 
I intend to follow my treatment plan 0 (0) 0 (0) 100 (108) 
I have no intentions of following my 
treatment plan 
0 (0) 0 (0) 100 (108) 
Interpersonal aspects of care Disagree Neither Agree 
The doctors and other health staff sometimes 
ignore what I tell them 
94 (101) 1 (1) 6 (6) 
The doctors and other health staff listen 
carefully to what I have to say 
2 (2) 0 (0) 98 (106) 
The doctors and other health staff answer all 
my questions 
1 (1) 0 (0) 99 (107) 
Sometimes the doctors and health staff use 
medical terms without explaining what they 
mean 
94 (101) 0 (0) 6 (7) 
I trust that the doctors and other health staff 
have my best interest at heart 
0 (0) 0 (0) 100 (108) 
The doctors and other health staff act like I’m 
wasting their time 
99 (107) 0 (0) 1 (1) 
The doctors and other health staff treat me in 1 (1) 0 (0) 99 (107) 
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ADQ constructs Self-reported views    % (n) 
a very friendly and courteous manner 
The doctors and other health staff show little 
concern for me 
100 (108) 0 (0) 0 (0) 
8.3.3.1 Perceived susceptibility 
The distribution of the responses about perceived susceptibility to advanced HIV 
disease for all three items of the construct was skewed in the direction of positive 
endorsement of adherence (Table 8-4). Only D3 ‘My body will fight off HIV in the 
future’ displayed a statistically significant association with adherence (p=0.009), 
suggesting greater adherence in women who agreed more with the idea that their body 
will fight off HIV in the future. This association was surprising as recent non-adherence 
was higher among women who neither agree nor disagree (43%) with the statement. 
Table 8-4: Frequency distribution, perceived susceptibility 
Construct  Adherence                 % (n)  
Perceived 
susceptibility‡ 
 Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
D1. Expect to be 
free of HIV in the 
future 
Disagree 20 (1) 0 (0) 80 (4) rs =0.10, 
p=0.31 
 Neither 42 (5) 8 (1) 50 (6)  
 Agree 15 (14) 16 (15) 68 (62)  
D2. Good chance of 
HIV getting worse 
Disagree 16 (15) 15 (14) 69 (66) rs =-0.16 
p=0.10 
 Neither 71 (5) 14 (1) 14 (1)  
 Agree 0 (0) 17 (1) 83 (5)  
D3. Body will fight 
off HIV in the future 
Disagree 30 (3) 20 (2) 50 (5) rs =0.25, 
p=0.009* 
 Neither 43 (6) 14 (2) 43 (6)  
 Agree 13 (11) 14 (12) 73 (61)  
Note: ‡ = Spearman’s rank correlation coefficient 
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8.3.3.2 Perceived severity 
There were no statistically significant associations between the perceived severity items 
and adherence as depicted in Table 8-5. 
Table 8-5: Frequency distribution, perceived severity 
Construct  Adherence                 % (n)  
Perceived severity‡  Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
C1. Many diseases 
more severe than 
HIV 
Disagree 14 (3) 9 (2) 77 (17) rs =-0.15 
p=0.11 
 Neither 13 (1) 0 (0) 88 (7)  
 Agree 21 (16) 18 (14) 62 (48)  
C2. HIV is not as 
bad as people say 
Disagree 15 (8) 19 (10) 67 (36) rs =-0.05 
p=0.64 
 Neither 11 (1) 11 (1) 78 (7)  
 Agree 24 (11) 11 (5) 64 (29)  
C3. HIV is a terrible 
disease 
Disagree 17 (6) 25 (9) 58 (21) rs =0.09 
p=0.35 
 Neither 29 (2) 0 (0) 71 (5)  
 Agree 18 (12) 11 (7) 71 (46)  
C4. Little hope for 
people with HIV 
 
Disagree 20 (18) 16 (14) 64 (56) rs =0.13 
p=0.18 
 Neither 0 (0) 0 (0) 100 (3)  
 Agree 12 (2) 12 (2) 76 (13)  
Note: ‡ =  Spearman’s rank correlation coefficient 
8.3.3.3 Intentions and interpersonal aspects of care 
Two other ADQ constructs which are not germane to the HBM but nonetheless could 
potentially impact adherence were Intentions emphasized by Fishbein and colleagues 
(Fishbein et al., 2003; Fishbein, 2008) and Interpersonal aspects of care emphasized by 
Schneider et al. (2004) and Johnson et al. (2006). There was little variation in the 
responses to these constructs (Graph 8-7, Graph 8-8), as participants overwhelmingly 
endorsed one scaled response. As such, there will be no further testing for associations 
between these items and adherence.  
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Graph 8-7: ADQ construct - Intentions 
 
Graph 8-8: ADQ construct - Interpersonal aspects of care 
 
8.4 Results summary 
The aim of this chapter was to examine the utility of the constructs of the HBM to 
understand and predict ART adherence. To this end, a stepwise analysis of the variables 
was executed with the results summarized below. 
 Cronbach’s alpha for the subscales did not yield acceptable thresholds of ≥ 0.7 
 Further analysis of the subscales with Omega and the GLB (alternatives to 
Cronbach’s alpha) also did not yield acceptable thresholds 
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 Bivariate distributions for perceived susceptibility and perceived severity items 
resulted in only one item (D3) from perceived susceptibility with a significant p-
value. However, greatest non-adherence was found in those who neither agreed 
nor disagreed with the item and as such this relationship was unexpected and 
hard to interpret. 
 The apparent ‘significance’ for variable D3 should be interpreted with caution, 
as many statistical tests were performed on the data. When multiple statistical 
tests are conducted at a p-value of 0.05, there’s a 5% probability of getting a 
significant result due to chance. 
 Surprisingly there was either very little or no variation in the other ADQ 
constructs such as perceived benefits, perceived barriers, intentions, and 
interpersonal aspects of care. 
 There were no significant associations with adherence for items in the perceived 
severity construct (C1-C4), despite some variation in the responses. 
8.5 Discussion 
Theoretical models play an important role in explaining and understanding phenomena 
than just a mere study without such underpinnings. Theory helps increase knowledge in 
particular fields, allows for testing of variables in different settings and populations, and 
can be an effective framework for behaviour change interventions (Fishbein, 2000; 
Creswell, 2014). Moreover, Holmes, Hughes and Morrison (2014) argue that 
interventions grounded in theory are best suited for explaining and predicting behaviour 
than those that are not. 
This adherence study was guided by the Health Belief Model, a widely used theoretical 
model that has been studied to understand behaviour and inform interventions. 
Constructs of the Health Belief Model (HBM) as operationalized by the Adherence 
Determinants Questionnaire (ADQ) were tested to understand and predict adherence to 
ART treatment within the Guyana context. Many studies have used the HBM to 
examine attitudes and beliefs of PLHIVs towards adherence (Gao et al., 2000; Malcolm 
et al., 2003; Reynolds et al., 2004). However, this appears to be the first study to utilize 
the HBM and the related constructs from the ADQ to measure adherence among HIV-
positive pregnant women, let alone pregnant women in Guyana.  
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Results of the assessment of the HBM indicated that only one item from the ADQ-
related construct of perceived susceptibility was significantly associated with adherence, 
however due to the many statistical tests performed on the data, this result must be 
viewed with caution. Many of the responses to the ADQ constructs (19/27) exhibited 
little or no variation as respondents overwhelmingly endorsed one response. 
In the previous chapters, I presented the results of a series of studies which aimed to 
both explore and examine ART adherence among HIV-positive women in Guyana. In 
the upcoming final chapter (Chapter 9), I will discuss the key findings in more detail, 
interpreting the data and what this all means for women’s adherence within the Guyana 
context.
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Chapter 9 - Discussion and Recommendations 
9.1 Introduction 
Over 50% of HIV-positive adults globally are women (WHO, 2011) and if pregnant 
may be at risk of transmitting the virus to the baby during pregnancy, childbirth and 
breastfeeding, as well as facing illness at the time of parenting. While HIV antiretroviral 
medications are available to treat the mother and prevent vertical transmission to the 
baby, high levels of adherence to ART are required to achieve optimal results for both. 
ART adherence is thus an important concern, since non-adherence can lead to resistant 
strains of the virus, debilitating health for the mother, and possible HIV transmission to 
the baby (Ickovics et al., 2002; Ciambrone et al., 2006; Vaz et al., 2007; Bardeguez et al., 
2008). UNAIDS’ ambitious target of “90-90-90” to curtail the epidemic by 2020 
(UNAIDS, 2014) will require early detection of infected women followed by provision 
of ART, preferably Option B+ (WHO, 2013), which recommends lifelong ART 
treatment for all pregnant or breastfeeding women irrespective of CD4 count or WHO 
clinical stage.  
The systematic review of the literature in Chapter 2 highlighted barriers to adherence in 
both resource-rich and resource-constrained countries. As a lower middle income 
country (WB, 2014b),  geographically located in South America, Guyana is more aligned 
culturally and politically with the islands of the Caribbean, a region with the second 
highest HIV prevalence (1.0%) after Sub-Saharan Africa (UNAIDS, 2013b). The 
systematic review further revealed that there is limited knowledge and a paucity of 
research about adherence among pregnant and postpartum women in the Caribbean in 
general and Guyana in particular. Thus it is important to gain an understanding of the 
ART adherence behaviours within this population, as well as the factors influencing 
adherence amid cultural and other local differences. This final chapter discusses the 
triangulated findings from the in-depth interviews and cross-sectional studies, including 
contribution to knowledge (research literature) and implications for future research and 
practice. 
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9.2 Relationship between the in-depth interviews and cross-sectional study 
findings 
The collection of both qualitative (in-depth interviews) and quantitative (cross-sectional 
study) data in this study to provide a comprehensive understanding (Creswell, 2014) of 
ART adherence among pregnant and postpartum women is a key strength of this thesis. 
Although both types of studies examined the ART experiences of HIV-positive women 
to present a holistic account of adherence, the in-depth interviews highlighted the 
different experiences of the women in the context of daily living. The open-ended 
questions allowed the women to express their views and provide details of their 
adherence behaviour which cannot be captured with the quantitative approach. 
Triangulation of findings from the studies 
 Mood and anxiety disorders – both types of studies indicated that there were 
high levels of depressive symptoms in this population, yet most women were 
always adherent with ART. 
 Adherence – both types of studies revealed that adherence was better during 
pregnancy. 
 HIV-infected women with higher daily vitamin intake than the uninfected 
women – it was anticipated that both groups of women would have similar 
levels of vitamin adherence given that women adopt healthy habits during 
pregnancy. However, the HIV-infected women’s awareness of their status and 
the inherent risks to self and baby would have motivated them to adhere. 
 Type of ART regimen not associated with adherence – based on the in-depth 
interviews, women were adherent irrespective of whether they were on a single 
or multiple compound, most likely to reduce MTCT. 
 Non-disclosure of HIV status resulting in greater ART adherence – the desire to 
reduce HIV transmission to the baby was a key motivating factor for adherence 
and women adopted ingenious strategies to ensure ART was taken. 
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 No association between depression (despite high levels) and non-adherence to 
ART – similar reasons as indicated in the two prior findings above. 
9.3 Contributions of the studies to the literature 
The major contribution of this thesis to knowledge is providing an understanding of the 
experiences and key factors contributing to pregnant and postpartum women’s ART 
adherence in Guyana. While there have been some published studies on the Caribbean 
region among PLHIV (Williams et al., 2007; Harvey et al., 2008; Allen et al., 2011), this 
study is the first to examine adherence among the pregnant HIV-positive population in 
Guyana. Further, this study has enhanced our understanding of women’s determination 
and the strategies used to ensure medication is taken to reduce MTCT and provides a 
somewhat unique insight into this population given its cultural and healthcare contexts. 
It serves to highlight the high coverage of ART, the motivation of pregnant HIV-
positive women to both adhere to general as well as HIV-specific treatment regimens. It 
also highlights the importance within this context and study population on the effect of 
religion/spirituality and cultural beliefs (notably including witchcraft) on ART 
adherence. 
The unique finding that non-disclosure did not adversely affect adherence contradicts 
other studies in the literature (Sanjobo, Frich and Fretheim, 2009; Wasti et al., 2012a) as 
women who had not disclosed their HIV status found innovative ways to ensure that 
ART medication was taken, revealing the commitment and drive of pregnant women in 
Guyana. 
Although the Health Belief Model (HBM) was considered an appropriate model to help 
understand pregnant and postpartum women’s ART adherence given its prior record in 
examining attitudes and beliefs of PLHIVs towards adherence (Gao et al., 2000; 
Malcolm et al., 2003; Reynolds et al., 2004), this study clearly identified its lack of utility 
for understanding adherence in HIV-positive pregnant women in Guyana. The results 
of the study discussed in Chapter 8 indicate that only one of the four HBM constructs, 
perceived susceptibility was associated with adherence, suggesting that the HBM is not a 
useful tool for understanding women’s adherence in the Guyana context, and perhaps 
new theoretical models with a weighting on the construct of susceptibility may be 
needed. However, these findings contribute to the body of research both in support of 
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and opposed to the HBM. It may be that the model is not strong enough to take in the 
various factors – indeed it does not have a component on innovation or disclosure. It 
also may be that the tool traditionally used to measure the HBM constructs is 
inadequate or inappropriate for this cultural setting. The findings suggest that a more 
robust model will be required for a theoretical understanding of adherence to ART in 
pregnant women in this context. 
Although the literature abounds with studies on the efficacy of simplified ART regimens 
to improve adherence (Bangsberg et al., 2010; Hodder et al., 2010; Cohen, Meyers and 
Davis, 2013; Raffi et al., 2015), very few studies have been conducted among women in 
general (Hanna et al., 2014) and none have been conducted among pregnant women. 
The findings from this study indicate that the single-tablet regimen did not appear to be 
the “magic bullet” to stem non-adherence and psychosocial issues, such as depression 
and inadequate food are significant contributors of non-adherence to this regimen. 
9.4 Strengths and limitations 
One of the strengths of the in-depth interviews study is that it is the first of its kind to 
provide an understanding of the ART experiences of pregnant and postpartum women 
in Guyana through the context of their daily lives, as well as an examination of their 
adherence behaviours. The use of a mixed-methods design allowed for a more 
comprehensive analysis of adherence. Triangulation of the findings from the in-depth 
interviews and survey enhanced interpretation of the results (Creswell, 2014). Another 
strength of this study is that ART adherence was measured over an extended period of 
three months which provided a more robust assessment of the women’s adherence. It 
was also the first study to examine the constructs of the Health Belief Model to gain a 
better understanding of ART adherence in a pregnant population in general and among 
Guyanese women in particular. Both studies could have been affected by recall bias 
whereby respondents’ memory of reported adherence differed from their actual 
adherence. 
The rigor of qualitative research has been the subject of much debate as measures of 
validity and reliability used to assess quantitative studies are inappropriate for qualitative 
studies (Krefting, 1991; Mays and Pope, 1995). Guba outlined four criteria to assess the 
validity of qualitative studies (Guba, 1981; Shenton, 2004) - credibility (internal validity), 
201 
 
transferability (generalisability), dependability (reliability) and confirmability (objectivity). 
Credibility of the study refers to the trustworthiness of the results or whether the data 
reflects reality. Descriptions of the women’s ART experiences were based on 
information they provided and that of healthcare providers. The reliability of the 
interview data was ensured through the use of taped responses and verbatim transcripts 
which are available for verification and subsequent analyses. Another important concept 
is transferability or how representative the sample is to the population it represents. To 
this end, details of the research setting were provided as well as contextual background 
information about the women. Both studies had high response rates as only one and 
three women declined to participate in the in-depth interviews and survey respectively. 
Finally, objectivity was achieved through reflexivity where the researcher’s role in the 
study was assessed and through triangulation of the women’s accounts with that of their 
providers. Despite these strengths, there were limitations for both studies which are 
highlighted below. 
9.4.1 Limitations of the cross-sectional studies of pregnant women with and 
without HIV 
As this was a cross-sectional study, the associations identified among the variables can 
only be considered correlations and may not be causal. Participants who either attended 
clinic intermittently or were lost-to-care were less likely to be recruited and thus did not 
have an opportunity to participate, so their unique experiences were not heard. 
Moreover, as we know from the literature such persons tend to be less adherent and this 
may have affected overall adherence rates. Future research should include a longitudinal 
study to determine women’s adherence over time.  
The small number of responses (<10) for some questions of the ADQ may have limited 
the ability to detect possible associations with adherence due to limited variance. There 
was complete endorsement of one category for many items (19/27) of the ADQ. 
Further, multiple comparison tests of the data may have increased the probability of a 
Type 1 error. In addition, self-reported adherence could not be correlated with viral load 
counts, since viral load data was available for only 12% of the women. Similarly, actual 
levels of vitamins could not be substantiated since serum levels were not measured. 
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Selecting the sample of HIV-positive women using a sampling frame would have been 
the ideal method, but a declining antenatal HIV prevalence resulted in low numbers of 
eligible women enrolled in care at the clinics, thus a convenience sample of all available 
women was used. 
All interviews were conducted at the clinics which may have increased the likelihood of 
social desirability bias. However, being in a familiar setting may have placed the women 
at ease, as well as being interviewed in a separate room away from the clinical activity. 
Though the survey was not particularly lengthy which usually contributes to respondent 
fatigue and response error, interviews were done at the women’s convenience and may 
have reduced these errors. 
Participants were selected from public health facilities with access to free ART, in 
comparison with women enrolled at private clinics (where medication is not free) and 
these women may have had different experiences. However, due to the high costs of 
medication and other associated laboratory tests, these numbers would be very low as 
patients identified as being HIV-positive in the private sector are given a choice of 
registering for care in the public sector or at two private hospitals where treatment and 
care are free-of-cost as they are funded by the US President’s emergency plan for AIDS 
relief (PEPFAR). 
Although self-reports may be compromised by either lapses in recall or the tendency for 
a socially acceptable response, prior studies have found them to be a reliable 
measurement tool as results have significantly correlated with other data such as serum 
levels (viral load, CD4 count), MEMS, and pharmacy data (DiMatteo, 2004; Kalichman 
et al., 2009; Ndubuka and Ehlers, 2011; Thirumurthy et al., 2012). Further, the author 
sought to reduce women’s anxieties by informing them from the outset that their 
responses would not be shared with clinic staff, and also did not delve into the 
adherence questions immediately after commencing the interview. Multiple measures are 
recommended to assess adherence and with appropriate funding this should be included 
as part of the longitudinal study. 
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9.4.2 Limitations of the in-depth interviews with pregnant and postpartum 
women 
The in-depth interviews would share some of the same limitations as the cross-sectional 
study discussed above, such as, social desirability bias, clinic defaulters, participants with 
access to free ART, discussion of adherence during a single session and use of self-
reports. Although the views of women who were lost to follow-up care were not 
captured in these interviews, the inclusion of healthcare providers with many years of 
experience working with this population allowed for a holistic view of the challenges 
faced by all women in their care. Future research should include the experiences of 
women who have defaulted from care. 
One method of validating the interview data was through triangulation with provider 
accounts and the survey findings.  Another validation method is to allow participants to 
pronounce on the findings to determine if they are accurate representations of their 
experiences and include these responses as part of the ongoing analysis. This technique 
was not feasible with the women due to the sensitivity of the research topic and issues 
of confidentiality; however a focus group discussion with providers may have provided 
further insights.  
One issue which could have been explored in more detail with the women and 
providers is the role of socio-cultural factors such as religion and superstition or 
witchcraft in their lives and its impact on their adherence behaviour. During the in-
depth interviews, women spoke of the important role religion/spirituality played in 
helping them cope and giving them the will to live, while others saw it as a means of 
healing themselves. 
Finally, it is possible that participation in this study may have influenced some 
participants to respond in a particular manner. This might have been their first detailed 
conversation on their HIV diagnosis and experiences. In addition, the discussion on 
adherence may have created a heightened awareness of their adherence behaviour.  
Similarly, I may also have been affected by listening for the first time as well to the 
women’s detailed accounts of their experiences and these perceptions could have 
filtered into the analysis of the data. 
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9.4.3 Weaknesses in measures/key variables 
Although use of a mixed-methods design provides a broader understanding of the 
research question, the extensive data collection required for this type of methodology 
invariably requires rationing of the types of measures and variables investigated in the 
interest of time and resources. First, measuring ART adherence has always been a 
challenge since there are no standardized measurement tools and definitions as 
previously discussed in Chapters 1 and 2. The adherence measures of past four 
weekdays, weekend and a distal period of three months was a bold step to assess 
adherence over a wider time frame than just a limited view of one point in time as has 
been the case in other study designs (Cohn et al., 2008; Igwegbe, Ugboaja and Nwajiaku, 
2010; Ayuo et al., 2013). This decision proved useful, as it highlighted a group of 
pregnant women who were recently adherent, but non-adherent in the past (Chapter 7). 
Socioeconomic status (SES), the combined total measure of income, education and 
occupation which has been associated with ART adherence (Rougemont et al., 2009; 
Birbeck et al., 2011) in some studies was not included as a variable in this study. 
However, the individual variables which contribute to this measure were assessed 
separately and were not found to be associated with ART adherence, similar to that 
found in other studies (Demas et al., 2005; Oliveira Filho et al., 2012; Wasti et al., 
2012b). SES has been considered unreliable in predicting ART adherence as other 
studies have found no association (Orrell et al., 2003; Falagas et al., 2008; Mellins et al., 
2008). 
Multiple measures of ART adherence are recommended (Farmer, 1999) due to the 
weaknesses of the different types of measures (Chapter 1). Viral load was included as 
another type of measure of adherence for this study, but the data was either unavailable 
or not recent enough to be used in the analysis. However, provider reports were 
obtained from the in-depth interviews (Chapter 3). 
The construct of self-efficacy was not measured in this study. Self-efficacy, a construct 
from Bandura’s Social Cognitive theory has been described as a key component for 
both initiating and maintaining behaviour change, as it measures the ability to 
successfully achieve an outcome (Bandura, 1977; Rosenstock, Strecher and Becker, 
1988). Self-efficacy was not originally a factor of the four original HBM components, 
205 
 
but was later added on to the model (Janz and Becker, 1984; Munro et al., 2007). It is 
also a component of other health behaviour models, such as the Integrative Model of 
behavioural prediction (IM), an updated model for the theories of Reasoned Action and 
Planned Behaviour, and the Information-Motivation-Behavioural Skills Model (Fisher et 
al., 2003; Fishbein, 2008). Several studies have identified a relationship between self-
efficacy and adherence whereby higher self-efficacy predicted better adherence (Gifford 
et al., 2000; Molassiotis et al., 2002; Erlen et al., 2010). As such, the role that this 
construct plays in the adherence behaviour of this population warrants some attention 
as most of the women during the in-depth interviews found creative ways to ensure that 
ART was taken amidst challenges (Chapter 3). Cues to action, though not measured 
directly, was expressed during the in-depth interviews as a strong desire to not have an 
infected baby, and emerged as a strong motivating factor for adherence. 
9.5 Key implications and recommendations 
The suboptimal level of adherence reported by the pregnant women during the survey 
and in-depth interviews is a worrying trend that warrants timely intervention for 
successful treatment outcomes. Based on the findings, drug-related issues may not 
account for all the variability seen, and that other factors beyond individual control, 
such as medication side effects and lack of food may play a role in this process. Women 
should be closely monitored during clinic visits to address potential barriers to optimum 
ART therapy. Evidence from randomised control trials and observational studies 
provide support for simple or low-cost interventions such as use of mobile phone short 
messaging system (SMS), reminder phone calls, counselling and education, and peer 
treatment supporters (Sampaio-Sa et al., 2008; Chang et al., 2010; Lester et al., 2010; 
Chung et al., 2011; Kunutsor et al., 2011; Pop-Eleches et al., 2011). The fact that both 
pregnant and postpartum women were united in their motivation to reduce MTCT, and 
to be around to care for their children can also be used as a source of encouragement 
for the women to adhere during counselling sessions. 
Research to date on ART medication suggest that non-adherence is primarily due to 
factors beyond the patient’s control such as the health system, regimen and poverty 
(Mukherjee et al., 2006; Munro et al., 2007), of which the latter two were identified in 
this study. Side effects of ART and pregnancy associated nausea compounding their 
experiences would exacerbate negative effects thereby making adherence difficult 
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(Nachega et al., 2012). Interventions should also target healthcare professionals and 
their relationships with patients (Simoni et al., 2003). DiMatteo, Haskard-Zolnierek and 
Martin (2012) argue that to improve adherence, the patient-provider relationship 
intervention should be guided by three actions: providing information and guidance on 
how to adhere; providing encouragement to motivate patients to adhere; and helping 
the patient to overcome barriers while developing a strategy for long-term care. During 
the in-depth interviews, an overwhelming majority of the women expressed a high 
degree of satisfaction with the care received from the healthcare staff and this would 
have been a motivating factor for their adherence despite the barriers they encountered. 
It was quite evident from the in-depth interviews that religion had a positive effect for 
some (when used as a coping mechanism), and negative effect for others (non-use of 
ART because they believe they have been healed by a religious leader) on adherence 
behaviour. Guyana is a deeply religious society with diverse religious groups and thus 
the role that religion/spirituality plays in the lives of women vis-a-vis their ART 
medication should be discussed during treatment and care sessions. An assessment by 
providers when women initiate treatment and at various times throughout the care and 
treatment cycle could ameliorate potential problems as suggested by Trevino et al. 
(2010) and Wasti et al. (2012a). This data suggests that a surface understanding of 
religious affiliation is insufficient to predict outcomes. Future studies need to explore in 
more detail the nature of religious beliefs, and cares and concerns arising from such 
beliefs in order to fully understand how religion can assist and what barriers may be 
encountered.  
The women in this study were clearly experiencing depressive symptoms of which the 
magnitude over time might be far greater than the levels they reported in both the in-
depth interviews and survey. The prevalence of depression in low to middle-income 
countries is higher than that of other settings (McCauley et al., 2011; Chowdhary et al., 
2014; Glover, 2014). As a lower middle income country (WB, 2014b), Guyana not only 
falls into this category but also does not provide mental health services in its primary 
health care settings. Moreover, a recently released report on suicide by WHO listed 
Guyana as having the highest estimated suicide rate (44 per 100,000) in the world 
(WHO, 2014b). Since there is a strong link between depression and suicide and given 
the levels of depression and suicidal ideation found in this study, mental health services 
as recommended by WHO and other researchers (Freeman et al., 2005; WHO, 2010b; 
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Pappin, Wouters and Booysen, 2012) should be incorporated into the routine HIV 
treatment and care package of services for pregnant women as well as primary care 
services (Freeman et al., 2005; Shin et al., 2011). In addition, alleviating the economic 
hardships identified in this study (food and finances) has been advocated as another 
type of intervention to address mental health problems since they are both contributors 
of mental distress (Shin et al., 2011; Burgess, 2015). Another study which might have 
relevance for this setting is the RCT study by Rotheram-Borus et al. (2014) in which 
peer mentors provided support to pregnant women living with HIV through to the 
postpartum period. The authors found reduced depressed mood and improvements in 
weight gain for infants. 
Pregnancy is considered a buffer against suicide (Appleby, 1991; Cooperman and 
Simoni, 2005). However, few resources are available for the prevention and treatment of 
mental disorders in general and suicide in particular in low to middle income countries 
(Nock et al., 2008; Tsai and Tomlinson, 2012). To address this critical issue, researchers 
have recommended screening for suicidal ideation during pregnancy and the postpartum 
period in primary health care settings (Tabb et al., 2013; Glover, 2014); providing social 
support (Hou et al., 2014). Finally, interventions that have been successfully initiated for 
depression such as the use of peer health workers (Futterman et al., 2010; Chowdhary et 
al., 2014) can be initiated to address suicidal ideation in this context. However, the 
combination of severe staff shortages and an overburdened workforce in Guyana’s 
health sector may pose challenges (PAHO, 2011; USAID, 2011). 
The HBM as a theoretical model and the ADQ may not be worthwhile tools to help 
understand or predict adherence in this population. Many ADQ item responses 
reflected overwhelming positive endorsement for treatment adherence, raising concerns 
about the ability of the ADQ to properly measure the HBM or its ability to measure 
these constructs within this population. Another model worth considering in 
understanding the women’s adherence is Fishbein’s Integrative Model for behavioural 
prediction (IM), an updated model for the theories of reasoned action and planned 
behaviour (Fishbein et al., 2003; Fishbein, 2008). Fishbein argues that this framework 
can be used to explain all types of behaviours and includes the constructs of intentions, 
environmental constraints and skills/abilities. Of the three, intention is considered the 
best predictor of determining whether a particular behaviour will be executed. 
Intentions are described as the willingness to engage in the behaviour. However, 
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Fishbein further argues that despite strong intentions an individual may still be unable to 
perform the desired behaviour as a result of environmental constraints and lack of skills. 
Based on the participants’ responses in the in-depth interviews, it can be inferred that 
intention centred on their determination to take the necessary steps to reduce MTCT. 
Some environmental constraints included lack of food, finances, and ART side effects, 
while skills related to their ability to follow the prescribed regimen. This model includes 
the construct of environmental constraints which is one of the criticisms of the HBM. 
Further testing of this model in this population is warranted. 
Reasons for non-adherence articulated during the in-depth interviews included lack of 
food and financial constraints. Although ART drugs are free of cost in Guyana, ART-
related treatment costs need to be factored into a comprehensive treatment and care 
package. While the national AIDS program (NAPS) has a food bank, coordination is 
needed with the clinics to ensure that women receive appropriate assistance relative to 
their needs. 
9.5.1 Future studies 
Adherence was measured during a single interview session for the cross-sectional study 
and collecting data at different time points may have provided a more comprehensive 
view of the women’s adherence over the duration of pregnancy. Therefore a 
longitudinal study is warranted to determine overall incidence and prevalence using 
multiple measures of adherence not just in pregnancy but encompassing the postpartum 
period as well given the paucity of data in this setting. It might also be of interest to 
assess the effects of non-adherence on current or subsequent pregnancy outcomes. 
The findings from the study indicated unacceptable levels of suicidal ideation and 
depression among the women. Few studies have been conducted on mental health in 
resource-limited settings. Priority areas for Guyana should include assessments of the 
magnitude of mental health issues within the general antenatal and HIV-positive 
populations. Other related research areas include determining the effects of mental 
health problems on adherence to ART and treatment outcomes (Freeman et al., 2005; 
Shin et al., 2011). 
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The desire for pregnancy is enshrined in women’s reproductive rights and given the 
advances in HIV treatment and care, the risk of vertical transmission and other HIV-
related morbidity and mortality can be greatly reduced with timely ART and other care 
interventions (Loutfy et al., 2009; Kimani et al., 2015). While there was some evidence 
in this study of the positive influence of pregnancy desires on adherence, further study 
is warranted on the effects of current and subsequent pregnancies on adherence and 
related outcomes, particularly unintended pregnancies, as prevention of unintended 
pregnancies is an effective strategy for reducing MTCT and maintaining the health of 
the mother (Kimani et al., 2015). 
Religious/spiritual beliefs had both positive and negative influences on adherence for 
the women. The magnitude of this issue needs to be examined as part of a larger study 
on how these variables influence coping in general and adherence in particular to 
provide the evidence for the type of  interventions  needed (Szaflarski, 2013).  
There is no doubt that ART has had a tremendous positive impact on improving the 
lives of HIV-positive women and reducing MTCT. However, the potential toxic effects 
of these ART drugs require routine monitoring, particularly since the full extent of their 
effects on women and children are unfolding (Newell and Bunders, 2013). Women in 
Guyana have transitioned from single dose Nevirapine (sdNVP) in 2001 to combined 
ART, and as such longitudinal studies are needed in this region to determine the nature 
and impact of ART on pregnancy outcomes and infants, so that the efficacy of these 
drugs are not marred by long-term complications and disability for women and children.  
9.6 Concluding remarks 
The findings from the in-depth interviews not only provide valuable insight into the 
lived ART experiences of pregnant and postpartum women in Guyana, but also identify 
critical issues such as medication side effects and coping mechanisms that providers can 
easily discuss with their patients during counselling sessions. This data may also be 
relevant for CARICOM countries with a similar culture and background and as such 
warrants further investigation.  
The high levels of suicidal ideation and depression reported in the in-depth interviews 
and triangulated with the data from the cross-sectional survey require a thorough 
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understanding of the mental health needs of this population to inform appropriate 
treatment modalities. Finally, the non-adherence rate identified in this study, particularly 
despite the availability of a simplified treatment regimen is cause for concern and 
underscores the need to continuously monitor women during treatment and care 
services. Interventions needed to improve ART adherence in this population need to be 
grounded in the psycho-social context of the lives of the women, particularly the 
interweaving roles of poverty and mental health issues in order to inform interventions 
that are culturally-sensitive and tailored to the needs of each patient. 
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Health, Guyana. 
Professor Lorraine Sherr 
RF Hospital and UC Medical School 
Primary Care and Population Health 
UCL 
Upper 3
rd
 Floor 
Rowland Hill Street 
London 
NW3 2PF 
12 January 2012 
Dear Professor Sherr 
Notification of Ethical Approval  
Ethics Application: 3518/001: Factors impacting adherence among HIV-positive 
pregnant and postpartum women attending government clinics in Guyana  
I am pleased to confirm that in my capacity as Chair of the UCL Research Ethics Committee I 
have approved your project for the duration of the study (i.e. until January 2013). I was 
particularly impressed with your application which was very clear and well-presented. 
However, approval is subject to the following conditions: 
1. You must seek Chair's approval for proposed amendments to the research for which 
this approval has been given. Ethical approval is specific to this project and must not 
be treated as applicable to research of a similar nature. Each research project is 
reviewed separately and if there are significant changes to the research protocol you 
should seek confirmation of continued ethical approval by completing the 'Amendment 
Approval Request Form'. 
The form identified above can be accessed by logging on to the ethics website homepage: 
http://www.grad.ucl.ac.uk/ethics/ and clicking on the button marked 'Key Responsibilities of the 
Researcher Following Approval'. 
2. It is your responsibility to report to the Committee any unanticipated problems or adverse 
events involving risks to participants or others. Both non-serious and serious adverse events 
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Reporting Non-Serious Adverse Events  
For non-serious adverse events you will need to inform Helen Dougal, Ethics 
Committee Administrator (ethics@ucl.ac.uk), within ten days of an adverse incident 
occurring and provide a full written report that should include any amendments to the 
participant information sheet and study protocol. The Chair or Vice-Chair of the Ethics 
Committee will confirm that the incident is non-serious and report to the Committee at 
the next meeting. The final view of the Committee wi ll be communicated to you. 
Reporting Serious Adverse Events  
The Ethics Committee should be notified of all serious adverse events via the Ethics 
Committee Administrator immediately the incident occurs. Where the adverse incident is 
unexpected and serious, the 
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Chair or Vice-Chair will decide whether the study should be terminated pending the 
opinion of an independent expert. The adverse event will be considered at the next 
Committee meeting and a decision will be made on the need to change the information 
leaflet and/or study protocol. 
On completion of the research you must submit a brief report (a maximum of two sides of 
A4) of your findings/concluding comments to the Committee, which includes in particular 
issues relating to the ethical implications of the research. 
With best wishes for the research. 
Yours sincerely 
 
S John Birch 
Chair of the UCL Research Ethics Committee 
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terminated pending the opinion of an independent expert. The adverse event will be 
considered at the next Committee meeting and a decision will be made on the need to 
change the information leaflet and/or study protocol.  
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Appendix C: Systematic review – search strategies 
Search Strategy for PsycINFO 
 1     exp HIV/ or HIV.mp. (31832) 
 2     (HIV virus infection or human immunodeficiency virus infection or 
HIV-1 or HIV-2).mp. [mp=title, abstract, heading word, table of contents, 
key concepts, original title, tests & measures] (1683) 
 3     AIDS.mp. or exp AIDS/ (30254) 
 4     (acquired immunodeficiency syndrome or acquired immune deficiency 
syndrome or acquired immuno-deficiency syndrome).mp. [mp=title, abstract, 
heading word, table of contents, key concepts, original title, tests & measures] 
(3415) 
 5     (PMTCT or MTCT).mp. [mp=title, abstract, heading word, table of 
contents, key concepts, original title, tests & measures] (140) 
 6     (mother-to-child transmission or mother-to-infant transmission or 
perinatal transmission or postnatal transmission or vertical transmission).mp. 
[mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] (387) 
 7     (ARV therapy or antiretroviral therapy or antiretroviral prophylaxis).mp. 
[mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] (1818) 
 8     (HAART or highly active antiretroviral therapy).mp. [mp=title, abstract, 
heading word, table of contents, key concepts, original title, tests & measures] 
(1029) 
 9     exp Treatment Compliance/ or exp Compliance/ or adherence.mp. 
(19844) 
 10     1 or 2 or 3 or 4 (42582) 
 11     5 or 6 (414) 
 12     7 or 8 (2038) 
 13     9 and 10 and 11 and 12 (11) 
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Search strategy for Embase 
 1     HIV.mp. or exp Human immunodeficiency virus/ (234374) 
 2     (HIV-1 or HIV-2 or HIV virus infection).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] (59503) 
 3     AIDS.mp. or exp acquired immune deficiency syndrome/ (164098) 
 4     (acquired immunodeficiency syndrome or acquired immuno-deficiency 
syndrome).mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] (16316) 
 5     exp virus transmission/ or exp vertical transmission/ or PMTCT.mp. 
(40742) 
 6     (MTCT or mother-to-child transmission or mother-to-infant 
transmission or perinatal transmission or postnatal transmission).mp. 
[mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
(4102) 
 7     (ARV therapy or antiretroviral therapy or ARV prophylaxis).mp. 
[mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
(32634) 
 8     (HAART or highly active antiretroviral therapy).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] (24655) 
 9     medication adherence.mp. or exp patient compliance/ (74931) 
 10     1 or 2 or 3 or 4 (322840) 
 11     5 or 6 (42262) 
 12     7 or 8 (33354) 
 13     9 and 10 and 11 and 12 (256) 
Search strategy for CINAHL Plus 
 S11 S5 and S8 and S9 and S10 (22) 
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 S10 S6 or S7   (5078) 
 S9  S1 or S2 or S3   (70765) 
 S8  (MH "Medication Compliance") OR (MH "Patient Compliance+") OR 
"adherence" OR (MH "Guideline Adherence")  (29863) 
 S7  HAART or highly active antiretroviral therapy  (1902) 
 S6  ARV therapy or antiretroviral therapy or ARV prophylaxis (4852) 
 S5   mother-to-child transmission or mother-to-infant transmission or 
perinatal transmission or postnatal transmission) or vertical transmission 
 (1140) 
 S4  "PMTCT or MTCT"     (0) 
 S3  acquired immune deficiency syndrome or acquired immuno-deficiency 
syndrome (519) 
 S2  (MH "Acquired Immunodeficiency Syndrome") OR "AIDS" (38605) 
 S1  (MH "HIV Infections+") OR (MH "HIV-1") OR "HIV" OR (MH 
"Human Immunodeficiency Virus+")  (58137) 
Search strategy for JSTOR 
HIV or HIV-1 or HIV-2 or HIV virus infection or human immunodeficiency virus 
infection OR AIDS or acquired immunodeficiency syndrome or acquired immuno-
deficiency syndrome or acquired immune deficiency syndrome AND PMTCT or MTCT 
or mother-to-child transmission or mother-to-infant transmission or perinatal 
transmission or postnatal transmission or vertical transmission AND ARV therapy or 
antiretroviral therapy or antiretroviral prophylaxis AND medication adherence or 
medication compliance or patient compliance or adherence (441) 
Search strategy for Web of Science 
 # 7 97  
 #6 AND #5 AND #4 AND #3  
 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
Timespan=All Years 
 # 6 >100,000  
 #2 OR #1  
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 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
Timespan=All Years  
 # 5 76,180  
 Topic=(medication adherence or medication compliance or patient 
compliance or adherence)  
 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
Timespan=All Years  
 # 4 31,030  
 Topic=(ARV therapy or antiretroviral therapy or antiretroviral prophylaxis)  
 # 3 16,147  
 Topic=(mother-to-child transmission or mother-to-infant transmission or 
perinatal transmission or postnatal transmission or vertical transmission) OR 
Topic=(PMTCT or MTCT)  
 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
Timespan=All Years Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, 
CPCI-SSH Timespan=All Years 
 # 2 >100,000  
 Topic=(AIDS or acquired immunodeficiency syndrome or acquired 
immuno-deficiency syndrome or acquired immune deficiency syndrome)  
 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
Timespan=All Years 
 # 1 >100,000  
 Topic=(HIV or HIV-1 or HIV-2) OR Topic=(HIV virus infection or human 
immunodeficiency virus infection)  
 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
Timespan=All Years 
Search strategy for Cochrane Library 
 #1 
 MeSH descriptor HIV 
explode all trees 
 2104 
 #2  human immunodeficiency  3045 
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virus infection or HIV virus 
infection 
 #3 
 MeSH descriptor Acquired 
Immunodeficiency Syndrome 
explode all trees 
 1162 
 #4 
 AIDS or acquired immuno-
deficiency syndrome or 
acquired immune deficiency 
syndrome 
 11706 
 #5 
 (mother-to-child transmission 
or mother-to-infant 
transmission or maternal-to-
child transmission) or (MTCT 
or PMTCT) or (maternal 
infant transmission) or 
(vertical transmission) or 
(perinatal transmission or 
postnatal transmission or 
post-natal transmission) 
 742 
 #6 
 (ARV therapy or ART therapy 
or antiretroviral therapy) or 
(HAART or highly active 
antiretroviral therapy) or 
(ARV prophylaxis or 
antiretroviral prophylaxis) 
 8407 
 #7 
 (medication adherence or 
medication compliance) or 
(treatment adherence or 
treatment compliance) or 
(patient adherence or patient 
compliance) 
 19612 
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 #8  (#1 OR #2 OR #3 OR #4)  13819 
 #9 
 (#8 AND #5 AND #6 AND 
#7) 
 25 
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Appendix D: Systematic review - Data Extraction Form 
 
 
Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
1 
Albrecht, S. 
et al., 2006 Zambia 
760 HIV-positive 
women; 10% 
(<20yrs), 67% 
(20-29 yrs), 21% 
(30-39 yrs), 1% 
(>40 yrs) 
Cohort (prospective); 
May 2001 to August 
2003; to determine 
factors affecting non-
adh to sdNVP for 
HIV-positive women 
and their infants 
Use of sdNVP among 
pregnant women prior 
to delivery and their 
infants post-delivery 
Non-adherence = 
both mother and 
infant not ingesting 
sdNVP 
74.1% delivered at 
ANC clinic, 10.1% 
(home) and 14.5% 
(hospital); 94% 
women & 91% infants 
got NVP; Although 
non-adherence was 
not quite an issue 
here, it was associated 
with home deliveries 
and poor health status 
of the baby at birth 
2 Bardeguez, 
A. et al., 
USA 
519 HIV-positive 
pregnant & 
postpartum 
Cohort study 
(prospective) August 
2002 to July 2005; to 
Combination ART; 
Adh measured via 
self-report - regimen, 
"Perfect" Adh = 
Clinic visit + 
completed self-report 
75% women had 
perfect adh in 
pregnancy which 
259 
 
 
 
Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
2008 women; 56% 
Black, 30% 
Hispanic, 14% 
White/Other; 
50% - 21-30 yrs, 
37% > 30 years, 
14% < 21 years; 
determine rates of 
self-reported ARV 
adherence pre and 
postpartum 
missed doses over 
past 4 days & time 
when dose was 
missed; 
Questionnaires on 
quality of life, mental 
health, substance use;  
form + info on drug 
use over past 4 days; 
"Imperfect" Adh = 
missing at least 1 
dose of meds or 
incomplete info on 
past 4 days 
decreased postpartum 
to 65% (6wks), 64% 
(24 wks) and 66% (48 
wks.); Overall, adh 
levels were low, but 
was better during 
prenatal period; Not 
missing prenatal 
vitamins was only 
variable significantly 
related to perfect adh;  
3 
Bii, S. et al., 
2007 Kenya 
146 HIV-positive 
postpartum 
women; Age 
range: 12 - 42 
(median - 28 yrs); 
Cross sectional study 
done between April 
& July 2005; to assess 
the use of sdNVP 
among HIV-positive 
146 postpartum 
women attending a 
family planning clinic 
were asked about 
sdNVP use prior to 
Adherence to sdNVP 
for pregnant women 
& their babies 
66% women delivered 
in health setting; 90% 
women & 91% infants 
got NVP; Non-
adherence was 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
study done at a 
clinic in a western 
Kenya hospital  
women delivery & for their 
babies after delivery 
using self-
administered 
questionnaires 
associated with: less 
than 20 yrs, being 
single, going to ANC 
for less than 2 visits, 
forgetting to take 
meds 
4 
Ciambrone, 
D. et al., 
2006 
Puerto 
Rico 
17 pregnant & 
postpartum HIV-
positive Latina 
women; mean age 
25 yrs; Medical 
clinic of 
University 
Qualitative study; 
March to July 2003; 
to assess the factors 
impacting adherence 
among HIV-positive 
pregnant & 
postpartum women 
& to determine 
support for an 
In-depth Interviews to 
convenience sample 
on ARV adherence, 
sociodemographics, 
confidentiality, side 
effects, stigma and 
support networks 
Grounded theory 
methodology for 
analysis; describe 
factors affecting 
adherence among 
prenatal & 
postpartum women 
52% women reported 
taking meds as per 
orders; Facilitators of 
adh: concern for 
foetus, family support, 
; Barriers: busy life, 
preoccupied with 
other matters, non-
disclosure of status, 
lack of family 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
MDOT program assistance in 
postpartum period, 
health needs of others 
took precedence over 
theirs 
5 
Cohn, S. et 
al., 2008 USA 
149 HIV-positive 
pregnant women 
from 28 sites in 
US; 55% Black, 
26% Hispanic, 
15% White; 32% 
were below 25 
years, 35% were 
over 30 years;  
Cohort study 
(prospective); 2002 – 
2005; to determine 
ARV adherence pre 
and postpartum; 
women entered in 
study at 20-34 weeks 
gestation & followed 
every 8 weeks 
prenatally & 12 
Each visit had 
questionnaires medical 
& pregnancy history,  
adherence, self-
efficacy, social 
support, mental 
health, substance use; 
women followed until 
12 weeks postpartum 
Blood taken for CD4 
"Recent & extended" 
adherence were 
evaluated via self-
report; Recent adh = 
not missing meds in 
the past 4 days; 
Extended adh = not 
missing any meds for 
over 3 months; 
Higher adh in 
antenatal period than 
postpartum; 74%  
recent antenatal adh 
vs 65% recent 
postpartum adh; 
Younger age (< 25 
yrs), smoking 
antenatally were 
associated with non-
adh; Predictors of 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
weeks postpartum and viral load non-adh: missed 
prenatal vitamins, 
illegal drugs usage  
6 
Delvaux, T. 
et al., 2009 Rwanda  
236 HIV-positive 
women with a 
mean age of 30 
years; Study done 
at 12 (random) 
public PMTCT 
sites 
Case control; April - 
May 2006; to 
determine reasons for 
non-adherence to 
sdNVP among HIV-
positive women who 
complied  or did not 
comply with regimen 
Participants who did 
not adhere were cases 
and those who did 
were controls; 
Interviews with 
pretested 
questionnaires on 
ARV use, 
sociodemographics, 
testing & delivery 
services 
Women were divided 
into those who did 
not adhere 
(cases=111) and 
those who adhered 
(controls=125); 
closed-ended 
interviews with 
trained staff. Topics 
included 
sociodemographics, 
antenatal care, 
testing, ARV 
61% non-adherent 
women got sdNVP, 
while 7% infants got 
their dose; Factors 
associated with non-
adh: non-disclosure of 
HIV status, less than 2 
ANC visits, home 
deliveries 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
prophylaxis; Non-
adherence= mother 
and/or infant not 
getting sdNVP; 
adherence= both 
mother & infant 
getting sdNVP 
7 
Demas, P. 
et al., 2005 USA 
78 pregnant HIV-
positive women; 
3 NY city sites; 
53% Black, 41% 
Hispanic, 6% 
White/Other 
Cross-sectional; April 
1997 to June 1998 
Objective was to add 
to knowledge on 
ZDV use during 
pregnancy using 
biological assays, 
sociodemographics & 
Zidovudine Adh 
measured by 
interviews, blood and 
urine analysis; Long 
term adh measured via 
MCV (mean 
corpuscular volume), 
short term adh 
measured with urine 
Adherence defined as 
having enough meds 
for 80% days from 
1st prescription to 
refill; Long term adh 
= MCV level < 95fl 
62% women were adh 
via urine analysis 
(short-term), 68% 
women were adh via 
MCV (long-term) 
analysis; Ethnicity 
(Black, Hispanic) & < 
20 years; Being a 
member of a support 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
psychosocial factors  assays group & disclosure to 
the woman's mother 
were associated with 
adh; demographics & 
clinical variables not 
related to adh 
8 
Duff, P. et 
al., 2010 Uganda 
53 HIV-positive 
pregnant and 
post-natal women 
attending 
government clinic 
in a hospital; 
average age in 
each of 4 groups 
(30, 36, 32 & 35) 
Qualitative study; 
Sept to Dec 2006; to 
determine the factors 
affecting adherence 
to ARV among 
pregnant & 
postpartum women 
HAART; In-depth 
interviews & 1 focus 
group; Study 
participants placed 
into 4 groups 
according to HAART 
status (eligible but not 
in program, enrolled 
but did not return, 
enrolled but did not 
Explore barriers to 
enrolling in care; no 
quantitative measure 
of adherence; 
Thematic content 
analysis 
Barriers to adh: high 
transportation costs, 
poverty, stigma, long 
wait for health care, 
non-disclosure,   
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
take HAART & 
women adhering to 
HAART);  
9 
Ickovics, J. 
et al., 2002 USA 
53 HIV-positive 
pregnant & 
postpartum 
women; Age 
range: 16 -42 
(mean 27.7 yrs); 
68% African Am, 
22% Latina; 
public health 
clinics in 4 US 
States; 
Cohort (prospective); 
Sub-study; July 1997 
to September 1998; 
to determine types of 
adherence to ZDV 
prenatally 
Combination ART; 
Adherence measured 
using MEMS caps 
during 3rd trimester & 
postpartum (6 weeks); 
medical record 
reviews & interviews 
during the 3rd 
trimester; 
Adherence measured 
by doses per day & 
"therapeutic 
coverage" to assess 
adherence within a 24 
hr period 
Adherence: 0% to 
100% in both prenatal 
& postpartum periods; 
Non-adh: 18% @ 3 
wks prenatal to 41% 
@ 3 wks postpartum; 
substantial decline in 
adh from prenatal to 
postpartum; Mean 
prenatal adh = 50%, 
mean postnatal adh = 
34.1%; Predictors of 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
adh not assessed; 
10 
Kirsten, I. 
et al., 2011 Tanzania 
122 HIV-positive 
pregnant & post-
partum women; 
Age range: 18 to 
37 yrs (median 
26); Study 
conducted at 
hospital in rural 
area of Tanzania;  
Cohort study 
(prospective); Oct 
2008 to July 2009; to 
determine adherence 
to ARV therapy & 
factors impacting adh 
Combination ART 
prophylaxis; 
questionnaires during 
antenatal care & pre 
and post-delivery; # 
of doses of AZT 
collected;  
Adh pre and post-
delivery was 
measured; Pre-
delivery adherence = 
# of collected AZT 
doses & not doses 
ingested; post-
delivery adherence = 
drugs given by nurses 
to mother & new 
born 
47/122 (39%) women 
lost to follow-up; 
35/122 (29%) refused 
pre-delivery AZT; 
Pre-delivery AZT 
adherence (mean) = 
77%; complete 
adherence prior to 
delivery = 38%; 
Facilitators of adh 
prior to delivery: 
disclosure to 
significant other, 
relative, friend; 
Barriers non-adh: 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
family commitments, 
memory lapses, young 
age, lack of a job, 
gestation < 24 wks; 
transportation 
problems; 8% mother-
child pairs had ≥80% 
adh & only 1 mother-
child pair had 95% 
adh 
11 
Laine, C. et 
al., 2000 USA 
2714 HIV-
positive prenatal 
women who had 
live births; no 
data on ethnicity, 
but Asian and 
Cohort study 
(retrospective); 1993-
1996; to determine 
adherence to ARVs 
using Medicaid 
pharmacy data 
Pharmacy-based 
claims approach to 
assessing adherence 
from Medicaid 
payment claims who 
were on treatment for 
Adequate adherence 
= meds to cover at 
least 80% of the time 
from 1st prescription 
to delivery 
34.2% women had 
"adequate" adherence; 
poor adh was 
associated with 
younger age (<20 
yrs.), ethnicity 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
Native Americans 
were excluded; 
among HIV-positive 
pregnant women 
over 2 months prior 
to delivery 
(Black/Hispanic), 
other chronic illnesses,  
12 
McDonald, 
K. and  
Kirkman, 
M., 2011 Australia 
16 HIV-positive 
pregnant & post-
partum women; 
age range: 25-
40+;  14 born in 
Australia, 2 
elsewhere     
Qualitative study; 
2001; to examine 
women’s stories 
about ARV during 
the prenatal period 
and also for their 
infants 
In-depth interviews 
on issues like 
diagnosis of disease, 
being an HIV-positive 
mother, support 
network, disclosure 
Framework analysis; 
women’s experiences 
with ARV for 
themselves & infants 
Non-adherence issues: 
Women were 
concerned about 
safety and usefulness 
of ARV drugs; did not 
want to be 
experimented on; 
concerned about 
effects of drugs on 
baby's health;  
13 
Mellins, C. 
et al., 2008 USA 
399 HIV-positive 
pregnant & 
postpartum 
Cohort (prospective); 
March 2001 - June 
2005; to determine 
Combination ART; 
Adherence measured 
via self-report at the 
Complete adh = 
combined score of 
complete adh to all 
Complete adh: 61% 
women during 
antenatal period, 44% 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
women in 4 US 
states & Puerto 
Rico; majority of 
women were 
Black & 
Hispanic, 
followed by 
White and 
Asian/Other 
adherence to ARV 
among pregnant & 
postpartum women 
3rd trimester & 6-
months postpartum; 
Other info collected: 
viral load, CD4 count, 
drugs use, 
sociodemographics 
meds over the past 2 
days + no missed 
meds in the past 
month 
postpartum; 
demographics were 
not associated with 
adherence; Factors 
predicting non-
adherence: body 
weight, hair loss, 
depression; Concern 
for baby's health was 
main reason for adh 
during pregnancy 
14 
Mepham, S 
et al., 2011 
South 
Africa 
100 HIV-positive 
pregnant Zulu 
women; health 
clinic; no ages 
Mixed-methods 
Study; Sub-Study of a 
5-site RCT;  2 wks in 
Nov 2008; to 
determine the 
Combination ART 
prophylaxis; random 
assignment into 2 
groups (49 short 
course ARV & 51 
Good adherence = 
>95% and poor 
adherence = <95% 
Adherence score = # 
61% women had good 
ARV prophylaxis; 
there was no 
remarkable difference 
in women on short 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
given;  problems 
experienced by Zulu 
HIV-positive 
pregnant women 
HAART); Interviews 
with 43 women, 
reviews of clinical & 
adh counselling notes; 
pill counts at 28, 29, 
every 4 weeks & 1 
week post delivery 
pills taken divided by 
total pills given 
course vs. HAART 
treatment; Factors 
affecting adherence: 
women unable to read 
English drug labels, 
lack of food & water 
to take medication, 
theft of medication, 
real/perceived fear of 
domestic violence,   
15 
Peltzer, K. 
et al., 2010 
South 
Africa 
815 post-partum 
HIV-positive 
women with 3-6 
month old infant; 
98.8% Black 
Africans (73% 
Cohort study 
(prospective); Sept 
2008 to March 2009; 
to assess the 
predictors of 
adherence to sdNVP 
Single dose NVP; 
Structured interviews; 
questionnaires; 
adherence measured 
by self-reports 
Non-adherence = 
mother and/or infant 
not taking NVP at 
any point in time;  
adherence = mother-
infant pairs who 
78% women had NVP 
before delivery & 77% 
infants had NVP; 
Reasons for non-adh: 
lack of knowledge on 
importance of pill, did 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
Zulu, 12% Swati, 
13% Other); 7 
sub-districts of 
Gert Sibande; 47 
clinics; age range 
16-58 yrs;  
among HIV-positive 
women 
received NVP as 
required 
not want to take pill 
during pregnancy, did 
not remember, 
significant 
other/family did not 
want them to take pill, 
pill lost; health care 
provider did not give 
pill to woman; 
PMTCT knowledge, 
term delivery and 
confidential HIV 
status at health facility 
were strongly 
associated with 
mothers NVP 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
adherence 
16 
Turner, B. 
et al., 2000 USA 
2,648 HIV-
positive 
postpartum 
women from NY 
state; no info 
given on ethnic 
breakdown, 
except that 
Asians & Native 
Americans 
Cohort study  
(retrospective); 1993 
to 1997; to assess 
patient and provider 
behaviour on ARV 
therapy & to quantify 
postpartum 
adherence using 
pharmacy-based 
measures 
Medicaid claims were 
checked for ART 
prescribed in the 
postpartum period for 
persons who were on 
treatment for over 2 
months 
Pharmacy-based 
Adherence = ≥80% 
days of prescribed 
meds from the 1st to 
last prescription 
26% women were 
given ARVs & 28% 
were compliant; 
depressed women had 
poor pharmacy-based 
adh 
17 
Vaz, M. et 
al., 2007 Brazil 
72 pregnant & 79 
non-pregnant 
HIV-positive 
women; mean age 
Cohort study 
(prospective); March 
2001 to June 2002;  
to determine how 
Adherence measured 
by pill counts & self-
reports; Pts did not 
know about pill 
Adherence =  ≥ 95% 
ARVs taken at 2 time 
points 
43% pregnant & 18% 
non-pregnant were 
adherent via pill 
count; adherence 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
of 39.4 non-
pregnant vs. 29.3 
pregnant 
pregnancy affects 
ARV adherence 
among a group of 
pregnant and non-
pregnant women 
counts; 2 pill counts 
per participant; self-
report done by asking 
about missed doses in 
past 4 days per drug & 
reasons for missed 
doses;  
decreased to 21% 
postpartum; self-
reports of adh were 
higher than pill counts 
in both groups; 
Reasons for non-adh: 
away from home 
without meds; 
Facilitators: being 
pregnant, less than 6 
pills/day, maximum of 
2 doses per day, older 
than 29 years of age 
18 
Wilson, T. 
et al., 2001 USA 
264 HIV-positive 
pregnant women 
at antenatal 
Cross-sectional study 
(prospective); June 
1996 to November 
Women interviewed at 
2 time points - > 24 
weeks gestation & > 
Adherence = # pills 
taken over past 4 
days;  Complete 
80% reported taking 
all doses of 
Zidovudine 
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Reference 
 
Country 
 
Participants 
Participants 
 
Methods 
 
Interventions 
 
Outcomes 
 
Results 
clinics in 4 US 
states; Age range: 
14-46 years 
(mean 28 years); 
73% African Am, 
19% Hispanic; 
1998; to determine 
medical and 
psychosocial issues 
affecting adherence 
among HIV-positive 
pregnant women 
32 weeks, but before 
delivery;  
adherence = taking 
all meds each day 
over 4 days; 
depression was also 
measured 
medication over past 4 
days; Predictors of 
adherence: no drug 
use, taking all prenatal 
vitamins, not missing 
medical appointments 
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Appendix E: Systematic review  - Quality Assessment for Quantitative Studies  
Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
Selection Bias 
Q1. Are 
participants 
representative 
of target pop 
 
Q2. What % 
of participants 
agreed to 
participate 
Not likely -
no random 
sampling; 
women were 
enrolled in 2 
clinics 
 
Can’t tell – 
no info given 
Not likely 
– no 
random 
sampling 
 
 
 
 
 
Not likely – 
no random 
selection 
 
 
 
 
 
Can’t tell – 
Not likely – 
no random 
selection 
 
 
 
 
 
Can’t tell – 
Very likely – 
sites & 
persons 
randomly 
selected 
 
 
 
100% agreed 
Can’t tell – no 
info given 
 
 
 
 
 
 
Not likely – 
no random  
selection 
 
 
 
 
Can’t tell – 
no info 
Some 
what likely – 
women 
included in 
systematic 
manner 
 
Can’t tell – no 
info given 
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
Can’t tell – 
no info 
given 
no info given no info 
given 
95.6% agreed given 
RATING Weak Weak Weak Weak Strong Moderate Weak Mod 
Study Design 
Q1. Type of 
study design 
 
Q2. Is this a 
randomized 
study 
Cohort 
design 
 
 
No – not 
randomized 
Cohort 
design 
 
 
No – not  
randomize
Cross-
sectional 
design 
 
No – not  
randomized 
Cohort 
design 
 
 
No – not  
randomized 
Case Control 
 
 
Yes  
Cross-
sectional 
 
 
No  
Cohort 
 
 
 
No 
Cohort 
 
 
 
No 
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
 d 
RATING Moderate Moderate Weak Moderate Moderate Weak Mod Mod 
Confounders 
Q1. Are there 
important 
differences 
between 
groups prior 
to intervention 
 
Q2. If Yes, 
N/A – only 
1 group 
 
 
 
 
 
N/A – 
only 1 
group 
 
 
 
 
N/A – only 1 
group 
 
 
 
 
 
Yes  - age, 
race, 
education 
 
 
 
 
Yes – age, 
education, 
marital status 
 
 
 
 
N/A – only 1 
group 
 
 
 
 
 
N/A –only 1 
group 
 
 
 
 
 
N/A – only 1 
group 
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
what % of 
confounders 
were 
controlled for 
N/A - as 
above 
 
N/A – as 
above 
N/A – as 
above 
 
Most 
Most N/A – as 
above 
N/A – as 
above 
 
N/A – as 
above 
RATING N/A N/A N/A Strong Strong N/A N/A N/A 
Blinding 
Q1. Were the 
researchers 
aware of the 
group 
allocation of 
the 
N/A – only 
1 group 
 
 
 
N/A – 
only 1 
group 
 
 
 
N/A – only 1 
group 
 
 
 
N/A – study 
not an RCT 
 
 
 
Yes 
 
 
 
 
N/A – only 1 
group 
 
 
 
N/A – only 
1 group 
 
 
 
N/A – only 1 
group 
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
participants 
 
Q2. Were the 
participants 
aware of the 
research 
questions 
 
 
 
N/A – as 
above 
 
 
 
N/A – as 
above 
 
 
 
N/A – as 
above 
 
 
 
N/A – as 
above 
 
 
 
Can’t tell 
 
 
 
N/A – as 
above 
 
 
 
N/A – as 
above 
 
 
N/A – as 
above 
RATING N/A N/A N/A N/A Weak N/A N/A N/A 
Data 
Collection 
Methods 
Can’t tell – 
no info given 
 
Yes – used 
validated 
Mental 
Health 
Can’t tell – 
no info given 
 
Yes – used 
validated 
ACTG 
adherence 
Can’t tell – 
was pre-tested, 
but no info on 
Yes – 
validated tools 
were used 
Can’t tell – 
no info 
given 
Can’t tell – no 
info given 
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
Q1. Were data 
collection 
tools shown to 
be valid 
 
Q2. Were data 
collection 
tools shown to 
be reliable 
 
 
 
 
 
Can’t tell – 
no info given 
Inventory 
 
 
 
Yes – used 
established 
tool 
 
 
 
 
 
Can’t tell – 
no info given 
questionnair
e 
 
Yes – used 
established 
tool 
validity 
 
 
Can’t tell – no 
info given 
 
 
 
 
Yes – as above 
 
 
 
 
Can’t tell – 
no info 
given 
 
 
 
Can’t tell – no 
info given 
RATING Weak Strong Weak Strong Weak Strong Weak Weak 
Withdrawals &         
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
drop outs 
Q1. Were 
withdrawals & 
dropouts 
reported by #s 
& reasons 
 
Q2. % of 
participants 
completing the 
study 
 
No 
 
 
 
 
 
Can’t tell – 
no info given 
 
No 
 
 
 
 
 
Can’t tell – 
no info 
 
No 
 
 
 
 
 
Can’t tell – 
no info given 
 
Yes – 12% 
withdrew 
 
 
 
88% 
complete 
study 
 
No 
 
 
 
 
 
Can’t tell – no 
info given 
 
Yes – 78/86 
women in final 
group 
 
 
90.7% 
complete 
study 
 
Yes – 53/65 
returned 
MEMS caps 
 
81.5% 
complete 
study 
 
Yes – 8/130 
drop outs 
 
 
93.8% in final 
group 
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Component Albrecht 
2006 
Bardeguez  
2008 
Bii  
2007 
Cohn  
2008 
Delvaux  
2009 
Demas  
2005 
Ickovics  
2002 
Kirsten  
2011 
given  
 
RATING Weak Weak Weak Strong Weak Strong Strong Strong 
Global. Rating Weak Weak Weak Moderate Weak Moderate Weak Moderate 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
Selection Bias 
Q1. Are 
participants 
representative 
of target pop 
 
Q2. What % 
of participants 
agreed to 
participate 
Can’t tell – no 
info given 
 
 
 
 
N/A – 
retrospective 
study 
Can’t tell – no 
info given 
 
 
 
 
Can’t tell – as 
above 
Very likely – 
there was 
random 
selection 
 
 
 
Can’t tell – no 
info given 
 
Can’t tell – no 
info given 
 
 
 
 
 
Can’t tell – no 
info given 
Can’t tell – no 
info given 
 
 
 
 
N/A – 
retrospective 
study 
Can’t tell – no 
info given 
 
 
 
 
Can’t tell – as 
above 
Can’t tell – no 
info given 
 
 
 
 
Can’t tell – as 
above 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
 
 
 
RATING Weak Weak Moderate Weak Weak Weak Weak 
Study Design 
Q1. Type of 
study design 
 
Q2. Is this a 
Cohort –
retrospective 
 
 
Cohort 
 
 
 
Mixed-
Methods 
study (Cohort 
+ qual) 
 
Yes – 49 
Cohort 
 
 
 
Cohort –
retrospective 
 
No 
Cohort 
 
 
 
Cross-sectional 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
randomized 
study 
 
No No women 
randomized 
to short-term 
therapy & 51 
in 
combination 
therapy 
 
Partial  - 
systematic 
sampling used 
for sites; no 
info on 
participants 
No  No 
RATING Moderate Moderate Moderate Moderate Moderate Moderate Weak 
Confounders 
Q1. Are there 
important 
differences 
N/A – only 1 
group 
 
N/A – only 1 
group 
 
Yes – age, 
education, 
marital status 
N/A – only 1 
group 
 
N/A – only 1 
group 
 
Yes -  age, 
race, 
education 
N/A – only 1 
group 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
between 
groups prior 
to intervention 
 
Q2. If Yes, 
what % of 
confounders 
were 
controlled for 
 
 
 
 
N/A – as above 
 
 
 
 
N/A – as 
above 
 
 
 
 
Can’t tell – no 
info given 
 
 
 
 
N/A – as 
above 
 
 
 
 
N/A – as above 
 
 
 
 
Most 
 
 
 
 
N/A – as 
above 
RATING N/A N/A Weak N/A N/A Strong N/A 
Blinding N/A –
retrospective 
N/A – only 1 Can’t tell – no N/A – only 1 N/A –
retrospective 
Yes N/A – only 1 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
Q1. Were the 
researchers 
aware of the 
group 
allocation of 
the 
participants 
 
Q2. Were the 
participants 
aware of the 
research 
questions 
study 
 
 
 
 
N/A – as above 
group 
 
 
 
 
 
N/A – as 
above 
info given 
 
 
 
 
Can’t tell – as 
above 
group 
 
 
 
 
N/A – only 
one group 
study 
 
 
 
 
N/A – as above 
 
 
 
 
 
 
Can’t tell 
group 
 
 
 
 
N/A – as 
above 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
RATING N/A N/A Moderate N/A N/A Weak N/A 
Data 
Collection 
Methods 
Q1. Were data 
collection 
tools shown to 
be valid 
 
Q2. Were data 
collection 
tools shown to 
Can’t tell – no 
info given 
 
 
 
 
Can’t tell – as 
above 
Yes – ACTG 
valid tool 
used 
 
 
 
Yes – as 
above 
Can’t tell – no 
info given 
 
 
 
Can’t tell – as 
above 
Yes –  
 
 
 
 
Yes 
Can’t tell – no 
info given 
 
 
 
 
Can’t tell – as 
above 
Can’t tell – no 
info given 
 
 
 
 
 
Can’t tell – as 
Yes, validated 
tool were used 
– AACTG & 
depression 
tools 
 
Yes – as above 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
be reliable above 
RATING Weak Strong Weak Strong Weak Weak Strong 
Withdrawals & 
drop outs 
Q1. Were 
withdrawals & 
dropouts 
reported by #s 
& reasons 
 
Q2. % of 
 
 
N/A – 
retrospective 
study 
 
 
 
 
Can’t tell – no 
info given 
 
 
Can’t tell – as 
 
 
N/A – one 
time interview 
 
 
N/A – as 
 
 
N/A – one 
time interview 
 
 
N/A – as 
 
 
N/A – 
retrospective 
study 
 
 
 
 
Yes – 23/95 
& 49/128 
 
 
 
 
 
Yes – 72/336 
drop outs 
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Component Laine  
2000 
Mellins  
2008 
Mepham  
2011 
Peltzer  
2010 
Turner  
2000 
Vaz 
2007 
Wilson 
2001 
participants 
completing the 
study 
N/A – as above 
 
above above above N/A – as above 
 
75.8% & 
61.7% in final 
group 
78.6% in final 
group 
RATING N/A Weak Moderate Moderate N/A Mod Moderate 
Global. Rating Weak Weak Weak Moderate Weak Weak Weak 
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Appendix F: Systematic review - CASP qualitative research checklist 
 Questions Ciambrone, D. et al., 2006 Duff, P. et al.,  2010 McDonald, K and Kirkman, M,  
2011 
1 Clear Aims 
Yes – to assess the factors affecting 
ARV adherence among HIV-positive 
pre and postpartum women 
Yes – to explore factors affecting ARV 
uptake among pregnant and 
postpartum women 
Yes – to assess pregnant women’s 
use of ARV for themselves & 
infants 
2 Methods Yes, qualitative approach appropriate Yes, qualitative approach appropriate 
Yes, qualitative approach 
appropriate 
3 
Research 
Design Yes, design ok Yes, design ok Yes, design ok 
4 Sampling 
Yes  - convenience sample used; 
reasons given for non-participants 
Partial –simple random sampling; 
informed consent; no reasons given for 
persons who refused 
Yes- volunteers  and consent 
obtained 
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 Questions Ciambrone, D. et al., 2006 Duff, P. et al.,  2010 McDonald, K and Kirkman, M,  
2011 
5 
Data 
Collection 
Yes – semi-structured interviews; 
recorded 
Yes – face-to-face interviews, FG; 
taped 
Yes – in-depth interviews; guide 
used; recorded; validation of data 
6 Reflexivity No No No 
7 Ethics 
Yes – ethical approval obtained; 
informed consent 
Yes – study approved ; info given to 
women; consent 
Yes - Ethical approval obtained; 
confidentiality preserved 
8 
Data 
Analysis 
Partial – grounded theory, but no info 
on theory 
Yes – thematic content analysis used; 
process explained, but researcher’s bias 
not discussed 
Yes – framework  analysis used; 
process explained 
9 Findings 
Yes – data validated by more than one 
person; findings adequately discussed 
Yes – explicit; findings supported with 
other research; triangulation 
Yes – findings backed up other 
research 
10 Value 
Yes – importance of work discussed; Yes – study compared with relevant 
Yes – importance of work 
discussed; other areas for research 
293 
 
 Questions Ciambrone, D. et al., 2006 Duff, P. et al.,  2010 McDonald, K and Kirkman, M,  
2011 
other areas for research identified literature identified 
 Overall 
Rating* 8/10 =  Good 8/10 =  Good 9/10 =  Good 
 
Overall rating = Good; Fair; Poor 
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Appendix G: Topic guide – pregnant women 
In-depth Interviews: HIV-positive pregnant women 
 
 
Theme 1:  Socio-demographic and interview information 
 
1.1 Code #:      1.9 Religion: 
1.2 Interview Date:     1.10 Highest level education: 
1.3 Interview Location:    1.11 Occupation: 
1.4 Interview Start Time:    1.12 Main income activity: 
1.5 Interview End Time:    1.13 Number of children: 
1.6 Age:      1.14 # of months Pregnant: 
1.7 Marital Status:     1.15 Place of Residence: 
1.8 Ethnicity:     1.16 Interviewer Code: 
    
 
Theme 2: Living Situation 
 
2.1 Can you tell me a bit about where you are living right now? 
 Who lives with you? 
 Rent/own home/other 
 
2.2 Describe how you spend your day?  
 What do you do starting from the moment you wake up? 
 
Theme 3:  HIV Diagnosis 
 
3.1 Can you tell me how you found out you had the virus? 
 How did you feel when you found out? 
 
3.2 When were you diagnosed with the virus? 
 
3.3 Did you know (have a gut feeling) that your HIV test results would be positive before the 
doctor/nurse told you so? 
 How come/How so? 
 
Theme 4:  Disclosure 
 
4.1 Does anyone (besides doctor/nurse at this clinic) know that you have the virus? 
 If Yes: 
o Who was the first person you told you had the virus? 
o How long after you knew you had the virus did you tell him/her? 
o Why did you tell him/her? 
o How did he/she react when you first told him/her? 
o Who else have you told? 
o Why did you tell?  
 
 If No: Why have you not told anyone that you have the virus? 
 
4.2 Is there a person(s) you can talk to/confide in about any issue you have with your 
health/medications/other matters? 
o Who? /Why this/these person(s)? 
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4.3 Could you describe the relationship with your current partner/spouse? 
 
 
Theme 5:  Mental/emotional health & coping 
 
5.1  How has this illness affected how you live day to day? 
 To what extent, has the virus affected your physical health/wellbeing? 
 To what extent has the virus affected your mental/emotional health/wellbeing? 
5.2 What concerns/worries do you have about your health? 
5.3 Are you happy/pleased with the way you are handling things in relation to your illness? 
5.4 Describe any positives/good things in your life that have come about as a result of having 
the virus? 
5.5 Describe any negatives/bad things in your life that have come about as a result of having 
the virus? 
5.6 How do you feel about the future with this illness? 
 
 
Theme 6:  Pregnancy: Thoughts, Desires & Expectations 
 
6.1 How did you feel when you found out you were pregnant and had the virus? 
6.2 Do you have any concerns/worries about this pregnancy? 
o Why? /Why not? 
6.3 How important is it for you to have/not have (more) children? 
o What are some of the reasons for the way you feel about this? 
6.4 What effect does HIV have on your desire to have/not have (more) children? 
 
 
Theme 7: Medication History 
 
7.1 How did you get put on treatment for the virus? 
 When were you first placed on meds for the virus (current/previous pregnancy)? 
 Have your meds changed over time? 
 Can you describe the number of pills you have to take per day? 
 How often do you have to take them per day? 
 How do you feel after you have taken the medication? 
 How does having to taking medicine for HIV daily affect your life (mentally, 
physically)? 
 
7.2 Do you use any other type of treatment such as herbs/bush medicine for your HIV? 
 What are your reasons for doing so? 
 
 
Theme 8: Adherence 
 
8.1 Can you describe the HIV medications you take and how you have to take them? 
(timing/meals) 
o What has been your experience taking the HIV medication? 
o Where do you keep meds? 
o How do you stick with food/water requirements? 
o If partner not aware of status, how are you able to take meds? 
 
8.2 Sometimes people forget to take their meds, have you ever missed taking your HIV 
medication? 
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 For how long did you not take them? 
 How often do you miss doses? 
 How many doses have you ever missed in a row? 
 
8.3 What are the main reasons that you miss taking your meds? 
 The last time that you missed taking your meds, what happened to make you not 
take them? 
 How did you feel at the time you were not able to take them? 
 In general, how do you feel when you don’t take all your meds? 
 
 
8.4 Were you on HIV meds before you got pregnant? 
 (If yes), Can you describe how you took your medication at that time? 
 Describe how you are taking your meds now that you are pregnant? 
 Is there any change in the way you are taking your meds now that you are pregnant? 
 
8.5 How do you remember to take your HIV meds? 
 Is there anyone who helps you to remember to take them?/Who? 
 How does that person help you to remember to take your meds? 
 
8.6 Do you get support from the clinic in terms of taking your medication? 
 Describe the kind of support you get? 
 Has the clinic ever been out of your medication? 
 (If yes), How long did you have to wait to get your meds? 
 
 
Theme 9: Medical Care 
 
9.1 How often do you have to come to the clinic to see the nurse/doctor for your HIV? 
 How long does it take to get from your home to the clinic? 
 Describe the type of transportation you have to take to get to the clinic? 
 Do you have other children at home that you have to take care of? 
 What do you do with the children when you have to come to the clinic? 
 
9.2 Can you tell me what happens when you come to the clinic for your appointment? 
 How much time do you spend on average at the clinic for an appointment? 
 What do you like about this clinic? 
 What do you dislike about this clinic? 
 If you were able to make changes at this clinic, what would you do? 
 
9.3 Have you missed any clinic appointments for your HIV care? 
 (If yes), Why were you unable to go to these appointments? 
 Can you describe any difficulties you have coming to the clinic for care? 
 
9.4 Do you think people treat you differently because of your HIV status? 
 Example of good/bad incident 
 
9.5 How do you feel the staff treat you at this clinic? 
 Example of good/bad incident 
 
 
Theme 10: Infant Feeding 
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10.1 Can you tell me what information/advice you received from the clinic about feeding 
your baby? 
 Can you tell me how the virus can affect the baby? 
 
10.2 Have you decided how you will feed the baby when it is born? 
 How did you make your decision on what to feed the baby? 
 Do you have any concerns about feeding your baby? What are they? 
 Is there someone at home to help you with the baby?/Who? 
 
10.3 How do people in the community feel about what a mother should feed her new-born 
baby?  
 How does your family feel?  
 Partner/Spouse? 
 
 
11.0 Closure: 
 
Do you have any questions you would like to ask me? 
 
Thank you for talking with me about your experiences.  If you have any questions, you can 
call me at the number on the information sheet/consent form. 
 
 
 
12.0 Interviewer comments 
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Appendix H: Topic guide – postpartum women 
In-depth Interviews: HIV-positive postpartum women 
 
 
Theme 1:  Socio-demographic and interview information 
 
1.9 Code #:      1.9 Religion: 
1.10 Interview Date:     1.10 Highest level education: 
1.11 Interview Location:    1.11 Occupation: 
1.12 Interview Start Time:    1.12 Main income activity: 
1.13 Interview End Time:    1.13 Number of children: 
1.14 Age:      1.14 Place of residence: 
1.15 Marital Status:     1.15 Interviewer Code: 
1.16 Ethnicity:     
 
 
Theme 2: Living Situation 
 
2.1 Can you tell me a bit about where you are living right now? 
 Who lives with you? 
 Rent/own home/other 
 
2.2 Describe how you spend your day?  
 What do you do starting from the moment you wake up? 
 
 
Theme 3:  HIV Diagnosis 
 
3.1 Can you tell me how you found out you had the virus? 
 How did you feel when you found out? 
 
3.2 When were you diagnosed with the virus? 
 
3.3 Did you know (have a gut feeling) that your HIV test results would be positive before the 
doctor/nurse told you so? 
 How come/How so? 
 
Theme 4:  Disclosure 
 
4.1 Does anyone (besides doctor/nurse at this clinic) know that you have the virus? 
 If Yes: 
o Who was the first person you told you had the virus? 
o How long after you knew you had the virus did you tell him/her? 
o Why did you tell him/her? 
o How did he/she react when you first told him/her? 
o Who else have you told? 
o Why did you tell?  
 
 If No: Why have you not told anyone that you have the virus? 
 
4.4 Is there a person(s) you can talk to/confide in about any issue you have with your 
health/medications/other matters? 
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o Who? /Why this/these person(s)? 
 
4.5 Could you describe the relationship with your current partner/spouse? 
 
Theme 5:  Mental/emotional health & coping 
 
5.2 How has this illness affected how you live day to day? 
 To what extent, has the virus affected your physical health/wellbeing? 
 To what extent has the virus affected your mental/emotional health/wellbeing? 
5.2 What concerns/worries do you have about your health? 
5.3 Are you happy/pleased with the way you are handling things in relation to your illness? 
5.4 Describe any positives/good things in your life that have come about as a result of having 
the virus? 
5.5 Describe any negatives/bad things in your life that have come about as a result of having 
the virus? 
5.7 How do you feel about the future with this illness? 
 
Theme 6:  Pregnancy: Thoughts, Desires & Expectations 
 
6.2 How did you feel when you found out you were pregnant and had the virus? 
6.2 Do you have any concerns/worries about this pregnancy? 
o Why? /Why not? 
6.3 How important is it for you to have/not have (more) children? 
o What are some of the reasons for the way you feel about this? 
What effect does HIV have on your desire to have/not have (more) children? 
 
Theme 7: Medication History 
 
7.1 How did you get put on treatment for the virus? 
 When were you first placed on meds for the virus (recent past pregnancy/other)? 
 Have your meds changed over time? 
 Can you describe the number of pills you have to take per day? 
 How often do you have to take them per day? 
 How do you feel after you have taken the medication? 
 How does having to taking medicine for HIV daily affected your life (mentally, 
physically)? 
 
7.2 Do you use any other type of treatment such as herbs/bush medicine for your HIV? 
 What are your reasons for doing so? 
 
Theme 8: Adherence 
 
(If the woman is no longer on HIV meds since she delivered, go to 8.5) 
 
8.1 Can you describe the HIV medications you take and how you have to take them? 
(timing/meals) 
o What has been your experience taking the HIV medication? 
o Where do you keep meds? 
o How do you stick with food/water requirements? 
o If partner not aware of status, how are you able to take meds? 
 
8.2 Sometimes people forget to take their meds, have you ever missed taking your HIV 
medication? 
 For how long did you not take them? 
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 How often do you miss doses? 
 How many doses have you ever missed in a row? 
 
8.3 What are the main reasons that you missed taking your meds? 
 The last time that you missed taking your meds, what happened to make you not 
take them? 
 How did you feel at the time you were not able to take them? 
 In general, how do you feel when you don’t take all your meds? 
 
8.4 Were you on HIV meds before you got pregnant? 
 If yes: Can you describe how you took your medication at that time? 
 How are you taking your meds now that you are not pregnant? 
 Are you taking your medication better now than when you were pregnant?/Why 
 
8.5 If no longer on meds: Describe how you took your HIV meds when you were pregnant? 
 
8.6 How do/did you remember to take your HIV meds? 
 Is there anyone who helps/helped you to remember to take them?/Who? 
 How does/did that person help you to remember to take your meds? 
 
8.7 Do you get support from the clinic in terms of taking your medication? 
 Describe the kind of support you get? 
 Has the clinic ever been out of your medication? 
 (If yes), How long did you have to wait to get your meds? 
 
 
Theme 9: Delivery 
 
9.1 Where did you deliver your baby? 
 (If hospital), How long did you spend in the hospital for the delivery? 
 Where did you go to stay after being discharged? 
 Was there anyone to help you with the new baby?/What did they do? 
 Did the baby get medication to prevent the virus when it was born? 
 Did you get medication to give the baby when you were discharged? 
 How often do you have to give the baby its medication? 
 Tell me about how you are giving the baby its meds to prevent the virus since 
you’ve been home? 
 Have you had any problems or concerns giving the baby its medication? 
 If no: How often do you miss giving the baby all its meds? 
 Can you tell me what happened the last time you missed? 
 Are you able to give the baby all of its medication on time? 
 
 
Theme 10: Medical Care 
 
10.1 How often do you have to come to the clinic to see the nurse/doctor for your HIV? 
 How long does it take to get from your home to the clinic? 
 Describe the type of transportation you have to take to get to the clinic? 
 Do you have other children at home that you have to take care of? 
 What do you do with the children when you have to come to the clinic? 
 
10.2 Have you missed any clinic appointments for your HIV care? 
 (If yes), Why were you unable to go to these appointments? 
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 Can you describe any difficulties you have coming to the clinic for care? 
 
10.3 Can you tell me what happens when you come to the clinic for your appointment? 
 How much time do you spend on average at the clinic for an appointment? 
 What do you like about this clinic? 
 What do you dislike about this clinic? 
 If you were able to make changes at this clinic, what would you do? 
 
10.4 Do you think people treat you differently because of your HIV status? 
 Example of good/bad incident 
 
10.5 How do you feel the staff treat you at this clinic? 
 Example of good/bad incident 
 
 
Theme 11: Infant Feeding 
 
11.1 Can you tell me what information/advice you received from the clinic about feeding 
your baby? 
 Can you tell me how the virus can affect the baby? 
 
11.2 Can you tell me about your experience breastfeeding/bottle-feeding the baby? 
 How did you make your decision on what to feed the baby? 
 Do you have any problems or concerns about feeding your baby? What are they? 
 How have you been able to stick with your feeding choice for the baby? Why?/Why 
not? 
 
11.3 How do people in the community feel about what a mother should feed her new-born 
baby?  
 How does your family feel?  
 Partner/Spouse? 
 
 
12.0 Closure: 
 
Do you have any questions you would like to ask me? 
 
Thank you for talking with me about your experiences. If you have any questions, you can 
call me at the number on the information sheet/consent form. 
 
 
13.0 Interviewer comments 
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Appendix I: Topic guide – healthcare workers 
In-depth Interviews: Healthcare Workers 
 
Theme 1:  Socio-demographic and interview information 
 
1.17 Code #:      1.9  Religion:   
1.18 Interview Date:     1.10 Highest level education:  
1.19 Interview Location:    1.11 Job Title: 
1.20 Interview Start Time:    1.12 Place of Work (Facility): 
1.21 Interview End Time:    1.13 Yrs. experience PLHA: 
1.22 Age:      1.14 Yrs. experience HIV+ women: 
1.23 Gender:     1.15 Interviewer Code: 
1.24 Ethnicity:     
 
     
Theme 2: Role in treatment & care  
 
2.1 What is your role in this clinic in relation to PMTCT? 
 Patients seen in a day? 
 Average time spent with each patient?  
 What do you do in a session with an HIV-positive (pregnant/postpartum) woman? 
 Are the PMTCT patients seen on separate days or are they mixed in with other 
clinic pts.? 
 Besides PMTCT patients, what other types of patients do you provide care for in 
this clinic? 
 
 
Theme 3:  Treatment criteria & response 
 
3.1 How do women in this clinic get put on ARVs? 
 Criteria for pregnant, postpartum, non-pregnant? 
 
3.2 What usually happens when a woman (pregnant, postpartum, non-pregnant) is put on 
treatment for the first time? 
 Information given? 
 Response of the woman to being placed on treatment? 
 Frequency of check-up visits? 
 
3.3 What questions or concerns do women have about their treatment? 
 pregnant, postpartum, non-pregnant 
 
 
Theme 4:  Women’s Adherence 
 
4.1 How well do you think women in this clinic (pregnant, postpartum, non-pregnant) take 
their medication? 
 What makes you think that? 
 
4.2 What challenges or problems do women have in taking their meds? 
 pregnant/postpartum/ non-pregnant 
 
4.3 What are some of the factors that help women take their meds? 
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 pregnant/postpartum/ non-pregnant 
 
4.4 Are there any types of women who are particularly good at taking their meds? 
 Age, education, occupation, etc? 
 Why are these types of women good at taking their meds? 
 
4.5 Are there any types of women who tend to have problems in taking their meds? 
 Why do these types of women have such problems? 
4.6 Do you think women take their meds better if they are on meds to reduce MTCT or for 
their own health? 
 
4.7 Do you think HIV-positive women take their meds better in pregnancy or after delivery? 
 Why do you think that? 
 
 
Theme 5:  Strategies to improve adherence 
 
5.1 How does this clinic support women with their adherence? 
 Have these strategies worked? 
 Why do they work/not work? 
 
5.2 Are there any issues related to this clinic that could affect adherence? 
 Clinic hours/location/ staff/services provided 
 
5.3 Let’s now move on to the HIV-exposed infant and their treatment, can you describe how 
the infants get their treatment at the hospital? 
 What type of meds do they get and for how long? 
 Where are the meds dispensed from? 
 Timing, location, and content of follow-up visits? 
 Advice given to the mother about giving meds to the infant? 
 Checks on whether the meds were given to the infant? 
 
5.4 What are the main problems and concerns women have giving the infant his/her HIV 
medication? 
 How are you able to help resolve these issues? 
 
 
Theme 6:  Infant Feeding 
 
6.1 Do you counsel women on their infant feeding choices?  
 If yes: What information do you give the women on their infant feeding choices 
(pregnant/postpartum)? 
 
6.2 What problems do women have making decisions about infant feeding? 
 
6.3 What problems do they have carrying out these decisions? 
 
6.4 Generally, how do people in this community think babies should be fed in the early 
months after birth? 
 How do these beliefs affect the feeding decision of the HIV-positive woman? 
 
 
7.0 Closure: 
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 Is there anything else you would like to share with me on your experiences caring 
for women with HIV? 
 
Thank you for talking with me about your experiences.  If you have any questions, you can 
call me at the number on the information sheet/consent form. 
 
 
8.0 Interviewer comments 
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Appendix J: Information sheets and consent forms – in-depth interviews 
Information Sheet – Pregnant & Postpartum Women 
 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care 
 
This study has been approved by the UCL Research Ethics Committee (Project ID: 
3518/001) and the Ministry of Health, Guyana (Project #: 48). 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
Tel: 592-618-6204/+44 207 830 2129 
E-mail: deborah.vitalis.10@ucl.ac.uk/l.sherr@ucl.ac.uk 
 
 
Hello, my name is [name] and I am a research student at UCL. I would like to 
invite you to participate in this study. Before you decide whether you would like 
to take part, it is important for you to read the following information carefully 
and discuss it with others if you wish. Ask me if there is anything that is not 
clear or if you would like more information. 
 
What is the study about? 
 
This study would like to learn about the issues affecting women who have been 
infected with HIV (a germ that affects the body’s ability to fight off disease) 
and how they are able to comply with treatment and care. I will be asking you 
about your feelings and things that affect you. I will also speak with other 
women and health workers about their experiences. About 33 people will be 
asked to participate in this study. 
 
What happens if you agree to take part? 
 
If you agree to take part, I will interview you at a time and place that is 
convenient for you.  I will speak with you alone in a quiet place for about one (1) 
hour.  I will take some notes and tape record our conversation to help me 
remember all that we discussed. Please let me know if you do not want me to 
record the interview. 
 
What happens if you don’t agree to take part? 
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It is up to you to decide whether to take part or not. If you decide to take 
part, you are still free to withdraw at any time without giving a reason.  You can 
refuse to answer any question I ask or stop the interview at any time.  You do 
not have to give me a reason to refuse to take part or stop the interview. If 
you decide to withdraw at any time, or decide not to take part, this will not 
affect any treatment or care you are getting. We also do not pay people to be 
interviewed. 
What are the benefits of participating? 
 
You may not get any direct benefits from participating in this study, but you 
will be helping us to improve care and treatment for women like yourself. 
 
What are the disadvantages and risks of participating? 
 
Although there will be no physical harm done to you, during the interview you 
will be asked questions about your experiences with HIV. If a question makes 
you uncomfortable, remember you don’t have to answer it and you can also stop 
the interview at any time without giving a reason. You can also ask me to 
destroy some or all of your answers by contacting me afterwards.  If you want 
to talk about something raised during the interview, you can let me know at the 
time, or contact me afterwards. If during the interview I notice that you are 
experiencing any problems, I will talk to you about getting some help with a 
counsellor if you want to.  
 
What will happen to the information you give? 
 
All the information you tell me will be kept strictly confidential. I will not write 
your name on my notes. The data will be kept in a computer database and only 
the researchers will be able to see it. The notes and tape will be kept under 
lock and key. If the study team reports your opinions or ideas, your name will 
not appear, and we will make sure that you cannot be identified.  
 
All data will be collected and stored in accordance with the Data Protection 
Act, 1998. 
 
What will happen to the results of the study? 
 
We plan to publish the results of the study in a journal. The results of the 
study will also be given to the Ministry of Health to help them improve their 
programme. Your name will not be in any of the results or reported to the 
clinic/Ministry. 
 
How can you get more information on the project? 
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If you have questions about any part of the research project, please contact 
Ms. Deborah Vitalis at  
 
Thank you for taking the time to read this information sheet. 
Information Sheet – Health Workers 
 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care 
 
This study has been approved by the UCL Research Ethics Committee (Project ID: 
3518/001) and the Ministry of Health, Guyana (Project #: 48). 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
 
 
 
 
Hello, my name is [name] and I am a research student at UCL. I would like to 
invite you to participate in this research study. Before you decide whether you 
would like to take part, it is important for you to read the following information 
carefully and discuss it with others if you wish. Ask me if there is anything that 
is not clear or if you would like more information. 
 
What is the study about? 
 
This study would like to learn about the issues affecting women who have been 
infected with HIV and how they are able to comply with treatment and care. I 
will be asking you about the Ministry of Health guidelines and your opinion on 
issues that may affect the women in your care. I will also speak with pregnant 
and postpartum women, and other health workers. About 33 people will be 
asked to participate in this study. 
 
What happens if you agree to take part? 
 
If you agree to take part, I will interview you at a time and place that is 
convenient for you.  I will speak with you alone in a quiet place for about one (1) 
hour.  I will take some notes and tape record our conversation to help me 
remember all that we discussed. Please let me know if you do not want me to 
record the interview. 
308 
 
What happens if you don’t agree to take part? 
 
It is up to you to decide whether to take part or not. If you decide to take 
part, you are still free to withdraw at any time without giving a reason.  You can 
refuse to answer any question I ask or stop the interview at any time.  You do 
not have to give me a reason to refuse to take part or stop the interview. If 
you decide to withdraw at any time, or decide not to take part, this will not 
have any negative effects on your position at this institution. We also do not 
pay people to be interviewed. 
 
What are the benefits of participating? 
 
You may not get any direct benefits from participating in this study, but you 
will be helping us to improve care and treatment for HIV-positive women in 
Guyana. 
 
What are the disadvantages and risks of participating? 
 
Although there will be no physical harm done to you, during the interview you 
will be asked questions about your experiences with HIV-positive patients. If a 
question makes you uncomfortable, remember you don’t have to answer it, and 
you can stop the interview at any time without giving a reason. You can also ask 
me to destroy some or all of your answers by contacting me afterwards. If you 
want to talk about something raised during the interview, you can let me know 
at the time, or contact me afterwards. If during the interview I notice that 
you are experiencing any problems, I will talk to you about getting some help 
with a counsellor if you want to. 
 
What will happen to the information you give? 
 
All the information you tell me will be kept strictly confidential. I will not write 
your name on my notes. The data will be kept in a computer database and only 
the researchers will be able to see it. The notes and tape will be kept under 
lock and key. If the study team reports your opinions or ideas, your name will 
not appear, and we will make sure that you cannot be identified.  
 
All data will be collected and stored in accordance with the Data Protection 
Act, 1998. 
 
What will happen to the results of the study? 
 
We plan to publish the results of the study in a journal. The results of the 
study will also be given to the Ministry of Health to help them improve their 
programme. Your name will not be in any of the results or reported to the 
clinic/Ministry. 
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How can you get more information on the project? 
If you have questions about any part of the research project, please contact 
Ms. Deborah Vitalis at mobile 592-618-6204 or Email 
deborah.vitalis.10@ucl.ac.uk 
 
Thank you for taking the time to read this information sheet. 
 
 
Informed Consent Form – Pregnant & Postpartum Women 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care 
 
This study has been approved by the UCL Research Ethics Committee (Project ID: 
3518/001) & the Ministry of Health, Guyana (Project #: 48). 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
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Participant’s Statement: 
I  …………………………………………......................................agree that the research project named 
above has been well explained to me and I agree to take part in the study.  I have read 
both the notes written above and the Information Sheet about the project, and I 
understand what the research study involves. 
Signature/Thumb Print:_______________________ Date:_______________ 
Researcher’s Statement: 
I  ……………………………………………………………………..confirm that I have carefully explained the 
purpose of the study to the participant and outlined any reasonably foreseeable risks 
or benefits (where applicable). 
Signature:________________________   Date:_______________ 
 
 
Informed Consent Form – Health Workers 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care 
 
This study has been approved by the UCL Research Ethics Committee (Project ID: 
3518/001) & the Ministry of Health, Guyana (Project #: 48). 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
 
 
 
Thank you for thinking about taking part in this research. You will be given a copy of 
this Consent Form to keep and refer to at any time. 
Any questions I have concerning this research have been answered 
 I understand that if I decide at any time during the research that I don’t 
want to participate in this project, I can tell the researchers and be 
withdrawn from it immediately. This will not have any negative effect on 
my position at this institution. 
 I agree to have this interview tape-recorded  
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 I consent to the use of this interview as part of the project. I also 
understand that my responses will be kept private and it will not be 
possible to identify me in any study publications or reports. I agree that 
the information I give may be used by others for future research.  
 I understand that the information I have submitted will be published as a 
report.  Confidentiality and anonymity will be maintained and it will not be 
possible to identify me from any publications. 
Participant’s Statement: 
I  …………………………………………......................................agree that the research project named 
above has been well explained to me and I agree to take part in the study.  I have read 
both the notes written above and the Information Sheet about the project, and I 
understand what the research study involves. 
Signature/Thumb Print:_______________________ Date:_______________ 
Researcher’s Statement: 
I  ……………………………………………………………………..confirm that I have carefully explained the 
purpose of the study to the participant and outlined any reasonably foreseeable risks 
or benefits (where applicable). 
Signature:________________________   Date:_______________ 
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Appendix K: General questionnaire – HIV-negative pregnant women 
GENERAL QUESTIONNAIRE - HIV-NEGATIVE PREGNANT WOMEN 
 
 
 
 
 
 
 
 
 
 
001 Participant’s ID #: [__|__|__]   
 
002 Clinic:   Name_________________________ Code [____|____] 
 
003 Region  A  Reg. 3 B  Reg. 4 C  Reg. 6 D  Reg. 10 
 
004 Region 4 1  ECD 2  EBD 3  Georgetown 
 
005 Place of Residence________________________________________ 
 
006 Location of Residence  1  Urban  2  Rural 
 
007 Interviewer: Name____________________________ Code [____|____] 
 
008 Today’s Date: (dd/mm/year) ___ ___/___ ___/___ ___ ___ ___  
 
 
Start Time___________________   
 
 
 
 
 
 
SECTION 1. SOCIODEMOGRAPHIC CHARACTERISTICS (SD) 
      
I. AGE   
SD100. In what month and year were you born? 
 
Month  ___ ___  
 
99  Don’t know 
 
 
Year  ___ ___ ___ ___ 
 
99  Don’t know 
 
 
SD101.  How old were you on your last birthday? 
 
This questionnaire takes about 30 minutes to complete.  All the answers you 
give will be confidential and participation is voluntary. If you do not want to 
answer a question, please let me know and I will move on to the next one. 
You can also stop the questions at any time if you do not want to continue. 
Let me begin by first asking you some background information about 
yourself such as your age, race. 
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Age in years: ____ ____ 
 
 
II. RACE   
 
SD102.  What is your race? 
1  African   6  Portuguese 
2  Amerindian  7  White 
3  East Indian   8  Other (Specify) 
_________________________________ 
4  Chinese   99  Don’t know/Not stated 
5  Mixed  
 
 
III. RELIGION   
 
SD103.  What is your religion? 
1  Christian      
2  Hindu      
3  Muslim     
4  Rastafarian     
5  None    
6  Other (specify) ________________________ 
99  Don’t know/Not Stated      
 
 
IV. EDUCATION   
 
SD104.  How far did you go in school? 
1  None     5  Post- Secondary (Technical Institute) 
2  Nursery/Kindergarten   6  University/Tertiary 
3  Primary     7  Other (specify) _______________ 
4  Secondary     99  Don’t know/Not stated 
 
 
V. MARITAL STATUS 
 
SD105.  What is your marital status? 
1  Married     5  Widowed 
2  Single     6  Divorced 
3  Common Law/Living home  99  Don’t know/Not stated 
4  Separated 
 
 
VI. INCOME 
 
SD106.   What was your main source of income during the past year?   
1  Employment/own account 
2  Remittances (overseas) 
3  Pension (NIS, former employer) 
4  Savings/interest on savings 
5  Disability benefits 
6  Spousal/partner support 
7  Other persons 
8  Other (specify) ______________________________ 
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99  Don’t know/Not stated 
 
 
SD107.   Do you work for pay outside the home?   
1  Yes 
2  No  If “no”, go to section “VII Health Insurance” 
 
 
SD108.   What job/work do you do? 
1  Housewife 
2  Domestic 
3  Cleaner 
4  Security Guard 
5  Teacher 
6  Clerk 
7  Other ___________________________________ 
 
 
SD109.   How often do you get paid in your main job/work? 
1  Weekly 
2  Fortnightly 
3  Monthly 
4  Quarterly (every 3 months) 
99  Don’t know/Not stated 
 
 
SD110.   What was your gross income (before tax, NIS) from your main job at the last pay 
period? 
 
$_____________    99  Don’t know/Not stated 
 
 
VII. HEALTH INSURANCE  
 
SD111.   Are you covered by any health insurance? 
1  Yes 
2  No 
 
If “no”, go to section “VIII Housing” 
SD112.  What type of health insurance do you have? 
1  National Insurance Scheme (NIS) 
2  Privately purchased health insurance 
3  Employer purchased insurance 
4  Foreign health insurance 
5  Other (specify) ________________________________ 
 
 
VIII. HOUSING 
 
SD113.   How many people are currently living in your household including yourself? 
 
1     2      3     4      5  More than 4, how many ______ 
 
 
SD114.   How many children less than 18 years of age currently live with you? 
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0      1     2      3     4      5  More than 4, how many ______ 
 
 
SD115.   Please describe the home where you live.  
 
Check “yes” or “no” for each question; check “yes” to all that apply. 
         Yes No 
A. It is owned by you (or someone in the household)   1  2  
B. It is rented by you (or someone in the household)   1  2  
C. It is occupied without paying rent     1  2  
D. You live with friends      1  2  
E. You live with family       1  2  
F. You have no permanent residence     1  2  
 
 
SECTION 2. REPRODUCTION/FERTILITY  (RF)   
 
 
 
 
 
 
RF200.   How old were you when you were first married or started living in a union? 
 
Age ___ ____ years  99  Don’t know/Not stated 
 
 
RF201.   How many children have you given birth to (if any) that were born alive? 
 
a. Total _____   b. Boys ______  c. Girls ______   99  Don’t know/Not stated 
 
If none, write 0 and skip to Question RF205 
 
RF202.   How many of these children are still alive? 
 
a. Total ______ b. Boys ______ c. Girls _____  99  Don’t know/Not stated 
 
 
RF203.   How old were you when you had your first live birth? 
 
Age ___ ____ years  99  Don’t know/Not stated 
 
 
RF204.   How old were you when you had your last child that was born alive? 
 
Age ___ ____ years  99  Don’t know/Not stated 
 
 
RF205.  Have you ever had a pregnancy that you lost either by miscarriage, or abortion, or 
which ended in a stillbirth? 
1  Yes  Number________ 
2  No  
99  Don’t know 
 
I am now going to ask you some questions about pregnancy and the 
children you have. 
316 
 
 
RF206.   How many months pregnant are you?  
 
a.  Weeks _____  b.  Months_______ 99  Don’t know/Not stated 
 
 
RF207.   Parity? 
1 Primagravida 
2 Multigravida 
 
 
RF208.   What date was your last menstrual period?   
(Complete just the month and year, if day unknown) 
 
DATE: dd/mm/yyyy  ___ ___/____ ____/___ ___ ___ ___ 
 
99  Don’t know 
 
 
RF209.   At the time you became pregnant, did you, yourself, actually want to have a/another 
baby at some time? 
1  Yes 
2  No  
99  Don’t know 
 
 
RF210.   At the time you became pregnant, did you want to become pregnant then, did you 
want to wait until later, or did you not want to have any (more) children at all? 
1  Then Go to Question RF212 
2  Later   
3  Not at all Go to Section 3 
 
RF211.   How much longer would you have liked to wait? 
1  Months ___ ____ 
2  Years ____ ____ 
99  Don’t know 
 
 
RF212.   After the child you are expecting now, would you like to have another child, or 
would you prefer not to have any more children? 
1  Have another child 
2  No more/none  Go to Section 3 
99  Don’t know  Go to Section 3 
 
 
 
RF213.   After the birth of the child you are expecting now, how long would you like to wait 
before the birth of another child? 
1  Months ____ ____ 
2  Years ____ _____ 
99  Don’t know 
 
 
SECTION 3. HEALTH BEHAVIORS & BELIEFS  (HB) 
 
HB300.   I am going to ask you about your personal views about medicines in 
general. There are no wrong or right answers, so please indicate the extent to 
which you agree or disagree with each statement. 
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  Strongly 
agree 
(5) 
Agree 
 
(4) 
uncertain 
(not 
sure) 
(3) 
Disagree 
 
(2) 
Strongly 
Disagree 
(1) 
BG1 Doctors use too many 
medicines 
     
BG2 People who take medicines 
should stop their treatment for 
a while every now and again 
     
BG9 Medicines help many people to 
live better lives 
     
BG3 Most medicines are addictive      
BG4 Natural remedies (herbs) are 
safer than medicines 
     
BG11 In most cases the benefits of 
medicines outweigh the risks 
     
BG10 In the future, medicines will be 
developed to cure most 
diseases 
     
BG6 Most medicines are poisons      
BG5 Medicines do more harm than 
good 
     
BG12 Medicines help many people to 
live longer 
     
BG7 Doctors place too much trust 
on medicines 
     
BG8 If doctors had more time with 
patients, they would prescribe 
fewer medicines 
     
 
 
HB301.   Experience taking medication in pill form  
 
What has been your experience swallowing/taking pills? 
0  No difficulty 
1  Somewhat unpleasant 
2  Extremely unpleasant 
 
 
HB302.   Readiness to take pills 
 
Do you normally take pills when you have a very bad headache? 
0  Never 
1  Rarely 
2  Usually 
3  Always 
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HB303.   Health Behaviors 
 
I am going to ask you about different types of behavior, please indicate how often you have 
engaged in each one over the past 2 weeks. 
 
 
In the past 2 weeks, how 
often did you: 
Never 
 
(0) 
Almost 
Never 
(1) 
Some-
times 
 
(2) 
Fairly 
Often 
(3) 
Very 
Often 
 
(4) 
a. …eat a balanced diet (food 
from the 6 food groups), 
including meats, fruits & 
green leafy vegetables? 
     
b. …get enough sleep 
(sleeping for 8 hours or 
more)? 
     
c. …drink milk, eat dairy 
products (such as cheese)? 
     
d. …eat snack foods (corn 
curls, chips) instead of a 
regular meal? 
     
e. …stand on your feet for 
long periods of time? 
     
f. …eat high fiber foods such 
as whole grain breads or 
cereals? 
     
g.  …lift heavy objects or do 
lots of bending? 
     
h. …eat more food than you 
needed to? 
     
i. …skip a meal, such as 
breakfast or lunch? 
     
 
 
SECTION 4. PRENATAL VITAMINS  (PV) 
 
PV400.   Knowledge of vitamin use 
 
Doctors recommend that women take a multivitamin (iron/folic acid) during pregnancy for 
which of the following reasons. 
1  To prevent high blood pressure 
2  To prevent birth defects and anaemia (weak blood) 
3  To make strong bones 
4  Some other reason 
99  Don’t know 
 
PV401.   During this pregnancy were you given or did you buy any iron tablets, iron syrup or 
sprinkles? 
1  Yes  
2  No   Go to Section 5 
99  Don’t know Go to Section 5 
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PV402.   In the past month, how often, if at all have you taken your iron tablets, iron syrup 
or sprinkles? 
0  Not at all 
1  1 or 2 days a week 
2  3 or 4 days a week 
3  5 or 6 days a week 
4  Every day  Go to Section 5 
 
PV403.   Reasons for missing prenatal vitamins 
 
Some people forget to take their pills sometimes, please let me know all the reasons below 
why you did not take your multivitamins/sprinkles? 
a. Nausea      1  Yes 2  No 
b. Vomiting      1  Yes 2  No 
c. Heartburn (burn stomach)    1  Yes 2  No   
d. Constipation     1  Yes 2  No 
e. Swallowing difficulty due to pill size  1  Yes 2  No 
f. Smells bad      1  Yes 2  No 
g. Felt healthy, so I thought I did not need them 1  Yes 2  No 
h. Had too many pills to take    1  Yes 2  No 
i. Ran out of vitamins/sprinkles   1  Yes 2  No 
j. To avoid side effects    1  Yes 2  No 
k. Do not like taking pills in general   1  Yes 2  No 
l. Did not remember     1  Yes 2  No   
m. Other ________________    1  Yes 2  No  
  
 
SECTION 5. SUBSTANCE USE   (SU) 
 
 
 
 
 
 
SU500.   During the past 30 days, how often have you had a drink containing alcohol – beer, 
wine, a mixed-drink, or any kind of alcoholic beverage? 
0  Never   Go to Question SU502   
1  Once a month  
2  2 or 3 times a month  
3  Once or twice a week  
4  3 or 4 times a week  
5  5 to 6 times a week  
6  Daily 
 
 
SU501.   During the past 30 days, on a typical day when you drank any alcoholic beverage, 
how many drinks did you have altogether? 
1  1 drink/day 
2  2 drinks/day  
3  3 drinks/day  
4  4 drinks/day  
5  5 or more drinks/day 
 
 
SU502.   When was the last time you used: 
Some people use alcohol from time to time. I will now ask you to what 
extent you use alcohol or other drugs.  There is no right or wrong answer to 
these questions. 
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     Never More than     Within the past Within the 
     Used one year         year up until past 
      Ago           1 month ago month  
a. Tobacco (cigarettes, cigars)? 0 1  2  3 
b. Marijuana (ganja)?   0 1  2  3 
c. Cocaine (crack)?   0 1  2  3 
d. Heroin?    0 1  2  3 
e. Other non-prescribed drugs  0 1  2  3 
(such as sleeping pills) 
 
 
SECTION 6. SOCIAL ISSUES   (SI) 
 
 
IF NO CURRENT PARTNER/SPOUSE, GO TO QUESTION 601 
 
SI600.   The following questions are about the relationship between you and your partner. 
Please be as honest as you can, and remember that all answers you give are confidential. 
 
 
 Never 
(1) 
Rarely  
(2) 
Some-
times 
(3) 
Fairly 
often 
(4) 
Fre-
quently 
(5) 
 
A. Hurt 
How often does your partner 
physically hurt you? 
     
 
B. Insult 
How often does your partner 
insult or talk down to you? 
     
 
C.Threaten 
How often does your partner 
threaten you with physical 
harm? 
     
 
D.Scream 
How often does your partner 
scream or cuss you? 
     
 
 
The following statements are feelings/problems that people sometimes have in response to 
stressful life experiences. Please let me know how much you have been bothered by the 
problem in the past two weeks. 
 
SI601.   Over the last 2 weeks, how often have you been bothered by any of the following 
problems? 
 
 Not at 
all  
(0) 
Several 
Days  
(1) 
More 
than half 
the days 
(2) 
Nearly 
every 
day 
(3) 
a Little interest or pleasure in doing things.     
b Feeling down, depressed or hopeless.     
c Trouble falling or staying asleep or sleeping 
too much. 
    
d Feeling tired or having little energy.     
e Poor appetite or overeating.     
f Feeling bad about yourself  - or that you are     
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 Not at 
all  
(0) 
Several 
Days  
(1) 
More 
than half 
the days 
(2) 
Nearly 
every 
day 
(3) 
a failure, or have let yourself or your family 
down. 
g Trouble concentrating on things, such as 
reading the newspaper, watching television 
or listening to the radio. 
    
h Moving or speaking so slowly that other 
people could have noticed, or the opposite – 
being so fidgety or restless that you have 
been moving round a lot more than usual. 
    
i Thoughts that you would be better off dead 
or of hurting yourself in some way. 
    
 
SI602. Questions about anxiety. 
 
a In the last 4 weeks, have you had an anxiety attack – suddenly 
feeling fear or panic? 
YES 
(1) 
NO 
(2) 
If you checked “NO”, go to Question #3. 
b Has this ever happened before?   
c Do some of these attacks come suddenly out of the blue – that is 
situations where you don’t expect to be nervous or uncomfortable 
  
d Do these attacks bother you a lot or are you worried about having 
another attack 
  
e During your last bad anxiety attack, did you have symptoms like 
shortness of breath, sweating, your heart racing or pounding 
dizziness or faintness, tingling or numbness, or nausea or upset 
stomach? 
  
 
SI603. If any problems were checked off above in SI601, ask the participant:   
How difficult have these problems made it for you to do your work, take care of things at 
home, or get along with other people? 
 
0  Not difficult at all 
1  Somewhat difficult 
2  Very difficult 
3  Extremely difficult 
 
 
 
 
SECTION 7. HIV KNOWLEDGE/BELIEFS  ( KB)  
 
 
 
 
 
 
 
KB700.  Please answer either “true”, “false” or “don’t know” to the following questions: 
 
We have now come to the final set of questions which checks to see how much you 
know about the virus (HIV) and AIDS.  This is not a test, so feel free to say you 
“don’t know” if you do not know the answer. 
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 True 
(1) 
False 
(2) 
Don’t 
Know 
(99) 
a It is possible to get HIV from having many sexual 
partners 
   
b It is possible to get HIV from a blood transfusion    
c It is possible to get HIV from using public toilets    
d It is possible to get HIV from donating blood    
e It is possible to get HIV from mosquito bites    
f It is possible to get HIV from sharing food/utensils with a 
person who has HIV/AIDS 
   
g A person infected with HIV can transmit the virus to 
his/her sexual partner during sex without a condom 
   
h Using a condom every time you have sex can protect 
against HIV transmission 
   
i A pregnant woman with HIV can transmit the virus to her 
unborn baby during pregnancy 
   
j A pregnant woman with HIV can  transmit the virus to 
her baby during delivery 
   
k A woman with HIV can transmit the virus to her baby 
during breastfeeding 
   
l All pregnant women with HIV/AIDS will have babies 
born with HIV 
   
m You can always tell that a person has HIV/AIDS by  just 
looking at him/her 
   
n There is a cure for HIV/AIDS    
o Taking HIV medication (ARVs) can help reduce mother-
to-child transmission (MTCT) during pregnancy 
   
p It is possible to get HIV through a curse or obeah    
q The use of bush medicine/herbs can cure HIV/AIDS    
r All women should get tested for HIV before becoming 
pregnant 
   
s A woman with HIV/AIDS should avoid getting pregnant    
t A woman with HIV/AIDS should avoid breastfeeding    
 
 
SECTION 8. HIV OPTIMISM  (HO) 
 
 
HO800.  Please indicate how you feel about 
the statements below 
Strongly 
disagree  
(1) 
 
Disagree 
 
(2) 
Agree 
 
(3) 
Strongly 
agree 
(4) 
 
a. I am less worried about HIV infection, 
now that treatments have improved 
    
b. I believe that new drug therapies 
(treatments)  make people with HIV less 
infectious 
    
 
 
End Time__________________   Duration_______________ 
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Thank you very much for your time and answering these questions! 
 
 
 
Appendix d 
 
TO BE OBTAINED FROM PARTICIPANT’S CHART/CLINICAL REGISTER 
Gestation (weeks):_____________________________ 
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Appendix L: General questionnaire – HIV-positive pregnant women 
GENERAL QUESTIONNAIRE - HIV-POSITIVE PREGNANT WOMEN 
 
 
 
 
 
 
 
 
 
001 Participant’s ID #: [__|__|__]   
 
002 Clinic:   Name_________________________ Code [____|____] 
 
003 Region  A  Reg. 3 B  Reg. 4 C  Reg. 6 D  Reg. 10 
 
004 Region 4 1  ECD 2  EBD 3  Georgetown 
 
005 Place of Residence________________________________________ 
 
006 Location of Residence  1  Urban  2  Rural 
 
007 Interviewer: Name____________________________ Code [____|____] 
 
008 Today’s Date: (dd/mm/year) ___ ___/___ ___/___ ___ ___ ___  
 
 
Start Time__________________  
 
 
 
 
 
 
SECTION 1. SOCIODEMOGRAPHIC CHARACTERISTICS  (SD)  
 
IX. AGE   
 
SD100.  In what month and year were you born? 
 
 
Month  ___ ___  
 
99  Don’t know 
 
 
Year  ___ ___ ___ ___ 
 
99  Don’t know 
 
 
SD101.  How old were you on your last birthday? 
This questionnaire takes about 30 to 45 minutes to complete.  All the answers 
you give will be confidential and participation is voluntary. If you do not want 
to answer a question, please let me know and I will move on to the next one. 
You can also stop the questions at any time if you do not want to continue. 
Let me begin by first asking you some background information about 
yourself, such as your age, race. 
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Age in years: ____ ____ 
 
 
X. RACE  
 
SD102.  What is your race? 
1  African/Black  6  Portuguese 
2  Amerindian  7  White 
3  East Indian   8  Other (Specify) 
_________________________________ 
4  Chinese   99  Don’t know/Not stated 
5  Mixed  
 
 
XI. RELIGION  
 
SD103.  What is your religion? 
1  Christian      
2  Hindu      
3  Muslim     
4  Rastafarian 
5  None     
6  Other (specify) ________________________ 
99  Don’t know/Not Stated 
 
 
XII. EDUCATION   
 
SD104.  How far did you go in school? 
1  None     5  Post- Secondary (Technical Institute) 
2  Nursery/Kindergarten   6  University/Tertiary 
3  Primary     7  Other (specify) 
_____________________ 
4  Secondary     99  Don’t know/Not stated 
 
 
XIII. MARITAL STATUS   
 
SD105.  What is your marital status? 
1  Married      5  Widowed 
2  Single      6  Divorced 
3  Common Law/Living home   99  Don’t know/Not stated 
4  Separated 
 
 
XIV. INCOME 
 
SD106.  What was your main source of income during the past year?   
1  Employment/own account 
2  Remittances (overseas) 
3  Pension (NIS, former employer) 
4  Savings/interest on savings 
5  Disability benefits 
6  Spousal/partner support 
7  Other persons 
326 
 
8  Other (specify) ______________________________ 
99  Don’t know/Not stated 
 
 
SD107.  Do you work for pay outside the home?   
1  Yes 
2  No  If “no”, go to section “VII Health Insurance” 
 
SD108.  What job/work do you do? 
1  Housewife 
2  Domestic 
3  Cleaner 
4  Security Guard 
5  Teacher 
6  Clerk 
7  Other _______________________________________ 
 
SD109.  How often do you get paid in your main job/work? 
1  Weekly 
2  Fortnightly 
3  Monthly 
4  Quarterly (every 3 months) 
99  Don’t know/Not stated 
 
SD110.  What was your gross income (before tax, NIS) from your main job at the last pay 
period? 
 
$_____________  99  Don’t know/Not stated 
 
 
XV. HEALTH INSURANCE  
 
SD111.  Are you covered by any health insurance? 
1  Yes 
2  No  If “no”, go to section “VIII Housing” 
 
 
SD112.  What type of health insurance do you have? 
1  National Insurance Scheme (NIS) 
2  Privately purchased health insurance 
3  Employer purchased insurance 
4  Foreign health insurance 
5  Other (specify) ________________________________ 
 
 
XVI. HOUSING 
 
SD113.  How many people are currently living in your household including yourself? 
 
1     2      3     4        5  More than 4, how many ______ 
 
 
SD114.  How many children less than 18 years of age currently live with you? 
 
0      1     2      3     4        5  More than 4, how many ______ 
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SD115.  Please describe the home where you live.  
Check “yes” or “no” for each question; check “yes” to all that apply. 
          Yes No 
A. It is owned by you (or someone in the household)    1  2 
 
B. It is rented by you (or someone in the household)    1  2 
 
C. It is occupied without paying rent      1  2 
 
D. You live with friends       1  2 
 
E. You live with family        1  2 
 
F. You have no permanent residence      1  2 
 
 
SECTION 2. REPRODUCTION/FERTILITY  (RF)   
 
 
 
 
 
RF200.   How old were you when you were first married or started living in a union? 
 
Age ___ ____ years  99  Don’t know/Not stated 
 
 
RF201.   How many children have you given birth to (if any) that were born alive? 
 
a. Total _______  b. Boys ______ c. Girls ______  99  Don’t 
know/Not stated 
 
If none, write 0 and skip to Question RF205 
 
 
RF202.   How many of these children are still alive? 
 
a. Total _______ b. Boys _______ c. Girls _______ 99  Don’t 
know/Not stated 
 
 
RF203.   How old were you when you had your first live birth? 
 
Age ___ ____ years  99  Don’t know/Not stated 
 
 
RF204.  How old were you when you had your last child that was born alive? 
 
Age ___ ____ years  99  Don’t know/Not stated 
 
 
RF205.  Have you ever had a pregnancy that you lost either by miscarriage, or abortion, or 
which ended in a stillbirth? 
1  Yes  Number________ 
2  No  
I am going to ask you some questions about pregnancy and the children 
you have. 
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99  Don’t know 
 
RF206.  How many months pregnant are you? 
 
a.  Weeks ______  b.  Months_______ 99  Don’t know/Not stated 
 
RF207.   Parity? 
1 Primagravida 
2 Multigravida 
 
RF208.  What date was your last menstrual period? (Complete just the month and year, if 
day unknown) 
 
DATE: dd/mm/yyyy  ___ ___/____ ____/___ ___ ___ ___ 
 
99  Don’t know 
 
RF209.  At the time you became pregnant, did you, yourself, actually want to have a/another 
baby at some time? 
1  Yes 
2  No  
99  Don’t know 
 
RF210.  At the time you became pregnant, did you want to become pregnant then, did you 
want to wait until later, or did you not want to have any (more) children at all? 
1  Then Go to Question RF212 
2  Later   
3  Not at all Go to Section 3 
 
 
RF211.   How much longer would you have liked to wait? 
1  Months ___ ____ 
2  Years ____ ____ 
99  Don’t know 
 
 
RF212.   After the child you are expecting now, would you like to have another child, or 
would you prefer not to have any more children? 
1  Have another child 
2  No more/none   Go to Section 3 
99  Don’t know   Go to Section 3 
 
RF213.   After the birth of the child you are expecting now, how long would you like to wait 
before the birth of another child? 
1  Months ____ ____ 
2  Years ____ _____ 
99  Don’t know 
 
 
SECTION 3. HEALTH BEHAVIORS & BELIEFS  (HB) 
 
HB300.    I am going to ask you about your personal views about medicines in general. 
There are no wrong or right answers, so please indicate the extent to which you agree or 
disagree with each statement. 
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  Strongly 
agree 
(5) 
Agree 
 
(4) 
uncertain 
(not 
sure) 
(3) 
Disagree 
 
(2) 
Strongly 
Disagree 
(1) 
BG1 Doctors use too many 
medicines 
     
BG2 People who take medicines 
should stop their treatment for 
a while every now and again 
     
BG9 Medicines help many people to 
live better lives 
     
BG3 Most medicines are addictive      
BG4 Natural remedies (herbs) are 
safer than medicines 
     
BG11 In most cases the benefits of 
medicines outweigh the risks 
     
BG10 In the future, medicines will be 
developed to cure most 
diseases 
     
BG6 Most medicines are poisons      
BG5 Medicines do more harm than 
good 
     
BG12 Medicines help many people to 
live longer 
     
BG7 Doctors place too much trust 
on medicines 
     
BG8 If doctors had more time with 
patients, they would prescribe 
fewer medicines 
     
 
 
HB301.   Experience taking medication in pill form  
 
What has been your experience swallowing/taking pills? 
0  No difficulty 
1  Somewhat unpleasant 
2  Extremely unpleasant 
 
HB302.   Readiness to take pills 
 
Do you normally take pills when you have a very bad headache? 
0  Never 
1  Rarely 
2  Usually 
3  Always 
 
HB303.   Health Behaviors 
 
I am going to ask you about different types of behavior, please indicate how often you have 
engaged in each one over the past 2 weeks. 
 
 
In the past 2 weeks, how 
Never 
 
Almost 
Never 
Some-
times 
Fairly 
Often 
Very 
Often 
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often did you: (0) (1) (2) (3) (4) 
a. …eat a balanced diet (food 
from the 6 food groups), 
including meats, fruits & 
green leafy vegetables? 
     
b. …get enough sleep 
(sleeping for 8 hours or 
more)? 
     
c. …drink milk, eat dairy 
products (such as cheese)? 
     
d. …eat snack foods (corn 
curls, chips) instead of a 
regular meal? 
     
e. …stand on your feet for 
long periods of time? 
     
f. …eat high fiber foods such 
as whole grain breads or 
cereals? 
     
g.  …lift heavy objects or do 
lots of bending? 
     
h. …eat more food than you 
needed to? 
     
i. …skip a meal, such as 
breakfast or lunch? 
     
 
 
SECTION 4. PRENATAL VITAMINS  (PV) 
 
 
PV400.   Knowledge of vitamin use 
 
Doctors recommend that women take a multivitamin (iron/folic acid) during pregnancy for 
which of the following reasons. 
1  To prevent high blood pressure 
2  To prevent birth defects and anaemia (weak blood) 
3  To make strong bones 
4  Some other reason 
99  Don’t know 
 
 
PV401.   During this pregnancy were you given or did you buy any iron tablets, iron syrup or 
sprinkles? 
1  Yes  
2  No   Go to Section 5 
99  Don’t know Go to Section 5 
 
 
PV402.   In the past month, how often, if at all have you taken your iron tablets, iron syrup 
or sprinkles? 
0  Not at all 
1  1 or 2 days a week 
2  3 or 4 days a week 
3  5 or 6 days a week 
4  Every day  Go to Section 5 
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PV403.   Reasons for missing prenatal vitamins 
 
Some people forget to take their pills sometimes, please let me know all the reasons below 
why you did not take your multivitamins/sprinkles? 
a. Nausea      1  Yes 2  No 
b. Vomiting      1  Yes 2  No 
c. Heartburn (burn stomach)    1  Yes 2  No 
d. Constipation     1  Yes 2  No 
e. Swallowing difficulty due to pill size  1  Yes 2  No 
f. Smells bad      1  Yes 2  No 
g. Felt healthy, so I thought I did not need them 1  Yes 2  No 
h. Had too many pills to take    1  Yes 2  No 
i. Ran out of vitamins/sprinkles   1  Yes 2  No 
j. To avoid side effects    1  Yes 2  No 
k. Do not like taking pills in general   1  Yes 2  No 
l. Did not remember     1  Yes 2  No  
m. Other ___________________________  1  Yes 2  No 
 
 
SECTION 5. SUBSTANCE USE   (SU) 
 
 
 
 
 
 
SU500.   During the past 30 days, how often have you had a drink containing alcohol – beer, 
wine, a mixed-drink, or any kind of alcoholic beverage? 
0  Never   Go to Question SU502   
1  Once a month  
2  2 or 3 times a month  
3  Once or twice a week  
4  3 or 4 times a week  
5  5 to 6 times a week  
6  Daily 
 
 
SU501.   During the past 30 days, on a typical day when you drank any alcoholic beverage, 
how many drinks did you have altogether? 
1  1 drink/day 
2  2 drinks/day  
3  3 drinks/day  
4  4 drinks/day  
5  5 or more drinks/day 
 
 
SU502.  When was the last time you used: 
     Never More than     Within the past Within the 
     Used one year         year up until past 
      Ago           1 month ago month  
 
f. Tobacco (cigarettes, cigars)? 0 1  2  3 
g. Marijuana (ganja/weed)?  0 1  2  3 
h. Cocaine (crack)?   0 1  2  3 
i. Heroin?    0 1  2  3 
Some people use alcohol from time to time. I will now ask you to what extent 
you use alcohol or other drugs.  There is no right or wrong answer to these 
questions. 
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j. Other non-prescribed drugs  0 1  2  3 
(such as sleeping pills) 
 
 
SECTION 6.  SOCIAL ISSUES  (SI) 
 
 
IF NO CURRENT PARTNER/SPOUSE, GO TO QUESTION 601 
 
SI600.   The following are questions about the relationship between you and your partner. 
Please be as honest as you can, and remember that all answers you give are confidential. 
 
 
 Never 
(1) 
Rarely  
(2) 
Some-
times 
(3) 
Fairly 
often 
(4) 
Fre-
quently 
(5) 
 
A. Hurt 
How often does your partner 
physically hurt you? 
     
 
B. Insult 
How often does your partner 
insult or talk down to you? 
     
 
c.Threaten 
How often does your partner 
threaten you with physical 
harm? 
     
 
D. Scream 
How often does your partner 
scream or cuss you? 
     
 
 
The following statements are feelings/problems that people sometimes have in response to 
stressful life experiences. Please let me know how much you have been bothered by the 
problem in the past two weeks. 
 
SI601.  Over the last 2 weeks, how often have you been bothered by any of the following 
problems? 
 
 
 Not at 
all  
(0) 
Several 
Days  
(1) 
More 
than half 
the days 
(2) 
Nearly 
every 
day 
(3) 
a Little interest or pleasure in doing things.     
b Feeling down, depressed or hopeless.     
c Trouble falling or staying asleep or sleeping 
too much. 
    
d Feeling tired or having little energy.     
e Poor appetite or overeating.     
f Feeling bad about yourself  - or that you are 
a failure, or have let yourself or your family 
down. 
    
g Trouble concentrating on things, such as 
reading the newspaper, watching television 
or listening to the radio. 
    
h Moving or speaking so slowly that other     
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 Not at 
all  
(0) 
Several 
Days  
(1) 
More 
than half 
the days 
(2) 
Nearly 
every 
day 
(3) 
people could have noticed, or the opposite – 
being so fidgety or restless that you have 
been moving round a lot more than usual. 
i Thoughts that you would be better off dead 
or of hurting yourself in some way. 
    
 
SI602. Questions about anxiety. 
 
a In the last 4 weeks, have you had an anxiety attack – suddenly 
feeling fear or panic? 
YES 
(1) 
NO 
(2) 
If you checked “NO”, go to Question #3. 
b Has this ever happened before?   
c Do some of these attacks come suddenly out of the blue – that is 
situations where you don’t expect to be nervous or uncomfortable 
  
d Do these attacks bother you a lot or are you worried about having 
another attack 
  
e During your last bad anxiety attack, did you have symptoms like 
shortness of breath, sweating, your heart racing or pounding 
dizziness or faintness, tingling or numbness, or nausea or upset 
stomach? 
  
 
 
SI603. If any problems were checked off above in SI601, ask the participant: 
How difficult have these problems made it for you to do your work, take care of things at 
home, or get along with other people? 
 
0  Not difficult at all 
1  Somewhat difficult 
2  Very difficult 
3  Extremely difficult 
 
 
SECTION 7. DISCLOSURE & SOCIAL SUPPORT  (DS) 
 
 
 
 
 
DS700.  How many people besides doctors and nurses have you told about your HIV-
positive status? 
0  None 
1  1-5 people 
2  6-10 people 
3  > (greater than)10 people 
 
DS701.  Have you disclosed your HIV status to your spouse/partner? 
1  Yes  
2  No 
3  No partner/spouse 
I will now ask you about the help you get from family and friends. There is no 
right or wrong answer to these questions. 
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DS702.  What is the HIV status of your spouse/partner? 
1  Positive 
2  Negative 
99  Don’t know 
 
 
DS703.  Are any of your family members alive?    
1  Yes  
2  No  Go to Question DS707 
 
Note: People besides your relatives (parents, brothers, sisters, uncles, aunts, grandparents, 
nephews, nieces, cousins, etc.) can count as family.  Count people who took care of you 
when you were growing up such as foster parents, close family friends. 
 
DS704.  Over the last year, how often have you been in touch with family members in 
person or by phone? 
1  Not at all 
2  Several times 
3  Almost every month 
4  Almost every week 
5  Almost every day or more 
 
DS705.  Do any members of your family know that you are HIV-positive? 
1  None of them  Go to Question DS707 
2  A few of them 
3  About half 
4  Most of them 
5  All of them 
 
 
DS706.  In general, how happy are you with the overall support (help) you get from your 
family? 
1  Not at all happy 
2  Somewhat happy 
3  Moderately happy 
4  Very happy 
5  Extremely happy 
 
DS707.  Besides family, how many good friends would you say you have? 
  
0      1     2      3     4      5    6  More than 5, how many ______ 
 
If the answer is “0”, go to Question DS711 
 
DS708.  Over the last year, how often have you been in touch with your good friends in 
person or by phone? 
1  Not at all 
2  Several times 
3  Almost every month 
4  Almost every week 
5  Almost every day or more 
 
DS709.  How many of your good friends do you think know that you are HIV-positive? 
1  None of them  Go to Question DS711  
2  A few of them 
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3  About half 
4  Most of them 
5  All of them 
 
DS710.  In general, how happy are you with the overall support (help) you get from your 
good friends? 
1  Not at all happy 
2  Somewhat happy 
3  Moderately happy 
4  Very happy 
5  Extremely happy 
 
DS711.  In general, how happy are you with the overall support (help) you get from your 
partner/husband? 
1  Not at all happy 
2  Somewhat happy 
3  Moderately happy 
4  Very happy 
5  Extremely happy 
6  No partner/husband 
7 Did not disclose to partner/husband 
 
 
SECTION 8. HIV INFECTION/MEDICATION STATUS  (IM)    
 
 
 
 
 
 
IM800.  Were you diagnosed with HIV during this pregnancy? 
1  Yes  
2  No 
 
IM801.  How long have you been diagnosed with HIV? 
 
a.   Weeks___ ___  b.  Months___ ___  c.  Years___ ___  
 
 
IM802.  Were you first prescribed HIV medication during this pregnancy? 
1  Yes  
2  No 
 
IM803.  How long have you been on medications for HIV? 
 
a.   Weeks___ ___  b.  Months___ ___  c.  Years___ ___ 
 
IM804.  Is this your first pregnancy since being diagnosed HIV-positive? 
1  Yes Go to Section 9  
2  No   
 
IM805.  Number of pregnancies since HIV-positive diagnosis? 
1  1  
2  2 
3  3  
These next few questions are about when you were diagnosed with HIV and 
information about your medication. 
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4  ≥ 4 
 
IM806.  HIV status of child(ren)? 
1  HIV-positive No------------------ 
2  HIV-negative No----------------- 
99  Don’t know No-----------------  
 
 
SECTION 9. ADHERENCE   (AD)  
 
AD900.  The questions below are about your views on your treatment and care for the 
virus. 
 
 Strongly 
disagree 
 
(1) 
Disagree 
 
 
(2) 
Neither 
agree 
nor 
disagree 
(3) 
Agree 
 
 
(4) 
Strongly 
agree 
 
(5) 
A Interpersonal Aspects of Care 
1 The doctors and other health 
staff sometimes ignore what I 
tell them 
     
2 The doctors and other health 
staff listen carefully to what I 
have to say 
     
3 The doctors and other health 
staff answer all my questions 
     
4 Sometimes the doctors and 
health staff use medical terms 
without explaining what they 
mean 
     
5 I trust that the doctors and other 
health staff have my best 
interest at heart 
     
6 The doctors and other health 
staff act like I’m wasting their 
time 
     
7 The doctors and other health 
staff treat me in a very friendly 
and courteous manner 
     
8 The doctors and other health 
staff show little concern for me 
     
B Perceived Utility (Benefits/Costs and Efficacy) 
1 The benefits of my treatment 
plan outweigh any problems I 
might have in following it 
     
2 My treatment plan is too much 
trouble for what I get out of it 
     
3 Because my treatment plan is 
too difficult, it is not worth 
following 
     
4 Following my treatment plan is      
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 Strongly 
disagree 
 
(1) 
Disagree 
 
 
(2) 
Neither 
agree 
nor 
disagree 
(3) 
Agree 
 
 
(4) 
Strongly 
agree 
 
(5) 
better for me than not following 
my treatment plan 
5 Following my treatment plan 
will help me to be healthy 
     
6 I’ll be just as healthy if I avoid 
my treatment plan 
     
7 It’s hard to believe that my 
treatment plan will help me 
     
C Perceived Severity 
1 There are many diseases more 
severe than HIV 
     
2 HIV is not as bad as people say      
3 HIV is a terrible disease      
4 There is little hope for people 
with HIV 
     
D Perceived Susceptibility 
1 I expect to be free of HIV in the 
future 
     
2 No matter what I do, there’s a 
good chance of my HIV getting 
worse 
     
3 My body will fight off HIV in 
the future 
     
E Subjective Norms (Complete only if disclosed to family/friends) 
1 Members of my immediate 
family think I should follow my 
treatment plan 
     
2 I want to do what members of 
my immediate family think I 
should do about my treatment 
plan 
     
3 My close friends think I should 
follow my treatment plan 
     
4 I want to do what my close 
friends think I should do about 
my treatment plan 
     
5 My relatives think I should 
follow my treatment plan 
     
6 I want to do what my relatives 
think I should do about my 
treatment plan 
     
F Intentions 
1 I have made a commitment to 
follow my treatment plan 
     
2 Following my treatment plan is 
not in my plans 
     
3 I intend to follow my treatment      
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 Strongly 
disagree 
 
(1) 
Disagree 
 
 
(2) 
Neither 
agree 
nor 
disagree 
(3) 
Agree 
 
 
(4) 
Strongly 
agree 
 
(5) 
plan 
4 I have no intention of following 
my treatment plan 
     
G Support/Barriers 
1 Lots of things get in the way of 
following my treatment plan 
     
2 I need more assistance in order 
to follow my treatment plan 
     
3 I get the help I need to carry out 
my treatment plan 
     
4 I am able to deal with my 
problems in following my 
treatment plan 
     
 
 
SECTION 10.  QUALITY OF LIFE   (QL) 
 
QL1000.  For the following questions, I am going to ask you about how the virus has 
affected your daily life during the past month. 
 
 All of  
the 
time 
(1) 
A lot  
of the 
time 
(2) 
Some 
of the 
time 
(3) 
A little 
of the 
time 
(4) 
None 
of the 
time 
(5) 
1 Overall Function 
a In the past 4 weeks, I’ve been satisfied with 
my physical activity. 
     
b In the past 4 weeks, I’ve been physically 
limited in my ability to do routine 
household chores. 
     
c In the past 4 weeks, pain has limited my 
ability to be physically active. 
     
d In the past 4 weeks, I’ve been worried about 
not being able to do my job/routine daily 
activities as I have in the past. 
     
e In the past 4 weeks, I’ve felt that having 
HIV has limited the amount of work I can 
do at my job/routine daily activities. 
     
f In the past 4 weeks, I’ve been too tired to be 
socially active. 
     
2 Life Satisfaction 
a In the past 4 weeks, I’ve enjoyed living.      
b In the past 4 weeks, I’ve felt in control of 
my life. 
     
c In the past 4 weeks, I’ve been satisfied with 
how socially active I am. 
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 All of  
the 
time 
(1) 
A lot  
of the 
time 
(2) 
Some 
of the 
time 
(3) 
A little 
of the 
time 
(4) 
None 
of the 
time 
(5) 
d In the past 4 weeks, I’ve been pleased with 
how healthy I’ve been. 
     
3 Health Worries 
a In the past 4 weeks, I haven’t been able to 
live the way I’d like to because I’m so 
worried about my health. 
     
b In the past 4 weeks, I’ve been worried about 
my CD4 count. 
     
c In the past 4 weeks, I’ve been worried about 
my viral load. 
     
d In the past 4 weeks, I’ve been worried about 
when I’m going to die. 
     
4 Financial Worries 
a In the past 4 weeks, I’ve been worried about 
having to live on a fixed income. 
     
b In the past 4 weeks, I’ve been worried about 
how to pay my bills. 
     
c In the past 4 weeks, money has been too 
tight for me to care for myself the way I 
think I should. 
     
 
Have you taken HIV medications in the past 4 weeks? If a respondent’s answer is ‘no’ 
s/he is directed to go to section 6; if ‘yes’ s/he is directed to continue on to question 5a. 
 
5 Medication Worries 
a In the past 4 weeks, taking my medicine has 
been a burden. 
     
b In the past 4 weeks, taking my medicine has 
made it hard to live a normal life. 
     
c In the past 4 weeks, taking my medicine has 
caused unpleasant side-effects. 
     
d In the past 4 weeks, I’ve been worried about 
the effects my medicine may have on my 
body. 
     
e In the past 4 weeks, I’ve been unsure about 
why I’m taking medicine. 
     
6 HIV Mastery 
a In the past 4 weeks, I’ve had regrets about 
the way I lived my life before knowing I 
had HIV. 
     
b In the past 4 weeks, I’ve been angry about 
my past HIV risk behavior. 
     
7 Disclosure Worries 
a In the past 4 weeks, I’ve limited what I tell 
others about myself. 
     
b In the past 4 weeks, I’ve been afraid to tell 
other people that I have HIV. 
     
c In the past 4 weeks, I’ve been worried about      
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 All of  
the 
time 
(1) 
A lot  
of the 
time 
(2) 
Some 
of the 
time 
(3) 
A little 
of the 
time 
(4) 
None 
of the 
time 
(5) 
my family members finding out that I have 
HIV. 
d In the past 4 weeks, I’ve been worried about 
people at my job/routine daily activities 
finding out that I have HIV. 
     
e In the past 4 weeks, I’ve been worried that 
I’ll lose my source of income if other 
people find out that I have HIV. 
     
8 Provider Trust 
a In the past 4 weeks, I’ve felt that I could see 
my doctor whenever I needed to. 
     
b In the past 4 weeks, I’ve felt that my doctor 
involves me in decision-making. 
     
c In the past 4 weeks, I’ve felt that my doctor 
cares about me. 
     
 
 
SECTION 11. HIV KNOWLEDGE   
 
 
 
 
 
 
 
KB1100.   HIV Knowledge & Beliefs   (KB) 
 
Please answer either “true”, “false” or “don’t know” to the questions below 
 
 True 
(1) 
False 
(2) 
Don’t 
Know 
(99) 
a It is possible to get HIV from having many sexual partners    
b It is possible to get HIV from a blood transfusion    
c It is possible to get HIV from using public toilets    
d It is possible to get HIV from donating blood    
e It is possible to get HIV from mosquito bites    
f It is possible to get HIV from sharing food/utensils with a person 
who has HIV/AIDS 
   
g A person infected with HIV can transmit the virus to his/her 
sexual partner during sex without a condom 
   
h Using a condom every time you have sex can protect against HIV 
transmission 
   
i A pregnant woman with HIV can transmit the virus to her unborn 
baby during pregnancy 
   
j A pregnant woman with HIV can  transmit the virus to her baby 
during delivery 
   
k A woman with HIV can transmit the virus to her baby during    
We have now come to the final set of questions to see how much you know about the 
virus (HIV) and AIDS.  This is not a test, so feel free to say you “don’t know” if you do 
not know the answer. 
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 True 
(1) 
False 
(2) 
Don’t 
Know 
(99) 
breastfeeding 
l All pregnant women with HIV/AIDS will have babies born with 
HIV 
   
m You can always tell that a person has HIV/AIDS by  just looking 
at him/her 
   
n There is a cure for HIV/AIDS    
o Taking HIV medication (ARVs) can help reduce mother-to-child 
transmission (MTCT) during pregnancy 
   
p It is possible to get HIV through a curse or obeah    
q The use of bush medicine/herbs can cure HIV/AIDS    
r All women should get tested for HIV before becoming pregnant    
s A woman with HIV/AIDS should avoid getting pregnant    
t A woman with HIV/AIDS should avoid breastfeeding    
 
 
TK1101.  HIV Treatment Knowledge   (TK) 
Please answer either “true”, “false” or “don’t know” to the questions below 
 
 True 
(1) 
False 
(2) 
Don’t 
Know 
(99) 
a Once the HIV viral load results are ‘undetectable’, HIV 
medications should be stopped.   
   
b If HIV medications are not taken at the right time of day, 
HIV drug resistance can occur.  
   
c HIV is cured when the HIV viral load blood test result is 
‘undetectable’ 
   
d Condoms during sex are not needed when the HIV viral 
load blood test results are at ‘undetectable’ levels. 
   
e It is better to take a half dose of HIV medications than 
stopping the HIV medications completely. 
   
f One can get infected with a drug-resistant type of HIV.    
g HIV medications can cause unpleasant side effects (e.g., 
nausea, diarrhea, vomiting). 
   
h If sexual partners are both HIV-positive, condoms are no 
longer needed. 
   
i Treatments are available to reduce HIV medication side 
effects. 
   
j Recreational drugs (e.g., cocaine) can affect the 
effectiveness of HIV medications. 
   
k Providing HIV medications to a pregnant woman reduces 
her baby’s risk of being infected with HIV. 
   
l There currently exists an HIV vaccine that prevents HIV 
infection. 
   
m HIV medications can be taken at a different time of day on 
weekends or holidays. 
   
n The use of bush medicine could make HIV medications 
less effective. 
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 True 
(1) 
False 
(2) 
Don’t 
Know 
(99) 
o It is best to stop HIV medications as soon as you feel 
better. 
   
p Missing a few doses of HIV pills can increase the amount 
of HIV virus in the body. 
   
q After a few months, it becomes less important to take HIV 
medications at the right time of day. 
   
r HIV medications help the body’s immune system get 
stronger (CD4 increase). 
   
s When HIV medications work well, the HIV viral load 
increases. 
   
t Taking antibiotic medication protects a person from getting 
infected with HIV. 
   
 
SECTION 12. HIV OPTIMISM   (HO) 
 
 
HO1200.  Please indicate how you feel 
about the statements below 
Strongly 
disagree  
(1) 
Disagree 
 
(2) 
Agree 
 
(3) 
Strongly 
agree 
(4) 
a. I am less worried about HIV infection, 
now that treatments have improved 
    
b. I believe that new drug therapies 
(treatments)  make people with HIV less 
infectious 
    
 
 
End Time__________________  Duration_______________ 
 
 
Thank you very much for your time and answering these questions! 
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Appendix M: Adherence questionnaire 
ADHERENCE QUESTIONNAIRE – HIV-POSITIVE (ANTEPARTUM) 
 
 
 
 
 
 
 
 
001 Participant’s ID #: [__|__|__]   
 
002 Clinic:   Name_________________________ Code [____|____] 
 
003 Region  A  Reg. 3 B  Reg. 4 C  Reg. 6 D  Reg. 10 
 
004 Region 4 1  ECD 2  EBD 3  Georgetown 
 
005 Place of Residence________________________________________ 
 
006 Location of Residence  1  Urban  2  Rural 
 
007 Interviewer: Name____________________________ Code [____|____] 
 
008 Today’s Date: (dd/mm/year) ___ ___/___ ___/___ ___ ___ ___  
 
 
Start Time____________________  
 
 
SECTION 1. HIV MEDICATION ADHERENCE   (MA)   
 
This section of the questionnaire asks about your HIV medications.  
 
 
 
 
 
 
 
 
 
 
The following questions are about your HIV medication regimen.  If you took only a 
portion of a dose on one or more of these days, please report the dose(s) as being missed.  
 
 
MA100.  During the past 4 days, on how many days have you missed taking all your 
doses? 
 
0  None  
1  One day  
2  Two days  
Most people with HIV have many pills to take at different times during the day. 
Many people find it hard to always remember their pills, and may miss taking 
them for various reasons. We need to understand how people with HIV are really 
doing with their pills. Please tell us what you are actually doing. Don’t worry 
about telling us that you don’t take all your pills. We need to know what is really 
happening, not what you think we “want to hear.” 
 
This questionnaire takes about 30 minutes to complete. The answers you give 
here will be used to plan ways to help other people who must take their HIV 
medications. Please answer all the questions as best as you can. Thank you for 
helping in this important study. 
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3  Three days  
4  Four days 
 
MA101.  Most HIV medications need to be taken on a schedule, such as “2 times a day” 
or “3 times a day” or “every 8 hours.” How closely did you follow your specific 
schedule over the last four days? 
 
0  None of the days   
1  1 day  
2  2 days  
3  3 days  
4  All 4 days  
 
MA102.  Does any of your HIV medications have special instructions, such as “take 
with food” or “on an empty stomach” or “with plenty of fluids?” 
1  Yes  Go to MA103   
2  No 
 
MA103.  If Yes, how often did you follow those special instructions over the last four days? 
0  None of the days   
1  1 day  
2  2 days  
3  3 days  
4  All 4 days 
 
MA104.  Some people find that they forget to take their pills on the weekend days. Did 
you miss any of your HIV medications last weekend— last Saturday or Sunday? 
1  Yes    
2  No 
 
MA105.  When was the last time you missed any of your HIV medications? Check one. 
0  Within the past week 
1  1-2 weeks ago 
2  2-4 weeks ago 
3  1-3 months ago 
4  More than 3 months ago 
5  Never skipped/missed medications  Go to Question NA201 
 
 
SECTION 2.  REASONS FOR MEDICATION NON-ADHERENCE  (NA)   
 
 
 
 
 
 
 
NA200.  On the occasions you missed taking your HIV medication, how often did you 
miss them as described below: (Choose one response for each question.) 
 
 Never 
(0) 
Rarely 
(1) 
Sometimes 
(2) 
Often 
(3) 
a Were away from home?     
b Were busy with other things?       
People may miss taking their medications for various reasons. I will now ask 
you about possible reasons why you may miss taking your medications.  
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 Never 
(0) 
Rarely 
(1) 
Sometimes 
(2) 
Often 
(3) 
c Simply forgot?     
d Had too many pills to take?     
e Wanted to avoid side effects?     
f Did not want others to notice you taking your 
medication? 
    
g Had a change in daily routine?     
h Felt like the HIV medication was 
toxic/harmful to you? 
    
i Fell asleep/slept through dose time     
j Felt sick or ill?     
k Felt depressed/overwhelmed?     
l Ran out of pills?     
m Felt healthy, so I thought I did not need them?     
n Were overwhelmed caring for other family 
members? 
    
o Were worried that the medication might hurt 
your baby? 
    
p Were throwing up     
q  Other:     
 
 
NA201.   To what extent do your friends help you remember to take your medication? 
0  Not at all   
1  A little  
2  Somewhat  
3  A lot  
4  No friends 
5  Friends not aware of my status 
 
 
NA202.  To what extent does your partner/husband help you remember to take your 
medication? 
0  Not at all   
1  A little  
2  Somewhat  
3  A lot  
4  No partner/husband 
5  Partner/husband not aware of my status 
 
 
NA203.  To what extent do your family members help you remember to take your 
medication? 
0  Not at all   
1  A little  
2  Somewhat  
3  A lot  
4  No family 
5  Family not aware of my status 
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NA204.  To what extent does the clinic staff (nurses, doctors, counselors) help you 
remember to take your medication? 
0  Not at all   
1  A little  
2  Somewhat  
3  A lot  
 
NA205.  In the past 30 days, have you used any of the following to help you remember to 
take your HIV medications? 
 
  
Used? 
If used, was it helpful? 
a Pill boxes Yes  1 No  2 Yes  1 No  2 
b Beepers/alarm Yes  1 No  2 Yes  1 No  2 
c Wrist watch/clock Yes  1 No  2 Yes  1 No  2 
d 
Connecting taking HIV meals with 
routine activities, such as meals, 
brushing teeth, TV program, etc. Yes  1 No  2 Yes  1 No  2 
e Family member/partner Yes  1 No  2 Yes  1 No  2 
f Friend Yes  1 No  2 Yes  1 No  2 
g Other (specify): Yes  1 No  2 Yes  1 No  2 
 
 
SECTION 3.  FACTORS THAT IMPACT ADHERENCE  (FA) 
 
 
FA300.  I will now ask you about symptoms that you may have had DURING THE 
PAST WEEK.  Please let me know if you did have the symptom, and how much it 
bothered you. 
 
 
  
Check all the symptoms you have 
had during the PAST WEEK. 
Yes 
  
 
Not at 
all  
 
(0) 
A 
little 
bit  
(1) 
Some-
what 
(2) 
Quite 
a bit 
(3) 
Very 
Much  
(4) 
1 Difficulty concentrating       
2 Pain       
3 Lack of energy       
4 Cough       
5 Changes in skin       
6 Dry mouth       
7 Nausea       
8 Feeling drowsy       
9 Numbness/tingling in hand and feet       
10 Difficulty sleeping       
11 Feeling bloated       
12 Problems with urination       
13 Vomiting       
14 Shortness of breath       
15 Diarrhea       
16 Sweats       
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17 Mouth sores       
18 Problems with sexual interest or 
activity 
      
19 Itching       
20 Lack of appetite       
21 Dizziness       
22 Difficulty swallowing       
23 Change in the way food tastes       
24 Weight loss       
25 Hair loss       
26 Constipation       
27 Swelling of arms and legs       
28 “I don’t look like myself”       
 Check all the symptoms you have 
had during the PAST WEEK. If 
Yes, how often did it occur? 
Yes 
 
 
Rarely 
 
(1) 
Occasionally 
 
(2) 
Fre-
quentl
y 
(3) 
Almos
t 
consta
ntly  
(4) 
29 Feeling sad      
30 Worrying      
31 Feeling irritable      
32 Feeling nervous      
33 Feeling hopeful/optimistic      
34 Feeling happy      
35 Feeling confident      
36 Suicidal thoughts      
 
 
FA301.  The following is a list of problems and complaints that people sometimes have 
in response to stressful life experiences. Please let me know how much you have been 
bothered by that problem in the last month. 
 
 
 
How has this affected you in the past month? 
Not at 
all (1) 
A little 
bit (2) 
Mod-
erately 
(3) 
Quite 
a bit 
(4) 
Extreme
ly (5) 
a Repeated, disturbing memories, 
thoughts, or images of being 
diagnosed with/having HIV? 
     
b Repeated, disturbing dreams of 
being diagnosed with/having HIV?  
     
c Suddenly acting or feeling as being 
diagnosed with HIV were happening 
again (as if you were reliving it)? 
     
d Feeling very upset when something 
reminded you of of being diagnosed 
with/having HIV? 
     
e Having physical reactions (e.g., 
heart pounding, trouble breathing, or 
sweating) when something reminded 
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How has this affected you in the past month? 
Not at 
all (1) 
A little 
bit (2) 
Mod-
erately 
(3) 
Quite 
a bit 
(4) 
Extreme
ly (5) 
you of being diagnosed with/having 
HIV? 
f Avoid thinking about or talking 
about of being diagnosed 
with/having HIV? or avoid having 
feelings related to it? 
     
g Avoid activities or situations 
because they remind you of  being 
diagnosed with/having HIV? 
     
h Trouble remembering important 
parts of being diagnosed with/having 
HIV? 
     
i Loss of interest in things that you 
used to enjoy? 
     
j Feeling distant or cut off from other 
people? 
     
k Feeling emotionally numb or being 
unable to have loving feelings for 
those close to you? 
     
l Feeling as if your future will 
somehow be cut short? 
     
m Trouble falling or staying asleep?      
n Feeling irritable or having angry 
outbursts? 
     
o Having difficulty concentrating?      
p Being “super alert” or watchful on 
guard? 
     
q Feeling  jumpy or easily startled?      
 
 
FA302.   We are interested in how people respond when they confront difficult or 
stressful events in their lives. There are lots of ways to try to deal with stress. These 
next set of questions ask about what you generally do and feel when you experience 
stressful events. Different events bring out somewhat different responses, but think 
about what you usually do when you are under a lot of stress. 
W 
e are interested in how people respond when they confront 
 
How have you been dealing with the stress of 
living with HIV or AIDS in the past month? 
I don’t do 
this at all  
 
(1) 
I do this 
a little 
bit 
 
(2) 
I do this a 
medium 
amount  
(3) 
I do 
this a 
lot  
 
(4) 
1. Active Coping     
a. I’ve been concentrating my efforts on doing 
something about the situation I’m in. 
    
b. I’ve been taking action to try to make the 
situation better. 
    
2. Planning     
a. I’ve been trying to come up with a strategy     
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How have you been dealing with the stress of 
living with HIV or AIDS in the past month? 
I don’t do 
this at all  
 
(1) 
I do this 
a little 
bit 
 
(2) 
I do this a 
medium 
amount  
(3) 
I do 
this a 
lot  
 
(4) 
about what to do. 
b. I’ve been thinking hard about what steps to 
take. 
    
3. Positive Reframing     
a. I’ve been trying to see it in a different light, 
to make it seem more positive. 
    
b. I’ve been looking for something good in 
what is happening. 
    
4. Acceptance     
a. I’ve been accepting the reality of the fact 
that it has happened. 
    
b. I’ve been learning to live with it.     
5. Humour     
a. I’ve been making jokes about it.     
b. I’ve been making fun of the situation.     
6. Religion     
a. I’ve been trying to find comfort in my 
religion or spiritual beliefs. 
    
b. I’ve been praying or meditating     
7. Using Emotional Support     
a. I’ve been getting emotional support from 
others. 
    
b. I’ve been getting comfort and 
understanding from someone. 
    
8. Using Instrumental Support     
a. I’ve been trying to get advice or help from 
other people about what to do. 
    
b. I’ve been getting help and advice from 
other people. 
    
9. Self Distraction     
a. I’ve been turning to work or other activities 
to take my mind off things. 
    
b. I’ve been doing something to think about it 
less such as going to the movies, watching 
TV, reading, daydreaming, sleeping or 
shopping. 
    
10. Denial     
a. I’ve been saying to myself  “this isn’t real”     
b. I’ve been refusing to believe that it has 
happened. 
    
11. Venting     
a. I’ve been saying things to let my unpleasant 
feelings escape. 
    
b. I’ve been expressing my negative feelings.     
12. Substance Use     
a. I’ve been using alcohol or other drugs to     
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How have you been dealing with the stress of 
living with HIV or AIDS in the past month? 
I don’t do 
this at all  
 
(1) 
I do this 
a little 
bit 
 
(2) 
I do this a 
medium 
amount  
(3) 
I do 
this a 
lot  
 
(4) 
make myself feel better. 
b. I’ve been using alcohol or other drugs to 
help me get through it. 
    
13. Behavioral Disengagement     
a. I’ve giving up trying to deal with it.     
b. I’ve giving up trying to cope.     
14. Self-Blame     
a. I’ve been criticizing myself.     
b. I’ve been blaming myself for things that 
happened. 
    
 
 
End Time_________________   Duration_______________ 
 
 
Thank you very much for taking the time to answer these questions. 
 
 
 
 
 
 
 
 
INTERVIEWER’S OBSERVATIONS 
 
To Be Filled In After Completing the Interview 
 
 
 
 
 
Appendix g 
Appendix h 
Appendix i 
Appendix j 
TO BE OBTAINED FROM PARTICIPANT’S CHART/CLINICAL 
REGISTER 
Recent CD4 cell count: __________  Date (dd/mm/yyyy)_____________ 
Recent Viral load: _____________  Date (dd/mm/yyyy)______________ 
ARV Treatment Regimen: ____________________________________________ 
Gestation (weeks):_____________________________ 
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Appendix N: Information sheets and consent forms - Survey  
Information Sheet:  HIV-negative pregnant women 
 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care 
 
This study has been approved by the UCL Research Ethics Committee [Project ID: 
3518/002], and the Ministry of Health, Guyana [Project #: 76]. 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
 
 
 
 
Hello, my name is [name] and I am a research student at UCL. I would like to 
invite you to participate in this study. Before you decide whether you would like 
to take part, it is important for you to read the following information carefully 
and discuss it with others if you wish. Ask me if there is anything that is not 
clear or if you would like more information. 
 
What is the study about? 
 
This study would like to learn about the issues affecting women infected with 
HIV (a germ that affects the body’s ability to fight off disease) who are 
pregnant and how they are able to comply with treatment and care. In order to 
get a better understanding of these issues, I will need to ask similar questions 
to a comparison group of women, like you, who are pregnant but not infected 
with HIV to see if there is any difference in how you comply with your care. I 
will be asking you about your feelings and things that affect you. I will also 
speak with other women about their experiences.  
 
What happens if you agree to take part? 
 
If you agree to take part, I will fill out one questionnaire based on your 
responses, once during your pregnancy. The questionnaire will be completed 
while you are at the clinic, or a time and place convenient for you.  It should 
take about 30 minutes.  If you decide to take part, you will be given this 
information sheet to keep and will be asked to sign a Consent Form. 
 
What happens if you don’t agree to take part? 
352 
 
It is up to you to decide whether to take part or not. If you decide to take 
part, you are still free to withdraw at any time without giving a reason.  You can 
refuse to answer any of the questions at any time, and you do not have to give 
me a reason for doing so. If you decide to withdraw at any time, or decide not 
to take part, this will not affect any treatment or care you are getting at the 
clinic. We also do not pay people to participate in this study. 
 
What are the benefits of participating? 
 
You may not get any direct benefits from participating in this study, but you 
will be helping us to improve care and treatment for women like yourself. 
 
What are the disadvantages and risks of participating? 
 
Although there will be no physical harm done to you, the questionnaire asks 
questions about your experiences with your pregnancy. If a question makes you 
uncomfortable, remember you don’t have to answer it and you can also stop the 
questionnaire at any time without giving a reason. You can also ask me to 
destroy some or all of your answers by contacting me afterwards.  If you want 
to talk about something raised by the questionnaire, you can let me know at the 
time, or contact me afterwards. If during the questionnaire I notice that you 
are experiencing any problems, I will talk to you about getting some help with a 
counsellor if you want to.  
 
What will happen to the information you give? 
 
All the information you tell me will be kept strictly confidential. Your name and 
other identifiers will not be written on the questionnaire. The data will be kept 
in a computer database and only the researchers will be able to see it. The 
questionnaire and personal information will be kept under lock and key. If the 
study team reports your opinions or ideas, your name will not appear, and we will 
make sure that you cannot be identified.  
All data will be collected and stored in accordance with the Data Protection 
Act, 1998. 
 
What will happen to the results of the study? 
 
We plan to publish the results of the study in a journal. The results of the 
study will also be given to the Ministry of Health to help them improve their 
programme. Your name will not be in any of the results or reported to the 
clinic/Ministry. 
How can you get more information on the project? 
If you have questions about any part of the research project, please contact 
Ms. Deborah Vitalis at mobile 592-618-6204. 
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Thank you for taking the time to read this information sheet. You will be given 
a Consent Form to read and fill in. 
 
Information Sheet: HIV-positive Pregnant Women 
 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care 
 
This study has been approved by the UCL Research Ethics Committee [Project ID: 
3518/002], and the Ministry of Health, Guyana [Project #76]. 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
 
 
 
 
Hello, my name is [name] and I am a research student at UCL. I would like to 
invite you to participate in this study. Before you decide whether you would like 
to take part, it is important for you to read the following information carefully 
and discuss it with others if you wish. Ask me if there is anything that is not 
clear or if you would like more information. 
 
What is the study about? 
 
This study would like to learn about the issues affecting women who have been 
infected with HIV (a germ that affects the body’s ability to fight off disease) 
and how they are able to comply with treatment and care. I will be asking you 
about your feelings and things that affect you. I will also speak with other 
women about their experiences.  
 
What happens if you agree to take part? 
 
If you agree to take part, I will fill out two questionnaires based on your 
responses, once during your pregnancy. The questionnaires will be completed 
while you are at the clinic, or a time and place convenient for you.  It should 
take about 30 minutes for each questionnaire.  If you decide to take part, you 
will be given this information sheet to keep and will be asked to sign a Consent 
Form. 
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What happens if you don’t agree to take part? 
 
It is up to you to decide whether to take part or not. If you decide to take 
part, you are still free to withdraw at any time without giving a reason.  You can 
refuse to answer any of the questions at any time, and you do not have to give 
me a reason for doing so. If you decide to withdraw at any time, or decide not 
to take part, this will not affect any treatment or care you are getting at the 
clinic. We also do not pay people to participate in this study. 
What are the benefits of participating? 
 
You may not get any direct benefits from participating in this study, but you 
will be helping us to improve care and treatment for women like yourself. 
 
What are the disadvantages and risks of participating? 
 
Although there will be no physical harm done to you, the questionnaire asks 
questions about your experiences with HIV. If a question makes you 
uncomfortable, remember you don’t have to answer it and you can also stop the 
questionnaire at any time without giving a reason. You can also ask me to 
destroy some or all of your answers by contacting me afterwards.  If you want 
to talk about something raised by the questionnaire, you can let me know at the 
time, or contact me afterwards. If during the questionnaire I notice that you 
are experiencing any problems, I will talk to you about getting some help with a 
counsellor if you want to.  
 
What will happen to the information you give? 
 
All the information you tell me will be kept strictly confidential. Your name and 
other identifiers will not be written on the questionnaire. The data will be kept 
in a computer database and only the researchers will be able to see it. The 
questionnaire and personal information will be kept under lock and key. If the 
study team reports your opinions or ideas, your name will not appear, and we will 
make sure that you cannot be identified.  
All data will be collected and stored in accordance with the Data Protection 
Act, 1998. 
 
 
What will happen to the results of the study? 
 
We plan to publish the results of the study in a journal. The results of the 
study will also be given to the Ministry of Health to help them improve their 
programme. Your name will not be in any of the results or reported to the 
clinic/Ministry. 
 
How can you get more information on the project? 
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If you have questions about any part of the research project, please contact 
Ms. Deborah Vitalis at mobile 592-618-6204. 
Thank you for taking the time to read this information sheet. You will be given 
a Consent Form to read and fill in. 
 
Informed Consent Form – Pregnant Women 
 
Title of the Study:  To explore factors that affect HIV-positive pregnant and postpartum 
women’s ability to comply with their treatment and care. 
 
This study has been approved by the UCL Research Ethics Committee (Project ID: 
3518/002) & the Ministry of Health, Guyana (Project #: 76). 
 
Name, Address & Contact Details of Investigators: 
Deborah Vitalis & Lorraine Sherr 
Department of Infection & Population Health 
Royal Free Hospital & Medical School/Upper 3
rd
 Floor 
Rowland Hill Street 
London, NW3 2PF 
England 
 
 
 
Thank you for thinking about taking part in this research. You will be given a copy of 
this Consent Form to keep and refer to at any time. 
Any questions I have concerning this research have been answered.   
 I understand that if I decide at any time during the research that I don’t 
want to participate in this project, I can tell the researchers and be 
withdrawn from it immediately. This will not affect any care or treatment 
I am getting at this clinic. 
 I consent to the use of my personal information as part of this research 
study. I also understand that my responses will be kept private and it will 
not be possible to identify me in any study publications or reports. I agree 
that the information I give may be used by others for future research. 
 I consent to the use of personal information in my clinic chart about me 
and my baby as part of this research study.  
 I understand that the information I have submitted will be published as a 
report.  Confidentiality and anonymity will be maintained and it will not be 
possible to identify me from any publications. 
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Participant’s Statement: 
 
I  …………………………………………......................................agree that the research project named 
above has been well explained to me and I agree to take part in the study.  I have read 
both the notes written above and the Information Sheet about the project, and I 
understand what the research study involves. 
Signature/Thumb Print:_______________________ Date:_______________ 
Researcher’s Statement: 
I  ……………………………………………………………………..confirm that I have carefully explained the 
purpose of the study to the participant and outlined any reasonably foreseeable risks 
or benefits (where applicable). 
Signature:________________________   Date:_______________ 
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Appendix O: Supplementary table - Prenatal vitamin knowledge and explanatory 
variables 
Characteristic HIV-negative HIV-positive 
Vitamin knowledge Correct     
% (n) 
p-value Correct     
% (n) 
p-value 
Socio-demographic Characteristics 
Region 
Region 3/6 
Region 4 
 
56 (9)  
66 (61)  
p=0.44  
64 (9) 
65 (61) 
p=0.97 
 
Age 
15-25 
26-44 
 
63 (43) 
68 (27)                          
p=0.65  
56 (20) 
69 (50) 
p=0.15 
Race 
E. Indian/Other 
Mixed 
African 
 
55 (16) 
70 (26) 
67 (28) 
p=0.42  
60 (9) 
57 (25) 
73 (36) 
p=0.22 
Religion 
Non-Christian 
Christian 
 
64 (9) 
65 (61) 
p=0.97  
60 (6) 
65 (64) 
p=0.74 
Education 
≤ Primary 
≥ Secondary 
 
62 (8)  
65 (62) 
p=0.79  
50 (8) 
67 (62) 
p=0.18 
 
Marital Status 
Single 
Partner 
 
67 (16) 
64 (54) 
p=0.83  
64 (23) 
65 (47) 
p=0.89 
Income source 
Job 
Family/Partner 
 
79 (33) 
56 (37) 
p=0.02*  
67 (33) 
63 (37) 
p=0.62 
Home ownership 
Other 
Own home 
 
58 (29) 
71 (41) 
p=0.17  
70 (30) 
62 (40) 
p=0.38 
Pregnancy Characteristics 
Gestation  
≤ 26 weeks 
≥ 27 weeks 
 
69 (29) 
62 (41) 
p=0.46  
65 (35) 
65 (35) 
p=1.0 
Parity 
Primiparous 
Multiparous 
 
66 (37) 
63 (33) 
p=0.78 
 
 
58 (14) 
67 (56) 
p=0.45 
Type of pregnancy 
Wanted 
Unwanted 
 
73 (35) 
58 (35) 
p=0.12  
65 (20) 
65 (50) 
p=0.97 
Psychosocial Characteristics 
Domestic violence 
HITS-positive 
HITS-negative 
 
33 (1)§ 
65 (53) 
p=0.29  
50 (2)§ 
67 (46) 
p=0.60 
Depression 
None 
Some  
 
67 (28) 
63 (42) 
p=0.75  
60 (24) 
68 (46) 
p=0.42 
Suicidal ideation  p=0.87  p=0.13 
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Yes 
No 
67 (10) 
65 (60) 
78 (18) 
61 (52) 
Health behaviour Characteristics 
Experience taking pills 
Unpleasant 
No difficulty 
 
59 (16) 
67 (54) 
p=0.49  
76 (13)§ 
63 (57) 
p=0.41 
Readiness to take pills 
Usually-always 
Rarely-never 
 
64 (14) 
65 (56) 
p=0.90  
74 (17) 
62 (53) 
p=0.30 
Vitamin intake  
< Daily 
Daily 
 
63 (20) 
66 (48) 
p=0.75  
63 (12) 
65 (57) 
p=0.89 
Healthy eating 
5-10 
11-12 
13-16 
 
69 (25) † 
62 (21) 
63 (24) 
p=0.38  
77 (24) ‡ 
51 (19) 
68 (27) 
p=0.63 
 
Gen. harm 
5-9 
10-11 
12-16 
 
80 (12)†  
71 (22) 
58 (36) 
p=0.07  
66 (27)† 
62 (33) 
71 (10) 
p=0.82 
Gen. overuse 
8-10 
11-12 
13-18 
 
55 (6) † 
79 (19) 
62 (45) 
p=0.60  
75 (43) ‡ 
50 (13) 
56 (14) 
p=0.01* 
Gen. benefit 
8-13 
14-15 
16-20 
 
67 (22)‡  
60 (26) 
69 (22) 
p=0.73 
 
 
100 (2)‡  
61 (19) 
65 (49) 
p=0.76 
HIV knowledge 
Poor (0-7)  
Good (8-11) 
Excellent (12-15) 
 
64 (7)‡ 
47 (21) 
81 (42) 
p=0.0004*  
0 (0)‡ 
39 (11) 
75 (59) 
p=0.02* 
HIV belief: kb16-obeah 
True 
False 
DK 
 
0 (0)§ 
72 (59) 
46 (11) 
p=0.01*  
0 (0)§ 
69 (65) 
45 (5) 
p=0.02* 
 
HIV belief: kb17 bush 
cure 
True 
False 
DK 
 
 
50 (4)§ 
69 (41 
61 (25) 
p=0.45  
 
20 (1)§ 
61 (47) 
85 (22) 
p=0.01* 
Alcohol use 
≥ Once weekly 
Never 
 
67 (8)§ 
65 (62) 
p=1.0  
67 (10) 
65 (60) 
p=0.87 
Tobacco use 
≥ Past month 
Never 
 
58 (7) 
66 (63) 
p=0.62  
81 (17)§ 
61 (53) 
p=0.13 
Note: § = Fisher’s exact test; ‡ = Mann-Whitney test; †= T-test 
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Appendix P: Supplementary table - Relationship between substance use and 
explanatory variables 
 Alcohol Tobacco 
 
Characteristic   % (n) 
HIV-
negative 
HIV-
positive 
HIV-
negative 
HIV-
positive 
 Never Never Never Never 
Region 
 
Region 3/6 
Region 4 
p=0.38 
 
81 (13)§ 
90 (83) 
p=0.41 
 
79 (11)§ 
87 (82) 
p=0.38 
 
81 (13)§ 
90 (83) 
p=0.47 
 
71 (10)§ 
82 (77) 
Age 
 
15-25 
26-44 
p=1.0 
 
88 (60)§ 
90 (36) 
p=1.0 
 
86 (31) 
86 (62) 
p=0.73 
 
90 (61) 
88 (35) 
p=0.20 
 
89 (32)§ 
76 (55) 
Race 
 
E. Indian/Other 
Mixed 
African 
p=0.86 
 
86 (25)§ 
89 (33) 
90 (38) 
p=0.64 
 
93 (14) 
86 (38) 
84 (41) 
p=0.02* 
 
90 (26)§ 
78 (29) 
98 (41) 
p=0.44 
 
73 (11) 
77 (34) 
86 (42) 
Religion 
 
Non-Christian 
Christian 
p=0.65 
 
86 (12)§ 
89 (84) 
p=0.35 
 
100 (10)§ 
85 (83) 
p=0.36 
 
100 (14)§ 
87 (82) 
p=0.10 
 
60 (6)§ 
83 (81) 
Education 
 
≤ Primary 
≥ Secondary 
p=0.64 
 
85 (11)§ 
89 (85) 
p=0.16 
 
75 (12)§ 
88 (81) 
p=0.64 
 
85 (11)§ 
89 (85) 
p=0.51 
 
75 (12)§ 
82 (75) 
Marital Status 
 
Single 
Partner 
p=0.46 
 
83 (20)§ 
90 (76) 
p=1.0 
 
86 (31) 
86 (62) 
p=0.73 
 
88 (21) § 
89 (75) 
p=0.04* 
 
69 (25) 
86 (62) 
Income source 
 
Job 
Family-Partner 
p=0.12 
 
95 (40)§ 
85 (56) 
p=0.16 
 
92 (45)§ 
82 (48) 
p=0.03* 
 
98 (41)§ 
83 (55) 
p=0.46 
 
84 (41) 
78 (46) 
Home ownership 
 
Own-home 
Other 
p=0.79 
 
90 (52) 
88 (44) 
p=0.25 
 
89 (58) 
81 (35) 
p=0.22 
 
93 (54)§ 
84 (42) 
p=0.86 
 
80 (52) 
81 (35) 
Gestation 
 
≤ 26 weeks 
≥ 27 weeks 
p=0.40 
 
86 (36) 
91 (60) 
p=0.78 
 
85 (46) 
87 (47) 
p=0.76 
 
90 (38)§ 
88 (58) 
p=0.22 
 
85 (46) 
76 (41) 
Parity 
 
Primiparous 
Multiparous 
p=0.89 
 
89 (50) 
88 (46) 
p=0.51 
 
92 (22)§ 
85 (71) 
p=0.07 
 
95 (53)§ 
83 (43) 
p=1.0 
 
83 (20)§ 
80 (67) 
Type of pregnancy 
 
p=0.22 
 
p=0.67 
 
p=0.54 
 
p=0.99 
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Wanted 
Unwanted 
94 (45)§ 
85 (51) 
84 (26) 
87 (67) 
92 (44)§ 
87 (52) 
81 (25) 
81 (62) 
Dom. Violence 
 
HITS-positive 
HITS-negative 
p=0.29 
 
67 (2)§ 
90 (73) 
p=0.45 
 
75 (3)§ 
87 (60) 
p=0.04* 
 
33 (1)§ 
89 (72) 
p=1.0 
 
100 (4)§ 
84 (58) 
Depression 
 
None 
Some 
p=0.03* 
 
98 (41)§ 
83 (55) 
p=0.75 
 
88 (35) 
85 (58) 
p=0.03* 
 
98 (41)§ 
83 (55) 
p=0.02* 
 
93 (37)§ 
74 (50) 
Suicidal ideation 
 
Yes 
No 
p=0.37 
 
80 (12)§ 
90 (84) 
p=0.01* 
 
70 (16) 
91 (77) 
p=0.67 
 
87 (13)§ 
89 (83) 
p=0.04* 
 
65 (15) 
85 (72) 
Healthy eating 
 
5-10 
11-12 
13-16 
p=0.41 
 
86 (31)† 
88 (30) 
92 (35) 
p=0.09 
 
81 (25)‡ 
86 (32) 
90 (36) 
p=0.004* 
 
78 (28)† 
91 (31) 
97 (37) 
p=0.36 
 
84 (26)‡ 
76 (28) 
83 (33) 
Note: § = Fisher’s exact; ‡ = Mann-Whitney; † = T-test 
 
Appendix Q: Sensitivity analysis 
Relationship between demographic factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Demographic characteristics† 
Region 
Region 3/611 
Region 4 
 
33 (2) 
18 (11) 
 
33 (2) 
15 (9) 
 
33 (2) 
67 (41) 
p=0.14 
 
Age 
15-25 
26-44 
 
27 (4) 
17 (9) 
 
0 (0) 
21 (11) 
 
73 (11) 
62 (32) 
p= 0.65 
 
Race 
E. Indian/Other 
Mixed 
African 
 
22 (2) 
20 (6) 
18 (5) 
 
11 (1) 
17 (5) 
18 (5) 
 
67 (6) 
63 (19) 
64 (18) 
p=0.97 
 
Religion 
Non-Christian 
Christian 
 
17 (1) 
20 (12) 
 
17 (1) 
16 (10) 
 
67 (4) 
64 (39) 
p=0.88 
 
Education 
≤ Primary 
≥ Secondary 
 
11 (1) 
21 (12) 
 
33 (3) 
14 (8) 
 
56 (5) 
66 (38) 
p=0.80 
 
Marital Status 
Single 
 
20 (4) 
 
15 (3) 
 
65 (13) 
p= 0.96 
 
                                                 
11 Regions 3 and 6 were combined since they are two urban regions with a small number of respondents 
361 
 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Partner 19 (9) 17 (8) 64 (30) 
Income source 
Job 
Family/Partner 
 
13 (4) 
26 (9) 
 
22 (7) 
11 (4) 
 
66 (21) 
63 (22) 
p= 0.56 
 
Home ownership 
Other 
Own-home 
 
19 (5) 
20 (8) 
 
19 (5) 
15 (6) 
 
63 (17) 
65 (26) 
p= 0.93 
 
Note: † = Univariate ordinal logistic regression 
 
Relationship between pregnancy-related factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Pregnancy characteristics† 
Gestation 
≤ 26 weeks 
≥ 27 weeks 
 
20 (7) 
19 (6) 
 
17 (6) 
16 (5) 
 
63 (22) 
66 (21) 
p= 0.82 
 
Parity 
Primiparous 
Multiparous 
 
27 (3) 
18 (10) 
 
9 (1) 
18 (10) 
 
64 (7) 
64 (36) 
p= 0.80 
 
Type of Pregnancy 
Wanted 
Unwanted 
 
18 (4) 
20 (9) 
 
23 (5) 
13 (6) 
 
59 (13) 
67 (30) 
p= 0.67 
 
Note: † = Univariate ordinal logistic regression 
 
Relationship between psychosocial factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
Adherent 
p-value 
Psychosocial characteristics 
Domestic violence† 
HITS-positive 
HITS-negative 
 
0 (0) 
20 (9) 
 
50 (1) 
17 (8) 
 
50 (1) 
63 (29) 
p= 0.94 
Depression† 
None 
Some  
 
22 (6) 
18 (7) 
 
7 (2) 
23 (9) 
 
70 (19) 
60 (24) 
p= 0.58 
 
Suicidal ideation† 
Yes 
No 
 
21 (3) 
19 (10) 
 
29 (4) 
13 (7) 
 
50 (7) 
68 (36) 
p= 0.31 
 
Post-traumatic stress† 
PTSD-positive 
PTSD-negative 
 
0 (0) 
21 (13) 
 
25 (1) 
16 (10) 
 
75 (3) 
63 (40) 
p=0.54 
 
Coping – adaptive‡ 
0-40 
 
11 (2) 
 
16 (3) 
 
74 (14) 
rs = -0.05, 
p=0.68 
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 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
Adherent 
p-value 
41-64 23 (11) 17 (8) 60 (29)  
Coping – maladaptive‡ 
0-18 
19-38 
 
16 (4) 
21 (9) 
 
20 (5) 
14 (6) 
 
64 (16) 
64 (27) 
rs = -0.06, 
p=0.61 
 
Physical symptoms‡ 
0-0.26 
0.27-0.7 
0.8-2.3 
 
13 (2) 
28 (7) 
15 (4) 
 
20 (3) 
0 (0) 
30 (8) 
 
67 (10) 
72 (18) 
56 (15) 
rs = -0.01, 
p=0.93 
 
Psych symptoms‡ 
0-0.3 
0.4-1.1 
1.2-3.7 
 
27 (6) 
18 (4) 
13 (3) 
 
14 (3) 
18 (4) 
17 (4) 
 
59 (13) 
64 (14) 
70 (16) 
rs = 0.11, 
p=0.36 
 
Global distress index‡ 
0-0.3 
0.4-1.13 
1.14-2.8 
 
27 (6) 
14 (3) 
17 (4) 
 
5 (1) 
18 (4) 
26 (6) 
 
68 (15) 
68 (15) 
57 (13) 
rs = -0.01, 
p=0.93 
 
Positive mood‡ 
0-7 
8-12 
 
20 (3) 
19 (10) 
 
13 (2) 
17 (9) 
 
67 (10) 
63 (33) 
rs = -0.06, 
p=0.62 
 
Quality of life - overall 
function‡ 
0-25 
26-30 
 
 
13 (1) 
20 (12) 
 
 
25 (2) 
15 (9) 
 
 
62 (5) 
64 (38) 
rs = 0.13, 
p=0.29 
 
 
Quality of life – life 
satisfaction‡ 
0-15 
16-20 
 
 
16 (3) 
21 (10) 
 
 
16 (3) 
17 (8) 
 
 
68 (13) 
63 (30) 
rs = 0.09, 
p=0.47 
 
Quality of life – health 
worries‡ 
0-15 
16-20 
 
 
21 (4) 
19 (9) 
 
 
26 (5) 
13 (6) 
 
 
53 (10) 
69 (33) 
rs = 0.06, 
p=0.60 
 
 
Quality of life – 
financial worries‡ 
0-10 
11-15 
 
 
17 (4) 
20 (9) 
 
 
22 (5) 
14 (6) 
 
 
61 (14) 
66 (29) 
rs = -0.02, 
p=0.85 
 
Quality of life – 
medication worries‡ 
0-22 
23-25 
 
 
70 (7) 
11 (6) 
 
 
0 (0) 
19 (11) 
 
 
30 (3) 
70 (40) 
rs = 0.31, 
p=0.01* 
 
Quality of life – HIV 
mastery‡ 
0-5 
6-10 
 
 
31 (4) 
17 (9) 
 
 
0 (0) 
20 (11) 
 
 
69 (9) 
63 (34) 
rs = 0.08, 
p=0.51 
 
 
Quality of life – 
disclosure worries‡ 
0-6 
7-25 
 
 
20 (3) 
19 (10) 
 
 
13 (2) 
17 (9) 
 
 
67 (10) 
63 (33) 
rs = 0.06, 
p=0.64 
 
 
Quality of life –    rs = -0.11, 
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 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
Adherent 
p-value 
provider trust‡ 
0-12 
13-15 
 
11 (1) 
21 (12) 
 
11 (1) 
17 (10) 
 
78 (7) 
62 (36) 
p=0.40 
 
Note: ‡ =Spearman’s; † = Univariate ordinal logistic regression 
 
Relationship between health behaviour factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Health behaviours and knowledge 
Experience taking pills†12 
Unpleasant 
No difficulty 
 
11 (1) 
21 (12) 
 
11 (1) 
17 (10) 
 
78 (7) 
62 (36) 
p= 0.37 
 
Readiness to take pills†13 
Usually-always 
Rarely-never 
 
7 (1) 
23 (12) 
 
27 (4) 
13 (7) 
 
67 (10) 
63 (33) 
p= 0.57 
 
Vitamin intake in past 
month† 
< Daily 
Daily 
 
 
31 (4) 
17 (9) 
 
 
31 (4) 
13 (7) 
 
 
38 (5) 
70 (37) 
p= 0.058* 
 
 
Healthy eating‡ 
5-10 
11-12 
13-16 
 
24 (5) 
9 (2) 
26 (6) 
 
14 (3) 
30 (7) 
4 (1) 
 
62 (13) 
61 (14) 
70 (16) 
rs = 0.06, 
p=0.60 
 
Belief that taking 
medication in general is 
harmful‡ 
5-9 
10-11 
12-16 
 
 
 
12 (5) 
23 (12) 
21 (3) 
 
 
 
10 (4) 
17 (9) 
21 (3) 
 
 
 
78 (32) 
60 (32) 
57 (8) 
rs = -0.19, 
p=0.05* 
 
 
 
 
Beliefs in general overuse 
of medication by doctors‡ 
 
8-10 
11-12 
13-18 
 
 
 
24 (9) 
21 (3) 
7 (1) 
 
 
 
13 (5) 
7 (1) 
33(5) 
 
 
 
63 (24) 
71 (10) 
60 (9) 
rs = 0.02, 
p=0.86 
 
 
Beliefs in general benefits 
of taking mediation in 
general‡ 
8-13 
14-15 
16-20 
 
 
 
0 (0) 
14 (3) 
22 (10) 
 
 
 
100 (1) 
19 (4) 
13 (6) 
 
 
 
0 (0) 
67 (14) 
64 (29) 
rs = -0.03, 
p=0.78 
 
                                                 
12 Experience in taking other types of pills 
13 Readiness to take other types of pills 
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 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
Alcohol use† 
 ≥ weekly 
Never 
 
20 (2) 
19 (11) 
 
30 (3) 
14 (8) 
 
50 (5) 
67 (38) 
p=0.44 
 
Tobacco use† 
≥ past month 
Never 
 
23 (3) 
19 (10) 
 
38 (5) 
11 (6) 
 
38 (5) 
70 (38) 
p= 0.09 
 
Note: ‡ =Spearman’s; † = Univariate ordinal logistic regression 
 
Relationship of HIV diagnosis factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
HIV diagnosis, disclosure and support 
Diagnosed current 
pregnancy† 
Yes 
No 
 
 
50 (1) 
18 (12) 
 
 
50 (1) 
15 (10) 
 
 
0 (0) 
66 (43) 
p=0.12 
 
1st pregnancy since 
diagnosis† 
Yes 
No 
 
 
21 (4) 
19 (9) 
 
 
16 (3) 
17 (8) 
 
 
63 (12) 
65 (31) 
p= 0.88 
 
 
Disclosure – partner† 
No 
Yes 
 
30 (3) 
18 (10) 
 
10 (1) 
18 (10) 
 
60 (6) 
65 (37) 
p=0.61 
 
Disclosure – family† 
No 
Yes 
 
13 (2) 
21 (11) 
 
7 (1) 
19 (10) 
 
80 (12) 
60 (31) 
p=0.18 
 
Disclosure –friends† 
No 
Yes 
 
11 (2) 
15 (4) 
 
11(2) 
27 (7) 
 
79 (15) 
58 (15) 
p=0.17 
 
Know partner’s status† 
No 
Yes 
 
19 (3) 
20 (10) 
 
6 (1) 
20 (10) 
 
75 (12) 
61 (31) 
p= 0.40 
 
Support – family† 
No 
Yes 
 
40 (2) 
19 (9) 
 
20 (1) 
19 (9) 
 
40 (2) 
62 (29) 
p=0.29 
 
Support – partner† 
No 
Yes 
 
25 (3) 
19 (9) 
 
8 (1) 
19 (9) 
 
67 (8) 
62 (29) 
p= 0.91 
 
Time since HIV 
diagnosis (weeks)‡ 
24 - 207 
208 – 311 
≥ 312 
 
 
18 (4) 
12 (2) 
25 (7) 
 
 
14 (3) 
29 (5) 
11 (3) 
 
 
68 (15) 
59 (10) 
64 (18) 
rs = -0.02, 
p=0.88 
 
Note: ‡ = Spearman’s; † = Univariate ordinal logistic regression 
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Relationship of ART & ART-related factors and adherence 
 Antiretroviral therapy     % (n)  
Characteristic Recent non-
adherence 
Recent 
adherence 
Always 
adherent 
p-value 
ART and ART-related characteristics 
Time on ART (weeks)‡  
16-155 
156-520 
 
20 (6) 
19 (7) 
 
20 (6) 
14 (5) 
 
60 (18) 
68 (25) 
rs = 0.09, 
p=0.45 
 
ART initiated in 
current pregnancy† 
Yes 
No 
 
 
50 (1) 
18 (12) 
 
 
0 (0) 
17 (11) 
 
 
50 (1) 
65 (42) 
p= 0.48 
 
CD4† 
≤ 350 
351-500 
> 500 
 
22 (4) 
17 (3) 
20 (6) 
 
11 (2) 
28 (5) 
10 (3) 
 
67 (12) 
56 (10) 
70 (21) 
p= 0.74 
 
ARV regimen† 
Multi-drug 
Single drug 
 
23 (5) 
18 (8) 
 
0 (0) 
24 (11) 
 
77 (17) 
58 (26) 
p=0.26 
 
HIV knowledge score‡ 
8-11 1 
12-152  
 
6 (1) 
24 (12) 
 
11 (2) 
18 (9) 
 
83 (15) 
57 (28) 
rs = -0.25, 
p=0.04* 
 
HIV belief: witchcraft† 
True 
False 
DK 
 
0 (0) 
22 (13) 
0 (0) 
 
0 (0) 
18 (11) 
0 (0) 
 
0 (0) 
60 (36) 
100 (7) 
p=0.99 
 
HIV belief: bush cure† 
True 
False 
DK 
 
50 (1) 
16 (8) 
27 (4) 
 
0 (0) 
20 (10) 
7 (1) 
 
50 (1) 
64 (32) 
67 (10) 
p=0.84 
 
HIV treatment know‡ 
0-6 
7-13 
14-20 
 
100 (1) 
22 (2) 
18 (10) 
 
0 (0) 
11 (1) 
18 (10) 
 
0 (0) 
67 (6) 
65 (37) 
rs = -0.01, 
p=0.91 
 
Note: ‡=Spearman’s; † = Univariate ordinal logistic regression; 1=good; 2= excellent 
 
Ordered logistic regression model for ART adherence 
Characteristic Unadjusted Adjusted 
 OR 95% CI p-value OR 95% CI p-value 
Quality of life -
medication 
worries 
 
 
 
1.57§ 
 
- 
1.2 – 2.1 
 
 
p=0.003 
 
 
1.83§ 
 
- 
1.3 – 2.6 
 
 
p=0.001* 
Vitamin intake† 
< Daily 
Daily 
 
1.0 
3.02 
 
- 
1.0 – 9.5 
 
 
p=0.058 
 
1.0 
3.64 
 
- 
0.9 – 14.4 
 
 
p=0.065 
Belief that 
medication in 
 
 
 
- 
 
 
 
 
 
- 
 
 
366 
 
Characteristic Unadjusted Adjusted 
 OR 95% CI p-value OR 95% CI p-value 
general is 
harmful 
 
0.72§ 
 
0.5 – 1.0 
 
p=0.061 
 
0.80§ 
 
0.5 -1.3 
 
p=0.328 
Tobacco use 
≥ past month 
Never 
 
1.0 
2.63 
 
- 
0.9 – 8.1 
 
 
p=0.090 
 
1.0 
4.09 
 
- 
1.2 – 14.3 
 
 
p=0.028* 
HIV knowledge 
score 
 
-5.92§ 
- 
0.5 – 1.0 
 
p=0.029 
 
0.63§ 
- 
0.4 – 1.0 
 
p=0.028* 
§ = OR from a one unit change in score variable 
† = women who took zero pills or took them as few as once weekly to at most 6 days 
per week 
 
